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Type 1 Diabetes (T1D) is one of the most common metabolic diseases in childhood 
Soltesz (298). There is a general agreement that the incidence of T1D has been increasing in 
children since the 1950’s. By 1998, using existing data on 37 studies (from 27 countries), the 
increase of worldwide incidence of T1D was on average 3.0% per year (Confidence Interval 
(CI) 95% 2.6-3.3) and it was predicted that it will be 40% higher in 2010 (231) in children 
aged 0-14 years. The causes of this increase are still under study; this thesis updates the 
current knowledge on the global incidence of T1D and taking advantage of the increasing 
availability of public databases examines the correlation between incidence and country 
characteristics.  
Methods 
A comprehensive systematic literature search of published articles on the incidence of 
T1D worldwide was conducted to study global variations of the incidence within countries. 
Were included in the study references whose main subjects were epidemiological studies 
with reports of T1D incidence from population-based data/registers, and reporting incidence 
by year and age at diagnosis. We followed the PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) group recommendations (213). The registration 
number in PROSPERO (International Prospective Register of Systematic Reviews) is: 
CRD420120023691.  
The initial goal of this thesis was to study the correlation between environmental 
variables available in public databases with the country incidence of T1D. Seventy-seven 
independent factors were searched in public databases of the World Health Organization 
(WHO), the United Nations (UN) and the World Bank (WB) websites and arranged in four 
domains Climate and environment, Demography, Economy, and Health Conditions. 
                                                
1 Available on http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012002369 
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Correlations and multiple linear regressions between indicators from these domains and 
incidence of T1D retrieved during the systematic review were then performed. The 
percentage of variance explained by environmental variables was assessed by 10-fold cross 
validation.  
We also carried out a similar analysis of the genetic component of T1D. The 
frequency of major HLA (Human Leukocyte Antigens) susceptible and protective 
haplotypes, corresponding to 21 HLA DR/DQ alleles (DR/DQ are subunits of antigens in 
humans), as reported by the Type 1 Diabetes Genetics Consortium Families (2008) (89) was 
explored. The Allele Frequency Net at the http://www.allelefrequencies.net/ (115) website 
was used to retrieve information on allele frequencies of worldwide populations. The 
principal statistical methods used were correlations and linear regression models.  
Finally, to better understand the dynamic trends of T1D among all the retrieved 
information on T1D incidence, we used the Age-Period-Cohort (APC) approaches in this 
thesis.  
For statistical and graphic analyses the R software (version 3.0.1) (255), and for data 
visualization the Tableau software (262) were used.  
Key findings 
Through the literature review, 265 selected references that contained epidemiological 
data about incidence cases of T1D among individuals aged 0-14 years, and 70 references of 
T1D incidence in those aged over 15 years, published between 1975 and 2014, were 
collected. Information was available on 86 of the 194 WHO countries and four “territories”. 
The incidence of T1D is highly variable between countries and regions worldwide in both 
children and adults. In the group of children (0-14 years) it varied from 0.08/100.000 
persons/year in Papua New Guinea (230) to 62.42/100.000 persons/year in Finland (128); in 
the group of young adults (15-19 years), the lowest incidence of T1D was reported in 
Mauritius, (1.1/100.000 persons/year) (332), and the highest in Estonia (39.9/100.000 
persons/year) (157) and in the 70-79 year age group, the lowest incidence was reported in 
Navarra, Spain (0.8/100.000 persons/year) (97) and the highest in Kronoberg, Sweden 
(55/100.000 persons/year) (320). Despite the fact that few studies on epidemiology of T1D in 
adults are available compared to those on children T1D, we were able to show that the 
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geographical variations of T1D incidence in adults paralleled those reported in children. 
Also, as opposed to what is known in children, we found that the incidence was in most 
studies larger in males than in females. 
Independently of the initial level of incidence, an incidence increase was observed in 
all continents from 1960 to 2010: Asia (incidence slope = 0.11 per 100.000 per year), Africa 
(incidence slope = 0.13 per 100.000 per year) and Latin America and the Caribbean 
(incidence slope = 0.13 per 100.000 per year) show the smallest increases, Europe (incidence 
0.22 per 100.000 per year) presents an intermediate increase, and North America (incidence 
slope = 0.45 per 100.000 per year) and Oceania (incidence slope = 0.53 per 100.000 per year) 
the largest. 
Finally, after having built a 6824 line x 59 column tidy database (Appendix A: 
Database I), in which we assembled all the incidences by age class and period of the studies 
from tables, texts and or figures in the 265 articles identified in the systematic review (223 
included in the analyses), we extracted data to analyzed information from 2,327,604,529 
person-years at risk from 192,741 cases using APC models. A strong cohort effect was 
observed; in addition the model shows an apparent period effect that decreases after 1987. 
Also as expected, the incidence of T1D increases with age. These variations are in part 
explained by the interaction between environmental factors and genetic components of the 
populations.  
For the environmental component, the highest incidences of T1D were noted in the 
more urbanized, wealthy and cool countries in the world, and with a higher body mass index 
(BMI) in males. In contrast, exposition to UV radiations showed a significant negative 
correlation with T1D. Using Stepwise Multiple Linear Regressions (MLR) models the most 
significant environmental predictors of the country-to-country variation of T1D incidence 
were UV radiation, number of mobile cellular subscriptions in the country, health 
expenditure per capita, hepatitis B immunization and mean BMI. 
For the genetic component, we then correlated the frequency of HLA alleles retrieved 
in the Allele Frequency Net with the incidence of T1D found through our systematic review. 
High heterogeneity of susceptible and protector haplotypes for T1D within populations was 
found. Seven significant correlations were noted. Using Stepwise MLR models, significant 
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variables were the susceptible alleles: DRB1*04:01 (p-value = 0.0001) and DRB1*08:01 (p-
value = 0.0032). 
Conclusions and implications 
During this thesis, using a comprehensive systematic review of the literature, we 
quantified the country-to-country variation in T1D incidence worldwide in children and 
adults, and show that a large part of this incidence could be accounted by the variability of 
environmental factors within the countries.  
This thesis was initially motivated by the increase in T1D incidence. Here we could 
quantify this increase and show that it was even larger than had been predicted in an earlier 
study (231). 
This thesis was also based on the will to take advantage of the increasing availability 
of public databases providing informing on the country-to-country variation of environmental 
and genetic factors. For the moment much data are missing, some of them are low quality, in 
particular in low-income countries, where information on T1D incidence is still lacking. 
However, we are confident that in the near future high quality information on T1D incidence 
will be available, as well as genetic and environmental factors that will allow deepening of 
the approach used here, and will unravel new clues on the gene-environment causality of 
T1D.  
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Le diabète de type 1 (DT1) est une des maladies métaboliques les plus répandues chez 
les enfants (298). Les recherches s'accordent pour dire qu'il y a une augmentation de 
l'incidence du DT1 chez les enfants depuis 1950. En 1998, en utilisant les données sur 37 
études (de 27 pays), l'augmentation de l'incidence mondiale du DT1 a été calculée à 3,0% en 
moyenne (intervalle de confiance (IC) 95% 2,6 à 3,3), et il a été prédit qu'elle serait de 40% 
en 2010 (231) chez les enfants âgés de 0 à 14 ans. Les causes de cette augmentation ne sont 
pas encore déterminées; cette thèse met à jour les connaissances actuelles sur l'incidence 
mondiale du DT1, en profitant de la disponibilité croissante des bases de données publiques 
et en examinant la corrélation entre l’incidence et les caractéristiques des pays. 
Méthodes 
Revue systématique de la littérature 
Une recherche exhaustive et systématique des articles publiés sur l'incidence du DT1 
dans le monde a été effectuée pour étudier les variations globales de cette incidence dans les 
divers pays. Ont été inclus dans cette étude, les articles épidémiologiques qui rapportent 
l'incidence de DT1 dans la population générale, et qui rapportent l’incidence par âge et par 
année au moment du diagnostic. Nous avons suivi les recommandations de PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) (213). Le numéro 
d'inscription à PROSPERO (International Prospective Register of Systematic Reviews) est: 
CRD420120023692.  
Nous avons développé une méthode comportant sept étapes pour obtenir une équation 
de recherche bibliographique, dans laquelle les 92 articles précédemment récupérés ont été 
trouvés (voir Annexe B), mais en ajoutant de nouvelles références qui sont identifiées ici 
                                                
2 Disponible sur http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012002369 
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comme «requête # 9». En résumé, les sept étapes utilisées pour obtenir la recherche finale 
sont: 
- Étape 1. L’analyse du terme MeSH (Medical Subject Headings) présent dans les 92 
articles sélectionnés et inclus dans la base de données. 
- Étape 2. Une nouvelle recherche dans MeSH Recherche avancée de PubMed en 
tenant compte les principaux termes MeSH trouvées dans l'étape 1. 
- Étape 3. La vérification du terme MeSH pour repérer les références non pertinentes, 
de manière à mieux repérer les termes MeSH les plus communs et les plus pertinents. 
- Étape 4. Etablir une nouvelle équation de recherche comme dans l'étape 1 avec les 
termes MeSH les plus communs trouvées dans les articles pertinents en utilisant le 
constructeur NOT pour exclure les articles non pertinents. 
- Étape 5. Comparer les références retrouvées dans les différentes (nouvelles) 
recherches. Par exemple, si nous avons deux recherches, la recherche A et la 
recherche B, en utilisant une stratégie telle que les diagrammes de Venn (A∪B, 
A∩B), les références retrouvées dans les recherches seront explorées comme suit: la 
recherche A NOT la recherche B et la recherche B NOT la recherche A. Les 60 
premières références de chaque recherche seront examinées: la recherche A, la 
recherche B, la recherche A NOT la recherche B, et la recherche B NOT la recherche 
A, en analysant les termes MeSH inclus afin de déterminer si elles sont pertinentes. 
Une fois que les termes MeSH ont été sélectionnés de façon plus précise, on a répété 
les étapes 3-5 dans la recherche sélectionnée jusqu'à ce que moins de 50% (25/60) des 
articles examinés ont été désignés pertinents. Dans cette stratégie, nous avons 
identifié les recherches pour lesquelles un numéro spécifique peut être attribué en 
fonction de la formulation de la recherche, par exemple : «requête # 0», ..., «requête # 
9». 
- Étape 6. Examiner les résultats de la requête sélectionnée pour vérifier que toutes les 
92 références de base de données sont inclues. 
- Étape 7. Répéter les étapes 2-7 jusqu'à ce qu'une majorité de 92 articles soient inclus. 
Les équations de recherche ont été mises à jour périodiquement, la ayant été mise à 
jour en Novembre 2014. Les détails des sept étapes proposées sont présentés dans l'Annexe 
C.  
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Extraction des données 
Les données brutes ont été extraites des articles, et introduites manuellement dans une 
grille de collection de données, « Annexe A: base de données I », en utilisant le logiciel 
Microsoft Excel. Les données de l'incidence ont été prélevées des études individuelles 
comme elles ont été signalées dans les publications dans les textes, les tables ou les 
graphiques; un logiciel a été utilisé pour extraire les données d'origine (x, y) à partir des 
images (1). La Table 1 présente les principales catégories de l'extraction des données inclues 
dans la base de données principale (Annexe A: base de données I). 
 
Table 1: Information extraite des documents et inclue dans la base de données 
 
Informations sur l'étude  Informations sur l'incidence 
Nombre d'identifications de la référence  Incidence moyenne par pays / zone  
Nom du premier auteur  L'âge du début et la période au cours de laquelle le DT1 a fait son apparition  
Date de publication (reçu / accepté / publié)  Incidence par genre: masculin, féminin et les deux ensemble. 
Région du monde / pays / domaine d'étude  Augmentation annuelle de l'incidence 
Période du début de l'étude / date de fin  Nombre de cas incidents 
Durée de l'étude  Population à risque pendant la période 
Tranche d'âge couverte par l'étude  Critères diagnostic de DT1  
Source d'information des données de la population   informations Complémentaires 
Conception de l'étude: historique, prospective ou 
les deux  
Indicateur sur la gestion du diabète en 2010 (OMS) 
Les analyses statistiques utilisées dans l'étude  Signaler si  l'information a été standardisée   
Pourcentage de détermination  Sources de l’information extraite (table, texte ou figure) 
 
Objectifs de la revue systématique 
Étudier les informations publiées sur l'incidence du DT1 au niveau mondial depuis 
1950. 
Objectifs spécifiques 
- Décrire l'incidence mondiale du DT1 au niveau de chaque pays. 
- Décrire l'épidémiologie du DT1 chez les enfants et les adultes au niveau mondial. 
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- Étudier la co-variation, au niveau des pays, de l'incidence du DT1 avec les 
déterminants environnementaux et génétiques disponibles dans les bases de 
données publiques. 
- Analyser si la tendance mondiale actuelle de l'incidence du DT1 est compatible 
avec un effet de période ou de cohorte de naissance. 
 
Statistiques 
Les tendances d'incidence ont été corrélées avec des facteurs environnementaux et 
génétiques, et modélisées en utilisant une approche APC.  
Pour les analyses statistiques et graphiques le logiciel R (version 3.0.1) a été utilisé 
(255), et pour la visualisation des données le logiciel Tableau (262). 
Déterminants environnementaux analysés 
L'objectif initial de cette thèse était d'étudier la corrélation entre les variables 
environnementales disponibles dans les bases de données publiques, et l'incidence du DT1 
selon les pays. Pour corréler les variables environnementales à l'incidence du DT1, présentées 
dans le chapitre 3, des facteurs indépendants ont été recherchés dans les bases de données 
publiques de l'Organisation Mondiale de la Santé (OMS), l'Organisation des Nations Unies 
(ONU) et la Banque Mondiale (WB), et disposés dans quatre domaines : Climat et 
environnement, Démographie, Economie, et Etat de Santé. Nous avons examiné tous les 
indicateurs présentant une relation plausible avec le DT1 et ceux qui précédemment on été 
rapportés dans la littérature comme corrélés avec le DT1, et pour lesquels il y avait moins de 
5% de valeurs manquantes. Ceci a donné 77 indicateurs. Des corrélations et des régressions 
linéaires multiples parmi les indicateurs récupérés, lors de la revue systématique de ces 
domaines ont ensuite été réalisées. Le pourcentage de la variance expliquée par des variables 
environnementales a été évalué par la méthode de 10 fois la validation croisée. 
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Analyse des déterminants génétiques  
Nous avons également réalisé une analyse similaire à celle décrite ci-dessus 
concernant les variables environnementales, pour les composantes génétiques du DT1 
présentés au chapitre 6. Pour les analyses génétiques, la fréquence des haplotypes de HLA 
(Human Leukocyte Antigens) qui confèrent la susceptibilité à, ou la protection contre le DT1, 
correspondant à 21 HLA allèles DR/DQ (DR/DQ sont des sous-unités d'antigènes chez les 
humains), rapportés par le Type 1 Familles génétiques du Consortium diabète (2008) a été 
exploré (89). L'Allele Frequency Net à http://www.allelefrequencies.net/ (115) a été utilisé 
pour récupérer des informations sur les fréquences des allèles dans les populations à travers 
le monde. Les principales méthodes statistiques utilisées étaient des corrélations et des 
modèles de régression linéaire. 
 
Analyses des tendances de l'incidence mondiale du DT1 
Enfin, afin de mieux comprendre les tendances dynamiques du DT1 avec toutes les 





Informations recueillies lors de la revue systématique 
Grâce à la revue de la littérature publiée entre 1975 et 2014, 265 références ont été 
sélectionnées, qui contenaient les données épidémiologiques sur les cas d’incidences de DT1 
chez les individus âgés de 0-14 ans. Chez les personnes de plus de 15 ans, 70 références ont 
été sélectionnées. 
Parmi les enfants âgés de 0 à 14 ans, cette revue systématique a récupéré 237 
documents de PubMed et GoogleScholar, couvrant 86 pays et quatre «territoires», et 28 
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documents supplémentaires, des résumés et des informations mises à jour pour la IDF 
(International Diabetes Federation) dans l'Atlas de la IDF (300) ont été joints. De ces 265 
références, nous avons extrait 527 ensembles de données. Parmi ces 527 ensembles de 
données, 298 étaient des études individuelles, et 201 étaient des études de collaboration 
internationale (114 de l'étude Diamond en 2006 (318), 44 de l'étude EURODIAB en 2000 
(90), 21 de l'étude EURODIAB en 2009 (242), 22 de l'étude EURODIAB en 2012 (243)), et 
28 de l'Atlas de l'IDF (300) ; Figure 1. 
Parmi les jeunes de plus de 15 ans, 70 articles rapportant l'incidence du DT1 dans le 
pays, et un article concernant deux pays ont été récupérés dans cette revue, résultant en un 
total de 71 études portant sur 35 pays, et 24 des 71 études étaient à l'échelle nationale. 43 
documents ont fourni des informations sur l'incidence du DT1 dans la classe d'âge 15-29 ans, 
26 dans la classe d'âge 30-59 ans et 6 chez les personnes de plus de 60 ans. 
 
Tendances de l'incidence mondiale du DT1 
L’incidence du DT1 est très variable selon les pays et les régions du monde pour les 
enfants et les adultes. Dans le groupe d'enfants de 0-14 ans, l’incidence varie de 0,08 / 
100.000 personnes / an en Papouasie-Nouvelle-Guinée (230) à 62,42 / 100.000 personnes / an 
en Finlande (128). Dans le groupe de jeunes de 15-19 ans, la plus faible incidence du DT1 a 
été signalée dans l'île Maurice, (1,1 / 100.000 personnes / an) (332), et la plus élevée en 
Estonie (39,9 / 100.000 personnes / an) (157) et dans le groupe d'âge de 70-79 ans, le taux le 
plus faible a été signalé en Navarre, Espagne (0,8 / 100.000 personnes / an) (97) et le plus 
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(n =) nombre de l'ensemble de données récupérées par pays. Symboles géométriques: les triangles indiquent l'ensemble des 
données de l'étude Diamond (n = 114) (318), les carrés indiquent les bases de données de   EURODIAB (n = 87) (90, 242, 
243), les signes "+"  indiquent les données de la IDF (n = 28 ) (241, 300) et les cercles sont des autres publications que nous 
avons récupérée (n = 298); ils sont colorés pour visualiser la tendance de l'incidence (vert: 1958 à rouge: 2009). La ligne 
noire représente l'incidence moyenne du DT1 de chaque pays. Pour la liste détaillée des études et ensemble des données voir 
Base de données  II. 
 
Figure 1: Variation de l'incidence du DT1 dans 90 pays 
Incidence of T1D per 100.000 per year in both sexes (0-14 years) 
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Indépendamment de l'incidence initiale, une tendance à l’augmentation de l'incidence 
dans tous les continents entre 1960 et 2010 a été observée: l'Asie (pente d’incidence = 0,11 
pour 100.000 personés par an), l'Afrique (pente d’incidence = 0,13 pour 100.000 par an) et 
l'Amérique latine et les Caraïbes (pente d’incidence = 0,13 pour 100.000 par an) ont montré 
les plus faibles hausses, l'Europe (pente d’incidence de 0,22 pour 100.000 par an) a présenté 
une augmentation intermédiaire, et l'Amérique du Nord (pente d’incidence = 0,45 pour 
100.000 par an) et l'Océanie (pente d’incidence = 0,53 pour 100.000 par an) la plus grande 
augmentation d’incidence. 
Incidence du DT1 chez les jeunes et les adultes 
Peu d'études sur l'épidémiologie du DT1 chez les adultes sont disponibles par rapport 
à celles sur les enfants atteints de DT1. Cependant, même avec la quantité limitée de données 
disponibles, nous avons pu montrer que les variations géographiques de l'incidence du DT1 
chez les adultes suivent une voie parallèle à celles rapportées chez les enfants. Une 
corrélation géographique importante, mesurée par le coefficient de corrélation de Spearman, 
a été trouvée entre l'incidence du DT1 chez les enfants de 0-14 ans et chez les adultes dans 
les classes d'âge 15-19 ans, 20-24 ans, 25-29 ans, 30-34 ans et globalement dans l'ensemble 
du groupe de 15 à 60 (r = 0,75; p -valeur: 5,7 X10-10). Dans 23 des 35 pays (66%) (55 de 71 
études), l'incidence du DT1 était plus élevée dans la tranche d'âge de 0 à 14 ans par rapport 
aux 15 à 19 ans. Contrairement à ce qui est connu chez les enfants, l'incidence était 
généralement plus élevée chez les hommes que chez les femmes. Le rapport moyen hommes-
femmes chez les adultes utilisé dans notre revue était 1,47 (IC à 95% pour la moyenne de 
1,33 à 1,60; SD = 0,49; n = 54; p = <0,0001). 
Tendances de l'incidence du DT1 en utilisant un modèle Age-Période-Cohorte  
Après avoir construit un base de données comportant 6824 lignes x 59 colonnes, dans 
laquelle nous avons recueilli toutes les incidences par classe d'âge et la période des études, 
Ces données ont été prélevées de tables, textes et/ou des figures contenus dans les 265 
articles identifiés par la revue systématique. Nous avons extrait des données à analyser (223 
articles sélectionnés) en utilisant des modèles APC, des informations équivalentes à 
2,327,604,529 années-personnes à risque et de 192,741 cas de DT1 ont été analysés. Avec le 
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Age$(years)$/$Last$year$of$the$five3year$period$ 1938 1943 1948 1953 1958 1963 1968 1973 1978 1983 1988 1993 1998 2003 2008 2013 Total
0"_"4" 2 5 5 6 15 32 35 48 77 121 215 281 183 111 43 7 1186
5"_"9 2 5 5 6 6 22 38 61 78 123 216 283 185 115 43 7 1195
10"_14 2 5 5 6 6 7 28 60 77 121 212 280 182 112 43 7 1153
Total 6 15 15 18 27 61 101 169 232 365 643 844 550 338 129 21 3534
modèle APC un fort effet de cohorte a été observé; le modèle indique également un effet 
période probable qui diminue après 1987. Finalement, comme prévu, l'incidence du DT1 
augmente avec l'âge. Ces variations s'expliquent en partie par l'interaction entre les facteurs 
environnementaux et les composants génétiques des populations. 
L'ensemble des données réunies dans le modèle APC provenaient de pays européens 
(n = 2007), suivie par l'Amérique du Nord (n = 527) et l'Asie (n = 499). La période de 1989 à 
1993 fut celle comportant le plus grand nombre d'ensembles de données (n = 844), suivie de 





 Le gradient du vert au rouge représente le nombre d'ensemble de données trouvé par classe d'âge et vert foncé 
<10 au rouge> 20. L'âge est la moyenne pour chaque classe d'âge (0-4, 5-9, 10-14), chaque période 
correspondant à cinq années calendrier. 
Figure 2: Répartition de l'information (bases de données) utilisée dans le modèle APC 
 
Déterminants environnementaux de l'incidence du DT1 
Pour la composante environnementale, les incidences les plus élevées de DT1 ont été 
trouvées dans les pays plus urbanisés, riches et froids dans le monde, et avec un indice de 
masse corporelle (IMC) élevé chez les hommes. En revanche, l'exposition aux radiations UV 
a montré une corrélation négative significative avec le DT1. L’utilisation de modèles de 
régression linéaire multiple (MLR) Stepwise effectués dans les quatre domaines explorés 
indiquent que les pourcentages de variance expliqués par les indicateurs étaient 
respectivement de 35% pour le Climat et l'environnement, 33% pour la Démographie, 45% 
de pour l'Economie et 46% pour les Conditions de Santé, et 51% dans le Modèle Final (41% 
après 10 fois la validation croisée), où toutes les variables sélectionnées ont été examinées. 
Les facteurs prédictifs environnementaux les plus importants de la variation de l'incidence du 
DT1 pays à pays étaient: rayonnement UV, nombre d'abonnements au cellulaire mobile dans 
le pays, les dépenses de santé par habitant, vaccination contre l'hépatite B et l'IMC moyen. 
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Les déterminants génétiques de l'incidence du DT1 
Pour les composants génétiques, nous avons corrélé la fréquence des allèles HLA 
récupérés sur l’Allele Frequency Net, avec l'incidence du DT1 par pays trouvé grâce à notre 
revue systématique. Une grande hétérogénéité des haplotypes susceptibles ou protecteurs face 
au DT1 au sein des populations a été trouvée. Sept corrélations significatives ont été 
détectées parmi les 21 allèles testés (12 conférant une susceptibilité et 9 une protection face 
au DT1). Après la MLR Stepwise les variables significatives étaient les allèles sensibles: 
DRB1*04:01 (p = 0,0001) et DRB1*08:01 (p = 0,0032). Dans le modèle le pourcentage brut 
ajusté de la variance expliquant (R2) était du 61%, et 30% après 10 fois la validation croisée. 
Seul l'allèle de protection DQB1*06:02 présentait une corrélation positive significative avec 
la répartition géographique de l'incidence du DT1. 
Conclusions et implications 
Au cours de cette thèse, grâce à l'aide d'une revue systématique et exhaustive de la 
littérature, nous avons quantifié la variation pays par pays de l'incidence du DT1 dans le 
monde chez les enfants et les adultes, nous montrons qu'une grande partie de cette incidence 
pourrait s’expliquer par la variabilité de facteurs environnementaux dans les pays. 
L’information de l'incidence du DT1 chez les enfants a été trouvée dans 265 
références couvrant 90 pays; l’information sur le DT1 chez les adultes n'est disponible que 
dans 35 pays, et seule une petite proportion (n = 14) des 71 études ont utilisé la détection 
d'auto-anticorps et / ou le dosage spécifique du C-peptide (34) comme critères de diagnostic 
du DT1 chez les adultes. 
Malgré le peu d'information sur le DT1 chez les adultes, nous avons trouvé une forte 
corrélation géographique des incidences chez les adultes et les enfants. Cette corrélation peut 
s’expliquer par le fait que les adultes atteints de DT1 partagent les allèles de gènes connus 
comme étant associés au DT1 juvénile, (49, 322), et / ou certaines causes environnementales 
prédisposant au DT1 (81). 
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Entre les déterminants génétiques de DT1 présentés au chapitre 6, où nous avons 
exploré certains haplotypes HLA face au DT1, dans le Complexe Majeur 
d'Histocompatibilité (CMH), qui joue un rôle crucial dans la pathogenèse du DT1 (182). 
Nous avons constaté que certains haplotypes de protection dans une population peuvent 
conférer une sensibilité dans d'autres populations. Le deuxième constat est que, parmi tous 
les allèles étudiés, DRB1 * 04:01 et DRB1 * 08:01 étaient des prédicteurs significatifs de 
l'incidence du DT1 dans l'ensemble des 56 pays pour lesquels nous pourrions corréler des 
allèles HLA. Cette constatation suggère que ces allèles sont déterminants dans le risque de 
DT1, comme cela a été suggéré par le T1D Genetics Consortium Families (89) qui ont 
montré que le risque du DT1 est conféré par des allèles DRB1. Apparemment, allèles 
sensibles sont plus fréquentes que les allèles de protection et des mécanismes épigénétiques 
sont impliqués (182). 
Entre les déterminants environnementaux indépendants de DT1 présentés dans le 
chapitre 3, quatre des cinq indicateurs sélectionnés sont connus comme étant des facteurs de 
risque de DT1: les rayons UV (214, 295, 304), les dépenses de santé par habitant (214), le 
pourcentage de couverture de la vaccination contre l'hépatite B (138) et la moyenne IMC 
(91). Le dernier indicateur est la proportion d'abonnements à un téléphonie mobile, en 
corrélation positive avec l'incidence DT1. C’est probablement un marqueur de style de vie 
qui n'a pas été capturé par l'une des 77 variables utilisées dans les analyses multiples 
effectuées. 
Cette thèse a été initialement motivée par l'augmentation de l'incidence du DT1, et 
nous avons pu quantifier cette augmentation et montrer qu'elle était encore plus grande que ce 
qui avait été prédit dans une étude antérieure (231). 
Après avoir utilisé un modèle APC, comme présenté dans le chapitre 6, nous avons 
observé que l'incidence du DT1 montre des tendances dynamiques à travers le monde. Un 
fort effet de cohorte de naissance et un effet apparent de période ont été observés. La courbe 
représentant l'effet de cohorte de naissance montre une augmentation constante après 1975; 
dans les années 1980 le risque relatif (RR) était = 1 et dans les années 2000, RR = 2,5. 
Étonnamment, une diminution de la courbe représentant un effet de période apparaît après le 
pic en 1987, principalement influencé par les données de la Finlande, le pays ayant la plus 
forte incidence de DT1 dans le monde. En outre, nous avons constaté que l'incidence du DT1 
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augment avec l'âge; le taux le plus élevé est celui des personnes de 10 à 14 ans. Nos résultats 
sont en accord avec l'hypothèse que des facteurs externes, y compris les déterminants de 
risque environnementaux, et d'autres causes non génétiques pourraient être des promoteurs ou 
des facteurs modificateurs impliqués dans le changement de tendances de l'incidence du DT1 
à travers le monde. 
Cette thèse a également profité de la disponibilité croissante de données publiques sur 
la variation des facteurs environnementaux et génétiques de pays à pays. Pour le moment, 
beaucoup de données manquent, certaines d'entre elles étaient de faible qualité, en particulier 
dans les pays à faibles revenus, où l'information sur l'incidence du DT1 n’est pas encore 
disponible. Cependant, nous sommes convaincus que dans un avenir proche  des informations 
de qualité sur l'incidence du DT1 seront disponibles, ainsi que les informations sur les 
facteurs génétiques et environnementaux, permettant l'approfondissement de l'approche 
utilisée ici, et pouvant révéler de nouveaux indices sur les causes génétiques et 
environnementales du DT1. 
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This thesis concerns the study of Type 1 Diabetes (T1D) and is based on the original 
articles presented in Chapters 3, 4, 5 and 6. Each chapter reproduces the articles with the 
kind permission of their authors, and in addition supplementary information is also presented 
at the end of each chapter.   
The information has been arranged in six chapters following the chronological order of 
the study. Global incidence of T1D presented and analyzed in different ways throughout this 
thesis was retrieved using a systematic literature review presented in chapter 1.  
Chapter 2 includes a general review of diabetes classification and the ‘state of the art’ 
in the epidemiology of T1D, including reports of the literature before and after 1950. It also, 
briefly describes the pathogenesis and etiology of T1D seen from an epidemiological point of 
view.  
The first part of chapter 3 contains the analyses of global T1D incidence among 
children aged 0-14 years. The incidence of T1D was correlated with 77 independent variables 
covering four domains: Climate and environment, Demography, Economy, Health conditions. 
Stepwise Multiple Linear Regression (MLR) models were carried out. The supplementary 
materials of this chapter also include the Principal Component Analyses (PCA) of the 
variables included in the final model, as well as preliminary analyses discriminating countries 
for which information on the incidence of the T1D was - or was not - retrieved. The second 
part of this chapter includes the analyses of trends, the cumulative incidence from birth 
cohorts between 1924 and 2004, and the analyses of age at onset calculated in the entire 
database. A description of epidemiological reports describing changes in incidence trends 
affecting predominantly the youngest age group is presented at the end of this chapter.  
We noticed that in addition to information on T1D incidence in children aged 0-14 
years, some of the retrieved studies also reported the incidence of T1D in older age groups. 
During exploration of the cumulative incidence of T1D based on the first analyses of this 
thesis, trends in adults seemed to parallel those in children. Following this observation, we 
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undertook to explore in depth the epidemiology of T1D in adults, as presented here in 
chapter 4. The main methodological problem related to the study of the epidemiology of T1D 
in adults is to distinguish this disease from others, such as Type 2 diabetes or Latent Immune 
Diabetes in Adults (LADA). For that reason, this chapter includes a detailed description of the 
criteria used to diagnose T1D in adults, which is focused on autoantibody detection. 
Comparisons between the incidences retrieved in adults and those retrieved in children are 
also presented.  
Chapter 5 describes the incidence trends of T1D and presents an APC analysis of 
global trends in incidence of T1D, from data collected between 1975 and 2014. By including 
a discriminating analysis by country, it was possible to model the effects of the age, the year 
and the birth cohort at diagnosis of T1D for children aged 0-14 among 89 countries 
worldwide.    
The epidemiology of T1D would not be complete without mentioning the role of 
genetic causes, mainly the participation of the Human Leukocyte Antigen (HLA) as 
determinant factor in the development of T1D and in the heterogeneity of levels of incidence 
retrieved around the globe. Chapter 6 presents the analyses of the genetic components of 
T1D, considering the latest Type 1 Diabetes Genetics Consortium Families (89); correlations 
and Stepwise MLR models were carried out as performed for the environmental component.  
Final considerations and perspectives are presented in the Conclusions section.  
Tables and figures are presented in order of appearance and are designated SI 
Table/Figure for those related with Supporting Information of the main publication of each 
chapter and for those presented in Additional Analyses, that include analyses or results 
unsuitable for publication but with additional information pertinent to this thesis, and AP 
Table/Figure for those published in the Appendix Section.  
The databases mentioned here will be placed for public examination and access, in the 
author’s Github website at: https://github.com/PaulaDiaz, once the press embargo of the 
manuscripts expires; Appendix A.  
Interactive visualization of the data is available at http://www.isis-diab.org and 
https://public.tableau.com/profile/paula.diaz - !/.  
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1 Systematic literature reviews used in this thesis 
 
Systematic literature reviews have become important in research and are often the 
starting point of any study. Here we used two systematic literature reviews to obtain data on 
the incidence of T1D around the world: the first concerns epidemiology of T1D in children, 
analyzed in chapters 1, 3, 5 and 6, and the second in adults, analyzed in chapter 4.  
Heterogeneity of the information in any data collection is a main issue, and is the 
reason why we followed the PRISMA statement (Preferred reporting for systematic reviews 
and meta-analyses) (213) recommendations as a method to collect data in a standardized way 
and to assess the quality of information of the retrieved studies. Each retrieved study was 
identified and all the information was extracted in a comprehensive format developed in our 
team. Additional updates of the revisions and the final decision about inclusion or not, and 
some references were discussed periodically during meetings and group discussions.  
Once we had the entire data collection, we selected the information to be included in 
the analyses that will be presented in the following chapters. Chapter 1 presents the 
objectives of the systematic reviews and the methodology used to obtain information. In the 
final section, this chapter presents a comparison of the current review with others reviews on 
the epidemiology of T1D, and the summary of the information retrieved on global 
epidemiology of T1D using data collected from 1975 to 2014. 
 The selected information provided by the current review is presented in chapter 3, 
that describes the incidence of T1D among children, in chapter 4, the epidemiology among 
adults, in chapter 5, and the APC approach of the incidence trends of T1D, and in chapter 6 
the analyses of incidence of T1D and genetic determinants. For each particular study, we 
developed large databases that are presented in the respective chapters, and are publicly 
available as guarantees of the transparency of this research. 
UPMC - ED 393 - 2015  Epidemiology of Type I Diabetes: 









UPMC - ED 393 - 2015  Epidemiology of Type I Diabetes: 




1.1 Objectives of the systematic reviews 
To study the global published information on the incidence of T1D since 1950s.  
1.1.1 Specific objectives 
- Describe the global incidence of T1D at the country level. 
- Describe the epidemiology of T1D among children and adults worldwide. 
- Study the co-variation, at the country level, of the incidence of T1D with 
environment and genetic determinants available in public databases. 
- Analyze if the current global trend in incidence of T1D is compatible with a 
period or birth cohort effect.  
1.2 Methodology of the systematic literature review 
A systematic literature review following the PRISMA recommendations (213) was 
conducted to retrieve published articles on the incidence and the age at onset of T1D 
worldwide. Literature search was conducted in the databases: MedLine accessed through 
PubMed and Science Citation Index Expanded databases accessed via the Web of Science 
(Thomson Reuters). In addition, general searches and examination of cited references in 
Google scholar were carried out. Finally, citing references identified through the lecture of 
the papers were included periodically. The registration number in PROSPERO is: 
CRD42012002369 (available on 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012002369 ).  
1.2.1 Validation of the query equation of the bibliographic search  
An exploratory bibliographic search allows the selection of the first 92 articles 
reporting incidence of T1D published between 1 January 1990 and November 2011 (here 
called ‘query # 0’); Appendix B. On February 3rd 2012, during a group meeting3 the query 
was assessed. After recommendations such as to include new MeSH (Medical Subject 
Headings) terms and to modify exclusion criteria, we developed a method based on 7 steps, 
to obtain a query equation in which all mentioned 92 articles previously retrieved were found 
                                                
3 Meeting assistants: Pr. Alain-Jacques Valleron, Pr. Pierre-Ives Boëlle, Sophie Valtat, Sofia Meurisse, Nga Mai, Pascal 
Championnat, Flavian Quintus, Thomas Obadia, Sthephany Gomme, Segolene Charaudeau.  Place: Hopital Saint-Antoine. 
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but adding new references. The entire processes aimed at obtaining the most sensitive and 
specific bibliographic search equation to retrieved original publications reporting incidence 
of T1D worldwide; here identified as ‘query # 9’. Search equations were updated 
periodically, the last update dating to November 2014. Details of the seven proposed steps 
are presented in Appendix C.  
Summary of the seven steps used to obtain the final query search: 
- Step 1. To perform an analysis of the MeSH terms presented in the 92 selected 
articles included in the database.  
- Step 2. To carry out new queries in the MeSH Advanced Search Builder of PubMed 
taking into account the main MeSH terms found in step 1. 
- Step 3. To check the MeSH terms for irrelevant references, so as to recognize the 
most common irrelevant MeSH terms.  
- Step 4. To introduce at the equation query of step 1 the most common MeSH terms 
found in irrelevant papers using the builder NOT to exclude irrelevant articles. 
- Step 5. To compare references linked in the different alternative queries. For example 
if we have two queries, query A and query B, using a strategy such as Venn diagrams 
(A∪B, A∩B), the references linked in the queries will be explored: query A, NOT 
query B, and query B, NOT query A. The first 60 references in each query will be 
examined: query A, query B, query A NOT B, and query B NOT A so as to analyze if 
they are relevant papers, and which one is the most accurate, then to repeat steps 3 to 
5 in the selected query until at least 50% (25/60) of the articles examined are 
pertinent. In this strategy we will identify the queries to which a specific number can 
be assigned according to the formulation of the queries. 
- Step 6. To examine the results of the selected query to verify that all 92 database 
references are included.  
- Step 7. Repeat steps 2 to 7 until a majority of 92 articles are included.  
1.2.2 Article selection for the query # 0: the 1st 92 included papers 
The inclusion criteria for preselected references were articles with reports of incidence 
of T1D from population data registers by year and age at diagnosis, in any country, city or 
region worldwide. There was no publication language restriction. A minimum degree of case-
ascertainment was not required. 
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The literature search was finalized removing all articles with at least one of the 
following exclusion criteria: 1) if the main objective was not the study of incidence of T1D 
(e.g., genetic factors, complications, treatments); 2) if the length of the report (following 
registers) of the incidence was ≤5 years; 3) if the study was not population-based, instead it 
was performed in selected groups, for example, studies based on volunteer subjects or on 
persons that belong a specific health assurance organization; 4) if the study did not report 
using the World Health Organization (WHO) (1985 or 1999) or American Diabetes 
Association (ADA) (1997 or 2011) as criteria of diagnosis; 5) if the study describes the 
incidence of T1D as a general topic, with no description by year and age at diagnosis, 6) if 
we could not translate the article; and 7) if the full text of the article remained unavailable. 
1.2.3 Bibliographic search used to retrieve incidence of T1D in adults   
A modification of the final search query equation (query # 9) presented in Appendix 
C was introduced to retrieve specific information on adults, the last update dating to January 
2015. The search included the following terms: "diabetes mellitus, type 1/epidemiology" 
AND "incidence" AND "adult", and it was conduced in English, French and Spanish. The 
entire query used to retrieve information is presented in chapter 4 (session 4.1.1.1) of this 
thesis.  
1.2.4 Data extraction  
Raw data were extracted from articles and introduced manually into a standard data 
collection grid (Appendix A: Database I) using the Microsoft Excel software. Incidence 
data were taken from the individual studies as they were reported in the publications in text, 
tables or graphs; a computer program was used to retrieve the original (x, y) data from the 
images (1). The names of countries corresponding to world regions in the database were both 
those from the WHO and from the UN. If the information was not available it was identified 
in the grid as ‘No available data’ (NA). Table 2 reports the main categories of data extraction 
included in the main database.  
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Table 2: Extracted information from the papers and included in the database 
 
Information about the study  Information about incidence 
Number of identification of the reference  Mean incidence by country-area 
Name of first author  Age at onset and period during which onset occurred 
Publication date (received / accepted / published)  Sexes: male, female and both sexes male and female 
World region / country / area of study  Annual increase in incidence 
Period of study start/end date  Number of incident cases 
Duration of the study  Population at risk during the period 
Range of age covered by the study  Criteria diagnosis of T1D  
Data source of population information  Additional information 
Study design, historical, prospective or both  Indicator about management of diabetes in 2010 (WHO) 
Statistical analyses used in the study  Signal about the standardization of the information 
Percentage of ascertainment  Source of extracted information (table, text or figure) 
 
 
To further evaluate the quality of the information retrieved, we searched for the 
reported percentage of completeness (ascertainment): the average percentage of concordance 
at least between two different independent sources of information containing incident cases 
of T1D in a specific region and period of time (179). Examples of primary sources of 
registers include data from hospitals, pediatricians, diabetologists, and others, and secondary 
sources, drug prescriptions, information from diabetes associations, summer camps, or 
general practitioners.  
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1.3 Reviews of the literature on global incidence of T1D  
 
Among all retrieved information, seven studies classified as reviews and describing 
the epidemiology of T1D were published before 2014. A summary is provided in Table 3.     
 
Table 3: Reviews reporting global incidence of T1D 
 
Author, year of 
Publication 








(160) 1965-1992 0-14 This reference shows the total incidence and incidence of T1D 
for males and females separately of 76 populations from 53 
countries using data from the Diamond study. A female 
predominance of 59% was found in those aged 0-14 years. 
Onkamo P., 1999 (231) 1960-1996 0-19 This study used a systematic search to retrieve information and 
analyzed 37 studies from 27 countries. A worldwide increase 
on average of 3.0% (95% CI 2.6,3.3) per year was observed.  
Ascher P., 2002 (21) 1990-1994 0-14 The reference describes the incidence trends of TID in Latin 
America  
Gale EA., 2002 (105) 1920-2000 0-29 The reference presents a historic review that describes the 
incidence of T1D before and after 1950. 
Borchers A.T., 
2010 
(40) 1995-2009 0-14 The article shows selected data from the Diamond Project 
Group for 1990–1999 with recent update references. 
Maahs DM., 2010 (201) Unspecified 0-29 The article gives a description of data published in the 
Diamond, the Eurodiab, and the Search studies. It includes 
general comments of risk factors. 
Vehik P., 2011 (343) 1965-2004 Unspecified The article gives a description of data published in 10 countries 
and describes possible reasons for the increase of T1D 
incidence. It includes general comments of risk factors 
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1.4 Comparison of incidence of T1D retrieved in the current review with 
other collaborative studies or reviews 
By 2012, this thesis included the information available worldwide on the incidence of 
T1D from 226 populations, from 68 countries, published in 161 articles between 1975 and 
2011; a comparison of the retrieved incidence of T1D with the Onkamo et al. (231) review, 
and with the studies Eurodiab (90) and Diamond (318) was then performed. Correlations 
between the current review and the studies were >0.95 in all cases; they are shown in Table 4 
and Figure 3.  
Table 4: Comparison of age-standardized incidence of T1D in children 0-14 years of age reported in 
four studies 
Study Ref. Study 
period 
n ref. * Correlation 
Current Review (A)  1975-2011 161 
 Diamond study (B) (318) 1990-1999 112 0.95 
Eurodiab (C) (90) 1989-1994 45 0.96 
Onkamo (D) (231) 1960-1996 36 0.97 
 














Previous reports vertical (y) axis: in red dots Diamond (318) (1990-1999); in green, Eurodiab (90) (1989-1994); 
in blue, Onkamo et at. (231) review (1989-1994). In the horizontal axis (x) the current study.  
Figure 3: Correlation of reported incidence of T1D among individuals 0-14 years reported in the 
thesis vs three previous studies.  
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1.5 Predicted and observed incidence of T1D by 2010 
Incidence of T1D has been increasing during the last decades. Predictions performed 
by Onkamo et al. in 1999 (231) for 37 populations, announced that by 2010 the incidence of 
T1D would be 40% higher compared with 1998. Using data from the current review, it was 
possible to compare the predicted and observed incidence of T1D; the observed incidence is 
higher than the predicted incidence in 7 of 10 studies that reported information of T1D in the 
group 0-14 years after 2005; Table 5.   
 
Table 5: Predicted and observed incidence of T1D in 10 studies 
 
Country, area 
Predicted incidence of T1D 
by 2010 
(Onkamo et al., (231)) 






















Austria 12.8 1979-1993 17.5 2004-2008 Patterson C, 2012 (243) 4.7 
Finland 50.2 1965-1996 62.42 2006-2011 Harjutsalo V, 2013 (128) 12.22 
Hungary 20.1 1978-1987 18.3 2004-2008 Patterson C, 2012 (243) -1.8 
Israel, Yemenite 
Jews 10.1 1965-1993 11.1 1997-2010 Blumenfeld O., 2014  
(39) 
1 
Lithuania 7.5 1983-1992 14.2 2004-2008 Patterson C, 2012 (243) 6.7 
Malta 16.8 1980-1996 23.87 2006-2010 Formosa N, 2012 (100) 7.07 
Norway 41.8 1973-1982 32.8 2004-2008 Patterson C, 2012 (243) -9 
Sweden 32.2 1978-1992 32.3 1983-2007 Dahlquist G. G., 2011 (74) 0.1 
UK, Oxford 33 1985-1995 25.10 2004-2008 Eurodiab, 2012 (243) -7.9 
UK, Yorkshire 21 1978-1992 25.50 2004-2008 Eurodiab, 2012 (243) 4.5 
 (a) Mean incidence of T1D per 100.000 per year (b) Difference between predicted and observed 
incidence of T1D. Ref.: Reference. 
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1.6 Information retrieved in the current review 
At the end of this thesis in 2015, among children aged 0-14 years, this systematic 
review retrieved 237 primary research papers from PubMed and GoogleScholar, covering 86 
countries and four “territories”, also referred as “90 countries” in this thesis. 28 additional 
papers, abstracts and updated information were from the International Diabetes Federation 
(IDF) Atlas (300). From these 265 references, we extracted 527 datasets. Among these 527 
datasets, 298 were from individual studies, and 201 were from international collaborative 
studies (114 from the Diamond study in 2006 (318), 44 from the Eurodiab study in 2000 (90), 
21 from the Eurodiab study in 2009 (242), 22 from the Eurodiab study in 2012 (243)), and 28 
from the IDF Atlas (300). Figure 4 and Figure 5; the detailed list and breakdown by place 
and time is in Appendix A: Database II. Information retrieved for those aged over 14 years 












Mean T1D incidence per 100.000 individuals aged 0-14 years per year is in color gradient. An interactive data 
visualization of this map is available at: 
https://public.tableau.com/profile/paula.diaz#!/vizhome/Globalincidenceoftype1diabetesinchildren/Dashboard1 
Figure 4: Geographical distribution of countries where T1D incidence has been reported in the 
literature 1975-2014 
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Information on the incidence of T1D for the 0-14 year-olds was found for 90 
countries, covering 69% of the world population; Figure 4 and Figure 5. This coverage 
varied widely depending on the WHO region (Table 6): the population coverage was 37% in 
the African region, where one country out of the 45 of the region reported a nation-wide 
study. It was 100% in the HIGH of the European WHO region. The epidemiological report of 
incidence of T1D shows no further references published after 2010 in Africa and Oceania. 
See details in Figure 6. Most of the retrieved publications were published between 1990-
1999 (n= 102 publications) and between 2000-2010 (n = 119 publications). Distribution of 
retrieved articles by year of publication is presented in Figure 7.  
 
Table 6: Distribution of the information available on the incidence of T1D worldwide 
 
WHO region AFRO AMRO EMRO EURO SEARO WPRO Non-
WHO 
Countries 
TOTAL WHO categories of 
income LMIC HIGH LMIC HIGH LMIC HIGH LMIC LMIC HIGH LMIC 
Number of countries in 
the region 
45 3 29 5 16 22 28 11 6 16 0 194 
Countries and territories 
with incidence report  
6 3 15 3 8 22 19 3 4 2 5 90 
Countries with Nation-
wide studies 
1 1 8 2 2 18 12 1 4 1 3 53 
0-14 years old 
population (thousands) 
350,355 67,978 163,233 10,830 189,816 67,243 88,940 534,895 30,933 335,038 7,413 1,846,674 
0-14 year old 
population with 
published information 
on T1D incidence (%) 
37% 100% 83% 86% 68% 100% 63% 74% 77% 79% 11% 69% 
 
 The WHO sub-regions are: AFRO (Africa), AMRO (Americas), EMRO (Eastern Mediterranean), 
EURO (Europe), SEARO (South-East Asia) and WPRO (Western Pacific). WHO Member States are divided 
into high-income  (HIGH) or low- and middle-income (LMIC) countries creating 10 groups (359). Non-WHO 
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In parenthesis: n = number of retrieved datasets by country. One dataset corresponds to the unique data retrieved from the 
literature. Geometric symbols: triangles indicate datasets from the Diamond study (n=114) (318), squares indicates 
databases from Eurodiab (n=87) (90, 242, 243), plus signs indicate data from the International Diabetes Federation (n=28) 
Atlas (241, 300) and circles are from the other publications that we retrieved (n=298); they were colored to visualize the 
trend in incidence (green: 1958 to red: 2009). The black line represents the mean country T1D incidence. For the detailed list 
of the studies / datasets see Appendix A: Database II.  
Figure 5: Variation of T1D incidence found in 90 countries 
 
Incidence of T1D per 100.000 per year in both sexes (0-14 years) 
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Individual studies are represented by dots.  
Figure 6: Publication year by World Region 
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2 General review of T1D 
Chapter 2 briefly describes the state of the art in the epidemiology of T1D. This 
chapter has three main parts: in the first, a definition of diabetes is given, in the second, we 
present a review of the epidemiology of T1D before and after 1950, and in the third part, 
different hypotheses about the etiology of T1D are described. 
Since there are no specific and standardized criteria to define T1D, the general 
classification based on blood glucose levels used in diabetes is applied to T1D. After 
detecting a blood glucose level compatible with diabetes, aspects of the clinical presentation 
make it possible to define the etiological classification of diabetes presented in this chapter in 
section 2.1.1; it is the most recent and extensively used classification used in the retrieved 
studies analyzed in this thesis. Nevertheless, diagnosis of diabetes has changed over time and 
epidemiology of T1D, based on the incidence value that could have been affected by the 
different classifications adopted at different periods; in section 2.1.2 of this chapter we 
present a summary of the evolution of the diagnosis criteria used to define diabetes. Because 
of these changes in the diagnosis criteria of T1D over time, and to decide if a given study 
should be included or not in the systematic reviews presented in chapter 1, we pay particular 
attention to establish if it was truly about T1D, based on etiological classification and/or 
diagnosis criteria, especially when they were published before 1985.  
Our current knowledge of the epidemiology of T1D is due in large part to 
intercontinental collaborative projects, such as Diamond, Eurodiab, Diabalt, multicenter 
studies at the country level such as the SEARCH study, and organizations such as the 
International Diabetes Federation (IDF), described briefly below in chapter 2.  
The last part of this chapter shortly describes several etio-phathological hypotheses 
mentioned in the literature as causes of T1D, some related with genetic, environmental or 
gene-environmental factors. A personal summary of the related categories found in the 
literature is also presented. These categories, are also mentioned in the following chapters: 
chapter 3 about epidemiology in children, chapter 4 epidemiology in adults, chapter 5 on 
global incidence trends of T1D using an APC model and chapter 6 about genetic 
determinants of T1D.  
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Diabetes is characterized by chronic disturbances of carbohydrate, fat and protein 
metabolism leading to long-term damage, dysfunction and failure of internal organs. The 
most important complications of diabetes include retinopathy, nephropathy, neuropathy and 
cardiovascular diseases (144). Global estimates of the prevalence suggest that in 2010 more 
than 285 million adults lived with some form of diabetes in the world (290), and the number 
of individuals with diabetes worldwide is expected to rise to 472 millions by 2030 (84).  
2.1.1 Etiological classification  
In 2011, the American Diabetes Association (ADA) (16) adopted the etiological 
classification of diabetes that includes four types:  
- Type 1 diabetes (results from beta-cell destruction, usually leading to total insulin 
deficiency)  
- Type 2 diabetes (results from a progressive insulin secretory defect on a 
background of insulin resistance) 
- Gestational diabetes mellitus (GDM) (diabetes diagnosed during pregnancy that 
is not clearly overt diabetes) 
- Other specific types of diabetes due to other causes, e.g., genetic defects in B-cell 
function, genetic defects in insulin action, diseases of the exocrine pancreas (such 
as cystic fibrosis), and drug or chemically-induced diabetes (such as in the 
treatment of HIV/AIDS or after organ transplantation) 
 
In addition, sub-categories of T1D were introduced, Type 1A for diabetes cell-
mediated autoimmune attack, and Type 1B for non-immune diabetes generally after ketosis 
(22). This latter classification is complex, depends on a sophisticated laboratory test, and is 
not included in the ADA classification proposed in 2011.    
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2.1.2 Diagnostic criteria of diabetes 
Until the late 1970s, large variations in the level of glucose as diagnosis criterion of 
diabetes were reported (337). The first intent to standardize the diagnosis and classification 
system for diabetes worldwide was presented in 1978 by the WHO and the National Diabetes 
Data Group and modified in 1985 and 1999. Also, in 1995, ADA promoted the formation of 
an international expert group to review the diagnosis criteria and classification of diabetes, 
and after two years of discussions, the review and the new criteria were published. At the 
same time, the WHO convened a new consultation, and published the WHO results in 1999. 
The current ADA (2011) criteria for the diagnosis of all kinds of diabetes are the following: 
1) symptoms of hyperglycemia including polyuria, polydipsia, weight loss plus random 
plasma glucose concentration >200 mg/dl (11 mM); 2), fasting (> 8 h fasting), plasma 
glucose > 126 mg/dl (7 mM); 3) 2 h postprandial glucose >200 mg/dl during an oral glucose 
tolerance test (OGTT) (22, 76). In addition the glycated hemoglobin (AIC) test recommended 
since 2009 by an International Expert Committee was adopted in 2010 (11, 16, 22) (Table 7).  
Classification of T1D and Type 2 diabetes (T2D) by glucose levels is not always easy. 
Clinical manifestations and disease progression could share similarities in both types of 
diabetes. Some patients with T2D may present ketoacidosis, whereas patients with T1D may 
have a late onset and very slow progression of the disease and even so they have features of 
an autoimmune disease. Moreover, T1D can appear at any age and incidence of the disease 
may be as prevalent in adults as in young people (23). Thus to avoid misclassifications of 
T1D, the data analyzed here and considered as diagnosis of T1D requires both the necessity 
of insulin administration and the associated ADA or WHO criteria. All the studies included in 
this thesis report the incidence of T1D or Insulin-Dependent Diabetes Mellitus (IDDM), for 
papers published before 1985. Information of other kind of diabetes, such as T2D or 
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Table 7: Comparison of diagnosis criteria of diabetes according to the WHO and the ADA 
 
ADA 2011 ADA 1997 WHO 1999 WHO 1985 
A1C ≥ 6.5%. The test 
should be performed in 
a laboratory using a 
method that is NGSP 
certified and 





FPG ≥ 126 mg/dl (7.0 
mmol/l). Fasting is 
defined as no caloric 
intake for at least 8 h.* 
FPG ≥ 126 mg/dl (7.0 
mmol/l). Fasting is 
defined as no caloric 
intake for at least 8 h.* 
FPG ≥ 126 mg/dl (7.0 
mmol/l). Fasting is 
defined as no caloric 
intake for at least 8 h.* 
FPG ≥ 140 mg/dl (7.8 
mmol/l). Fasting is 
defined as no caloric 
intake for at least 8 h.* 
2-h plasma glucose ≥ 200 
mg/dl (11.1 mmol/l) 
during an OGTT. The 
test should be performed 
as described by the 
WHO, using a glucose 
load containing the 
equivalent of 75 g 
anhydrous glucose 
dissolved in water.* 
2-h plasma glucose ≥ 200 
mg/dl (11.1 mmol/l) 
during an OGTT. The 
test should be performed 
as described by the 
WHO, using a glucose 
load containing the 
equivalent of 75 g 
anhydrous glucose 
dissolved in water.** 
2-h plasma glucose ≥ 200 
mg/dl (11.1 mmol/l) 
during an OGTT, using 
a glucose load 
containing the 
equivalent of 75 g 
anhydrous glucose 
dissolved in water. 
2-h plasma glucose ≥ 200 
mg/dl (11.1 mmol/l) 
during an OGTT, using 
a glucose load 
containing the 
equivalent of 75 g 
anhydrous glucose 
dissolved in water.*** 
In a patient with classical 
symptoms of 
hyperglycemia or during 
a hyperglycemic crisis, a 
random plasma glucose 
≥ 200 mg/dl (11.1 
mmol/l). 
In a patient with classical 
symptoms of 
hyperglycemia or during 
a hyperglycemic crisis, a 
random plasma glucose 
≥ 200 mg/dl (11.1 
mmol/l). 
In a patient with classical 
symptoms of 
hyperglycemia or during 
a hyperglycemic crisis, a 
random plasma glucose 
≥ 200 mg/dl (11.1 
mmol/l). 
In a patient with classical 
symptoms of 
hyperglycemia or during 
a hyperglycemic crisis, a 
random plasma glucose 
≥ 200 mg/dl (11.1 
mmol/l). 
 
*In the absence of unequivocal hyperglycemia, the result should be confirmed by repeat testing. ** Not 
for routine test. *** Only recommended when the patient’s glucose level is not determined. Note. One 
criterion is enough to made the diagnosis. ADA: American Diabetes Association, WHO: World Health 
Organization, A1C: Glycated hemoglobin, NGSP: National Glycohemoglobin Standardization Program, 
DCCT: Diabetes Control and Complications Trial Reference Method, FPG: fasting plasma glucose, 
OGTT: oral glucose tolerance test. 
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2.2 Type 1 diabetes 
T1D represents 5–10% of all the cases of diabetes (22) and is the most prevalent 
metabolic disease in childhood (298). T1D is defined as a chronic, multi-causal and immune-
mediated disease characterized by selective loss of insulin-producing beta-cells in the 
pancreatic islets with as final result, an absolute deficiency of insulin (23, 24). T1D has also 
been known as Juvenile Diabetes or Childhood Diabetes, because during the first studies, the 
peak expression was seen between 0 and 14 years. It was also called IDDM (insulin 
dependent diabetes mellitus) in the 80’s.  
In general, T1D develops slowly. It has a subclinical period that can take a few 
months to 10 years (219), before the appearance of clinical manifestations, complications or 
in some cases death, as the first manifestation (23). Nowadays, sophisticated diagnostic 
methods, such as detection of anti-beta cells autoantibodies, are available. Nevertheless the 
detection of hyperglycemia based on plasma - either the fasting plasma glucose or the OGTT 
(2-h value in the 75-g oral glucose tolerance test) - is the main diagnostic criterion.  
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2.3 Epidemiology of T1D 
Epidemiology is the study of the distribution and magnitude of diseases in view of 
understanding their risk factors, causes or providing alternatives to prevent or to manage 
them. At the very basic, yet no less important level, is the measure of incidence; it quantifies 
the number of new events or cases of the disease that develops in a population of persons at 
risk during a specific time interval (118, 132). Studying incidence through registration of new 
cases of T1D has been seen as an opportunity to help people with diabetes.  
Only after 1921, when insulin was discovered, could people have access to medical 
care and better diagnostic processes, and it was then that reports of incidence started; 
previously only clinical series and mortality statistics had been used to evaluate the incidence 
of T1D (105).  
The first compilation of epidemiology knowledge of diabetes appeared in 1978 in 
Kelly West’s book, ‘Epidemiology of Diabetes and its Vascular Complications’ (355). In this 
book, the standardization of methodologies as well as diagnostic criteria (377) to define 
diabetes were proposed. Before that time very few references were available, most of them 
lacked standardization, different case definitions and age-groups were included, and without 
any method of ascertainment for data collection (190). 
2.3.1 Epidemiology of T1D before 1950 
According to Gale (105) knowledge on the epidemiology of T1D before insulin 
discovery is based on three studies on death rates in children younger than 15 years. The first, 
in the United States, reported an increase in death rate due to T1D from 1.3 per 100.000 
individuals per year in 1890, to 3.1 per 100.000 individuals per year in 1920; the second, 
from Denmark, reported a change in the death rate for T1D from 2 per 100.000 individuals 
per year in the period 1905-1909 to 3.1 per 100.000 individuals per year, in 1915-1919; and 
in the third, from Norway, an increase in the incidence of T1D from 2 to 7 per 100.000 
individuals per year between 1900 and 1920 was described (105).  
Later, between 1920 and 1950, the introduction of insulin prolonged the survival of 
patients and the incidence was reported in several countries. The landmark sources of 
incidence and prevalence for this period were two retrospective surveys in Oslo and Bergen 
UPMC - ED 393 - 2015  Epidemiology of Type I Diabetes: 




in Norway. The Oslo survey identified 4251 individuals aged less than 30 years with T1D, 
and the incidence remained relatively constant over the period 1925-1954; the average 
incidence was 4.1 per 100.000 individuals per year in children aged less than 15 years.  In the 
Bergen survey, during the period 1925-1939 the incidence was 7.9 per 100.000 individuals 
per year in individuals under 20 years; at that time, the rise in incidence was attributed to the 
increasing age of the population (105).  
During wartime, in Vasterbötten in Northern Sweden, the highest available rate of 
T1D incidence was observed: it was 10.2 per 100.000 individuals per year, rising to 37.9 per 
100.000 individuals per year during the period 1973-1977. In Finland, the country of the 
world with the highest incidence of T1D, the annual incidence in 1953 was estimated as 12.5 
per 100.000 individuals per year (105). 
2.3.2 Epidemiology of T1D after 1950 
The evaluation of incidence trends has been more rigorous after the 60s when 
epidemiological methods were developed and better registration statistics were available. 
Onkamo et al. reviewed the incidence of childhood diabetes from studies published from 
1960 to 1996. Thirty-seven studies from 27 countries were analyzed, and an increase in 
incidence of 3.0% per year (CI 95% 2.6-3.3) was reported (231).  
In the last 30 years, knowledge of the incidence of T1D has improved substantially 
thanks to collaborative projects in which information from population-based registers, 
standardized definitions of T1D, and methods for data collection and validation (298) are 
used. The Diabetes Epidemiology Research International Group (DERI) was the first group 
to analyze the data collected on the incidence of T1D between the end of the 1970s and the 
beginning of the 1980s (79, 122), work pursued by studies such as the Diabetes Mondiale 
study (DIAMOND) (318) and the Europe Diabetes study (EURODIAB) (90). Examples of 
national projects are the Registry for Type 1 Diabetes Mellitus in Italy (RIDI) study (53, 60) 
in Italy and the SEARCH for Diabetes in Youth (SEARCH) study (282) in the United States. 
In addition the Diabetes Atlas of the IDF, an international “umbrella organization” of over 
230 national diabetes associations in 170 countries and territories, is committed with the 
advocacy of global political priority for diabetes and accredited by the WHO and the UN 
(241, 300). 
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2.3.3 Global collaborative projects on the incidence of T1D 
2.3.3.1 Diamond Study 
The Diamond project Group started the study of the incidence and trends of childhood 
T1D worldwide in 1990 as an initiative of the WHO (360). The study aimed to determine the 
incidence of T1D in the period 1990-1999. It was carried out in 57 countries. In the period 
1990-94 the increase in the incidence was 2.8 % (IC 95% 1.3-3.4%) and between 1995-99 it 
was 3.4% (IC 95% 2.7-4.3%) (318).  
2.3.3.2 Eurodiab Study 
The Eurodiab study was established in 1988 and involved 24 centers (120) in 1992; in 
2000 forty-four centers represented most European countries and Israel: the average annual 
increase in the incidence of T1D between 1889 and 1994 in Europe was 3.4% per year (95% 
IC 2.5-4.4%) (90). The comparison of the information retrieved from 20 centers for the 
period 1989-2003 was 3.9% (242) and from 23 centers for the periods 1989-1998 and 1999-
2008 was: 3.4% per year and 3.3% per year (243).  
2.3.3.3 Diabalt Study 
The Diabalt study is a collaborative project focused on the T1D incidence in countries 
around the Baltic Sea: Finland, Estonia, Latvia and Lithuania, and started in 1989. Data 
collected between 1983 and 1992, demonstrated a wide variation in the incidence of the 
disease, Finland had an average age-standardized incidence of 35 per 100.000 individuals per 
year, Estonia 10.2 per 100.000 individuals per year, Lithuania 7.1 per 100.000 per year and 
Latvia 6.5 per 100.000 individuals per year. During the period of the study, the incidence 
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2.4 Pathogenesis and etiology of T1D 
Multiple factors in a complex interaction promote the pathogenesis of T1D. 
Pathological studies from necropsies of patients with T1D show the presence of insulitis, 
characterized by mononuclear cell infiltration (predominantly T cells, macrophages and B-
lymphocytes) within the pancreas islets with a severe selective loss of beta cells. These 
studies showed that at the same time there are islets where the beta cells have been destroyed, 
others that are being destroyed, and some that have not been destroyed (24). Other studies 
form biopsies of patients with recent onset of T1D suggest an interaction between the 
proteins of the cell surface that belongs to the tumor necrosis factor and play important role 
in immune regulation, Fas on beta cells and Fas ligand on infiltrating cells. This interaction 
could be the trigger of apoptosis of beta cells in the pancreas, as a mechanism of beta-cell 
destruction (23, 24). According to the natural evolution of the autoimmune disease, when the 
beta-cell mass is considerably lowered, the development of diabetes is irreversible (92); at the 
end, insulin secretion is reduced to such an extent that it is no longer sufficient to maintain a 
normal level of blood glucose, and clinical diabetes supervenes. 
The mechanisms of beta-cell destruction remain unknown; in humans these 
mechanisms are related with genetic and non-genetic factors. The genetic factors are of major 
importance (167). Also, exogenous factors play a major role in the development of T1D for 
many reasons, such as the following: a) less that 10% of individuals with HLA-conferred 
diabetes susceptibility progress to clinical disease, b) a pair-wise concordance of T1D of 
<40% among monozygotic twins, c) a more than 10-fold difference in disease incidence 
among Caucasians living in Europe, d) considerable increase in incidence over the past 50 
years, and e) migration studies indicating that the disease incidence has increased in 
population groups that moved from a low-incidence to a high-incidence region (167).   
2.4.1 Genetic factors associated with T1D  
The genetic influence on T1D has been studied and the researches show that some 
genes provide protection against T1D and others provide susceptibility. Nevertheless, twin-
and family-based studies have shown that genetic factors play an important role in modifying 
disease risk in T1D (186); the rapid increase in incidence of T1D is not explained by 
Mendelian inheritance (202) and is insufficient to explain 35–75% of the cases (202). About 
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85% of patients with recent diagnosis have no family history of diabetes (23) and T1D only 
appears in approximately 6% of siblings of patients with the disease (358).  
Only 2 chromosomal regions has been associated with T1D: the major 
histocompatibility complex (MHC) human leukocyte antigen (HLA) class II region on 
chromosome 6p21 [insulin-dependent diabetes mellitus 1 (IDDM1)] and the insulin gene 
region on chromosome 11p15 [insulin-dependent diabetes mellitus 2 (IDDM2)] (219). Genes 
located within the HLA-II account for approximately 50% of genetic risk of T1D. The HLA 
alleles associated with T1D susceptibility include HLA DR3, DR4, DQ2 (DQB1*0201–
DQA1*0501–DRB1*03), and DQ8 (DQB1*0302-DQA1*0301–DRB1*04). These alleles are 
present in 90% of the children with T1D (111), whereas, other HLA alleles are associated 
with disease protection, such as DR2, DQA1*0102, DQB1*0602, and children with these 
diabetes-protective HLA are unlikely to develop T1D (111, 158, 185, 219, 358). More details 
are presented in chapter 5: « Genetic Determinants of T1D ».  
2.4.2 Environmental factors associated with T1D 
The none-genetic risk factors include the environmental risk determinants and others 
none-genetic disease-modifying factors. These factors could be promoters of the activation of 
autoimmunity; this process appears after an apparent imbalance in the immune system of the 
patient in order to attack foreign pathogens (219) and culminates in the destruction of 
pancreatic beta cells (76). Despite intensive searches for environmental triggers, the number 
of candidates being assessed in clinical trials remains small (for example: viruses (40, 144, 
301), proteins from cow milk (66, 200, 276, 315), timing of vaccination (78) and relative lack 
of vitamin D). However, the exact etiology and pathogenesis of T1D is still unknown (6). 
Numerous factors such as epigenetic, microbiome, microbiology, metabolism, nutrient 
intake, and climatic, and environmental exposures have also been proposed as triggers of 
T1D (41, 69, 173). Other environmental determinants are presented here in chapter 2: 
«Incidence of T1D Incidence and Determinants Among Children».  
2.4.3 Interaction between genetic and environmental factors 
Our current knowledge on T1D supports the possibility hat the change in incidence 
trends of T1D around the world could be due to the interaction of genetic and non-genetic 
risk factors. In this case, non-genetic factors could be a) promoters of the activation of 
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autoimmunity, this process appears after an apparent imbalance in the immune system of the 
host in order to attack foreign pathogens (219) and culminates in the destruction of pancreatic 
beta cells (76), b) modifiers of disease pathogenesis rather than as triggers, or c) protectors 
attenuating the disease during different stages of the development, and depending on the 
quantity and the time of exposure (23). Table 8 lists some examples of non-genetic risk and 
of protecting factors in childhood at onset of T1D reported in the literature.    
 
Table 8: Risk and protectors related to T1D  
 
Factors associated with increased risk of T1D 
Age at day-care entry (proxy of maternity leave and viral load) 
Caesarian section delivery 
Climatic influences  
Early infant diet  
Fall in birth-weight 
Food processing consumption 
High maternal age 
Improvement of socio-economic conditions 
Increased body mass  
Lifestyle habits 
Linear growth during early childhood 
Overweight and obesity  
Psychological stress  
Relative lack of Vitamin D, E and Omega-3 fatty acids  
Reduced frequency of early infections 
Stressful life events 
Toxins  
Vaccine administration (probably coincidental)  
Viral infection during pregnancy 
Viral infections during childhood  
Factors associated with reduced risk of T1D 
Atopic diseases 
Breastfeeding/ duration of breastfeeding  
Early age at preschool day-care entry 
Early introduction of Vitamin D supplementation 
Healthy gut micro and macro biota 
Low birth weight 
Short birth length 
 
For more details see the following paragraphs in this chapter 2. 
UPMC - ED 393 - 2015  Epidemiology of Type I Diabetes: 





2.4.3.1 Seasonality and T1D 
There are differences in the variation of T1D diagnosis depending on the season, a 
peak in both sexes and in all age groups usually occurring in the winter; it is more pronounced 
in countries with marked differences between summer and winter temperatures. Knip et al. 
(167) found that diagnosis of T1D has a seasonal pattern, being more common during the cold 
season (171, 293), with variations from year to year. In addition, T1D does not necessarily 
induce beta-cell autoimmunity at the same time in all genetically susceptible siblings in the 
same family (167). As hypothesis, incidence of T1D could be related with changes in the 
epidemiology of enterovirus infections, been higher during cold weather (301), and for this 
reason, the diagnosis of T1D onset could be related to seasons (144, 200). Other possible 
explanations are that seasonal variation of onset could be stimulating factors of the disease 
processes, or related with nutritional factors that can be different depending on the seasons. 
The possibility exists that certain foods harbouring unknown infectious or potentially toxic 
agents (26) are also implicated.  
In this thesis, using information collected up to November 2011, an exploratory 
analysis of the seasonal and diagnosis of T1D was carried out based on references containing 
the word “season” in the title or abstract. The season in which T1D was diagnosed was 
reported in 87% (60 of 69) of the studies; the incidence peak was in winter, followed by 
autumn, spring and summer; Figure 8.  
The season of birth of the patients with T1D diagnosis was reported in 10% (7 of 69) 
of the studies, spring being the season with most births, followed by summer, autumn and 
winter; Figure 9.  
The month of birth of the patients with T1D was indicated in 7.2%  (5 of 69) of the 
studies, birth in December and January being the months leading to the subsequent highest 
incidence of T1D diagnosis. Figure 10.  
 
UPMC - ED 393 - 2015  Epidemiology of Type I Diabetes: 
























































































UPMC - ED 393 - 2015  Epidemiology of Type I Diabetes: 




2.4.3.2 Frequency of recruited patients of the Isis-Diab cohort by month of diagnosis 
and month of birth 
Figures 11 and 12 show the distribution of recruited patients aged 0-16 years of the 
Isis-Diab cohort, an ongoing prospective cohort of French patients with T1D since 2007. 













Figure 11: Month of diagnosis of patients with T1D in the Isis-Diab cohort 
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2.4.4 Hypotheses related with etiology of T1D 
With time, several hypotheses has been proposed to explain possible etiological 
factors of T1D, the most favored being the following:  
2.4.4.1 Hygiene Hypothesis 
The hygiene hypothesis proposed by Strachan (1989) (306) suggests that exposure to 
pathogens early in life, such as by contact with older siblings, or acquired prenatally from an 
infected mother by contact with her older children, prevents autoimmune diseases; however, 
in modern society individuals lack exposure to such factors, they could be genetically 
predisposed to diseases of the immune system but cannot protect themselves from 
autoimmune phenomena (301). Bach (2002) described potential mechanisms affecting the 
immune system (25).  Kolb and Elliot proposed that an improved hygienic environment could 
be responsible of the increase in incidence trends of T1D (169). Later, Gale concluded that 
early exposure to micro-organisms, such as parasites and indigenous biota of the gut, could 
have a protective effect against T1D mediated by regulatory T lymphocytes (104). 
Experiments in animal models have shown that infection might inhibit the development of 
diabetes (66, 200). On the other hand, some viral infections appear as triggers of T1D.  
2.4.4.1.1 Polio Hypothesis 
This is an extension of the hygiene hypothesis. It suggests that certain viruses, such as 
poliovirus, will become less frequent by efficient mass vaccination programs, and by 
increasing the standards of hygiene. Paradoxically, the incidence of paralytic polio, a 
complication of acute polio infection, began to increase when the frequency of acute 
poliovirus infections started to decrease at the beginning of the last century, possibly due to 
decreased levels of protective maternal poliovirus antibodies transferred transplacentally and 
through breast milk to the infant. Similarly, diabetes is increasing rapidly in countries such as 
Finland and Sweden where thanks to vaccination programs the frequency of enterovirus 
infections has tended to decrease over the last decades (167, 346). This situation could 
however increase the susceptibility of young children to the diabetogenic effect of different 
enteroviruses (167, 200, 301). 
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2.4.4.1.2 Virus Hypothesis 
Population-based studies have suggested that viruses probably play an important role 
in initiating autoimmunity toward beta cells and therefore in initiating or accelerating T1D 
pathogenesis (144, 301). In two prospective series of young children an increased genetic 
susceptibility to T1D after infection by viruses was reported (167). Data from retrospective 
and prospective epidemiological studies suggest that the principal viruses associated with the 
development of T1D are viruses of the Enterovirus genus, mainly Coxsackievirus B4 (CoxB4 
or CV-B4). These viruses are ubiquitous and are largely transmitted by the fecal–oral route 
via the ingestion of water or food containing contaminated faeces. Enteroviruses belong to 
the Picornaviridae family, that includes the Rhinovirus, Hepatovirus, Parechovirus, 
Cardiovirus, Kobuvirus, Aphthovirus, Erbovirus and Teschovirus genera. CoxB4 has a 
natural tropism for beta cells and a molecular mimicry which favors the destruction of beta-
cell islets (315). Other viruses associated with T1D although less intensively are Rubella 
virus, Mumps virus, Cytomegalovirus, retroviruses, and rotaviruses (144, 167). In addition, 
several studies suggest that possibly many common viral RNA infections may induce islet 
autoimmunity in genetically susceptible individuals (6). Such infections would begin a 
vicious circle affecting gut microbiota (the principal intestinal mucosa barrier) and altering 
intestinal immune responsiveness. This in turn would encourage changes of the composition 
of the microbiota and disturb the role of gut as modulator of beta-cell autoimmunity and/or as 
the place to initiate beta-cell autoimmunity. It is conceivable that if a decreased microbial 
load occurs at an early age, this may have an important impact on the programming of the 
immune system by altering gut-associated lymphoid tissue (167); finally together with viral 
infections, these modifications would trigger T1D (336, 354).  
2.4.4.2 Cow’s Milk Hypothesis  
Antibodies to proteins of cow’s milk have been detected in the serum of in children 
with T1D as of 1988. For Savilahti et al. (276), the introduction of antigenic bovine insulin 
via cow’s milk in food increases the immune reaction leading to the hypothesis that early 
introduction of cow’s milk proteins in the infant’s diet may play a role in the development of 
autoimmunity to T1D (66, 200, 315). In a study made in Chile the level of anti-BSA-IgG was 
measured (BSA: bovine serum albumin), as well as of other antibodies. The anti-BSA-IgG 
was positive (using a cut-off point of 25.6 ng/ml) in 98% of diabetic children and absent from 
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the control population (15). On the other hand, some studies support the hypothesis that 
breastfeeding may play a protective role against the development of T1D (6, 200, 315).  
In babies, beta lactoglobulin, which is present in cow’s milk but not in human milk, 
may initiate an immune response that is cross-reactive with glycodelin (a glycoprotein that 
belongs to the lipocalin superfamily), and this response could interfere with the ability of 
glycodelin, to modulate immune responses (66, 113). This situation is similar to the one that 
occurred with the celiac disease and gluten, the wheat-deficient diet in World War II in the 
Netherlands: its postwar improvement identified the culprit, and autoimmune disease-causing 
agent (307). It has been proposed that association of HLA in celiac disease, in which HLA 
DR3-DQ2 is the dominant susceptibility haplotype, can be explained by the superior ability 
of the DQ2 molecule to bind proline-rich gluten peptides that have survived gastrointestinal 
digestion and have been deamidated by tissue transglutaminase (166). In agreement with this 
model, insulin is a crucial autoantigen in T1D because it is the only autoantigen specific of 
beta cells in postnatal life and because bovine insulin present in cow’s milk differs from 
human insulin by three amino acids: two in the A chain and one in the B chain (167). These 
formulas generally are the first dietary source of foreign complex proteins to which an infant 
is exposed in developed countries.  
In a multiple logistic regression analysis, Knip et al. (167) observed that IgA 
antibodies against B-lactoglobulin were strongly associated with an increased risk of diabetes 
during childhood, independent of the islet cell antibody status and of early weaning to a 
cow’s milk–based formula. There apparently exists an immune response, initially induced by 
bovine insulin that cross-reacts and may target human insulin in beta cells. These 
observations could be interpreted as supporting the idea that enhanced consumption of cow’s 
milk before the presentation of clinical T1D is a risk factor (167). 
2.4.4.3 Accelerator Hypothesis  
This theory by Wilkin (2001) (362) focus on obesity and insulin resistance as major 
accelerator of diabetes; it suggests that increasing body mass plays a key role in the 
development of both T1D and T2D. The combination of beta-cell up-regulation (insulin 
resistance, determined by weight gain) and autoimmunity (genetically regulated by the HLA 
genotype) determines the rate of beta-cell apoptosis (361, 363). According this hypothesis, 
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the increasing worldwide obesity stresses susceptible beta cells, and as consequence its early 
demise (358).  
2.4.4.4 Spring harvest Hypothesis  
This theory is based on the finding that the overall rise in T1D incidence was 
observed in very young children; according to this hypothesis, environmental factors 
determine and modulate the progression of diminishing beta-cell mass in susceptible 
individuals. In this theory Gale (2005) (106) emphasizes T1D progression rather than disease 
initiation, in which protection against environmental events in early life should be the focus.  
2.4.4.5 Unifying Hypothesis  
Ludvigsson (2006) (200) proposed that a patient may have peculiarities or both T1D 
and T2D, because certain mechanisms lead to islet inflammation and others to insulin 
demand that at the end cause insulin deficiency – mediated by autoimmune reaction in 
genetically predisposed individuals - and clinical manifestations of diabetes. According to the 
author, related with deficiency of immune system are increased hygiene and vitamin D 
deficiencies, while related with the autoimmune reaction, certain viruses, dietary bovine 
insulin, or toxic agents could be implicated.  
2.4.4.6 Overload Hypothesis  
Dahlquist (2006) has suggested that environmental determinants, via different 
mechanisms, “overload beta-cells”. Insulin resistance or increased insulin requirement could 
cause beta-cell overload. If so, the focus should be placed on “accelerating factors rather than 
potential triggers of autoimmunity” that operate after the initiation of autoimmunity. 
Accelerating factors have been proposed as implicated in this process: high growth rate, 
infections, psychological stress and cold climate (72).  
2.4.4.7 Diet Hypothesis  
This theory proposes that dietary factors play a role in the development of T1D. 
Intake of agents such as nitrite / nitrate (239, 339) or early introduction of solid foods 
(cereals) (226, 227) are implicated. In contrast, the duration of breastfeeding (66, 200, 276, 
315) is a factor associated with reduced risk of T1D. 
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2.4.4.8 Human contamination by environmental chemicals  
Based on epidemiological evidence, Howard (2012) (137) argues that several 
environment chemicals, such as N-nitroso compounds, air pollutants and persistent organic 
pollutants can act as “endocrine disruptors” affecting the development and function of the 
immune system, and as a consequence contribute to the development of T1D. According to 
this theory the principles of dose-effect and timing of exposure are determinant in their 
biological effects.  
2.4.4.9 Multidisciplinary approach 
Vehik et al. (2013) (342) discuss how advances in epidemiology, genetics, 
microbiology and immunology have provided new frontiers to understand the etiology of 
T1D. The relationship between early life environment – in utero and early postnatal period -, 
the development of gut immunity (microbiome) and epigenetic factors affect the risk of T1D 
(mediated by the innate or adaptive immune system). Environmental factors involved are for 
example a diet early in life, vitamin D levels, mode of delivery and enteroviral infections.  
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2.4.5 Personal summary of factors related with etiology and incidence of T1D 
Throughout this study, several factors related with the etiology of T1D, and 
mentioned above in various hypotheses, were explored. In view of summarizing the 
knowledge reviewed during this thesis, three main related categories of determinants were 
identified: i) autoimmunity, and ii) life style and iii) social determinants of health.  
In the autoimmune category, emerging elements are: a) the gut immune mechanisms 
(affected by diet and composition of the micro / macrobiota flora), b) the lymphocyte T 
helper (Th1/Th2) response to infections (depending on the kind and timing in which the 
infection was produced), c) the vitamin D deficiency related with exposure to UV radiation 
(this could be determined by the effect of seasons, geographic location, outdoor activities, 
etc.), and d) the accelerated weight gain (producing insulin resistance and an overload of beta 
cells); Figure 13.  
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In the category related with life style, emerging factors are: a) the current obesity 
trends and accelerated weight gain childhood and adolescence observed mainly in Western 
countries (in line with the Accelerator and the Overload Hypothesis), b) the sedentary life 
style that could be associated with less outdoor activities, less exposition to UV radiation, 
increased technology dependence, and also with higher obesity rates, and c) the wealth of the 
countries associated with access to modern facilities, processed food, environment pollution, 
etc., factors that could be new or unknown triggers or accelerators of autoimmunity 
processes; also related with more developed countries are higher percentage of urban 
population and changes in patterns of childhood diseases (related with the Hygiene and Polio 




Figure 14: Tentative clarification of the life style related factors with T1D 
 
 
Finally, epidemiology of T1D is influenced by social determinants, resulting from 
differences in economy and health care systems of the countries. Emerging factors of this 
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(GDP) or Gross National Income (GNI)), b) health care system (that determines the access to 
health care and the number of physicians and nurses specialized in diabetes care per 
inhabitant, and as consequence better and early diagnosis, access to medicaments and 
supplies such as syringes and reimbursements, and complications management and 
prevention), c) health registration system (including central registers of incidence cases), d) 
health priorities of the country (Is T1D considered an health priority in the country, as 
compared with other diseases?), and e) other social factors, such as relation urban/rural 
population, physical structure of the city, availability and accessibility of public transport and 
public space could affect the epidemiology of T1D; Figure 15.  
 
 
 GDP: Gross Domestic Product, GNI: Gross National Income. 
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3 Epidemiology of T1D among children 
T1D is one of the most common chronic diseases in children: each year 79.000 
children develop the disease worldwide (241). The disease has been increasing by 3% per 
year (318) and despite geographical variations, a global epidemic is now recognized (99). To 
explain this increase in the incidence and the geographical differences, diverse factors have 
been implicated; nevertheless the role of these factors remains unclear.  
The fist part of chapter 3 is focused on the global conditions as key triggers. The 
results addressed here were published as an abstract in 2014 in the Revue d’Épidémiologie et 
de Santé Publique and in 2015, as a full research article in PLoS ONE. In this chapter we 
propose the analysis of predictors of T1D incidence using information of independent 
variables retrieved in public databases (the World Health Organization (WHO), the United 
Nations (UN) and the World Bank (WB)). In these databases we searched for indicators, with 
as few missing values as possible until a maximum of 5% was reached, that could be 
correlated with the incidence of T1D in 80 countries. Using regression models and stepwise 
backward selections, we present significant predictors of T1D among 77 independent 
variables in four domains: Climate and Environment, Demography, Economy, and Health 
Conditions. In addition, a comparison between such indicators for countries with and without 
available information is presented in the Supplemental Materials of this chapter. The 
significant predictors of T1D described in this chapter are also used to understand the gene-
environment relation shown in unpublished analyses of chapter 5 about APC analyses and in 
chapter 6 about genetic determinants of T1D.  
The second part of chapter 3 is focused on the cumulative incidence of T1D. To 
study the descriptive epidemiology of T1D, one of basic instruments – but no less important 
– is the incidence. The measure of incidence quantifies the number of new events or cases of 
the disease that occur in a population of individuals at risk during a specific time interval. It 
may be expressed in absolute numbers (cumulative incidence) or in rates (incidence rate or 
density). Cumulative incidence is the proportion of individuals who become diseased during 
a specific period of time, and it provides an estimate of the probability, or risk, that an 
individual will develop a disease during a specified period of time (118, 132). 
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The first step in studying the incidence is typically the evaluation of geographic and 
temporal variations in the disease; this was presented in chapter 1, and chapter 3 will 
explore such variability in depth.  
In addition, chapter 3 presents preliminary analyses on epidemiological changes of 
T1D by continents and countries, the time course of the cumulative incidence of T1D in 
successive cohorts of children born since 1924, and a review of studies reporting the early 
age at onset of T1D observed in some countries (242). Elements that have motivated the 
development of the APC analyses are presented in chapter 5.  
In summary, chapter 3 presents new results through the systematic examination of 
the correlation of the incidence of T1D in children with various environmental variables and 
a variety of additional information on the descriptive epidemiology of T1D. The results 
presented here could be considered as an attempt to show the power of data published in 
public databases in answering fundamental questions in public health.  
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The incidence of Type 1 Diabetes (T1D) in children varies dramatically between countries.
Part of the explanation must be sought in environmental factors. Increasingly, public data-
bases provide information on country-to-country environmental differences.
Methods
Information on the incidence of T1D and country characteristics were searched for in the
194 World Health Organization (WHO) member countries. T1D incidence was extracted
from a systematic literature review of all papers published between 1975 and 2014, includ-
ing the 2013 update from the International Diabetes Federation. The information on country
characteristics was searched in public databases. We considered all indicators with a plau-
sible relation with T1D and those previously reported as correlated with T1D, and for which
there was less than 5%missing values. This yielded 77 indicators. Four domains were ex-
plored: Climate and environment, Demography, Economy, and Health Conditions. Bonfer-
roni correction to correct false discovery rate (FDR) was used in bivariate analyses.
Stepwise multiple regressions, served to identify independent predictors of the geographi-
cal variation of T1D.
Findings
T1D incidence was estimated for 80 WHO countries. Forty-one significant correlations be-
tween T1D and the selected indicators were found. Stepwise Multiple Linear Regressions
performed in the four explored domains indicated that the percentages of variance ex-
plained by the indicators were respectively 35% for Climate and environment, 33% for De-
mography, 45% for Economy, and 46% for Health conditions, and 51% in the Final model,
where all variables selected by domain were considered. Significant environmental predic-
tors of the country-to-country variation of T1D incidence included UV radiation, number of
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mobile cellular subscriptions in the country, health expenditure per capita, hepatitis B immu-
nization and mean body mass index (BMI).
Conclusions
The increasing availability of public databases providing information in all global environ-
mental domains should allow new analyses to identify further geographical, behavioral, so-
cial and economic factors, or indicators that point to latent causal factors of T1D.
Introduction
It has long been noticed that the incidence of Type 1 Diabetes (T1D) is highly variable from one
country to another. For example, the 62.42/100.000 persons/year incidence found in Finland [1]
was 780-fold larger than the 0.08/100.000 persons/year incidence in Papua New Guinea [2]; dif-
ferences in T1D incidence are also observed between countries where the health care systems are
comparable. The variability of T1D incidence is even visible within countries; for example, in
Italy, T1D incidence varied between 54.4/100.000 persons/year in Sardinia [3] and 4.4/100.000
persons/year in Lombardia [4]. The reason for these differences is not precisely known, but is
most unlikely due to classification bias, as the disease cannot go untreated, and the diagnosis is
relative easy to perform in children [5]. The country-to-country T1D variability is known to be
partly explained by genetic variations. Indeed, HLA (human leukocyte antigen) and 33 other
genes are associated with elevated risk of T1D (T1DbaseVersion 4.18 updated on 30/9/2014
available at http://www.t1dbase.org) [5–11]. The genetic characteristics of several populations
have been found to—at least partially—explain the level of their T1D incidence [12]. For exam-
ple, the low incidence in Japan, and more generally in southeast Asia, was strongly associated
with the absence of highly susceptible haplotypes, such as DRB1!03-DQB1!0201 and DRB1!04-
DQB1!0302 found in Caucasian populations [13] or DRB1!030101-DQB1!0201 [14] found in
Arab populations (Bahrainis, Lebanese, and Tunisians). Instead, the major susceptible HLA hap-
lotypes in the Japanese and Korean populations were DRB1!0405-DQB1!0401 and
DRB1!0901-DQB1!0303 [15].
Another peculiarity of T1D epidemiology is that a dramatic increase of the incidence (on av-
erage 3% per year [16]) was observed over the last decades in many countries, in particular Eu-
ropean countries with previously low incidences. This increase cannot be explained by genetic
factors, since the genetic structure of these countries cannot have varied greatly over such a
short period of time. The reasons are more likely to be found in environmental factors (taking
here environment broadly, as encompassing physical, chemical, social and life-style factors).
However, no single environmental factor, or configuration of factors, that could explain the
patterns of differences has ever been identified. More likely, there are complex networks of en-
vironmental causes, and of gene-environmental causes that remain to be discovered.
The search of genetic factors of T1D was facilitated during the last 10 years by the GWAS
(genome-wide association studies) technology that replaced the gene candidate approaches
and instead scanned the entire genome to find SNPs (Single-Nucleotide Polymorphisms) that
were significantly associated with T1D [17]. The discovery of an SNP was not the discovery of
a “gene”, but was a marker leading to the possible discovery of a gene. Here, we translate this
data-driven approach to search for environmental markers related to variations of T1D inci-
dence that might eventually lead to environmental causes, possibly in interaction with genetic
factors. One could indeed expect that, in this age of information, plenty of environmental
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characteristics could be readily available, insofar as local and global organizations collect such
data, and provide them free to researchers, with easy interface on the Internet. A limitation
commonly advocated is that country statistics are in many cases of too low quality. However,
for two related reasons, this argument does not hold, or will not hold for long: a) why collect,
maintain and publish such statistics if they cannot be used by researchers? and b) how can one
encourage a better quality for these statistics—meaning more resources devoted to them—if
they are never used?
Here, we present the attempt we made to use open public data to identify climate and envi-
ronmental, demographic, economic, and health characteristics correlated with variations in
T1D incidence between countries.
Material and Methods
Incidence of T1D data by country
The country T1D incidence was obtained thanks to a systematic review following the PRISMA
recommendations [18] (S1 Checklist). All relevant original papers published in English be-
tween 1975 and 2014 including reviews (Diamond [16] and Eurodiab studies [19–21], the In-
ternational Diabetes Federation (IDF) atlas [22, 23]) were analyzed (see Flow diagram of the
literature search in S1 Fig., the full search strategy on S1 Table, and the list of selected publica-
tions in S2 Table), registration number in the International Prospective Register of Systematic
Reviews (PROSPERO): CRD42012002369 (S1 Protocol).
The T1D incidence value per 100.000 persons/year for individuals in the age group 0–14
years for both sexes used here for each country was obtained as follows. 1) When only one
dataset was available for a given country, the figure obtained from this study was used, even if
the study was not nationwide. 2) If more than one dataset was available including nationwide
and local studies, the most recent published nationwide study in the country was used. 3) If
only local studies in a single area within the country were available, the most recent dataset was
selected. 4) If local studies reporting incidences were available for different areas in the country,
the mean incidence after grouping the most recent published studies for each area was used.
Country indicators
Three open public databases from the World Health Organization (WHO) [24], the United
Nations (UN) [25] and the World bank (WB) [26] were used to search indicators in four do-
mains: Climate and environment (land use and physical environment), Demography, Economy
(including health resources and expenses), and Health. We only kept indicators with less than
5% missing values in the 80 countries for which we could estimate T1D incidence (see Results,
below).
In total we used 77 indicators: two (latitude and longitude) were obtained thanks to Google
Maps [27], 29 were retrieved from the WHO [24], three from the UN [25] and 43 from the WB
[26]. When several values were available for one indicator, the value obtained in 2012, or on
the date closest to 2012 was chosen (see Fig. 1 for a list of the 77 indicators, and S1 Database
for the entire database used in the calculation of the correlations).
Statistics
The R software (version 3.0.1) served for statistical and graphic analyses [28]. Spearman corre-
lation was used to compute the correlation between the 77 selected country indicators and the
T1D incidence. To account for multiple testing leading to a false discovery rate (FDR), the
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Fig 1. Correlations between T1D incidence and 77 country indicators. The correlations were computed
in the 80WHO countries where T1D incidence could be estimated. Dots: no significant correlations. Squares:
significant correlations with p!0.2. Significant correlations after Bonferroni correction (p-value! 0.000649)
are highlighted. Abbreviations: PM: particular matter, UV: ultraviolet, GDP: Gross Domestic Product, GNI:
Type 1 Diabetes Incidence and Environmental Country Characteristics
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Bonferroni correction was used [29]: a p-value! 0.000649 (= 0.05/77 variables) was considered
as indicating significance at the 5% level.
We employed Stepwise Multiple Linear Regression (SMLR) methods to obtain the best pre-
dictors of T1D incidence within the original list of 77 variables. This process was carried out in
two times: first, SMLR served to select independent predictors of T1D within each of the 4 en-
vironmental domains considered; second, the final subset of independent variables using the
four sets of predictors obtained in the first step was selected.
In the by-domain analysis, all variables were entered for which the p value testing the corre-
lation with incidence was smaller than 0.20. When a couple of variables was correlated with
r>0.80, only one of the variables was used in the regression analysis to avoid computational is-
sues associated with colinearity.
Then, starting with the full model, we made a manual backward selection of the variables,
selecting at each step one variable. This variable was the one that, after being dropped, maxi-
mized the adjusted R2. The process was stopped at the step where the adjusted R2 decreased
[30]. Then, taking the list of variables obtained, a new SMLR was performed that identified the
smallest subset, based on the Akaike information criterion (AIC) [31]. Model assumptions for
linear models were checked by visual inspection of the residuals.
The same process was used in the final analysis, starting with all significant predictors
found in the analyses by domain. 10-Fold Cross-validation after bootstrapping [32] served to
evaluate the predictive value of the final model. Graphic representation used the DAAG pack-
age [33].
Results
Incidences were retrieved for 80 countries; they varied widely between continents, countries
and regions (see S2 Table and S1 Database for the incidences). Among children aged 0–14
years the lowest nationwide incidences (! 1 per 100.000/year) were in Eastern Asia (China),
South-East Asia (Thailand), Melanesia Oceania (Papua New Guinea), and South America and
the Caribbean (Dominican Republic, and Paraguay). The highest nationwide incidences (" 30
per 100.000/year) were in Northern Europe (Finland, Sweden, Norway).
The correlations between the incidence and the 77 selected independent variables grouped
into four domains are shown in Fig. 1 (for details and sources of information see S1 Database).
Forty-one of 77 variables survived the Bonferroni correction and were significantly correlated
with incidence at a significant p-value! 0.000649 (= 0.05/77). Thirty-five variables, for which
the correlation between any two of them was less than 0.8, and had a correlation coefficient
with T1D incidence with p<0.20 were entered in the stepwise regression models.
The detail of the 35 (of 77) variables that were entered in stepwise multiple regressions is
shown in Fig. 2 (panel A) and the results of multivariate models by domains in S3 Table. In
the Climate and Environment domain, seven of the 18 original variables qualified to be entered
in the model; after the SLRM selection, the three selected variables were: UV radiation, CO2
emissions and outdoor air pollution (particular matter: PM10 μg/m3). The adjusted % of vari-
ance explained (R2) in the model was 35.2%. The four excluded variables were: % of agricultur-
al land, latitude, nitrous oxide emissions and annual precipitations.
Gross National Income, BMI: Body Mass Index, CVD: Cardiovascular Diseases, CA: Cancer, DM: Diabetes
Mellitus, CHRD: Chronic Respiratory Diseases, Adj. R2: Adjusted-R2. Red: positive correlations, blue:
negative correlations. (a) Age-standardized estimate; (b) Per 100,000 individuals; (c) Coverage among 1-
year-olds (%). See S1 Database for the entire database.
doi:10.1371/journal.pone.0118298.g001
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In the Demography domain, six of the 15 original variables qualified to be entered in the
model; after the SLRM selection the four selected variables were: adolescent fertility rate, total
fertility rate, proportion of the population aged over 65 years, and proportion of urban popula-
tion; (adjusted R2 32.7%). The two excluded variables were: life expectancy at birth, and female
mean age of childbearing.
In the Economy domain, nine of the 13 original variables qualified to be entered in the
model; after the SLRM selection the six selected variables were: energy use, proportion of mo-
bile cellular subscriptions, education expenditure, % of improved sanitation facilities, health ex-
penditure per capita, and % of annual Gross domestic product (GDP) growth; (adjusted R2
45.0%). The three excluded variables were: GDP per capita, population using solid fuels and ex-
ternal resources for health.
In theHealth domain, 13 of the 31 original variables qualified to be entered in the model;
after the SLRM selection the seven selected variables were: deaths from chronic respiratory dis-
eases, hepatitis B immunization coverage in<1 year of age, alcohol consumption, mean body
mass index (BMI) in male>20, mean total cholesterol in male>25, preterm birth rate, and
Fig 2. Stepwise identification of predictors of T1D Incidence (a) by domain and (b) final. The lines are the 35/77 variables with p<0.2. Green bars
indicate variables that were excluded during the stepwise multiple regression (the length of the bar indicates the number of steps at which it was excluded).
Blue bars indicate that variables were selected after SMLR was applied. The dark blue bars indicate that the independent predictors of T1D were highly
significant; panel (A): in the by-domain analysis; panel (B): in the final model. The final analysis was performed on the variables selected in the by-domain
analysis (shown in dark blue in panel (A). Abbreviations: Dom: Domain, PM: particular matter, UV: ultraviolet, GDP: Gross Domestic Product, BMI: Body
Mass Index, CVD: Cardiovascular Diseases, CA: Cancer, DM: Diabetes Mellitus, CHRD: Chronic Respiratory Diseases, Adj.R2: Adjusted-R2. (a) Variable
dropped after applied Akaike information criterion (AIC).
doi:10.1371/journal.pone.0118298.g002
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prevalence of undernourishment in the population (adjusted R2 46%). The six excluded vari-
ables were: infant mortality rate, cardiovascular diseases and diabetes, deaths for non-commu-
nicable diseases! 60, incidence of tuberculosis, haemophilus influenza type B (Hib3) vaccine
immunization, and diphtheria tetanus toxoid and pertussis (DTP3) immunization.
In the final model, the five independent predictors were: UV radiation, number of mobile
cellular subscriptions, health expenditure per capita, hepatitis B immunization and mean BMI
(Table 1, details in S3 Table). The predicted incidence variation associated with the variation
of each predictor can be computed from the values shown in Table 1: for example, for one unit
increase in UV radiation in J/mt2, a mean 0.2% decrease in the incidence of T1D is expected.
For an increase of 1% in the percentage of hepatitis B vaccination among 1 year-olds, an 8.5%
decrease in the incidence of T1D is expected; for one unit increase in the percentage of BMI in
males, a 1.3% increase in the incidence of T1D can be expected. The predictive value of the re-
gression equation was visualized by comparing the predicted incidences with the observed inci-
dences. Finland is noticeably an outlier in this empirical covariation predicted by the model
(Fig. 3). 10-fold cross-validation indicated that the fraction of the variability of the global inci-
dence of T1D was estimated to be 41% (S2 Fig.).
Discussion
Our work explored whether the information available in public databases could help to study
the environmental part of the country-to-country variations of T1D incidence. We found 77
variables with less than 5% missing values in the 80 countries for which the systematic review
we carried out provided an estimate of the 0–14 T1D incidence.
These 77 variables explored four domains (Climate and environment, Demography, Econo-
my, Health). In each of these domains, a stepwise multiple regression analyses identified the
subset of variables of the domain which were independent predictors of the variation in the
geographical T1D incidence. Then, analyzing these 4 subsets of domain variables, we identified
five final independent environmental indicators: four of the five were known as risk factors of
T1D: UV radiation [34–36], health expenditure per capita [34], coverage of hepatitis B vaccina-
tion [37] and mean BMI [38]. The last indicator was the proportion of mobile subscriptions,
positively correlated with T1D incidence. It is probably a marker of a life-style that was not
captured by any of the 77 variables used in the multiple analyses.
Coming to the domain-by-domain analysis Fig. 2 (Panel B), in the Climate and Environ-
ment domain, the first indicator that emerged was UV radiation. This may be related to
Table 1. Final Stepwise MLR model.
Code Coefﬁcients Estimate Std. Error p Value
(Intercept) -25.240 15.390 0.106
CE_18 UV radiation (J/mt2, 2004) -0.002 0.001 0.055
DD_21 Fertility rate, total (births per woman) 2.181 1.309 0.100
ED_41 Mobile cellular subscriptions (per 100 people) 0.066 0.027 0.018
EH_45 Health expenditure per capita (constant 2005 intern. $) 0.001 0.001 0.019
HI_59 Hepatitis B (HepB3) immunization coverage (a) -0.085 0.027 0.002
HR_47 Mean BMI (kg/m2) Male >20 years of age (b) 1.263 0.611 0.042
The model included all signiﬁcant predictors found in the analyses by domain.
(a) Among 1-year-olds (%)
(b) age-standardized estimate.
doi:10.1371/journal.pone.0118298.t001
Type 1 Diabetes Incidence and Environmental Country Characteristics
PLOS ONE | DOI:10.1371/journal.pone.0118298 February 23, 2015 7 / 12
 
UPMC - ED 393 - 2015  Epidemiology of Type I Diabetes: 




vitamin D deficiency [39] as reported in previous studies [34]. The second indicator of this do-
main was CO2 emissions. An association between air pollution and T1D incidence has been re-
cently described [40].
In the Demography domain, the only indicator that emerged in the final model was total fer-
tility rate. The predictors dropped were: the adolescent fertility rate, the proportion of the pop-
ulation aged over 65 years, and the proportion of urban population. Concerning the
proportion of urban population that was positively correlated with T1D incidence in this study
as found in Lithuania [41], there are conflicting results in the literature: higher incidences was
found in rural areas of the United Kingdom [42], and in semirural areas of Sweden [43], while
no urban-rural difference in the incidence of T1D was found in Estonia [44].
In the Economy domain, three variables emerged, among which two were in the final list of
independent predictors: proportion of mobile cellular subscriptions and health expenditure per
capita. The third one was education expenditure. Higher incidences in wealthy countries, as
measured by the GDP [45] and health expenditure per capita [34], have been described previ-
ously. In addition, other studies from Sweden [43, 46, 47], the United Kingdom [42, 48], and
Canada [49] described similar associations between T1D and socioeconomic variables.
Fig 3. The predicted incidence of T1D among 80 countries vs. the observed incidence. Red dot: Finland. See S2 Fig. for predicted indices obtained
after 10-fold Cross-validation.
doi:10.1371/journal.pone.0118298.g003
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Within the Health domain, seven independent predictors were identified, among which two
were in the final list: mean BMI in male>20, that had already been identified as risk factor
[38], and hepatitis B immunization coverage in children<1 year of age, also recently proposed
as a potential protector factor [37].
A first limitation of this study is that we could only rely on a relatively short set of variables
retrieved in the public databases that met the condition of an acceptable fraction of missing
data that we set arbitrarily at 5%. A second limitation was the differences in the temporality of
the T1D data collected and the predictors. The mean year of the studies we used to estimate
T1D incidence was 1997, while the mean year of the data for the 77 selected predictors was
2009. An important drawback, shared by all ecological studies, is that the correlations cannot
be directly interpreted in terms of causality of the disease. However, they can be considered as
providing signals that may help to unravel latent, yet unknown causes.
Furthermore, an important part of the variation in T1D incidence cannot be captured by an
approach that only focuses on environmental factors. It is well known to be in a large part ex-
plained by genetic characteristics of the populations that were not analyzed here. Indeed, ethnic
differences in T1D incidence between countries, and even within countries, have long been re-
ported [13, 15, 50] and the most susceptible and protective haplotype determinants of T1D
were identified [50]. However one difficulty is that this genetic information is lacking in many
countries of the world, which limits the possibility of extending to genetics the kind of global
analysis we presented here. For example, we explored the Allele Frequency Net at http://www.
allelefrequencies.net/ [51], a public electronic repository for allele frequency of populations; we
found that information on the haplotype DRB1!0405—DQA1!0301—DQB1!0302 for which
the T1D Odd Ratio was extremely high (11.37 reported by the Type 1 Diabetes Genetics Con-
sortium Families [50]) was available in only 6 countries. Moreover, the genetic characteristics
of a country are much less homogeneous than the environmental characteristics, because of the
presence of various ethnic groups within the same country, while many of the environmental
variables that we studied can be considered as identical (latitude, geographical characteristics)
in the subgroups of a country.
In the future, it can be expected that analyses similar to this one, taking advantage of the in-
creased availability and quality of public databases characterizing the human populations
would be a path to help identify some of the still unknown causes, and networks of causes, of
TID.
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3.1.1.1 CONSORT PRISMA checklist 
SI Table 9: CONSORT PRISMA checklist  
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
72 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  72 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
73 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
74 
Protocol S1 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
74, Figure S1, Table S1,  
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
74, Figure S1, Table S1. 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  Table S1, Figure S1, 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in 
the meta-analysis).  
74 - Protocol S1 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
74 - Protocol S1 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
74 - Protocol S1 
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the Protocol S1 
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Section/topic  # Checklist item  Reported on page #  
study or outcome level), and how this information is to be used in any data synthesis.  
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  74 - Protocol S1 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
74 - Protocol S1 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
73 - Protocol S1 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
76, Figure S1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
Table S2 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Table S2 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot.  
Table S2 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Table S2, Database S1 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
78 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
78 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  78 
FUNDING   





From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org. 
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3.1.1.2 Flow diagram literature search for T1D incidences 
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3.1.1.3 Publication list of the incidence of T1D by country and area 
SI Table 10: Publication list of the incidence of T1D by country and area 















Author, Pub yr.  Ref. 
Algeria                 
 Oran 1990_1999 8.60 8.60 NA PBDR P or H  Diamond, 2006 (318) 
Argentina                 
 Cordoba 1991_1992 7.55 7.00 90.0 PBDR P or H  Diamond, 2006 (318) 
 Avellaneda 1990_1996 7.55 6.30 94.0 PBDR P or H  Diamond, 2006 (318) 
 Tierra del Fuego 1993_1996 7.55 10.30 100.0 PBDR P or H  Diamond, 2006 (318) 
 Corrientes 1992_1999 7.55 6.60 95.0 PBDR P or H  Diamond, 2006 (318) 
Australia                 
 NW 2000_2006 22.50 22.50 97.1 PBDR P Catanzariti L, 2009 (58) 
Austria                 
 NW 2004_2008 17.50 17.50 97.2 PBDR P Patterson C, 2012 (243) 
Bahamas                 
 NW 2001_2002 10.10 10.10 NA MBR P Peter S A, 2005 (246) 
Barbados                 
 NW 1990_1993 2.00 2.00 NA PBDR P or H  Diamond, 2006 (318) 
Belarus                 
 Gomel, Minsk 1997_2002 5.60 5.60 100.0 PBDR NA Zalutskaya A, 2004 (374) 
Belgium                 
 Antwerp 2004_2008 15.90 15.90 94.9 PBDR P Patterson C, 2012 (243) 
Bosnia and Herzegovina                 
 Tuzla Canton 1995_2004 7.53 6.93 100.0 PBDR P Tahirovic H, 2007 (312) 
 Republic of Srpska 1998_2010 7.53 8.13 100.0 PBDR P Radosevic B, 2013  (256) 
Brazil                 
 Sao Paulo (Bauru) 1986_2006 8.83 10.66 94.7 PBDR P Negrato C, 2010 (221) 
 
Rio Grande do Sul (Passo 
Fundo) 1996_1999 8.83 7.00 82.5 PBDR P or H  Diamond, 2006 (318) 
Bulgaria                 
 Eastern 1989_1994 8.53 6.80 99.9 PBDR P Eurodiab, 2000 (90) 
 Varna 1990_1999 8.53 8.10 100.0 PBDR P or H  Diamond, 2006 (318) 
 Western 1990_1999 8.53 10.70 99.5 PBDR P or H  Diamond, 2006 (318) 
Canada                 
 Toronto (c) 1976_1978 21.73 9.00 97.2 PBDR P, H Ehrlich R M, 1982 (86) 
 Manitoba 1985_1993 21.73 20.65 95.0 PBDR P Blanchard J F, 1997 (36) 
 Prince Edward Island 1990_1993 21.73 24.50 100.0 PBDR P or H  Diamond, 2006 (318) 
 Alberta (Edmonton) 1990_1996 21.73 23.30 85.5 PBDR P or H  Diamond, 2006 (318) 
 Calgary 1990_1999 21.73 20.60 100.0 PBDR P or H  Diamond, 2006 (318) 
 Québec 1989_2000 21.73 15.34 NA PBDR P Legault L, 2006 (184) 
 Newfoundland and Labrador 1987_2010 21.73 38.68 NA PBDR P, H Newhook L A, 2012 (225) 
Chile                 
 IX Region 1980_1993 3.84 1.37 97.0 PBDR P Larenas G, 1996 (180) 
 
Santiago of Chile (Communes 
of Metropolitan region) 2000_2005 3.84 6.30 100.0 PBDR P Torres-Avilés F, 2010 (323) 
 NW 1988_1994 0.47 0.47 93.0 PBDR P, H Yang Z, 2005 (371) 
Colombia                 
 Bogota 1990_1990 2.15 3.80 97.0 PBDR P or H  Diamond, 2006 (318) 
 Cali 1995_1999 2.15 0.50 NA PBDR P or H  Diamond, 2006 (318) 
Croatia                 
 NW 1995_2003 8.90 8.90 98.5 PBDR P Stipanic G, 2012 (305) 
Cuba                 
 NW 1990_1999 2.30 2.30 62.5 PBDR P or H  Diamond, 2006 (318) 
Cyprus                 
 NW 1990_2009 12.34 12.34 50.0 PBDR NA Skordis N, 2012 (294) 
Czech Republic                 
 NW 2004_2008 19.30 19.30 97.4 PBDR P Patterson C, 2012 (243) 
Dem. People's Republic of Korea               
 Seoul 1990_1991 1.10 1.10 NA PBDR P or H  Diamond, 2006 (318) 
Denmark                 
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Author, Pub yr.  Ref. 
 NW 2004_2008 25.10 25.10 99.2 PBDR P Patterson C, 2012 (243) 
Dominican Republic                 
 NW 1995_1999 0.50 0.50 53.0 PBDR P or H  Diamond, 2006 (318) 
Egypt                 
 Alexandria, Damanhour 1992_1992 8.00 8.00 NA OPD NA Arab M, 1992 (18) 
Estonia                 
 NW 1983_2006 13.09 13.09 98.0 PBDR P, H Teeaar T, 2010 (316) 
Ethiopia                 
 Gondar 1995_2008 0.33 0.33 NA MBR P Alemu S, 2009 (12) 
 Jimma 2002_2008 0.33 0.33 NA MBR P Alemu S, 2009 (12) 
Finland                 
 NW 2006_2011 62.42 62.42 NS OPD NA Harjutsalo V, 2013 (128) 
France                 
 Franche-Comté 1980_1998 9.24 7.01 80.6 PBDR H Mauny F, 2005 (208) 
 
Aquitanie, Lorraine, 
Normandia Basse, Normandia 
Haut 1990_1994 9.24 8.50 97.0 PBDR P or H  Diamond, 2006 (318) 
 Aquitaine 1998_2004 9.24 12.20 NA OPD NA Barat P, 2008 (28) 
Georgia                 
 NW 1998_1999 4.60 4.60 NA OPD NA Amirkhanashvili, 2000 (17) 
Germany                 
 Düsselforf 1999_2003 20.98 18.30 95.4 PBDR P Patterson C, 2009 (242) 
 Baden-Württemberg 2004_2007 20.98 21.80 100.0 PBDR P Patterson C, 2012 (243) 
 North Rhine-Westphalia 2004_2008 20.98 23.70 98.6 PBDR P Patterson C, 2012 (243) 
 Saxony 2004_2008 20.98 20.10 93.6 PBDR P Patterson C, 2012 (243) 
Greece                 
 NW 1992_1992 6.03 6.03 NA PBDR P 
Dacou-Voutetakis C, 
1995 (70) 
Hungary                 
 
18 of 19 countries (All, less 
Budapest) 2004_2008 18.30 18.30 98.7 PBDR P Patterson C, 2012 (243) 
Iceland                 
 NW 1989_1994 13.50 13.50 100.0 PBDR P Eurodiab, 2000 (90) 
India                 
 Madras 1991_1994 11.00 11.00 90.0 PBDR H Ramachandran A, 1996 (258) 
Iran (Islamic Republic of)                 
 Fars 1991_1996 3.68 3.68 100.0 PBDR P Pishdad G R, 2005 (248) 
Ireland                 
 NW 1997_1997 16.37 16.37 90.6 PBDR P Roche E F, 2002 (267) 
Israel                 
 NW: Population: Arabs 1997_2003 9.17 7.59 NA PBDR P Koton S, 2007 (171) 
 
NW: Population: Jews and 
others 1997_2003 9.17 10.76 NA PBDR P Koton S, 2007 (171) 
Italy                 
 NW_39.7% population 1990_2003 12.55 12.55 NA PBDR P Bruno G, 2010 (43) 
Japan                 
 NW 1998_2001 2.35 2.35 NA PBDR P Kawasaki E, 2006 (163) 
Jordan                 
 NW 1992_1996 3.33 3.33 95.0 NS P, H Ajlouni K, 1999 (9) 
Kuwait                 
 NW 1992_1999 22.30 22.30 87.5 PBDR P or H  Diamond, 2006 (318) 
Latvia                 
 NW 1990_1999 7.40 7.40 NA PBDR P or H  Diamond, 2006 (318) 
Libyan Arab Jamahiriya                 
 Benghazi 1991_1999 9.00 9.00 NA PBDR P or H  Diamond, 2006 (318) 
Lithuania                 
 NW 2004_2008 14.20 14.20 NA PBDR P Patterson C, 2012 (243) 
Luxembourg                 
 NW 2004_2008 19.00 19.00 100.0 PBDR P Patterson C, 2012 (243) 
Malta                 
 NW 2006_2010 23.87 23.87 100.0 PBDR P Formosa N, 2012 (100) 
Mauritius                 
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 NW 1990_1994 1.30 1.30 67.5 PBDR P or H  Diamond, 2006 (318) 
Mexico                 
 NW (d) 2000_2010 5.93 5.93 NA PBDR H Gomez-Diaz RA, 2012 (114) 
Montenegro                 
 NW 2004_2008 17.50 17.50 100.0 PBDR P Patterson C, 2012 (243) 
Netherlands                 
 NW 1996_1999 18.80 18.80 NA OPD NA Van Wouwe J P, 2002 (340) 
New Zealand                 
 NW 1999_2000 18.00 18.00 95.0 PBDR NA 
Campbell-Stokes PL, 
2005 (51) 
Norway                 
 NW 2004_2008 32.80 32.80 92.0 PBDR P Patterson C, 2012 (243) 
Oman                 
 NW 1993_1995 2.59 2.59 96.0 PBDR P Soliman A T, 1996 (297) 
Pakistan                 
 Karachi 1990_1999 0.50 0.50 51.0 PBDR P or H  Diamond, 2006 (318) 
Papua New Guinea                 
 NW 1996_2000 0.08 0.08 NA MBR P Ogle, 2001 (230) 
Paraguay                 
 NW 1990_1999 0.90 0.90 NA PBDR P or H  Diamond, 2006 (318) 
Peru                 
 Lima 1990_1994 0.50 0.50 67.5 PBDR P or H  Diamond, 2006 (318) 
Poland                 
 NW 1989_2004 11.23 11.23 NA PBDR P Jarosz-Chobot P, 2011 (148) 
Portugal                 
 Algarve 1990_1994 13.10 14.60 87.0 PBDR P or H  Diamond, 2006 (318) 
 Portalegre 1990_1994 13.10 21.30 93.0 PBDR P or H  Diamond, 2006 (318) 
 Coimbra 1990_1999 13.10 9.60 100.0 PBDR P or H  Diamond, 2006 (318) 
 Madeira Island 1990_1999 13.10 6.90 100.0 PBDR P or H  Diamond, 2006 (318) 
Qatar                 
 NW 1992_1996 11.40 11.40 NA OPD NA Al-Zyoud M, 1997 (10) 
Romania                 
 NW 2000_2004 5.40 5.40 NA OPD NA Serban V, 2005 (285) 
Russian Federation                 
 Novosibirsk 1990_1999 9.48 6.90 93.5 PBDR P or H  Diamond, 2006 (318) 
 Moscow 1996_2005 9.48 12.07 94.0 PBDR P Pronina E A, 2008 (251) 
Saudi Arabia                 
 Eastern Province 1986_1997 21.59 12.30 100.0 PBDR NA Kulaylat N A, 2000 (174) 
 Al-Madinah (North West) (a) 2004_2009 21.59 30.88 NA PBDR P Habeb A M, 2011 (125) 
Serbia                 
 Belgrade (e) 2000_2004 12.90 12.90 NA OPD NA Vlajinac  H D, 1995  (347) 
Singapore                 
 NW (a) 1992_1994 2.42 2.42 92.2 PBDR P Lee WW, 1998 (183) 
Slovakia                 
 NW 1999_2003 13.60 13.60 100.0 PBDR P Patterson C, 2009 (242) 
Slovenia                 
 NW 1998_2010 13.83 13.83 100.0 PBDR P Radosevic B, 2013 (256) 
Spain                 
 Madrid 1985_1988 15.75 10.60 90.0 PBDR H Serrano Rios M, 1990 (287) 
 Caceres (b) 1988_1999 15.75 16.67 99.2 PBDR H Lora-Gomez R E, 2005 (198) 
 Badajoz 1992_1996 15.75 17.23 95.0 PBDR P 
Morales-Perez F M, 
2000 (218) 
 Navarre 2003_2004 15.75 22.17 99.6 PBDR P Bahíllo M, 2007  
 Catalonia 2004_2008 15.75 12.10 97.6 PBDR P Patterson C, 2012 (243) 
Sudan                 
 Gezira 1990_1990 7.68 5.00 100.0 PBDR P or H  Diamond, 2006 (318) 
 Khartoum 1991_1995 7.68 10.10 97.0 PBDR NA Elamin et al, 1997 (87) 
Sweden                 
 NW 1983_2007 32.28 32.28 98.0 PBDR P Dahlquist G G, 2011 (74) 
Switzerland                 
 NW 2004_2008 13.10 13.10 91.3 PBDR P Patterson C, 2012 (243) 
TFYR Macedonia                 
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 NW 2004_2008 5.80 5.80 100.0 PBDR P Patterson C, 2012 (243) 
Thailand                 
 Northeastern 1996_2005 0.58 0.58 NA MBR H Panamonta O, 2011 (238) 
Tunisia                 
 Beja, Monastir, Gafsa 1990_1994 7.40 6.69 96.0 PBDR P Ben Khalifa F, 1997 (32) 
 Kairoan 1991_1993 7.40 7.60 NA PBDR P or H  Diamond, 2006 (318) 
 Beja 1990_1999 7.40 7.70 NA PBDR P or H  Diamond, 2006 (318) 
 Gafsa 1990_1999 7.40 8.50 NA PBDR P or H  Diamond, 2006 (318) 
 Monastir 1990_1999 7.40 5.80 NA PBDR P or H  Diamond, 2006 (318) 
Ukraine                 
 NW 1985_1992 8.10 8.10 NA OPD NA Timchenko O I, 1996 (321) 
United Kingdom                 
 NW 1991_2008 19.32 19.32 NA PBDR P Imkampe AK, 2011 (141) 
United Republic of Tanzania               
 Dar es Salaam 1982_1991 0.92 0.92 NA MBR P Swai A B, 1993 (311) 
United States of America                 
 
Seven areas (Population: 
African American Young) 2002_2005 14.01 17.53 NA PBDR P Bell R, 2009 (31) 
 
Seven areas (Population: 
Asian-Pacific Islander Young) 2002_2005 14.01 7.30 NA PBDR P Bell R, 2009 (31) 
 
Seven areas (Population: 
Hispanic Young) 2002_2005 14.01 15.60 NA PBDR P Bell R, 2009 (31) 
 
Seven areas (Population: 
Navajo Young) 2002_2005 14.01 2.13 NA PBDR P Bell R, 2009 (31) 
 
Seven areas (Population: 
Non-Hispanic Withe Young) 2002_2005 14.01 27.47 NA PBDR P Bell R, 2009 (31) 
Uruguay                 
 Montevideo 1992_1992 8.30 8.30 97.0 PBDR P or H  Diamond, 2006 (318) 
Uzbekistan                 
 NW 2000_2000 1.20 1.20 NA OPD NA Rakhimova G G N, 2002  (257) 
Venezuela (Bolivarian Republic of)               
 Caracas 1990_1994 0.10 0.10 NA PBDR P or H  Diamond, 2006 (318) 
  
Table showing the list of publications reporting T1D incidence used in the analyses (*). Information source: 
(PBDR) population-based data register, (MBR) medical-based record, (OPD) other population denominators, 
(NS) non-specified. % Ascertainment: percentage of completeness between primary and secondary sources of 
registers. Data collection process reported in the article: (P) prospective - incident cases collected prospectively 
-, (H) historical -incident cases collected retrospectively -. First author and year of publication. Number of 
reference. NW: Nationwide study. Note: the age range for the reported incidence was 0-14 years, except in the 
following cases: (a) 0-12, (b) 0-13, (c) 0-18, (d) 0-19, (e) updated International Diabetes Federation (IDF) 2013.  
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Model Code Coefficients  Estimate CI 2.5% CI 97.5% Std. Error t-value p-value 
Climate and environment                Res. standard error: 7.834 on 73 
DF; Adjusted R2: 0.3519; F-
statistic: 14.76 on 3 and 73 DF, p-
value: 1.324e-07 
  (Intercept) 18.113 13.071 23.155 2.530 7.160 0.000 
CE_10 CO2 emissions (metric tons per capita) 0.462 0.189 0.735 0.137 3.371 0.001 
CE_16 Outdoor air pollution (Annual PM10 [µg/m3]) -0.008 -0.060 0.045 0.026 -0.288 0.774 
CE_18 UV radiation (J/mt2, 2004) -0.003 -0.005 -0.002 0.001 -4.427 0.000 
Demography   
            
Res. standard error: 7.948 on 75 
DF; Adjusted R2: 0.3274; F-
statistic: 10.61 on 4 and 75 DF, p-
value: 7.2e-07; AIC=336.5 
  (Intercept) -12.909 -79.608 11.928 6.690 -1.930 0.057 
DD_19 Adolescent fertility rate (births per 1,000 women ages 15-19) -0.121 -0.199 -0.019 0.043 -2.776 0.007 
DD_21 Fertility rate, total (births per woman) 4.071 0.956 8.011 1.716 2.373 0.020 
DD_27 Population ages 65 and above (% of total) 0.744 0.181 1.125 0.217 3.430 0.001 
DD_33 Urban population (% of total population) 0.147 -0.032 0.237 0.049 2.986 0.004 
Economy factors                 
Res. standard error:  7.362 on 66 
DF; Adjusted R2: 0.4499; F-
statistic: 10.81 on 6 and 66 DF, p-
value: 2.397e-08 
  (Intercept) -1.488 -11.044 8.068 4.786 -0.311 0.757 
ED_39 Energy use (kg of oil equivalent per capita) 0.001 0.000 0.001 0.000 1.761 0.083 
ED_41 Mobile cellular subscriptions (per 100 people) 0.105 0.039 0.172 0.033 3.151 0.002 
ED_36 Adjusted savings: education expenditure (% of GNI) 1.131 0.052 2.209 0.540 2.092 0.040 
ED_37 Improved sanitation facilities (% of population with access) -0.097 -0.225 0.031 0.064 -1.506 0.137 
EH_45 Health expenditure per capita, (constant 2005 international $) 0.002 0.001 0.003 0.001 2.999 0.004 
EC_33 GDP growth (annual %) -0.473 -1.028 0.083 0.278 -1.700 0.094 
Health conditions                
Res. standard error: 7.23 on 65 
DF; Adjusted R2: 0.4604; F-
statistic: 9.776 on 7 and 65 DF, p-
value: 2.949e-08 
  (Intercept) -105.151 -163.500 -46.802 29.216 -3.599 0.001 
HD_71 Chronic respiratory diseases, deaths. (a)(b) Male 0.074 -0.018 0.166 0.046 1.615 0.111 
HI_59 Hepatitis B (HepB3) immunization (c) -0.118 -0.174 -0.062 0.028 -4.208 0.000 
HR_56 Total alcohol in liters of pure alcohol >15yr. -0.194 -0.640 0.251 0.223 -0.872 0.387 
HR_47 Mean BMI (kg/m2) (a) Male >20 yr. 3.319 1.411 5.228 0.956 3.474 0.001 
HR_51 Mean Total Cholesterol in mmol/l (a) Male >25yr.  8.205 -0.026 16.437 4.122 1.991 0.051 
HR_54 Preterm birth rate (per 100 live births) -0.604 -1.489 0.281 0.443 -1.363 0.178 
HR_55 Prevalence of undernourishment (% of population) 0.189 -0.168 0.545 0.178 1.058 0.294 
Final Summary Model*                 
Res. standard error: 6.84 on 70 
DF; Adjusted R2: 0.5114; F-
statistic: 14.26 on 6 and 70 DF, p-
value: 1.539e-10; AIC=302.76 
  (Intercept) -25.240 -55.934 5.460 15.390 -1.640 0.106 
CE_18 UV radiation (J/mt2, 2004) -0.002 -0.003 0.000 0.001 -1.952 0.055 
DD_21 Fertility rate, total (births per woman) 2.181 -0.430 4.793 1.309 1.666 0.100 
ED_41 Mobile cellular subscriptions (per 100 people) 0.066 0.012 0.121 0.027 2.428 0.018 
EH_45 Health expenditure per capita (constant 2005 international $) 0.001 0.000 0.003 0.001 2.401 0.019 
HI_59 Hepatitis B (HepB3) immunization (c) -0.085 -0.139 -0.032 0.027 -3.187 0.002 
HR_47 Mean BMI (kg/m2) (a) Male >20 yr.  1.263 0.045 2.480 0.611 2.068 0.042 
 





















CI, Confidence Intervals. (a) Age-standardized estimate; (b) per 100,000 individuals; (c) Coverage among 1-year-olds (%). 
SI Table 11: Models by domains and final summary model  
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Small symbols show cross-validation predicted values of T1D incidence. Raw R2  = 0.55, 10-Fold cross-
validated R2 =0.409 
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3.2 Additional analysis of the article: Covariation of the incidence of T1D 
with country characteristics available in public databases 
3.2.1 Correlations between T1D reported in 80 countries vs. 77 global indicators 
Table 12 includes all the information presented in Figure 1 of the paper published in 
Plos One (81) shown in chapter 3. In addition the number of countries with available 
information, the summary measures for each variable, and the reference are presented. The 
tidy database is available on Appendix A: Database III. See Appendix D for the correlation 
matrix between incidence of T1D and independent variables by domains and Appendix E for 
the variable selection of the models. 













variable                     


















 CA_1 Agricultural land (% of land area) 80 0.07 5.29E-01 37.41 21.00 WB 
 CA_2 Arable land (% of land area) 80 0.10 3.96E-01 17.03 14.28 WB 
 CA_3 Cereal production (metric tons) 79 -0.03 8.02E-01 27600000 80200000 WB 
 CA_4 Cereal yield (kg per hectare) 78 0.33 2.77E-03 4419.00 2079.00 WB * 
CA_5 Fertilizer consumption (kilograms per hectare of arable land) 76 0.02 8.63E-01 233.10 487.80 WB 
 CA_6 Forest area (% of land area) 80 -0.06 5.85E-01 28.53 19.39 WB 
 CA_7 Permanent cropland (% of land area) 79 -0.36 1.08E-03 1.83 2.79 WB * 
Environment 
 CE_8 Annual precipitation by country: values in millimeters. (Mean 1961-1999) 77 -0.16 1.71E-01 845.60 582.50 WB-C * 
CE_9 Annual temperatures by country: values in degrees Celsius. (Mean 1961-1999) 77 -0.44 5.45E-05 13.76 8.48 WB-C * 
CE_10 CO2 emissions (metric tons per capita) 80 0.61 1.38E-09 7.16 6.57 WB * 
CE_11 Latitude 80 0.56 5.31E-08 29.88 26.30 GM * 
CE_12 Longitude 80 -0.14 2.15E-01 15.08 59.45 GM 
 CE_13 Methane emissions (kt of CO2 equivalent) 75 -0.18 1.32E-01 81100.00 
219000.0
0 WB * 
CE_14 Nitrous oxide emissions (thousand metric tons of CO2 equivalent) 75 -0.15 1.94E-01 30500.00 79200.00 WB * 
CE_15 Nitrous oxide emissions in industrial and energy processes (% of total nitrous oxide emissions) 75 0.32 5.69E-03 17.68 12.29 WB * 
CE_16 Outdoor air pollution (Annual PM10 [ug/m3]) 77 -0.42 1.38E-04 52.07 39.62 WHO * 
CE_17 PM10, country level (ug/m3) 76 -0.32 5.25E-03 32.57 26.88 WB * 







 DD_19 Adolescent fertility rate (births per 1,000 women ages 15-19) 80 -0.47 1.06E-05 26.89 25.70 WB * 
DD_20 Female mean age of childbearing (years) 80 0.44 3.62E-05 28.88 1.59 UN * 
DD_21 Fertility rate, total (births per woman) 80 -0.25 2.65E-02 1.99 0.78 WB * 
DD_22 Life expectancy at birth, female (years) 80 0.58 1.94E-08 78.60 5.62 WB * 
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Mean SD Ref  DD_23 Life expectancy at birth, m le (years) 80 0.60 3.53E-09 73.17 5.65 WB * 
DD_24 Life expectancy at birth, total (years) 80 0.60 2.92E-09 75.82 5.52 WB * 
DD_25 Population ages 0-14 (% of total) 80 -0.42 1.10E-04 21.17 7.58 WB * 
DD_26 Population 15-64 years of age (% of total) 80 0.07 5.29E-01 67.12 4.60 WB 
 DD_27 Population ages 65 and above (% of total) 80 0.51 1.52E-06 11.72 5.74 WB * 
DD_28 Population growth (annual %) 80 -0.20 8.05E-02 0.98 1.51 WB * 
DD_29 Population, female (% of total) 80 0.14 2.15E-01 50.01 3.87 WB 
 
DD_30 
Probability of dying between birth and the age of 40 
years (both sexes combined) (deaths under age 40 
per 1,000 live births) 80 -0.65 9.91E-11 51.96 47.70 UN * 
DD_31 Rural population (% of total population) 80 -0.41 1.46E-04 30.14 19.79 WB * 
DD_32 Total population 0-14 years (both sexes combined) 80 -0.32 4.16E-03 15200.00 49900.00 UN * 









 EC_33 GDP growth (annual %) 79 -0.47 1.07E-05 3.42 3.87 WB * 
EC_34 GDP per capita (constant 2005 US$) 79 0.72 9.05E-14 17800.00 17900.00 WB * 
EC_35 GDP per capita, PPP (constant 2005 international $) 78 0.71 5.24E-13 20100.00 14500.00 WB * 
Development 
 ED_36 Adjusted savings: education expenditure (% of GNI) 75 0.45 5.56E-05 4.75 1.91 WB * 
ED_37 Improved sanitation facilities (% of population with access) 78 0.67 2.08E-11 88.06 21.23 WB * 
ED_38 Improved water source (% of population with access) 79 0.67 1.60E-11 93.68 12.83 WB * 
ED_39 Energy use (kg of oil equivalent per capita) 79 0.69 1.22E-12 3303.00 3045.00 WB * 
ED_40 Energy use (kg of oil equivalent) per $1,000 GDP (constant 2005 PPP) 77 -0.14 2.13E-01 183.60 113.80 WB 
 ED_41 Mobile cellular subscriptions (per 100 persons) 80 0.44 4.93E-05 113.30 35.84 WB * 
ED_42 Population using solid fuels (total population: urban + rural) 80 -0.50 2.68E-06 11.32 22.71 WHO * 
Health Economy 
 EH_43 External resources for health (% of total expenditure on health) 79 -0.62 7.62E-10 2.06 7.28 WB * 
EH_44 Health expenditure per capita (current US$) 79 0.73 1.62E-14 1942.00 2198.00 WB * 








Risk Factors for Non-Communicable Diseases 
 HR_46 Mean BMI (kg/m
2) (age-standardized estimate) 
Female +20 80 0.11 3.32E-01 26.19 2.003 WHO 
 HR_47 Mean BMI (kg/m
2) (age-standardized estimate) 
Male +20 80 0.63 2.58E-10 26.2 1.728 WHO * 
HR_48 Mean systolic blood pressure in mm Hg (age-standardized estimate) Female +25 80 -0.18 1.19E-01 124.9 4.037 WHO * 
HR_49 Mean systolic blood pressure in mm Hg (age-standardized estimate) Male +25 80 0.19 8.41E-02 131 3.671 WHO * 
HR_50 Mean total Cholesterol in mmol/l (age-standardized estimate) Female+25 80 0.62 1.25E-09 5.018 0.2841 WHO * 
HR_51 Mean total Cholesterol in mmol/l (age-standardized estimate) Male +25 80 0.70 5.18E-13 4.95 0.3504 WHO * 
HR_52 Obesity: % of defined population with a BMI ≥ 30 kg/m2 (age-standardized estimate) Both Sexes +20 80 0.33 3.06E-03 21.18 8.347 WHO * 
HR_53 Overweight: % population with a BMI ≥ 25 kg/m2 (age-standardized estimate) Both Sexes +20 80 0.37 7.49E-04 52.52 14.03 WHO * 
HR_54 Preterm birth rate (per 100 live births) 79 -0.27 1.44E-02 8.46 2.46 WHO * 
HR_55 Prevalence of undernourishment (% of population) 75 -0.59 2.41E-08 8.25 8.31 WB * 
HR_56 Total alcohol in liters of pure alcohol per capita consumption, estimation for 2008, both sexes +15 79 0.44 4.38E-05 8.55 5.09 WHO * 
Infectious Diseases and Immunization 
 HI_57 Diphtheria tetanus toxoid and pertussis (DTP3) immunization coverage among 1-year-olds (%) 80 0.24 3.00E-02 93.51 7.43 WHO * 
HI_58 Haemophilus influenzae type B vaccine (Hib3) immunization coverage among 1-year-olds (%) 80 0.48 5.20E-06 81.96 29.99 WHO * 
HI_59 Hepatitis B (HepB3) immunization coverage among 1-year-olds (%) 80 -0.18 1.07E-01 77.83 33.97 WHO * 
HI_60 Incidence of tuberculosis (per 100,000 persons) 80 -0.61 1.91E-09 49.38 72.24 WB * 
UPMC - ED 393 - 2015  Epidemiology of Type I Diabetes: 















variable                     




Mean SD Ref  HI_61 Measles - number of reported cases (standardized using population 0-14 years, per 100,000 persons)  80 0.05 6.91E-01 1753.85 12200.35 WHO 
 HI_62 Measles (MCV) immunization coverage among 1-year-olds (%) 80 0.02 8.28E-01 93.18 6.91 WHO 
 HI_63 Measles immunization coverage among children ages 12-23 months (%) 79 -0.03 7.70E-01 92.75 8.35 WB 
 HI_64 Pertussis - number of reported cases (standardized using population 0-14 years, per 100,000 persons)  76 0.08 4.91E-01 2112.76 16092.82 WHO 
 
HI_65 
Polio (Pol3) immunization coverage among 1-year-
olds (%) 
 80 0.23 4.46E-02 93.58 7.37 WHO * 
Deaths from Non-Communicable Diseases 
 HD_66 Cancers, deaths per 100,000 (age-standardized estimate) Female 80 0.22 4.60E-02 94.44 16.25 WHO * 
HD_67 Cancers, deaths per 100,000 (age-standardized estimate) Male 80 0.28 1.26E-02 146.00 43.67 WHO * 
HD_68 Cardiovascular diseases and diabetes, deaths per 100,000 (age-standardized estimate) Female 80 -0.50 2.77E-06 229.60 125.00 WHO * 
HD_69 Cardiovascular diseases and diabetes, deaths per 100,000 (age-standardized estimate) Male 80 -0.39 3.10E-04 325.60 170.20 WHO * 
HD_70 Chronic respiratory diseases, deaths per 100,000 (age-standardized estimate) Female 80 -0.34 1.99E-03 22.79 20.95 WHO * 
HD_71 Chronic respiratory diseases, deaths per 100,000 (age-standardized estimate) Male 80 -0.37 7.89E-04 41.85 30.49 WHO * 
HD_72 NCD deaths under age 60 (% of all non communicable diseases deaths) Both sexes 80 -0.58 1.31E-08 21.06 10.76 WHO * 
HD_73 
Probability of dying between exact ages 30 and 70 
from any cardiovascular disease, cancer, diabetes, or 
chronic respiratory disease (%) 80 -0.44 3.98E-05 18.58 6.52 WHO * 
Infant and Maternal Mortality Rates 
 HM_7
5 
Infant mortality rate (probability of dying between 
birth and age 1 per 1000 live births) Both sexes 80 -0.66 2.01E-11 11.44 12.84 WHO * 
HM_7
6 
Maternal mortality ratio (modeled estimate, per 
100,000 live births) 80 -0.62 1.12E-09 55.82 109.00 WB * 
HM_7
7 
Mortality rate, under-5 (probability of dying by age 
5 per 1000 live births) 80 -0.67 7.57E-12 14.15 17.12 WB * 
  
 Note: in gray correlations reporting a p-value ≤ 0.000649 (Using Bonferroni correction [0.05/n 
variables]), (*) p-value ≤0.2. References: (WB) World Bank (2012) Indicators. Available from 
http://data.worldbank.org/indicator, accessed 11-08 2012; (WB-C) World Bank (2012) Climate Change 
Knowledge Portal:  Historical Data. Available from http://data.worldbank.org/developers/climate-data-api, 
accessed 11-08 2012; (WHO) WHO (2012) Global Health Observatory Data Repository. Available from 
http://apps.who.int/gho/data/?vid=2472, accessed 11-08 2012; (UN) United Nations, Department of Economic 
and Social Affairs (2011) World Population Prospects, the 2010 Revision. Available from 
http://esa.un.org/wpp/Excel-Data/population.htm, accessed May 31 2012; (GM) Google Maps API 
Geographical coordinates 2013. Available from http://universimmedia.pagesperso-orange.fr/geo/loc.htm. 
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3.2.2 Principal component analyses of the variables included in the final model  
Principal Component Analyses (PCA) were performed to evaluate the final full model 
of the article presented in chapter 3 (81) before the backward selection presented in AP 
Table 35. The principal components using the set of all significant variables (at p-value 
≤0.05) after applying MLM for each domain are presented in SI Figure 18. Related with the 
incidence of T1D three clusters were identified: associated with the geographic position 
(circle in blue), with urban conditions (circle in green), and with develop and wealthy (circle 
in red). The variable that best summarize negative correlations was UV radiation (CE_18) in 
the geographic cluster, related with lack of sun exposition and vitamin D3 hypothesis (338, 
367); for positive correlations, the percentage of urban population (DD_33) and the BMI in 
males (HR_47), in the urban conditions cluster were noted, related with the “accelerator 
hypothesis” (361), the “overload hypothesis” (71), and the presence of endocrine disruptors 
(136, 137), and population aged over 65 years (DD_27) in the developing and wealthy 
cluster. See Appendix D for the correlation matrix between incidence of T1D and 













CE_10: CO2 emissions (metric tons per capita); CE_18: UV radiation (J/mt2, 2004); DD_19: Adolescent 
fertility rate (births per 1,000 women aged 15-19); DD_21: Fertility rate, total (births per woman); DD_27: 
Population aged 65 and above (% of total); DD_33: Urban population (% of total population); ED_41: Mobile 
cellular subscriptions (per 100 persons); ED_36: Adjusted savings: education expenditure (% of GNI); EH_45: 
Health expenditure per capita, PPP (constant 2005 international $); HI_59: Hepatitis B (HepB3) immunization 
coverage among 1-year-olds (%); HR_47: Mean BMI (kg/m2) (age-standardized estimate) Male >20 years of 
age. 
SI Figure 18: Variables Factor Map (PCA): significant variables for all domains 
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Introduction La surveillance du contrôle glycémique des patients diabétiques
par l’hémoglobine glyquée (HbA1c) s’avère difficile dans certaines zones du
Brésil éloignées des centres urbains et ayant un accès restreint à des laboratoires
d’analyses médicales. Des appareils portables mesurant l’HbA1c en instantané
sur une goutte de sang capillaire pourraient rendre service dans ce cadre.
Méthodes La performance de l’appareil portable A1cNow+ (Bayer) a été tes-
tée en conditions cliniques habituelles chez 55 patients diabétiques volontaires
du service d’endocrinologie de l’hôpital de référence de l’état de Pernambouc.
Leur HbA1c a été mesurée par l’appareil et sur sang veineux, par la méthode
Vitros 5,1FS prise comme référence. L’exactitude des résultats de l’A1CNow+
par rapport à la référence a été jugée par le graphique de Bland-Altman. Son
utilité en clinique a été évaluée par le calcul de la sensibilité et de la spécifi-
cité par rapport au seuil de 7 % d’HbA1c, en dessous duquel le diabète est jugé
contrôlé.
Résultats L’écart moyen entre l’A1CNow+ et la méthode Vitros 5,1FS
était de +0,67 % (IC : +0,52 à +0,81). Les limites d’agrément du graphique
allaient de–0,45 % (IC :–0,71 à–0,19) à +1,82 % (IC : 1,52 à 2,05). La sensi-
bilité par rapport au seuil de 7 % était de 100 %, et la spécificité de 67,7 %.
Dix patients sur 55 étaient mal classés par l’A1CNow+, tous étant des faux
positifs.
Conclusion La spécificité et l’exactitude de l’A1cNow+ en conditions cli-
niques habituelles ne sont pas suffisantes pour proposer son utilisation dans les
zones où l’accès à un laboratoire d’analyses médicales est difficile.
Mots clés Hémoglobine glyquée ; Diabète sucré ; Analyseur portable ;
Soins primaires de santé




Prévalence et facteurs de risque de la maladie
rénale chronique dans une population noire :
échantillon de la Clinique régionale du Kivu
J. Bagula a, L. Maroyi b, M. Burnier c, O. Devuyst d
a Clinique régionale du Kivu, Service de néphrologie et dialyse, R.D. Congo
b Clinique régionale du Kivu, Service d’épidémiologie et dialyse, R.D. Congo
c Centre hospitalier universitaire vaudois, Service de néphrologie et
hypertension, Suisse
d Centre de physiologie rénale, Université de Zurich, Suisse
Introduction La prévalence de la maladie rénale chronique (MRC) est incon-
nue en Afrique. L’ampleur de cette maladie dans la population noire a été estimée.
Une étude de population à grande échelle doit être menée dans la Région des
Grands-Lacs pour cerner l’ampleur réelle de cette maladie. Nous avons mené
une étude de population à Bukavu pour identifier la prévalence et les facteurs
de risque de la maladie rénale chronique.
Méthode Un échantillon de 1289 patients âgés de 18 ans a été recueilli de
janvier 2013 à janvier 2014 selon la méthode Steps, interviewé et testé pour
identifier l’hématurie, l’albuminurie et estimer la fonction rénale. La méthode de
Jaffé cinétique a été utilisée pour la créatinine sérique. Les logiciels SPSS 18.0,
2010/Windows et Medical 9.1.01, 2010 ont été utilisés pour l’analyse statistique.
Pour la comparaison des fréquences, le test Chi2 avec correction de Yates a été
utilisé.
Résultats La prévalence ajustée a été respectivement de 38,8 % (95 %
CI : 36,2–41,5 %) l’hypertension, de 16,2 % (95 % CI : 2,8–4,9 %) pour
l’albuminurie, de 3,9 % (95 % CI : 2,8–4,9 %) pour l’hématurie et de 2,1 %
(95 % CI : 1,3–2,9 %) pour la réduction de l’eGFR. L’hypertension artérielle
et la présence de l’albuminurie ont été fortement et indépendamment associées
avec l’hyperuricémie et l’élévation de l’hématocrite.
Conclusion Cette étude épidémiologique est la première menée dans la popu-
lation noire. Nous avons trouvé une prévalence élevée de la MRC associée à une
haute prévalence de l’albumine, de l’hypertension et de l’hématocrite dans la
population à Bukavu. La présente étude indique un besoin urgent de développer
des stratégies compréhensives dont la cible sera la réduction de la MRC, basées
sur une compréhension de ses facteurs de risque.
Mots clés Maladie rénale ; Clinique régionale du Kivu ; Bukavu




Impact du dépistage organisé du cancer
colorectal sur la détection des adénomes dans
la population de Côte-d’Or
V. Cottet a, V. Jooste b, V. Dancourt c, J. Faivre b, A.-M. Bouvier b
a Inserm U866, Registre des polypes de Côte-d’Or, CHU de Dijon, Dijon,
France
b Inserm U866, Registre Bourguignon des cancers digestifs, CHU de Dijon,
Dijon, France
c Inserm U866, ADECA 21-58, Dijon, France
Introduction L’amélioration de la détection des adénomes, lésions précan-
céreuses courantes chez les personnes âgées de 50 à 74 ans, et leur résection
par coloscopie est un des enjeux majeurs du programme de dépistage organisé
du cancer colorectal (DO). Notre objectif était d’évaluer à partir des données
de Registre, si la mise en place du DO en 2003 a permis d’améliorer en pra-
tique courante le taux de détection des adénomes, en particulier à haut risque de
cancérisation (AHR).
Méthodes À partir du seul Registre enregistrant tous les polypes colorectaux
sur l’ensemble d’un département depuis 1976, tous les résidents de Côte-d’Or
âgés de 50 à 74 ans ayant eu un premier adénome ou carcinome in situ entre
1997 et 2008 ont été inclus. Les taux standardisés de détection des adénomes
ont été étudiés selon deux périodes « pré-dépistage (1997–2002) » et « post-
dépistage (2003–2008) », en distinguant les individus ayant participé au DO des
non-participants et les individus avec test positif des faux négatifs.
Résultats Parmi les 8041 individus inclus, 38,7 % avaient un AHR. Le taux
standardisé de détection des AHR était de 136,1/100 000 pour la période pré-
dépistage et 256,6/100 000 pour la période post-dépistage, avec un taux de
variation de 89 % entre les deux périodes. Pour les adénomes à bas risque,
le taux de variation correspondant était de 68 %.
Conclusion Il s’agit de la première étude en population générale mon-
trant l’impact marqué du DO sur la détection des AHR puisque les structures
d’organisation du DO ne disposent pas de ce type de données sur une grande
période de temps et à l’échelle d’un département.




Incidence mondiale de diabète de type 1 :
revue systématique et corrélation avec des
bases de données publiques
P.A. Diaz-Valencia a,b, P. Bougnères c,d,e, A.-J. Valleron a,b
a Inserm Unité 986, Le Kremlin-Bicêtre, France
b Université Pierre et Marie Curie-Paris 6, Paris, France
c Inserm Unité 986, Le Kremlin-Bicêtre. France
d Université Paris-Sud-Faculté de médecine, Le Kremlin-Bicêtre, France
e AP–HP, Hôpital Kremlin Bicêtre, Service endocrinologie, Le Kremlin
Bicêtre, France
Introduction L’incidence du diabète de type 1 (DT1) varie considérablement
selon les pays au niveau mondial ; on observe une augmentation significative de
cette incidence au cours des dernières décennies.
Méthodes Une revue systématique de la littérature a été effectuée. L’incidence
du DT1 chez les enfants âgés de 0 à 14 ans a été corrélée avec les données
publiques disponibles au niveau mondial dans les domaines de l’environnement,
la démographie, l’économie et la santé. Les recommandations de PRISMA ont
été respectées.
Résultats Au total, 527 ensembles de données concernant l’incidence du
DT1 ont été obtenus à partir de 265 publications originales (1975–2013). Les
articles contenaient des informations sur 90 territoires, 69 % de la population
globale des enfants de 0–14 ans. L’incidence varie de 0,08/100 000 en
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Papouasie-Nouvelle-Guinée à 62,42/100 000 en Finlande. En effectuant
une régression multiple, on met en évidence une corrélation positive entre
l’incidence du DT1 et l’indice de masse corporelle ainsi que deux variables
liées aux revenus du pays (la consommation d’énergie électrique et le nombre
d’abonnés à la téléphonie mobile). Des corrélations négatives ont été trouvés
avec : le rayonnement UV, les émissions de CO2, la consommation d’alcool, et
la vaccination contre l’hépatite B (toutes les valeurs de p < 0,05).
Discussion Les incidences de DT1 sont plus hautes dans les pays à revenu
élevé. Les variations entre les pays sont encore inexpliquées. La disponibilité
d’informations sur l’incidence et l’accès aux bases de données publiques, per-
mettra de faire plus d’analyses systématiques d’association et ainsi d’identifier
les facteurs associés à la maladie.
Mots clés Épidémiologie ; Incidence ; Revue systématique ; Diabète de
type 1




Prévalence de la schizophrénie au sud du
Bénin
J. Ezin Houngbé a, M.G. Gansou a, R. Agongbonou b, Y. Amonles a,
C.M. Tognide a, D. Houinato c, V. Avahoui c
a Centre national hospitalier et universitaire, Service de psychiatrie, Cotonou,
Bénin
b Programme national de lutte contre les maladies non transmissibles,
Cotonou, Bénin
c LEMACEN, FSS, Cotonou, Bénin
Introduction La schizophrénie, psychose chronique dissociative, constitue un
problème majeur de santé publique. Sa prévalence mondiale est de 1 %. Aucune
étude en population générale béninoise ne s’est penchée sur cette pathologie,
d’où notre étude qui avait pour but d’étudier les aspects épidémiologiques de la
schizophrénie dans la zone sanitaire Ouidah-Kpomassè-Tori Bossito en 2013.
Méthodes Il s’est agi d’une étude transversale descriptive et analytique. Elle
s’est déroulée du 17 au 24 août 2013 dans la zone sanitaire Ouidah-Kpomassè-
Tori-Bossito. Elle a été menée selon une technique de sondage en grappes et
a porté sur 1530 sujets. Les données ont été collectées à l’aide de l’outil MINI
(« Mini International Neuropsychiatric Interview ») version 5.0.0 et d’un guide
structuré comportant des données spécifiques à la santé mentale. Elles ont été
saisies et analysées à l’aide des logiciels Epi data et Epi-info. Les comparaisons
de fréquence ont été faites à l’aide du test de Chi2 et un p < 0,05 a été considéré
comme significatif.
Résultats La prévalence de la schizophrénie était de 1,1 %. Elle était signi-
ficativement plus élevée chez les personnes ayant un antécédent familial de
schizophrénie (p = 0,04), les chômeurs (p < 10−4) et les séparés/divorcés/veuf
(ve)s (p = 10−3). En revanche, cette étude n’a pas retrouvé d’association entre
la schizophrénie et les autres variables étudiées.
Discussion Cette étude montre l’importance de la schizophrénie dans cette
zone. La prévalence observée est comparable à celle retrouvée dans la littérature.




Prévalence et facteurs associés aux troubles
de l’humeur
D. Houinato a, E. Kpadonou Fiossi b, F. Hounyo b, Y. Amonles c,
V. Avahoui a, J. Ezin Houngbe c, T. Agossou b
a LEMACEN, FSS, Cotonou, Bénin
b Département de santé mentale, CNHU, Abomey-Calavi, Bénin
c Centre national hospitalier et universitaire, Service de psychiatrie, Cotonou,
Bénin
Introduction Parmi les troubles mentaux, ceux portant sur l’humeur occupent
une place primordiale. Les troubles de l’humeur comprennent les troubles
dépressifs, la manie et les troubles bipolaires. L’objectif général de notre étude
était d’étudier la prévalence des troubles de l’humeur dans la zone sanitaire
Ouidah Kpomassè Tori-Bossito du Bénin.
Méthodes Il s’agissait d’une étude transversale, de type quantitatif, à visée
descriptive et analytique. La population d’étude était constituée de sujets âgés
de 15 ans et plus résidant dans la zone sanitaire.
Résultats Les 1530 sujets inclus dans l’étude étaient répartis en 665 (43,5 %)
sujets de sexe masculin et en 865 (56,5 %) sujets de sexe féminin avec un sex-
ratio de 0,77. Parmi les enquêtés, 23,5 % ont présenté un épisode dépressif
majeur actuel (EDM) et la prévalence de l’EDM actuel était plus élevée chez les
femmes (28,0 %) contre 17,7 % chez les hommes. La prévalence de la dysthymie
était de 3,1 % et 3,0 % des sujets de sexe masculin. La prévalence des épisodes
maniaques a été de 3,1 % et de 2,9 % chez les sujets de sexe masculin contre
3,2 % chez les sujets de sexe féminin. La prévalence des troubles bipolaires était
de 3,7 % des enquêtés et en fonction du sexe, elle était significativement plus
élevée chez les sujets féminins (4,5 %).
Discussion Il ressort de cette étude que la prévalence des troubles de l’humeur
était élevée dans la zone sanitaire avec à la tête les troubles dépressifs. Les épi-
sodes maniaques et les troubles bipolaires quoique relativement moins fréquents,
demeuraient présents dans cette population.




Épidémiologie du syndrome métabolique
dans la population urbaine en Algérie. Oran,
Algérie
L. Houti a,b,c, I. Hamani-Medjaoui d, S.A. Lardjam-Hetraf c,
H. Ouhaibi-Djellouli c,e, L. Goumidi f, S. Mediene-Benchekor c,e
a Faculté de médecine, Université Djillali Liabes de Sidi Bel Abbès, Sidi Bel
Abbès, Algérie
b Laboratoire des systèmes d’information en santé, Université d’Oran, Oran,
Algérie
c Laboratoire de génétique moléculaire et cellulaire, Université des sciences et
de technologie d’Oran Mohamed Boudiaf, Oran, Algérie
d Caisse nationale des assurances sociales des travailleurs salariés, Clinique
spécialisée en orthopédie et rééducation des victimes des accidents de travail,
Oran, Algérie
e Département de biotechnologie, Faculté des sciences de la nature et de la vie,
Université d’Oran, Oran, Algérie
f Inserm U744, Institut Pasteur de Lille; Université Lille Nord de France,
Lille, France
Introduction Le vieillissement combiné aux changements du mode de vie a
conduit à une transition épidémiologique en Afrique du Nord. Ces changements
ont un impact significatif sur l’incidence des maladies cardiovasculaires. Dans
ce contexte, les prévalences du syndrome métabolique et des facteurs associés
sont mal connues. Cette étude se propose de mesurer ces prévalences dans la
population urbaine d’Oran.
Méthodes Une enquête en population a été réalisée, en 2007–2009 dans la
population oranaise (30 à 64 ans). Les sujets, tirés au sort dans la liste des assurés
sociaux de la ville d’Oran, ont été adressés au laboratoire CNASS. Au total,
787 sujets (ratio M/F = 0,94) ont participé à l’enquête. Le syndrome métabolique
est défini selon les critères de la « National Cholesterol Education Program,
Adult Treatment Panel III ».
Résultats La prévalence du syndrome métabolique, défini selon les critères
NCEP-ATPIII, est de 20,0 % et plus élevée chez les femmes versus les hommes
(25,9 contre 13,7 %; p < 10−4). Parmi les composantes du syndrome, les facteurs
de risque le plus souvent observés chez les femmes sont une faible concentration
de HDL-cholestérol (60,4 versus 44,2 % chez les hommes) et l’obésité abdomi-
nale (46,8 versus 30,1 % chez les hommes) tandis que les hommes affichent plus
l’hypertension artérielle (42,5 versus 34,8 % chez les femmes).
Discussion Le syndrome métabolique est fréquent dans la population urbaine
au Nord de l’Algérie, principalement chez les femmes qui montrent des fré-
quences élevées de cholestérol-HDL bas et d’obésité abdominale.
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Introduction La surveillance du contrôle glycémique des patients diabétiques
par l’hémoglobine glyquée (HbA1c) s’avère difficile dans certaines zones u
Brésil éloignées des centres urbains et ayant un accès restreint à des laboratoires
d’analyses médicales. Des appareils portables mesurant l’HbA1c en instantané
sur une goutte de sang capillaire pourraient rendre service dans ce cadre.
Méthodes La performance de l’appareil portable A1cNow+ (Bayer) a été tes-
tée en conditions cliniques habituelles chez 55 patients diabétiques volontaires
du service d’endocrinologie de l’hôpital de référence de l’état de Pernambouc.
Leur HbA1c a été mesurée par l’appareil et sur sang veineux, par la méthode
Vitros 5,1FS prise comme référence. L’exactitude des résultats de l’A1CNow+
par rapport à la référence a été jugée par le graphique de Bland-Altman. Son
utilité en clinique a été évaluée par le calcul de la sensibilité et de la spécifi-
cité par rapport au seuil de 7 % d’HbA1c, en dessous duquel le diabète est j gé
contrôlé.
Résultats L’écart moyen entre l’A1CNow+ et la méthode Vitros 5,1FS
était de +0,67 % (IC : +0,52 à +0,81). Les limites d’agrément du graphique
allaient de–0,45 % (IC :–0,71 à–0,19) à +1,82 % (IC : 1,52 à 2,05). La sensi-
bilité par rapport au seuil de 7 % était de 100 %, et la spécificité de 67,7 %.
Dix patients sur 55 étaient mal classés par l’A1CNow+, tous étant des faux
positifs.
Conclusion La spécificité et l’exactitude de l’A1cNow+ en conditions cli-
niques habituelles ne sont pas suffisantes pour proposer son utilisation dans les
zones où l’accès à un laboratoire d’analyses médicales est difficile.
Mots clés Hémoglobine glyquée ; Diabète sucré ; Analyseur portable ;
Soins primaires de santé




Prévalence et facteurs de risque de la m ladie
rénale chronique dans une population noire :
échantillon de la Clinique régionale du Kivu
J. Bagula a, L. Maroyi b, M. Burnier c, O. Devuyst d
a Clinique régionale du Kivu, Service de néphrologie et dialyse, R.D. Congo
b Clinique régionale du Kivu, Service d’épidémiologie et dialyse, R.D. Congo
c Centre hospitalier universitaire vaudois, Service de néphrologie et
hypertension, Suisse
d Centre de physiologie rénale, Université de Zurich, Suisse
Introduction La prévalence de la maladie rénale chronique (MRC) est incon-
nue en Afrique. L’ampleur de cette maladie dans la population noire a été estimée.
Une étude de population à grande échelle doit être menée dans la Région des
Grands-Lacs pour cerner l’ampleur réelle de cette maladie. Nous avons mené
une étude de population à Bukavu pour identifier la prévalence et les facteurs
de risque de la maladie rénale chronique.
Méthode Un échantillon de 1289 patients âgés de 18 ans a été recueilli de
janvier 2013 à janvier 2014 selon la méthode Steps, interviewé et testé pour
identifier l’hématurie, l’albuminurie et estimer la fonction rénale. La méthode de
Jaffé cinétique a été utilisée pour la créatinine sérique. Les logiciels SPSS 18.0,
2010/Windows et Medical 9.1.01, 2010 ont été utilisés pour l’analyse statistique.
Pour la comparaison des fréquences, le test hi2 avec correction de Yates a été
utilisé.
Résultats La prévalence ajustée a été respectivement de 38,8 % (95 %
CI : 36,2–41,5 %) l’hypertension, de 16,2 % (95 % CI : 2,8–4,9 %) pour
l’albuminurie, de 3,9 % (95 % CI : 2,8–4,9 %) pour l’hématurie et de 2,1 %
(95 % CI : 1,3–2,9 %) pour la réduction de l’eGFR. L’hypertension artérielle
et la présence de l’albuminurie ont été fortement et indépendamment associées
avec l’hyperuricémie et l’élévation de l’hématocrite.
Conclusion Cette étude épidémiologique est la première menée dans la popu-
lation noire. Nous avons trouvé une prévalence élevée de la MRC associée à une
haute prévalence de l’albumine, de l’hypertension et de l’hématocrite dans la
population à Bukavu. La présente étude indique un besoin urgent de développer
des stratégies compréhensives dont la cible sera la réduction de la MRC, basées
sur une compréhension de ses facteurs de risque.
Mots clés Maladie rénale ; Clinique régionale du Kivu ; Bukavu




Impact du dépistage organisé du cancer
colorectal sur la détection des adénomes dans
la population de Côte-d’Or
V. Cottet a, V. Jooste b, V. Dancourt c, J. Faivre b, A.-M. Bouvier b
a Inserm U866, Registre des polypes de Côte-d’Or, CHU de Dijon, Dijon,
France
b Inserm U866, Registre Bourguignon des cancers digestifs, CHU de Dijon,
Dijon, France
c Inserm U866, ADECA 21-58, Dijon, France
Introduction L’amélioration de la détection des adénomes, lésions précan-
céreuses courantes chez les personnes âgées de 50 à 74 ans, et leur résection
par coloscopie est un des enjeux majeurs du programme de dépistage organisé
du cancer colorectal (DO). Notre objectif était d’évaluer à partir des données
de Registre, si la mise en place du DO en 2003 a permis d’améliorer en pra-
tique courante le taux de détection des adénomes, en particulier à haut risque de
cancérisation (AHR).
Méthodes À partir du seul Registre enregistrant tous les polypes colorectaux
sur l’ensemble d’un département depuis 1976, tous les résidents de Côte-d’Or
âgés de 50 à 74 ans ayant eu un premier adénome ou carcinome in situ entre
1997 et 2008 ont été inclus. Les taux standardisés de détection des adénomes
ont été étudiés selo deux périodes « pré-dépistage (1997–2002) » et « post-
dépistage (2003–2008) », en distingua t les individus ayant participé au DO des
non-participants et les individus avec test positif des faux négatifs.
Résultats Parmi les 8041 individus inclus, 38,7 % avaient un AHR. Le taux
standardisé de détection des AHR était de 136,1/100 000 pour la période pré-
dépistage et 256,6/100 000 pour la période post-dépistage, avec un taux de
variation de 89 % entre les deux périodes. Pour les adénomes à bas risque,
le taux de variation correspondant était de 68 %.
Conclusion Il s’agit d la première étude en population générale mon-
trant l’impact marqué du DO sur la étection des AHR puisque les structures
d’organisation du DO ne disposent pas de ce type de données sur une grande
période de temps et à l’échelle d’un département.




Incidence mondiale de diabète de type 1 :
revue systématique et corrélation avec des
bases de données publiques
P.A. Diaz-Valencia a,b, P. Bougnères c,d,e, A.-J. Valleron a,b
a Inserm Unité 986, Le Kremlin-Bicêtre, France
b Université Pierre et Marie Curie-Paris 6, Paris, France
c Inserm Unité 986, Le Kremlin-Bicêtre. France
d Université Paris-Sud-Faculté de médecine, Le Kremlin-Bicêtre, France
e AP–HP, Hôpital Kremlin Bicêtre, Service endocrinologie, Le Kremlin
Bicêtre, France
Introduction L’incidence du diabète de type 1 (DT1) varie considérab ement
selon les pays au niveau mondial ; on observe une augmentation significative de
cette incidence au cours des dernières décennies.
Méthodes Une revue systématique de la littérature a été effectuée. L’incidence
du DT1 chez les enfants âgés de 0 à 14 ans a été corrélée avec les données
publiques disponibles au niveau mondial dans les domaines de l’environnement,
la émographie, l’économie et la santé. Les recommandations de PRISMA ont
été respectées.
Résultats Au total, 527 ensembles de données concernant l’incidence du
DT1 ont été obtenus à partir de 265 publications originales (1975–2013). Les
articles contenaient des informations sur 90 territoires, 69 % de la population
globale des enfants de 0–14 ans. L’incidence varie de 0,08/100 000 en
3.2.3 Published Abstract: Incidence mondiale du diabète de type 1: revue 
systématique et corrélation avec des bases de données publiques 
A preliminary version of the analyses presented in the paper: Covariation of the 
incidence of T1D with country characteristics available in public databases (81) was 
presented during the VI International Congres  of Epid miol gy, and publishe  in French in 
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3.3 Additional analyses of the epidemiology of T1D among children 
3.3.1 Comparison of countries with and without information using 95 indicators 
Eighty countries with information on incidence of T1D and 116 without information 
were compared. For these analyses, the criteria of variable selection did not consider the 
exclusion of variables when information was unavailable in “less than 5% of the countries”. 
This yielded 95 independent variables in total, 18 more indicators than presented above, see 
SI Table 13. 
When compared to the countries with T1D information, those for which such 
information was lacking had: a four-fold higher under-five mortality rate (p=3.40×10-18), a 
two-fold higher premature mortality rate (p=6.28×10-19), 1.5 more deaths labeled as 
“cardiovascular diseases and diabetes” (p=4.78×10-11); their fraction of urban population was 
50% lower (p=1.70×10-15), and their health expenditures per capita (319) were 8.7 fold lower 
(p=3.25×10-15).  











Countries with available           
information on T1D 
Countries without 





















Agricultural Land area in Km2. (Mean 2000-2008)  194 39 20 74 40 23 111 8.57E-01 UN 
Agricultural land: % of land area. (Mean 2000-2009) 185 438100 
101200
0 74 139300 268700 120 3.08E-02 WB 
Alternative and nuclear energy: % of total energy 
used. (Mean 2000-2010) 134 12 18 71 6 11 63 1.91E-02 WB 
Arable Land area in Km2. (Mean 2000-2008) 194 138800 335400 74 29800 58200 120 4.61E-04 WB 
Fertilizer consumption: kilograms (Kg) per hectare 
of arable land. (Mean 2002-2009) 153 269 470 70 166 489 83 5.50E-07 UN 
Forest Area in Km2. (Mean 2010) 192 406900 
122600
0 73 83380 190000 119 4.88E-02 WB 
Land under Permanent Crops in km2. (Mean 2008) 188 10660 24230 73 5941 16760 115 3.38E-01 UN 
Use of Fertilizers per 1000 hectares of Agricultural 
Land Area: Nitrogen. (Mean 2002-2008) 143 193 1201 65 37 114 78 4.62E-07 WB 
Use of Fertilizers per 1000 hectares of Agricultural 
Land Area: Phosphate.  (Mean 2002-2008) 142 19 25 64 6 11 78 2.80E-09 UN 
Use of Fertilizers per 1000 hectares of Agricultural 
Land Area: Potash. (Mean 2002-2008) 142 30 104 65 6 15 77 6.86E-08 UN 
Climate 
Annual precipitation by country: values in 
millimeters (mm). (Mean 1961-1999) 169 882 553 71 1294 872 98 3.77E-03 
WB
-C 
Annual temperatures by country: values in degrees 
Celsius. (Mean 1961-1999) 169 13 8 71 22 6 98 2.03E-10 
WB
-C 
Latitude 196 30 26 75 11 19 121 6.04E-10 GM 
Longitude 196 13 59 75 20 71 121 2.55E-01 GM 
UV radiation. (Mean 2004) 176 3056 1369 70 4711 1093 106 9.77E-13 
WH
O 
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Countries with available           
information on T1D 
Countries without 






Mean SD n Mean  SD n 
Environment 
CO2 emissions in metric tons per capita. (Mean 
2000-2009) 182 7 5 73 3 7 109 5.42E-14 WB 
Combustible renewables and waste: % of total 
energy. (Mean 2000-2010) 134 10 16 71 33 32 63 3.45E-03 WB 
NOx emissions per capita in Kg. (Mean 2010)  140 46 189 60 61 407 80 7.93E-07 WB 
Percentage of renewable Electricity Production. 
(Mean 2007) 188 23 28 70 31 35 118 7.35E-01 WB 
PM10, country level in micrograms per cubic meter. 








Adolescent fertility rate (births per 1,000 women 
ages 15-19 (Mean 2000-2010) 187 29 27 75 73 48 112 7.14E-13 WB 
Births by five-year age group of mother, major area, 
region and country, 1980-2100 (thousands) age of 
mothers: 20-24 yr. (Mean 2005-2010) 196 585 2847 75 317 659 121 2.23E-01 UN 
Births by five-year age group of mother, major area, 
region and country, 1980-2100 (thousands) age of 
mothers: 25-29 yr. (Mean 2005-2010) 196 1840 7853 75 662 1218 121 7.82E-01 UN 
Births by five-year age group of mother, major area, 
region and country, 1980-2100 (thousands) age of 
mothers: 30-34 yr. (Mean 2005-2010) 196 1506 5151 75 602 1123 121 1.33E-01 UN 
Births by five-year age group of mother, major area, 
region and country, 1980-2100 (thousands) age of 
mothers: 35-39 yr. (Mean 2005-2010) 196 850 2142 75 397 770 121 1.84E-02 UN 
Births by five-year age group of mother, major area, 
region and country, 1980-2100 (thousands) age of 
mothers: 40-44 yr. (Mean 2005-2010) 196 363 772 75 205 402 121 4.81E-02 UN 
Births by five-year age group of mother, major area, 
region and country, 1980-2100 (thousands) age of 
mothers: 45-49 yr. (Mean 2005-2010) 196 94 210 75 72 151 121 5.11E-01 UN 
Births by five-year age group of mother, major area, 
region and country, only 2005-2010 (thousands) (15-
19 yr). (Mean 2005-2010) 196 16 48 75 19 46 121 9.04E-02 UN 
Birth rate. (Mean 2010) 187 14 6 75 27 10 112 6.68E-17 WB 
Life expectancy at birth (both sexes combined) by 
major area, region and country. (Mean 2000-2005) 196 76 5 75 65 10 121 1.09E-14 UN 
Life expectancy at birth (both sexes combined) by 
major area, region and country. (Mean 2005-2010) 196 75 5 75 63 11 121 1.38E-15 UN 
Population 0-14 years of age (% of total population). 
(Mean 2010) 187 21 7 75 34 9 112 1.42E-16 WB 
Population density (people per km2 of land area). 
(Mean 2010) 187 325 1133 75 320 1836 112 5.71E-01 WB 
Probabilistic projections of population aged 0-14 
years old. (Mean 2010) 186 14720 53870 71 5979 11260 115 2.14E-01 UN 
Rural population (% of total population). (Mean 
2000-2010) 187 29 18 75 56 21 112 2.04E-14 WB 
Rural population (% of total population). (Mean 
2011) 187 28 18 75 54 21 112 5.31E-14 WB 
Sex ratio (male(s)/female) under 15 years. (Mean 
2011) 166 1 0 66 1 0 100 6.02E-10 UN 
Total fertility rates (estimation: median). (Mean 
2005-2010) 186 2 1 71 4 2 115 2.80E-16 WB 
Total fertility rates: births per woman. (Mean 2010) 187 2 1 75 3 1 112 3.04E-15 WB 
Urban population (% of total population. (Mean 












Expenditure per student, primary (% of GDP per 
capita). (Mean 2000-2010) 141 18 8 60 13 6 81 8.18E-07 WB 
GDP, PPP (current international 100,000 U $) PPP 
GDP is gross domestic product converted to 187 9077000 
227300
00 75 926500 2311000 112 1.09E-10 WB 
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Countries with available           
information on T1D 
Countries without 






Mean SD n Mean  SD n 
international dollars. (Mean 2011) 
GNI per capita, PPP (current international $). (Mean 
2011) 187 20360 17020 75 5309 10160 112 9.41E-11 WB 
Gross capital formation (annual % growth). (Mean 
2008) 187 4 11 75 5 11 112 5.00E-01 WB 
Health expenditure per capita (current US$). (Mean 
2010) 187 1951 2235 75 225 333 112 3.25E-15 WB 
Improved sanitation facilities (% of population with 
access). (Mean 2000-2010) 174 89 19 69 56 30 105 7.88E-14 WB 
Improved sanitation facilities: urban (% of urban 
population with access). (Mean 2000-2010) 176 93 14 70 67 26 106 2.19E-13 WB 
Physicians (per 1,000 people). (Mean 2010) 187 2 2 75 1 1 112 2.63E-13 WB 
Poverty gap at $2 a day (PPP) (%). (Mean 2000-










Infancy and childhood 
Diarrhea treatment (% of children under 5 receiving 
oral rehydration and continued feeding). (Mean 
2000-2010)  98 49 13 18 40 14 80 1.56E-02 WB 
Exclusive breastfeeding (% of children under 6 
months). (Mean 2010) 187 2 11 75 7 18 112 1.22E-02 WB 
Immunization, DPT (% of children ages 12-23 
months). (Mean 2000-2010)  178 93 7 72 80 17 106 1.75E-09 WB 
Immunization, measles (% of children ages 12-23 
months). (Mean 2000-2010)  178 92 7 72 79 17 106 5.46E-08 WB 
Low-birth weight babies (% of births). (Mean 2000) 187 2 3 75 6 7 112 3.00E-05 WB 
Malnutrition prevalence, weight for age (% of 
children under 5). (Mean 2000-2010) 123 2 5 32 6 5 91 1.63E-08 WB 
Morbi-mortality 
Cancer deaths 2008 179 246 57 72 207 52 107 1.65E-06 
WH
O 
Cardiovascular diseases and diabetes (deaths per 
100,000 individuals) (Mean 2008) 179 526 263 72 818 234 107 4.78E-11 
WH
O 
Diabetes deaths  (per 1000 persons) (Mean 2008) 196 90990 67420 75 97730 77690 121 7.49E-01 
WH
O 
Maternal mortality ratio (national estimate, per 
100,000 live births). (Mean 2000-2010)  133 83 189 41 365 346 92 8.41E-10 WB 
Mortality rate, under-5 (per 1,000 live births). (Mean 
1990-2011) 179 19 21 71 76 55 108 3.40E-18 
WH
O 
Mortality rate, under-5 (per 1,000 live births). (Mean 
2000-2010) 178 16 20 72 73 54 106 1.72E-18 WB 
Non-communicable diseases (deaths under age 60). 
(Mean 2008) 179 19 9 72 37 10 107 6.28E-19 
WH
O 
Notified cases of malaria (per 100,000 persons) 102 140000 360100 20 140200 315000 82 8.04E-01 WB 
Tuberculosis incident cases (per 100,000 persons). 
(Mean 2011) 178 39 58 71 192 214 107 4.35E-14 WB 
Overweight and obesity 
Mean body mass index (BMI) in kg/m2 of defined 
population (age standardized estimate), Female. Age 
+ 20 years of age. (Mean 2008) 178 26 2 72 25 3 106 4.22E-02 
WH
O 
Mean body mass index (BMI) in kg/m2 of defined 
population (age standardized estimate), Male. Age + 
20 years of age. (Mean 2008) 178 26 2 72 24 2 106 5.82E-11 
WH
O 
Prevalence of obesity, BMI ≥ 30 (age standardized 
estimate), Both sexes.  Age + 20 years of age. (Mean 
2008) 178 21 8 72 15 12 106 8.98E-05 
WH
O 
Prevalence of obesity, BMI ≥ 30 (age standardized 
estimate), Female.  Age + 20 years of age. (Mean 
2008) 178 23 10 72 20 15 106 5.59E-02 
WH
O 
Prevalence of obesity, BMI ≥ 30 (age standardized 
estimate), Male.  Age + 20 years of age. (Mean 
2008) 178 19 8 72 11 10 106 2.84E-10 
WH
O 
Prevalence of overweight, BMI ≥ 25 (age 178 50 14 72 44 21 106 7.51E-02 
WH
O 
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Countries with available           
information on T1D 
Countries without 






Mean SD n Mean  SD n 
standardized estimate), Both sexes.  Age + 20 years 
of age. (Mean 2008) 
Prevalence of overweight, BMI ≥ 25 (age 
standardized estimate), Female.  Age + 20 years of 
age. (Mean 2008) 178 53 13 72 40 20 106 1.81E-05 
WH
O 
Prevalence of overweight, BMI ≥ 25 (age 
standardized estimate), Male.  Age + 20 years of 




Current cigarettes smokers (youth rate), Both sexes. 
(Mean 2010) 147 15 10 49 9 7 98 6.83E-04 
WH
O 
Current cigarettes smokers (youth rate), Female. 
(Mean 2010) 147 13 11 49 6 6 98 8.77E-05 
WH
O 
Current cigarettes smokers (youth rate). Male. 
(Mean 2010) 147 16 9 49 13 9 98 1.60E-02 
WH
O 
Current smokers of any tobacco product (age 
standardized estimate), Female. (Mean 2009) 138 18 11 61 7 7 77 2.89E-08 
WH
O 
Current smokers of any tobacco product (age 
standardized rate), Both sexes. (Mean 2009) 136 26 9 60 19 10 76 9.34E-06 
WH
O 
Current smokers of any tobacco product (age 
standardized rate), Male. (Mean 2009) 139 35 11 60 31 15 79 5.06E-02 
WH
O 
Current users of any tobacco product (youth rate), 
Both sexes. (Mean 2010) 147 19 9 49 18 10 98 2.84E-01 
WH
O 
Current users of any tobacco product (youth rate), 
Female. (Mean 2010) 147 17 10 49 14 10 98 1.48E-01 
WH
O 
Current users of any tobacco product (youth rate), 
Male. (Mean 2010) 147 22 9 49 22 11 98 6.77E-01 
WH
O 
Exposure to smoke at home, both sexes. (Mean 
2010) 140 45 18 45 36 14 95 1.90E-03 
WH
O 
Exposure to smoke at home, female. (Mean 2010) 140 46 19 45 35 15 95 9.16E-04 
WH
O 
Exposure to smoke at home, male. (Mean 2010) 140 44 17 45 37 14 95 7.13E-03 
WH
O 
Exposure to smoke outside home, both sexes. (Mean 
2010) 139 59 17 45 53 13 94 9.27E-03 
WH
O 
Exposure to smoke outside home, female. (Mean 
2010) 139 59 18 45 51 14 94 2.32E-03 
WH
O 
Exposure to smoke outside home. (Mean 2010) 139 59 16 45 55 13 94 4.66E-02 
WH
O 
Smoking prevalence, females (% of adults). (Mean 
2009)  187 14 12 75 5 6 112 5.17E-07 WB 
Smoking prevalence, males (% of adults). (Mean 










Internet users (per 100 people). (Mean 2000-2010) 186 35 22 75 9 12 111 2.02E-17 WB 
Literacy rate, adult total (% of people ages 15 and 
above. (Mean 2000) 187 13 32 75 21 35 112 5.67E-02 WB 
Literacy rate, youth total (% of people ages 15-24). 
(Mean 2010) 187 44 49 75 54 44 112 9.23E-01 WB 
Mobile cellular subscriptions (per 100 people). 
(Mean 2000-2010) 186 72 30 75 33 25 111 3.76E-15 WB 
Motor vehicles (per 1,000 people). (Mean 2000-10) 164 351 221 73 83 107 91 4.13E-16 WB 
 
Note: in red correlations reporting a p-value ≤ 0.05. References: (WB) World Bank (2012) Indicators. Available 
from http://data.worldbank.org/indicator, accessed 11-08 2012; (WB-C) World Bank (2012) Climate Change 
Knowledge Portal:  Historical Data. Available from http://data.worldbank.org/developers/climate-data-api, 
accessed 11-08 2012; (WHO) WHO (2012) Global Health Observatory Data Repository. Available from 
http://apps.who.int/gho/data/?vid=2472, accessed 11-08 2012; (UN) United Nations, Department of Economic 
and Social Affairs (2011) World Population Prospects, the 2010 Revision. Available from 
http://esa.un.org/wpp/Excel-Data/population.htm, accessed May 31 2012; (GM) Google Maps API 
Geographical coordinates 2013. Available from http://universimmedia.pagesperso-orange.fr/geo/loc.htm.  
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3.3.2 Analyses of cumulative incidence of T1D 
3.3.2.1 Steps performed to obtain cumulative incidence of T1D 
To obtain the cumulative incidence of T1D by age at onset and birth cohort, a 
protocol consisting in 3 steps was proposed and is the following:  
3.3.2.1.1 Step 1. Grouping data 
First, stratification by incidence level proposed in the Diamond study (161, 231, 318), 
which is an arbitrary distribution of the cases in five groups: i) very low, <1 case per 100.000 
individuals per year; ii) low, 1-4.99 per 100.000 per year; iii) intermediate, 5-9.99 per 
100.000 per year; iv) high, 10-19.99 per 100.000 per year; and v) very high, ≥ 20 per 100.000 
per year. The identification of the correct level of incidence for each reference was performed 
after averaging all the data reported in each reference and comparing the result with the 
respective categories to classify the reference from very low to very high incidence level. 
Due to enormous variability in the incidence of T1D, it was conceivable that one country 
might belong to more than one category of incidence level; for example, in this thesis, 26 
references reported the incidence in Italy: Sardinia was classified as very high incidence, the 
entire nation as high, and the Rome and Lazio region belonged to the intermediate category.  
Second, the average of a specific place to summarize the available information in a 
specific area in a country was generated. The process consisted in pooled studies that 
belonged to a similar geographic area, such as all nation-wide, regional, or local studies 
performed in a specific country. For example, also in Italy, the mean for all studies reporting 
the incidence in Sardinia, the mean of Lombardia, the mean of Turin, and the mean of the 
whole nation were carried out independently.  
Third, using dynamic tables operated by the Microsoft Excel software, six summary 
tables were obtained, one for each level of incidence (from very low to very high). Each 
retrieved table then represents the diagonal (Lexis’s diagram) of the mean incidence for each 
category of incidence level. To compare the final results, all final tables presented the same 
structure of data-frame; each one contains in the rows the age at onset of T1D (listed from 0 
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to 40 years of age) and in the columns the mean incidence by each birth cohort (1924 to 
2008). To complete the data-frame non-available data were identified as “NA”. 
3.3.2.1.2 Step 2. Generating cumulative incidence 
To obtain cumulative incidence the final tables were independently exported to the R 
program (255). Using the function cumsum, the cumulative sum of incidences by birth cohort 
and age at onset for each category of analysis was generated. The average of the cumulative 
incidences each five-years of birth cohorts was obtained later. The result was exported as a 
list containing three columns each one respectively, with the age at onset from 0 to 40 years, 
5-year-periods of birth cohort (starting in 1924 and extending to 2008), and the cumulated 
incidence. Any treatment was considered for non-available data. 
3.3.2.1.3 Step 3. Plotting data 
Using the library ggplot 2 in the R program (255) and the information exported into 
the lists described above, the curves representing the mean cumulative incidence country 
level by 5-year-periods of  birth cohorts, and by age at onset were plotted; SI Figures 19-23.  
3.3.2.2 Findings  
Cumulative incidence by birth cohorts dropped after 2004 in countries with very high 
incidence, and around 1994 in countries with intermediate, low and very low incidence of 
T1D. The SI Figures 19-23 presented below show the increase in the incidence of T1D with 
successive birth cohorts; nevertheless, after the period 1994-1998, in countries with very 
high, intermediate and very low incidence levels, new cohorts exceed the previous cohort 
indicating a relative stabilization or a new tendency of T1D worldwide. The negative trend of 
T1D is persistent after stratification by country-incidence-level.  
There are enormous variations in incidence trends of T1D in individuals aged 0-40 
years after stratifying the analysis according to incidence-country-level. Maximum 
cumulative incidence of T1D per 100.000 persons was respectively, 649.5 for countries with 
very high-incidence level, 394.8 for high, 220.4 for intermediate, 56.2 for low, 10.3 for very 
low-incidence countries, and 486 after cumulating all countries. 
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SI Figure 19: Cumulative incidence of T1D in very high-incidence countries very high: ≥ 20 cases 



















SI Figure 20: Cumulative incidence of T1D in high-incidence countries: 10-19.99 cases per 100.000 
individuals per year by birth cohorts (1924-2008) 
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SI Figure 21: Cumulative incidence of T1D in intermediate-incidence countries: 5-9.99 cases per 




















SI Figure 22: Cumulative incidence of T1D in low-incidence countries: 1-4. cases per 100.000 
individuals per year by birth cohorts (1924-2008) 
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SI Figure 23: Cumulative incidence of T1D in very low-incidence countries: <1 case per 100.000 
individuals per year by birth cohorts (1924-2008) 
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3.3.3 Worldwide Incidence trends of T1D 
Independently of the initial level of incidence a positive slope is observed for all 
continents plotting data published from 1960 to 2010. Asia (incidence slope = 0.11 case per 
100.000 individuals per year), Africa (incidence slope = 0.13 case per 100.000 individuals 
per year) and Latin America and the Caribbean (incidence slope = 0.13 case per 100.000 
individuals per year) show the smallest increases, Europe (incidence slope = 0.22 case per 
100.000 individuals per year) presents an intermediate increase, and North America 
(incidence slope = 0.45 case per 100.000 individuals per year) and Oceania (incidence slope 
= 0.53 case per 100.000 individuals per year) the largest. (SI Figure 24). Since 1980, the 
speed of the increase had varied depending on the country: comparing only nation-wide 
studies performed in Europe, the slope of the variation of incidence of T1D with time has 
varied from a incidence slope = 0.12 case per 100.000 individuals per year (Latvia) to a 























 The analysis of the variations of T1D incidence across continents is based on datasets for which the 
percent of ascertainment was reported. Y-axis: incidence of T1D per 100.000 individuals of both sexes (0-14 
years old) per year. X-axis: time of the mean point of duration of each study. Circles represent each retrieved 
study.  
SI Figure 24: T1D incidence trends in major UN areas among studies reporting ascertainment 
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 The analysis of the variation of T1D incidence with time in European countries was restricted to 
nationwide studies having reported the percentage of ascertainment. Y-axis: incidence of T1D per 100.000 
individuals of both sexes (0-14 years old) per year. X-axis: time of the mean point of duration of each study. 
Circles represent each retrieved study.   
 
 
SI Figure 25: T1D incidence trends in Europe among nation-wide studies reporting ascertainment  
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3.3.4 Anticipation phenomenon in the age at onset of T1D 
The increase in the global trends of T1D is clear, and this seems to be a global 
phenomenon independent of whether the risk of the population is low or high. Also, the 
variation in the age at onset of T1D in the last decades has been reported. Since 1955, a little 
variation of the incidence in the younger age groups in Oslo, Norway had been reported, in a 
remarkable longitudinal study of the population that was analyzed from data collected 
between 1925 and 1954 (357).  
Today, even though the increase in T1D incidence apparently has affected all age 
groups worldwide, several research teams have been working on the epidemiology of T1D 
and have reported that apparently, the age at onset is decreasing, and in most studies the 
incidence of T1D increased in children between 0 and 14 years, and has been most 
pronounced in the youngest age group, among of children between 0 and 4 years of age. This 
is consistent with the greatest rate of increase in childhood onset of T1D incidence in the 
group of 0-4 years of age (224). This situation may be a reflection of a situation of 
“anticipation” in which individuals with susceptible genotypes may develop the disease at an 
earlier age than previously (118), a concept first proposed by Kurtz et al. in 1988 (175), by 
this time called “accelerated onset”.  
The reason for the continuous decline in the age at onset is unclear. Some authors 
affirm that the rising incidence of T1D is caused by an earlier clinical presentation rather than 
due to a global increase in the incidence of T1D in all age categories. Changes in the 
exposure to environmental factors may promote or accelerate the subclinical disease process 
in young subjects genetically predisposed to T1D (352), and a more permissive early life 
environment favorable to the development of T1D could also be implicated (344). 
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3.3.4.1 Epidemiological reports showing the change in incidence trend in the youngest 
age groups 
Green et al. reported that in Europe during the period 1989-1998 the annual increase 
in the incidence of T1D was higher in the very young child group (0-4 years of age), than in 
the 5-9 or 10-14 years age group, 4.5% (CI 95% 3.8-5.9) versus 3.7% (CI 95% 2.9-4.5) and 
2.1% (CI 95% 1.4-2.8) respectively (121).  In the Eurodiab study, a particular finding was 
that the increase in incidence was particularly rapid in children under 5 years of age. The 
rates of increases were: 6.3% (CI 95% 4.1-8.5), 3.1% (CI 95% 1.5-4.8) and 2.4% (CI 95% 
1.0-3.8) in children aged 0-4, 5-9 and 10-14 years respectively (90). Other multicenter 
prospective registration of European studies, published in 2007, evaluated the incidence 
trends in 20 population-based registers in 17 countries. As main finding, the annual incidence 
of T1D increased for all centers and was on average 3.9% (CI 95% 3.6-4.2), rising to 5.4% 
(CI 95% 4.8-6.1) in the group 0-4 years, 4.3% (CI 95% 3.8,4.8) to in the group 5-9 years, and 
to 2.9% (CI 95% 2.5-3.3) in the group 10-14 years of age (242).  
The results of the European studies are consistent with the hypothesis of the decrease 
of the age at onset of childhood diabetes. Other unaggregated studies, conducted in Europe 
and North America provided similar results. An article published in 2008 in Germany, 
concluded that although the absolute incidence was highest in the group of 10-14 years of 
age, the age at onset of T1D has decreased, and the highest rise in incidence occurred in the 
group of 0-4 year-old patients (5.8%, CI 95% 2.5-9.3). In the group of 5-9 and 10-14 year-old 
patients, it was 3.4% (CI 95% 0.8-6.0) and 2.7% (CI 95% 0.3-5.1), respectively (85).  Also in 
2008, an article was published reporting that in Aquitaine, France, the annual increase of 
incidence was highest in the group of 0-4 years, 7.59% in comparison with the group of 5-9 
(4.06%) and 10-14 years (1.28%) (28). In a Swedish study published in 2011, on 14.721 
incident cases of T1D aged 0-14 years in the period 1978-2007, confirms that children aged 
0-5 years are the most affected by T1D. This publication argues that the rise in the incidence 
of T1D is coincident with a birth cohort effect (33). Also, a Czech study published in 2000 
registered that the age at onset of diabetes had presented a significant log-linear increasing 
trend in children (in those aged 0-4 years the increment was 6.9%, (p = 0.033) and in the 
group of 5-9 years it was 4.8% (p = 0.038)) (64).  
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In Colorado, USA, the incidence of T1D in children aged 0-4 years had increased 
more compared with the other age groups: 1.96 (CI 95% 1.6,2.4) in the 0-4 year-old group, 
1.6 (CI 95% 1.3-1.8) in the 5-9 year-old group, 1.5 (CI 95% 1.3-1.7) in the 10-14 year-old 
group, and 1.6 (CI 95% 1.2-2.1) in the 15-17 year-old group (344). 
In Israel, the annual increase in incidence in the period 2000-2008 was 5.82% (CI 
95% 1.80-9.98) and the group of children aged less than 5 years had the highest increase; it 
increased by 104%, from 5.41 (CI 95% 3.44-7.37) per 100.000 person years to 11.04 (CI 
95% 8.27-13.81) per 100.000 person years in the periods 2000-2002 and 2006-2008 
respectively. As a consequence, the age at onset of T1D decreased from 10.21 (SD 4.48) to 
9.25 (SD 4.54) (p = 0.07) in this time interval (284). 
In contrast with the above reports, others studies carried out in Italy (43), Finland 
(177)  and Western Australian (130), observed an increase in T1D in all groups of age. These 
results are against of the observation of an earlier age of onset of T1D (40).  
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3.3.5 Median age at onset of T1D  
In Aquitaine, Franc, the median age at onset of diabetes was 10.04 years (CI 95% 
6.64-12.53) in the period 1988-1996 and 8.83 years (CI 95% 5.48,11.73) in the period 1997-
2004 (28). In the study of Northern Italy, the incident cases were identified in the a majority 
of cases during puberty, and with respect to the group aged 0-4 years, the Relative Risk (RR) 
was 1.64 (CI 95% 1.41-1.91) (46).  
Using data retrieved in this thesis, the distribution of the age at onset of T1D was 
explored among 1690 data reporting the incidence of T1D by classes of age: 0-4, 5-9 and 10-
14 years. The analyses show that the mean incidence for the age group was 10.0 cases per 
100.000 individuals per year in the age group 0-4, 16.8 cases per 100.000 individuals per year 
in the group 5-9, and 19.2 cases per 100.000 individuals per year in the group 10-14; SI 
Figure 26. 
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4 Epidemiology of T1D in young adults and adults 
 
This thesis was initially focused on the study of T1D in children only because one 
usually thinks that the so-called “juvenile” diabetes is a disease specific of the youngest age 
groups. Nevertheless, no limit of age at onset of T1D was detected during the data collection 
for this thesis, as mentioned in chapter 1. With time, interesting papers appeared reporting 
the incidence of T1D in older individuals in several countries, and then in preliminary 
analyses, we observed that cumulative incidence among individuals older than 15 years 
followed patterns similar to those observed in children, as mentioned in section 3.4 of 
chapter 3. It was then that we decided to study the epidemiology of T1D in adults as 
presented here.  
All possible studies reporting T1D in people aged over 15 years and published in 
indexed databases by the time this thesis was undertaken, were searched. Special attention 
was focused on the diagnostic criteria used to define T1D in adults as well as on the use of 
autoantibodies and detection of the C-peptide, a sub-product of insulin, as criteria to define 
T1D.  
Finally, even though the map of the epidemiology of T1D in children as described in 
chapters 1 and 2 is as yet incomplete, we could see that this statement was even more valid 
for the epidemiology of T1D in adults, since available information was retrieved in only 17% 
(35 of 196) of the world countries. Moreover, interesting results were found, such as high 
correlation between incidences in children and adults, a same pattern of variability observed 
in children and a surprising male predominance of T1D among adults (82).  
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Global epidemiology of type 1 diabetes in young
adults and adults: a systematic review
Paula A Diaz-Valencia1,2*, Pierre Bougnères1,3 and Alain-Jacques Valleron1,2
Abstract
Background: Although type 1 diabetes (T1D) can affect patients of all ages, most epidemiological studies of T1D
focus on disease forms with clinical diagnosis during childhood and adolescence. Clinically, adult T1D is difficult to
discriminate from certain forms of Type 2 Diabetes (T2D) and from Latent Autoimmune Diabetes in Adults (LADA).
We searched the information available worldwide on the incidence of T1D among individuals over 15 years of age,
and which diagnostic criteria should be used use to qualify T1D in adults. We then studied the variation of T1D
incidence with age in adults, and compared it to the incidence in the <15 years-old.
Methods: A systematic review of the literature was performed to retrieve original papers in English, French and
Spanish published up to November 6, 2014, reporting the incidence of T1D among individuals aged over 15 years.
The study was carried out according to the PRISMA recommendations.
Results: We retrieved information reporting incidence of T1D among individuals aged more than 15 years in 35
countries, and published in 70 articles between 1982 and 2014. Specific anti-beta-cell proteins or C-peptide detection
were performed in 14 of 70 articles (20%). The most frequent diagnostic criteria used were clinical symptoms and
immediate insulin therapy. Country-to-country variations of incidence in those aged >15 years paralleled those
of children in all age groups. T1D incidence was larger in males than in females in 44 of the 54 (81%) studies
reporting incidence by sex in people >15 years of age. The overall mean male-to-female ratio in the review was
1.47 (95% CI = 1.33-1.60, SD = 0.49, n = 54, p = <0.0001). Overall, T1D incidence decreased in adulthood, after the
age of 14 years.
Conclusions: Few studies on epidemiology of T1D in adults are available worldwide, as compared to those
reporting on children with T1D. The geographical variations of T1D incidence in adults parallel those reported in
children. As opposed to what is known in children, the incidence is generally larger in males than in females.
There is an unmet need to evaluate the incidence of autoimmune T1D in adults, using specific autoantibody
detection, and to better analyze epidemiological specificities – if any – of adult T1D.
PROSPERO registration number: CRD42012002369.
Keywords: Type 1 diabetes, Systematic review, Adults, Incidence, Epidemiology
Background
The worldwide epidemiology of childhood Type 1 dia-
betes (T1D) was extensively described in the 6th edition
of the International Diabetes Federation (IDF) [1]. Data
were retrieved in approximately 45% of the countries
[1-4]. In contrast, we are unaware of a similar review on
the worldwide epidemiology of adult T1D diabetes,
although T1D is known to occur even late in adults
[5-7]. A major limitation of the epidemiology of T1D in
adults is certainly the difficulty there is to distinguish
it from Type 2 diabetes (T2D) requiring insulin treat-
ment or from Latent Autoimmune Diabetes in Adults
(LADA), when specific markers of autoimmunity are
not searched.
Here, our primary objective was to describe – through
a systematic review of the literature – the available pub-
lished information on adult T1D incidence, and the
diagnostic criteria used for case definition. A secondary
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objective was to study how the variations of T1D inci-
dence in adults mirrored those in children.
Methods
Literature review
A systematic review was conducted according to the
PRISMA recommendations to retrieve original papers
published in English, French and Spanish up to Novem-
ber 6th, 2014, in peer-reviewed journals reporting the in-
cidence of T1D among individuals aged more than
15 years, in population-based studies (i.e. collected in a
defined geographic area [8]) and reporting the diagnostic
criteria used to define T1D.
The databases used for the literature search were
Medline (PubMed), Google Scholar and Thomson
Reuters (Web of Knowledge). The protocol of the
search was registered in the International Prospective
Register of Systematic Reviews (PROSPERO) and is avail-
able on http://www.crd.york.ac.uk/PROSPERO/display_
record.asp?ID=CRD42012002369 (Registration number:
2012:CRD42012002369). Figure 1 presents the flow dia-
gram of the bibliographic search, Additional file 1 for the
full electronic search strategy, and Additional file 2 for the
PRISMA checklist.
Data collection
For each study, the following information was extracted:
– the identification of the study: authors, title, journal,
publication year,
– the period and country of study. The country was
categorized by its World Health Organization
(WHO) region and economic level: high-income
(HIGH) or low- and middle-income (LMIC) [9],
Articles screened based on 
title and abstract
n = 178 
113 Excluded 
18 Articles excluded 
o 6: did not report incidence of T1D 
o 3: did not give diagnostic criteria  
o 5: concern LADA 
o 3: concern individuals aged less 
than 16 years 
o 1: pdf not available on website, no 
reply from the author* 
Articles remaining based on 
full text review 
n = 59 

























Full-text articles assessed 
for eligibility 
n = 65 
Additional articles included from other 
sources (Web of Knowledge, Google 
Scholar, citing and cited references) or 
published in other language different 
than English 
n = 11
Total of included articles in the 
systematic review reporting 
incidence of Type 1 diabetes among 
individuals aged over 15 years:
n = 70 articles** 
Figure 1 PRISMA Flow diagram bibliographic search strategies. * Kumar P, et al. Indian Med Assoc. 2008;106(11):708–711. ** The article:
Radosevic B, et al. Pediatr Diabetes. 2013;14(4):273–4 gives information from two countries: 1) Bosnia and Herzegovina: Republic of Srpska and
2) Slovenia, Nationwide.
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– the geographic coverage of the study: nationwide
(when the study was performed in the entire nation)
and local (when it was restricted to a given region,
city, or a geographically defined population),
– the diagnostic criteria used to define T1D in adults:
detection of autoantibodies against beta-cells
(such as: islet cell antibody (ICA), insulin
autoantibody (IAA), islet antigen-2 autoantibody
(IA-2), anti-glutamic acid decarboxylase antibodies
(GAD)), measurement of the fasting C-peptide
level [7], need for permanent insulin therapy, time
when the administration of insulin therapy was
started, and clinical signals of T1D diabetes such as
ketosis, ketonuria and weight loss,
– the sources of data/registers reporting T1D incidence
in the studies, defined according to LaPorte et al. [10]
as: primary source of information: a “well-established
system of standardized registries for identifying new
cases”, for example national or regional registers,
secondary source of information: other different
sources of cases “that would provide a check on
the degree of ascertainment”, for example medical
records or hospital discharges, and tertiary source
of information: a third approach for identifying
cases, for example, through surveillance system or
death certificates,
– the reported percentage of completeness/
ascertainment between sources of information
reporting incidence [10],
– the incidence rates reported in the text, tables or graph
(expressed as new cases per 100.000 persons/year) by
sex and age classes,
– additional information such as those concerning
rural/urban, or ethnic differences.
Data analyses
The country distribution of the T1D incidence informa-
tion and the analysis of the diagnostic criteria used were
performed on the entire set of articles retrieved. For the
few papers for which the results were presented by eth-
nic origin, we estimated the mean value of the incidence
for the given period in the countries/regions concerned.
Correlation between adult and children T1D incidences
In the geographical correlation analyses between chil-
dren and adult incidences, we considered for each coun-
try the more recent nationwide study published, or if
not available, the last published set of local studies
retrieved from a given area in the country; in addition,
we included all published papers reporting auto-
antibodies against beta-cells or C-peptide. To obtain an
estimate of the incidence of T1D in children in the
countries for which the adult incidence was available, we
used the data provided by the same adult paper, when
available. The incidence of T1D in children was not
available in 9 of these papers included in the geograph-
ical correlation analyses. In this case, it was estimated
through a separate systematic review focused on the cor-
responding countries and periods (see Additional file 3).
Statistics
Data were extracted from graphs using GraphClick [11].
The country-to-country co-variation of children and
adult incidences was quantified by the Spearman correl-
ation and a linear regression.
The R software (version 3.0.1) was used for statistical
and graphic analyses [12].
Results
Description of the information obtained from the
systematic review on adult T1D
Seventy articles reporting incidence of T1D in young
adults and adults aged over than 15 years concerned one
country, and one article concerning two countries were
retrieved in this systematic review, resulting in a total of
71 studies covering 35 countries (Table 1). Twenty-four
of the 71 studies were nationwide; 43 papers provided
information on the T1D incidence in the age class 15–
29 years, 26 in the age class 30–59 years, and 6 in the
persons aged >60 years.
A primary source of information was reported in 99%
(70 of 71) of the studies: among these reported sources,
60% (42 of 70) were from medical/hospital records, 36%
(25 of 70) from national or regional registers, and 4%
(3 of 70) from other sources, such as community-
based surveys; a secondary source of information was
reported in 90% (64 of 71) of the studies: among these
reported sources, 58% (37 of 64) were from medical/
hospital records, 16% (10 of 64) from associations of
patients, 14% (9 of 64) from drug or supplies prescription
registers, 8% (5 of 64) from national or regional registers,
and 5% (3 of 64) from death certificates and schools reg-
isters; finally, a tertiary source of information was re-
ported in 21% (15 of 71) of the studies: among these
reported sources, 27% (4 of 15) were from national or re-
gional registers, 27% (4 of 15) from associations of pa-
tients, 20% (3 of 15) from death certificates, 20% (3 of 15)
from drug or supplies prescription registers, and 7%
(1 of 15) from medical registers; see details in Table 1.
Percentage of ascertainment (completeness) between
sources of information was evaluated in 53 of 71 (75%)
studies. The mean percentage of ascertainment of these
53 studies was 94% (Table 1).
In the group of young adults (15–19), the lowest inci-
dence of T1D was reported in Mauritius, (1.1/100.000
persons/year) [13], and the highest in Estonia (39.9/
100.000 persons/year) [19]. In the 70–79 year age group,
the lowest incidence was reported in Navarra, Spain
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Table 1 Systematic review of T1D in adults, diagnostic criteria and sources of information























Primary Secondary Tertiary % of
ascertainment
African Region, LMIC
Mauritius: NW Tuomileht J.,
1993†






[14] 0-19 1982-1991 No Yes From diagnosis Yes NA NA Medical reports Hospital records NA NA






[15] 0-29 1990-1994 Yes (a) Yes From diagnosis Yes Yes Yes Medical
reports from
endocrinologists






[16] 0-34 1981-1990 No Yes From diagnosis NA Yes NA National Diabetes
Program













1988-1992 No Yes Within 1 week
of diagnosis









1988-1988 No Yes From diagnosis Yes Yes Yes NA NA NA NA
Lithuania: NW Ostrauskas R.,
2011†
[20] 15-34 1991-2008 No Yes Within 2 weeks
of diagnosis










[21] 0-39 1991-2000 No Yes Within 2 weeks
of diagnosis








Lithuania: NW Ostrauskas R.,
2000
[22] 15-39 1991-1997 No Yes Within 2 weeks
of diagnosis
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Table 1 Systematic review of T1D in adults, diagnostic criteria and sources of information (Continued)
Poland: Warsaw Wysock M. J.,
1992†

















1981-1991 No Yes From diagnosis Yes Yes NA Bucharest Diabetes
Registry
NA NA NA
Slovakia: NW Kyvik K O,
2004†







Austria: Upper Rami B.,
2001†

















































































Finland: NW Lammi N.,
2007†
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Israel: NW Koton S., 2007 [40] 0-17 1997-2003 No Yes From diagnosis Yes NA NA Israel juvenile
diabetes register
NA NA NA
Italy: Lombardie Garancini, P.,
1991†





Italy: Pavia Tenconi M. T.,
1995†
[42] 0-29 1988-1992 No Yes From diagnosis Yes NA NA Hospital records Drug registers NA 100
Italy: Sardinia Muntoni S,
1992†







[44] 0-29 1993-1996 No Yes From diagnosis Yes NA NA Hospital records Drug registers NA 100
Italy: Turin Bruno G.,
2009†
[45] 15-29 2000-2004 Yes Yes Within 6
months of
diagnosis
NA NA NA Hospital records Drug registers NA NA
Italy: Turin Bruno G.,
2005†
[46] 30-49 1999-2001 Yes Yes Within 6
months of
diagnosis
NA Yes NA Diabetes clinics Drug registers NA 99.0
Italy: Turin Bruno G.,
1993















Malta: NW Schranz A. G.,
1989†
[49] 0-24 1980-1987 No Yes Within 3 moths
of diagnosis











Norway: NW Joner G.,
1991†
[51] 15-29 1978-1982 No Yes From diagnosis NA NA NA Pediatricians and
endocrinologists
reports
Hospital records NA 90.0
Slovenia: NW Radosevic B.,
2013†
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Spain: Catalonia Abellana R.,
2009†






Spain: Catalonia Goday A.,
1992











2009-2012 Yes Yes Within 6
months of
diagnosis




Spain: Navarra Forga L.,
2013†
[57] 0-79 2009-2011 Yes Yes Within 6
months of
diagnosis




Sweden: NW Dahlquist G. G.,
2011†






Sweden: NW Östman J.,
2008






















Sweden: NW Nyström L.,
1992






Sweden: NW Blohme G.,
1992










[63] 0-100 1998-2001 Yes Yes Within 4 weeks
of diagnosis













[64] 0-34 1991-2008 No Yes Within 3 moths
of diagnosis
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Table 1 Systematic review of T1D in adults, diagnostic criteria and sources of information (Continued)
Region of the Americas, LMIC
Barbados: NW Jordan O. W.,
1994†
[66] 0-29 1982-1991 No Yes From diagnosis Yes NA NA Hospital records Others health
care registers
NA 94.0
Region of the Americas, HIGH
Canada: Quebec Legault L.,
2006†
































[70] 0-17 2000-2004 No Yes Within 2 weeks
of diagnosis













[71] 0-17 1978-1988 No Yes Within 2 weeks
of diagnosis
Yes NA NA Pediatricians and
endocrinologists
reports













































[76] 17-34 1974-1988 No NA* None declared Yes NA NA Hospital discharges NA NA NA
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Japan: Osaka Sasaki A.,
1992†









1981-1986 No Yes Within 1 year
of diagnosis













Other Regions currently non WHO

















[82] 0-19 2001-2010 No Yes From diagnosis Yes Yes Yes Medical reports Medical providers NA 98.7
WHO Member States are divided into high-income (HIGH) or low- and middle-income (LMIC) states [30]. AA: autoantibodies, NW: Nation-wide study, NA: Unavailable data. (a) When there were diagnostic doubts, (b) Only
for patients aged over 40 years at onset, (c) Not performed in all cases; the author of this study was contacted to confirm the proportion of these cases, but by the time of submission of this paper no answer was available.
T1D: Type 1 Diabetes. Highlighted: reports of the systematic review using the autoantibodies/C-peptide as diagnosis criteria. (†) Studies used in the statistical analyses. (*) Data were not available but researchers assumed that
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(0.8/100.000 persons/year) [57] and the highest in
Kronoberg, Sweden (55/100.000 persons /year) [63].
The details of all retrieved incidence by study and age
classes are in Additional file 4: Table S1.
Diagnostic criteria used to define T1D in adults reported
in 71 epidemiological studies
Autoantibodies against beta-cell antigens or the C-peptide
were included in the T1D diagnostic criteria in 14 studies
[15,30-32,34,35,45,46,54,56,57,63,74,81], detection of ICAs
was reported in 9 studies [15,30-32,34,45,46,54,63], IAA in
4 studies [30-32,54], IA2 in 5 studies [30-32,56,57], and
GAD in 11 studies [30-32,35,45,46,56,57,63,74,81]. The
C-peptide was measured in 7 studies. In one paper differ-
ence of auto-antibodies by age group (0–19) was explored
but no significant differences were detected [74]. The other
reported diagnostic criteria for T1D were the need for in-
sulin therapy (reported in 70 of 71 studies), clinical symp-
toms of diabetes (reported in 56 of 71 studies), low or
normal body weight (14 of 71 studies), and ketosis or keto-
nuria (26 of 71 studies). The details are shown in Table 1.
Comparison of adult and children T1D incidences
The variations of incidence of T1D in adults with country
and age were studied in each area for which we retrieved
information on a geographically defined population. This
concerned 35 countries.
Variation of T1D incidence with age in adults
In 23 out of 35 (66%) countries (55 of 71 studies), the in-
cidence of T1D was higher in the age range of 0–14
compared with 15–19 years. When restricted to the 14
reports for which the criteria of diagnosis of T1D were
auto-antibodies against beta-cells or C-peptide detection,
the variation of adult incidence with age showed a con-
sistent decrease after the age of 14 years (Figure 2 and
Additional file 4: Table S1).
Geographical correlation of adult and child T1D incidence
A significant geographical correlation, as measured by
the Spearman correlation coefficient, was found between
adult T1D incidence and 0–14 incidence in the age clas-






























Group of age 
BE1: Weets I, 2007 
BE2: Weets I, 2002 
BE3: Vandewalle C, 1997  
DK: Molbak A. G, 1994 
ES1: Abellana R, 2009 
ES2: Forga L, 2014 
ES3: Forga L, 2013 
FI: Lammi N, 2007 
IR: Pishdad GR, 2005 
IT: Bruno G, 2005 
IT: Bruno G, 2009  
SE: Thunander M, 2008 
TW: Lin W-H, 2013 
US: Bell R, 2009 
Figure 2 Age variation of incidence from childhood to adult age. On this figure, the adult estimates of incidence were taken from the 14
reports of the systematic review using the autoantibodies/C-peptide as diagnostic criteria. Full lines correspond to articles from which both child
as well as adult information could be retrieved. The dotted lines are those for which the child information was searched in the same country as
in the adult paper, but was from a different paper (see Additional file 3 for details on this literature search). The corresponding countries are
shown as: BE1: Belgium (2007) [30]; BE2: Belgium (2002) [31]; BE3: Belgium (1997) [32]; DK: Denmark [34]; ES1: Spain, Catalonia [54]; ES2: Spain,
Navarra (2014) [56]; ES3: Spain, Navarra (2013) [57]; FI: Finland [35]; IR: Iran (Islamic Republic of) [15]; IT: Italy [45,46]; SE: Sweden [63], TW: Taiwan
[81]; US: United States of America [74].
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Figure 3 (See legend on next page.)
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and overall in the entire 15–60 group (r = 0.75, p-value:
5.7 × 10−10). The correlation was not significant in the
oldest class where sparse data were available, but the re-
lation was similar (Figure 3).
Comparison of male and female T1D adult incidences
T1D incidence was larger in males aged 15 to 39 years
than in females in 44 (81%) of the 54 studies reporting
incidence by sex (Additional file 5: Table S2). The mean
male-to-female ratio in our review was 1.47 (95% CI for
mean 1.33-1.60, SD = 0.49, n = 54, p = < 0.0001).
Discussion
A first result of this systematic review is the paucity of
data available on adult incidence of T1D as compared to
those concerning children. The 71 studies retrieved pro-
vided information on adult T1D in only 35 countries,
40% of the 88 countries with primary childhood T1D
incidence information in the 6th IDF atlas [1].
A second result is that only a small proportion (n = 14)
of the 71 studies used detection of specific autoantibodies
and/or dosage of C-peptide [83] as diagnostic criteria of
adult T1D.
A third result was that in a majority of the retrieved
studies, adult T1D incidence was greater in men than in
women, which contrasts with incidence of T1D in chil-
dren where sex ratio is around one [2,84]. Using com-
parative data, Karvonen et al. also described a male
excess among young adults in the 15–39 years of age
[85]. Sex differences in exposure to possible environ-
mental triggers of T1D, in hormonal/genetic suscep-
tibility, in lifestyle have been proposed as possible
explanations for this difference [62].
A last striking observation of the current analysis is
the strong geographical correlation of the incidences in
adults and children. This correlation may be explained
by the fact that adults with T1D share the gene alleles
known to be associated to incidence of T1D in children,
[86,87], and/or some predisposing environmental causes
[4]. For example, in a previous study on incidence of
T1D in children, a significant positive correlation
was detected between the percentage of urban popu-
lation and the incidence of T1D in children (r = 0.41
p-value: < 0.0001) [4]; in this review a significantly
higher urban proportion of T1D incidence among
adults was found in 4 of the 7 studies reporting differences
between rural vs urban areas [15,21,42,75].
There was an overall decrease of incidence with age in
adults and young adults after the age of 14. A second
peak of T1D around the age of 50, as described by
Krolewski et al. [88], was only reported in 7% (4 of 58)
of the studies [18,63,80,89].
The paucity of data made it impossible to document
an increase in adult T1D incidence that would parallel
the dramatic increase observed in children [2,3,90]. In-
deed, successive studies in the same region over different
periods reporting incidence in people aged >30 years of
age were only found for Belgium [30-32], Lithuania
[20-22] and Sweden [58-62]. Similarly, this review did
not dispose of sufficient data to document differences in
the clinical presentation of T1D of adults and children
as suggested elsewhere [32,40]; indeed only two of the
71 studies describe differences in clinical presentation of
T1D between adults and children [89,91].
Improving the quantity and quality of information on
adult T1D is not only useful to better understand the
epidemiology and natural history of T1D, but can have
practical consequences, as delay of T1D diagnosis may
mean retardation in insulin treatment, lost opportunities
for potential prevention of acute and chronic complica-
tions, and even death [92]: in Croatia [18], 14% of the
incident cases were identified solely through death cer-
tificates, and high mortality was found in the newly-
diagnosed T1D aged over 50.
Conclusions
Overall, the results of this systematic review should en-
courage the launching of epidemiological studies of adult
T1D with specific diagnostic criteria.
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Figure 3 Geographical correlation of T1D incidence between individuals aged 0–14 years and adults. Studies using autoantibodies/C-Peptide
for T1D case definition are identified by Red diamonds. The corresponding countries are shown as: BE1: Belgium (2007) [30]; BE2: Belgium (2002) [31];
BE3: Belgium (1997) [32]; DK: Denmark [34]; ES1: Spain, Catalonia [54]; ES2: Spain, Navarra (2014) [56]; ES3: Spain, Navarra (2013) [57]; FI: Finland [35]; IR:
Iran (Islamic Republic of) [15]; IT: Italy [45,46]; SE: Sweden [63], TW: Taiwan [81]; US: United States of America [74]. Sp. Cor: Spearman correlation.
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criteria. (a) 0–9 years of age, (b) 10–19 years of age, (c) 10–18 years of
age, (d) 15–17 years of age, (e) 15–18 years of age, (−−-): unavailable
data. (*): Data was retrieved from a different study; for details see
Additional file 3. (†) Studies used in the geographical correlation
analyses. (‡) Special population. (§) The five areas were Ohio (8 counties),
Washington State (5 counties), South Carolina, Colorado and California;
the table presents the mean incidence calculated, retrieved from 5
populations: African American, Asian Pacific Islander, Navajo, Hispanic
and non-Hispanic young.
Additional file 5: Table S2. T1D incidences by sex in young adults and
adults found in the Systematic Review. Male-to-Female ratios >1 are
highlighted. Ref: Reference. First author and publication year in reports of
the systematic review using the autoantibodies/C-peptide as diagnosis
criteria are highlighted. Inc: incidence per 100.000 persons per year. NW:
Nation-wide study. HIGH, LMIC: High, Low-Medium Income Level. (†) Studies
used for analyses. (§) The five areas were Ohio (8 counties), Washington
State (5 counties), South Carolina, Colorado and California; the table
presents the mean incidence calculated retrieved from 5 populations:
African American, Asian Pacific Islander, Navajo, Hispanic and non-Hispanic
young. Incidence was calculated as the mean of retrieved information: (a) in
Jews and other non-Arabs and Arabs; (b) in White and Black populations;
(c) in Non-Hispanic Whites and Hispanic Whites. (d) Study giving the total
incidence by sex, not by age classes.
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4.1.1 Supporting Information  
4.1.1.1 Search equation used for the bibliographic analysis of incidence of T1D in 
adults 




"diabetes mellitus, type 1/epidemiology"[MAJR] AND (("incidence"[MeSH Major Topic] 
OR incidence[Title/Abstract]) AND (adult[TIAB] OR adult[MeSH Terms]) AND 
"humans"[MeSH Terms]) AND (Journal Article[PT] NOT ("Diabetic Neuropathies"[MeSH 
Terms] OR "Diabetic Nephropathies"[MeSH Terms] OR "Cholesterol"[MeSH Terms] OR 
"Antigens"[MeSH Terms] OR "histocompatibility antigens class ii"[MeSH Terms] OR 
"insulin"[MeSH Terms] OR "Vitamin D"[MeSH Terms] OR "Diabetic ketoacidosis"[MeSH 
Terms] OR "Vascular Diseases" [MeSH Terms] OR "Arteriosclerosis" [MeSH Terms] OR 
"Lipoproteins" [MeSH Terms] OR "Vascular Endothelial Growth Factors" [MeSH Terms] 
OR "Comorbidity" [MeSH Terms]) ! AND English[Lang]: 178 Retrieved articles4.  
 
 
Note 1. The last terms of the equation (after “Diabetic Neuropathies” were added to focus the 
bibliographic search on incidence papers by removing all those dealing, for example, with the 
incidence of complications of T1D. 
 
Note 2: Through a general search, we searched in other languages than English. We identified 115 
articles published in French and 70 in Spanish, from which we assessed full text for eligibility of 7 
papers published in French and 14 in Spanish. At the end, one paper in French and two in Spanish 
were included in the analysis. 
                                                
4 Glossary for PubMed search:" [MAJR]: MeSH Major Topic, a MeSH term that is one of the main topics 
discussed in the article; [MeSH]: MeSH Terms, the National Library of Medicine's controlled vocabulary of 
biomedical terms that is used to describe the subject of each indexed journal article in MEDLINE; [SH]: MeSH 
Subheadings; it describes more completely a particular aspect of a subject; [TIAB]: Title/Abstract, the search 
include words and numbers included in the title, abstract, and other abstract of a citation; [PT]: Publication Type, 
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4.1.1.2 CONSORT PRISMA checklist 
SI Table 14: CONSORT PRISMA checklist 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  116 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, 
and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
116-117 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  117 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
117 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
117, 118 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
117, 118 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) 
in the search and date last searched.  
117, 118 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  Additional file 
1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis).  
118, Figure 1 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators.  
119, Figure 1 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
119 
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
119, 
Additional files 
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Section/topic  # Checklist item  Reported on page #  
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  119 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
119 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
Additional files 
4 and 5 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
Figure 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
120 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  120, Table 1 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot.  
Additional files 
4 and 5, Table 
1 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.   
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
129 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
129 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  129 
FUNDING   




From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  
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4.1.1.3 List of additional papers used in the child-adult correlations 
 
SI Table 15: List of selected papers reporting incidence of T1D in 0-14 year-olds in 9 countries 
 
 
This list was obtained through a separate review focused on 9 countries considered (1st 
column). These values were used in the child-adult correlations. 
 










Australia: New South Wales  Diamond, 2006 14.5 1990-1993 (318) 
Slovakia: NW Diamond, 2006 8.90 1990-1999 (318) 
Denmark: Copenhagen and Frederiksborg Eurodiab, 2000 16.00 1989-1994 (90) 
Finland: NW Diamond, 2006 40.90 1990-1999 (318) 
Italy: Turin Bruno G, 2009 11.86 1984-2004 (46) 
Italy: Turin Bruno G, 2009 14.8 2000-2004 (46) 
Norway: NW Joner G, 1989 20.22 1973-1982 (150) 
Lithuania: NW Patterson CC, 2012 14.20 2004-2008 (243) 
United States: Wisconsin Allen C, 1986 18.10 1970-1979 (13) 
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4.1.1.4 Geographic repartition, and reported adult T1D incidences found in the SR 
SI Table 16: Geographic repartition, and reported adult T1D incidences found in the SR 
 




Period 0-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-59 60-69 70-79 80-100 
African Region, LMIC  
 
                             
Mauritius: NW Tuomilehto J., 1993 
† 
(332) 0-19 1986-1990 2.1 1.1 --- --- --- --- --- --- --- --- --- --- 
United Republic of Tanzania:  
Dar es Salaam 
Swai A. B., 1993 † (311) 0-19 1982-1991 0.9 3.4 --- --- --- --- --- --- --- --- --- --- 
Eastern Mediterranean Region, LMIC 
 
                           
Iran (Islamic Republic of): Fars Pishdad G. R., 2005 
† 
(248) 0-29 1990-1994 3.7 4.7 3.4 3.3 --- --- --- --- --- --- --- --- 
Libyan Arab Jamahiriya:  
Benghazi 
Kadiki O. A., 1996 
† 
(153) 0-34 1981-1990 8.1 16.9 7.0 10.4 12.4 --- --- --- --- --- --- --- 
Tunisia: Beja, Monastir, Gafsa Ben Khalifa F., 
1998 † 
(32) 0-19 1990-1994 6.7 7.5 --- --- --- --- --- --- --- --- --- --- 
European Reion, LMIC   
 
                           
Croatia: Zagreb Roglic G., 1995 † (268) 0->55 1988-1992 7.4 9.6 9.6 6.5 6.5 5.4 5.4 4.1 4.5 --- --- --- 
Estonia: NW Kalits I., 1990 † (157) 0->50 1988-1988 10.5 39.9 9.2 9.2 11.1 11.1 12.3 12.3 3.4 --- --- --- 
Lithuania: NW Ostrauskas R., 2011 
† 
(235) 15-34 1991-2008 14.2* 7.4 7.1 8.9 9.8   --- --- --- --- --- --- 
Lithuania: NW Pundziute-Lycka 
A., 2003  
(254) 0-39 1991-2000 8.4(a) 11.1(b) 7.8 7.8 7.8 7.8 --- --- --- --- --- --- 
Lithuania: NW Ostrauskas R., 2000 (234) 15-39 1991-1997 --- 6.9 6.9 5.5 8.8 7.8 --- --- --- --- --- --- 
Poland: Bialystok  Kretowski A., 2001 
† 
(172) 0-29 1994-1998 7.3 6.0 6.0 6.0 --- --- --- --- --- --- --- --- 
Poland: Province of Rzeszow Sobel-Maruniak A., 
2006 † 
(296) 0-29 1980-1999 6.4 5.8 5.8 5.8 --- --- --- --- --- --- --- --- 
Poland: Province of Rzeszow Grzywa M. A., 
1995  
(123) 0-29 1980-1992 5.4 6.0 5.0 5.7 --- --- --- --- --- --- --- --- 
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Period 0-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-59 60-69 70-79 80-100 
1992 † 
Romania: Bucharest Ionescu-Tirgoviste 
C., 1994 † 
(143) 0-≥85 1981-1991 3.5 5.6 5.1 7.9 3.5 4.4 5.5 8.0 7.5 9.2 8.6 3.1 
Slovakia: NW Kyvik K. O., 2004 † (176) 15-29 1996-1997 8.9* 4.8 4.8 4.8 --- --- --- --- --- --- --- --- 
European Region, HIGH 
 
                             
Austria: Upper Rami B., 2001 † (259) 0-29 1994-1996 9.0 10.0 4.9 6.7 --- --- --- --- --- --- --- --- 
Belgium: Antwerp Weets I., 2007 † (353) 0-39 1989-2003 12.8 10.9 10.2 10.0 8.5 6.2 --- --- --- --- --- --- 
Belgium: Antwerp Weets I., 2002 † (352) 0-39 1989-2000 11.8 8.8 8.8 8.8 8.8 8.8       
Belgium: Antwerp Vandewalle C., 
1997 † 
(341) 0-39 1989-1995 11.8 10.1 8.3 10.0 9.20 7.3 --- --- --- --- --- --- 
Bosnia and Herzegovina:  
Republic of Srpska 
Radosevic B., 2013 
† 
(256) 0-18 1998-2010 13.8 5.1 (e) --- --- --- --- --- --- --- --- --- --- 
Denmark: Copenhagen and  
Frederiksborg 
Molbak A. G., 1994 
† 
(215) 30-95 1973-1977 16.0* --- --- --- 7.4 8.2 5.5 11.0 8.4 10.4 11.2 4.9 
Finland: NW Lammi N., 2007 † (177) 15-39 1992-1996 40.9* 22.5 16.1 16.2 15.2 10.1 --- --- --- --- --- --- 
France: Aquitaine, Lorraine,  
Basse Normandie, Haute  
Normandie 
Charkaluk M. L., 
2002 † 
(59) 0-19 1988-1997 8.9 6.1 --- --- --- --- --- --- --- --- --- --- 
France: Aquitaine, Lorraine,  




(187) 0-19 1988-1995 7.6 5.3 --- --- --- --- --- --- --- --- --- --- 
Israel: NW Blumenfeld O., 
2014 † 
(39) 0-17 1997-2010 11.1 9.2(d) --- --- --- --- --- --- --- --- --- --- 
Israel: NW Sella T., 2011 (284) 0-17 2000-2008 13.3 11.1(d) --- --- --- --- --- --- --- --- --- --- 
Israel: NW Koton S., 2007  (171) 0-17 1997-2003 9.2 8.8 (d) --- --- --- --- --- --- --- --- --- --- 
Italy: Lombardie Garancini P., 1991 
† 
(108) 0-34 1981-1982 4.2 3.8 3.7 3.0 5.0 --- --- --- --- --- --- --- 
Italy: Pavia Tenconi M. T., 
1995 † 
(317) 0-29 1988-1992 10.0 6.9 6.3 8.6 --- --- --- --- --- --- --- --- 
Italy: Sardinia (Oristano) Frongia O., 1997 † (102) 0-29 1993-1996 54.4 21.6 21.9 22.4 --- --- --- --- --- --- --- --- 
Italy: Sardinia  Muntoni S., 1992 † (220) 0-29 1989-1990 30.7 22.8 17.0 16.4 --- --- --- --- --- --- --- --- 
Italy: Turin Bruno G., 2009 †  15-29 2000-2004 14.8* 9.5 9.5 9.5 --- --- --- --- --- --- --- --- 
Italy: Turin Bruno G., 2005 † (47) 30-49 1999-2001 11.9* --- --- --- 6.1 6.7 7.9 8.7 --- --- --- --- 
Italy: Turin Bruno G., 1993 (45) 0-29 1984-1988 8.2 6.9 5.9 4.6 --- --- --- --- --- --- --- --- 
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Period 0-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-59 60-69 70-79 80-100 
1988 † 
Malta: NW Schranz A. G., 1989 
† 
(280) 0-24 1980-1987 13.8 12.2 13.5 --- --- --- --- --- --- --- --- --- 
Netherlands: NW Ruwaard D., 1994 † (271) 0-19 1988-1990 11.5 15.0 --- --- --- --- --- --- --- --- --- --- 
Norway: NW Joner G., 1991 † (149) 15-29 1978-1982 20.2* 17.5 14.5 18.8 --- --- --- --- --- --- --- --- 
Slovenia: NW Radosevic B., 2013 
† 
(256) 0-18 1998-2010 13.8 7.5 (e) --- --- --- --- --- --- --- --- --- --- 
Spain: Badajoz Morales-Perez F. 
M., 2000 † 
(218) 0-29 1992-1996 17.2 9.9 10.7 5.9 --- --- --- --- --- --- --- --- 
Spain: Canarias Islands Carrillo Dominguez 
A., 2000 † 
(55) 0-30 1995-1996 23.2 9.2 9.2 9.2 --- --- --- --- --- --- --- --- 
Spain: Catalonia Abellana R., 2009 † (5) 0-29 1989-1998 14.4 10.2 10.2 10.2 --- --- --- --- --- --- --- --- 
Spain: Catalonia Goday A. 1992  (112) 0-29 1987-1990 11.5 11.4 11.3 8.5 --- --- --- --- --- --- --- --- 
Spain: Navarra Forga L., 2014 † (98) 0->45 2009-2012 19.7 15.8 15.8 15.8 7.6 7.6 7.6 2.2 2.2 2.2 2.2 --- 
Spain: Navarra Forga L., 2013 † (97) 0-79 2009-2011 20.7 15.6 15.6 15.6 9.1 9.1 4.7 4.7 5.1 0.5 0.7 --- 
Sweden: NW Dahlquist G. G., 
2011 † 
(74) 0-34 1983-2007 32.3 16.1 13.6 11.6 9.4 --- --- --- --- --- --- --- 
Sweden: NW Östman J., 2008 (233) 15-34 1983-2002 --- 14.8 13.9 12.5 9.8 --- --- --- --- --- --- --- 
Sweden: NW Pundziute-Lycka 
A., 2002 
(252) 0-34 1983-1998 28.0 15.2 13.2 12.1 9.9 --- --- --- --- --- --- --- 
Sweden: NW Nyström L., 1992 (229) 0-34 1983-1987 25.9 14.7 12.8 11.7 9.7 --- --- --- --- --- --- --- 
Sweden: NW Blohme G., 1992 (37) 15-34 1983-1987 --- 14.8 12.7 11.7 9.8 --- --- --- --- --- --- --- 
Sweden: Kronoberg Thunander M., 2008 
† 
(320) 0-100 1998-2001 41.1 27.2 19.7 19.7 11.7 11.7 20.0 20.0 36.1 35.3 55.0 27.3 
United Kingdom: NW Imkampe A. K., 
2011 †  
(141) 0-34 1991-2008 19.3 12.2 12.2 12.2 12.2 --- --- --- --- --- --- --- 
United Kingdom: Oxford  
region 
Bingley P. J., 1989 (35) 0-21 1985-1986 15.7 16.2 --- --- --- --- --- --- --- --- --- --- 
Region of the Americas, LMIC  
 
                           
Barbados: NW Jordan O. W., 1994 
† 
(152) 0-29 1982-1991 5.6 3.3 3.3 3.3 --- --- --- --- --- --- --- --- 
Region of the Americas, HIGH 
 
                             
Canada: Quebec Legault L., 2006 † (184) 0-18 2000 15.3 11.1 (d) --- --- --- --- --- --- --- --- --- --- 
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Period 0-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-59 60-69 70-79 80-100 
Alabama (Jefferson County) 1991 † 
United States of America:  
Alabama (Jefferson County) 
Wagenknecht L. E., 
1989  
(349) 0-19 1979-1985 18.3 9.3 --- --- --- --- --- --- --- --- --- --- 
United States of America:  
Colorado 
Vehik K., 2007 † (344) 0-17 2000-2004 21.8 16.1 (d) --- --- --- --- --- --- --- --- --- --- 
United States of America:  
Colorado 
Kostraba J. N., 1992 (170) 0-17 1978-1988 12.8 8.7 --- --- --- --- --- --- --- --- --- --- 
United States of America:   
Pennsylvania (Allegheny) 
Libman I. M., 1998 
† 
(191) 0-19 1990-1994 17.4 12.3 --- --- --- --- --- --- --- --- --- --- 
United States of America:  
Rhode Island  
Fishbein H. A., 
1982 † 
(96) 0-29 1979-1980 12.7 11.0 14.0 17.0 --- --- --- --- --- --- --- --- 
United States of America: five  
areas § 
Bell R., 2009 † (31) 0-19 2002-2005 14.0 8.0 --- --- --- --- --- --- --- --- --- --- 
United States of America:  
Wisconsin 
Allen C., 1986 † (13) 0-29 1970-1979 18.1 12.7 9.0 11.1 --- --- --- --- --- --- --- --- 
United States of America: The    
United States Navy 
Gorham C., 1993 ‡  (117) 17-34 1974-1988 18.1 10.4 21.8 27.3 61.7 --- --- --- --- --- --- --- 
Western Pacific Region, HIGH 
 
                           
Australia: New South Wales Tran F., 2014 † (326) 10-18 2001-2008 14.5* 22.0(c) --- --- --- --- --- --- --- --- --- --- 
Australia: Sydney (Southern  
Metropolitan Heath Region) 
Sutton L., 1989 † (308) 0-19 1984-1987 12.91 10.78 --- --- --- --- --- --- --- --- --- --- 
Japan: Osaka Sasaki A., 1992 † (275) 0-18 1978-1988 1.89 1.65(e) --- --- --- --- --- --- --- --- --- --- 
New Zealand: Canterbury Scott, R. S., 1991†  (281) 
 
0-≥80 1981-1986 12.2 16.9 (b) 8.1 8.1 10.6 10.6 11.8 11.8 13.1 18.6 21.7 --- 
Other Regions currently non-WHO  
 
               
Taiwan: NW Lin W. -H., 2013 † (192) 0-≥60 1999-2010 5.1 3.68 2.23 0.98 0.73 --- --- --- --- --- --- --- 
US Virgin Islands: NW Washington R. E., 
2013 † 
(351) 0-19 2001-2010 11.2(a)  19.1(b) --- --- --- --- --- --- --- --- --- --- 
Incidence was per 100.000 persons per year. T1D: Type 1 Diabetes. NW: Nation-wide study. HIGH, LMIC: High, Low-Medium Income Level.  Highlighted: reports of the 
systematic review using the autoantibodies/C-peptide as diagnosis criteria. (a) 0-9 years of age, (b) 10-19 years of age, (c) 10-18 years of age, (d) 15-17 years of age, 
(e) 15-18 years of age, (---): unavailable data. (*): Data was retrieved from a different study; for details see Additional file 3.  (†) Studies used in the geographical correlation 
analyses. (‡) Special population. (§) The five areas were Ohio (8 counties), Washington State (5 counties), South Carolina, Colorado and California; the table presents the 
mean incidence calculated, retrieved from 5 populations: African American, Asian Pacific Islander, Navajo, Hispanic and non-Hispanic young.
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4.1.1.5 Incidence of T1D by sex in young adults and adults 
SI Table 17: T1D incidences by sex in young adults and adults found in the systematic review 
Country, Area First Author, 









African Region, LMIC    
  
        
Mauritius: NW Tuomilehto J., 1993 † (332) 1986-1990 15-19 0.4 1.7 0.24 
Eastern Mediterranean Region, 
LMIC   
  
        
Iran (Islamic Republic of): Fars Pishdad G. R., 2005 † (248) 1990-1994 15-29 2.7 4.0 0.68 
Libyan Arab Jamahiriya: Benghazi Kadiki O. A., 1996 † (153) 1981-1990 15-34 14.2 9.0 1.58 
Tunisia: Beja, Monastir, Gafsa Ben Khalifa F., 1998 † (32) 1990-1994 15-19 6.2 8.8 0.70 
European Region, LMIC   
  
        
Estonia, NW Kalits I., 1990 † (157) 1988-1988 15-39 18.2 21.9 0.83 
Lithuania, NW Ostrauskas R., 2011 † (235) 1991-2008 15-34 10.4 6.1 1.71 
Lithuania, NW 
Pundziute-Lycka A., 
2003  (254) 1991-2000 20-39 10.2 5.4 1.89 
Lithuania, NW Ostrauskas R., 2000 (234) 1991-1997 15-39 9.7 5.7 1.70 
Poland: Province of Rzeszow Sobel-Maruniak A., 2006 (296) 1980-1999 15-29 6.8 4.7 1.45 
Poland: Province of Rzeszow Grzywa M. A., 1995 † (123) 1980-1992 15-29 6.0 5.1 1.16 
Poland: Warsaw Wysocki M. J., 1992 † (366) 1983-1988 15-29 6.5 4.4 1.48 
Slovakia: NW Kyvik K. O., 2004 † (176) 1996-1997 25-29 5.8 3.9 1.49 
European Region, HIGH   
  
        
Austria: Upper Rami B., 2001 † (259) 1994-1996 25-30 8.2 4.4 1.86 
Belgium: Antwerp Weets I., 2002 † (352) 1989-2000 15-39 7.0 10.6 0.66 
Belgium: Antwerp Vandewalle C., 1997 † (341) 1989-1995 15-39 11.0 6.9 1.59 
Bosnia and Herzegovina: Republic of 
Srpska Radosevic B., 2013 † (256) 1998-2010 15-18 6.3 3.9 1.62 
Denmark: Copenhagen and 
Frederiksborg Molbak A. G., 1994 † (215) 1973-1977 >30 9.1 7.5 1.21 
Finland: NW Lammi N., 2007 † (177) 1992-1996 15-39 20.1 11.8 1.70 
Israel: NW 
Blumenfeld O., 2014 † 
(a) (39) 1997-2010 15-17 11.0 7.4 1.49 
Israel: NW Koton S., 2007  (171) 1997-2003 15-17 10.6 7.1 1.49 
Italy: Lombardie Garancini P., 1991 † (108) 1981-1982 15-34 4.9 2.9 1.69 
Italy: Pavia Tenconi M. T., 1995 † (317) 1988-1992 15-29 6.9 6.9 1.00 
Italy: Sardinia  Muntoni S., 1992 † (220) 1989-1990 15-29 25.3 12.1 2.09 
Italy: Sardinia (Oristano) Frongia O., 1997 † (102) 1993-1996 15-29 21.7 22.3 0.97 
Italy: Turin Bruno G, 2009 † (46) 2000-2004 15-29 8.2 5.9 1.39 
Italy: Turin Bruno G, 2005 † (47) 1999-2001 30-39 9.2 5.4 1.70 
Italy: Turin Bruno G., 1993 (45) 1984-1988 15-29 7.4 4.2 1.75 
Malta: NW Schranz A. G., 1989 † (280) 1980-1987 15-24 13.3 12.2 1.09 
Netherlands: NW Ruwaard D., 1994 † (271) 1988-1990 15-19 16.6 13.3 1.25 
Norway: NW Joner G., 1991 † (149) 1978-1982 15-29 19.0 15.0 1.27 
Slovenia: NW Radosevic B., 2013 † (256) 1998-2010 15-18 8.4 6.6 1.27 
Spain: Badajoz 
Morales-Perez F. M., 
2000 † (218) 1992-1996 15-29 10.2 7.3 1.40 
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Country, Area First Author, 









Spain: Canarias Islands 
Carrillo Dominguez A., 
2000 † (55) 1995-1996 15-29 12.2 6.2 1.97 
Spain: Catalonia Abellana R., 2009 † (5) 1989-1998 15-29 10.6 7.0 1.51 
Spain: Catalonia Goday A., 1992 (112) 1987-1990 15-29 12.6 7.2 1.75 
Spain: Navarra Forga L., 2014 † (98) 2009-2012 15-29 23.0 8.2 2.80 
Spain: Navarra Forga L., 2013 † (97) 2009-2011 15-29 22.4 8.3 2.69 
Sweden: NW Dahlquist G. G, 2011 † (74) 1983-2007 15-34 18.9 9.2 2.05 
Sweden: NW Östman J., 2008 (233) 1983-2002 15-34 16.4 8.9 1.84 
Sweden: NW 
Pundziute-Lycka A., 
2002 (252) 1983-1998 15-34 16.1 9.1 1.77 
Sweden: NW Nyström L., 1992 (229) 1983-1987 15-34 15.8 8.6 1.85 
Sweden: NW Blohme G., 1992 (37) 1983-1987 15-34 15.9 8.6 1.85 
Sweden: Kronoberg Thunander M., 2008 † (320) 1998-2001 20-39 21.6 9.4 2.29 
United Kingdom: NW Imkampe A. K., 2011 † (141) 1991-2008 15-34 16.5 8.5 1.94 
United Kingdom: Oxford region Bingley P. J., 1989  (35) 1985-1986 15-19 16.0 16.5 0.97 
Region of the Americas, HIGH   
  
        
United States of America: Alabama 
(Jefferson County) 
Wagenknecht L. E., 1989  
(b) (349) 1979-1985 15-19 8.6 10.0 0.86 
United States of America: Colorado Vehik K., 2007 † (c) (344) 2000-2004 15-17 10.7 8.2 1.31 
United States of America: Colorado Kostraba J. N., 1992 (170) 1978-1988 15-17 9.8 7.6 1.30 
United States of America: five areas § Bell R., 2009 † (31) 2002-2005 15-19 8.3 7.7 1.08 
United States of America: Wisconsin Allen C., 1986 † (13) 1970-1979 15-29 11.7 8.3 1.41 
United States of America: The United 
States Navy Gorham C., 1993 (b) (117) 1974-1988 17-34 24.4 24.9 0.98 
Western Pacific Region, HIGH   
  
        
Japan: Osaka Sasaki A., 1992 † (275) 1978-1988 15-18 1.8 1.5 1.21 
New Zealand: Canterbury Scott, R. S., 1991†  
(281) 
 1981-1986 20-39 11.4 7.3 1.56 
Other Regions currently non-WHO    
  
        
Taiwan: NW Lin W. -H., 2013 † (192) 1999-2010 15-29 3.2 4.1 0.77 
 
 
No available information    
  
        
African Region, LMIC    
  
        
United Republic of Tanzania: Dar es 
Salaam Swai A. B., 1993 † (311) 1982-1991 NA NA NA NA 
European Region, LMIC   
  
        
Croatia: Zagreb Roglic G., 1995 † (268) 1988-1992 NA NA NA NA 
Poland: Bialystok  Kretowski A., 2001 † (172) 1994-1998 NA NA NA NA 
Romania: Bucharest 
Ionescu-Tirgoviste C., 
1994 † (143) 1981-1991 NA NA NA NA 
European Region, HIGH   
  
        
Belgium: Antwerp Weets I., 2007 † (353) 1989-2003 NA NA NA NA 
France: Aquitaine, Lorraine, Basse 
Normandie, Haute Normandie Charkaluk M. L., 2002 † (59) 1988-1997 NA NA NA NA 
France: Aquitaine, Lorraine, Haute-
Normandie, and Basse-Normandie. Levy-Marchal C., 1998  (187) 1988-1995 NA NA NA NA 
Israel: NW Sella T., 2010 (d) (284) 2000-2008 NA NA NA NA 
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Country, Area First Author, 










De Beaufort C. E., 1988 
† (d) (75) 1977-1986 NA NA NA NA 
Region of the Americas, HIGH   
  
        
Canada: Quebec Legault L., 2006 †  (184) 2000 NA NA NA NA 
United States of America: Alabama 
(Jefferson County) 
Wagenknecht L. E., 1991 
† (d) (350) 1979-1988 NA NA NA NA 
United States of America:  
Pennsylvania (Allegheny) Libman I. M., 1998 † (d) (191) 1990-1994 NA NA NA NA 
United States of America: Rhode Island  
Fishbein H. A., 1982 † 
(d) (96) 1979-1980 NA NA NA NA 
Region of the Americas, LMIC    
  
        
Barbados: NW Jordan O. W., 1994 † (d) (152) 1982-1991 NA NA NA NA 
Western Pacific Region, HIGH   
  
        
Australia: New South Wales Tran F., 2014 † (326) 2001-2008 NA NA  NA NA 
Australia: Sydney (Southern 
Metropolitan Heath Region) Sutton L., 1989 † (308) 1984-1987 NA NA NA NA 
Other Regions currently non-WHO    
  
        
US Virgin Islands: NW 
Washington R. E., 2013 
† (351) 2001-2010 NA NA NA NA 
Male-to-female ratios >1 are highlighted. Ref: Reference. First author and publication 
year in reports of the systematic review using the autoantibodies/C-peptide as diagnosis 
criteria are highlighted. Inc: incidence per 100.000 persons per year. NW: Nation-wide study. 
HIGH, LMIC: High, Low-Medium Income Level. (†) Studies used for analyses. (§) The five 
areas were Ohio (8 counties), Washington State (5 counties), South Carolina, Colorado and 
California; the table presents the mean incidence calculated retrieved from 5 populations: 
African American, Asian Pacific Islander, Navajo, Hispanic and non-Hispanic young. 
Incidence was calculated as the mean of retrieved information: (a) in Jews and other non-
Arabs and Arabs; (b) in White and Black populations; (c) in Non-Hispanic Whites and 
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4.2 Additional analyses of the study: Global epidemiology of T1D in young 
adults and adults: a systematic review 
 
4.2.1 Ethnicity differences in T1D Incidence of T1D in Adults 
Among 71 studies described in chapter 3, ethnicity differences were reported in 7 
studies. In Mauritius, the incidence was similar among individuals of Asian Indian, Chinese 
or Creole origin (332). In Israel, a significant difference was found between Jews and Arabs 
(39, 171). In Unites States, in Pennsylvania, the incidence was higher in non-Whites than in 
Whites (191), in Alabama the opposite was found (349, 350), whereas, in Colorado no 
significant differences were found after exploring the incidence of T1D in different periods 
(344).  
4.2.2 Rural-urban differences in T1D Incidence of T1D in Adults 
Only ten percent (7 of the 71) of the studies explored the differences in the incidence 
of T1D in rural vs urban areas. A significantly higher urban proportion of the incidence of 
T1D among young adults and adults was found in 4 of these 7, (Iran (Fars) (248), Lithuania 
(nation-wide) (254), Italy (Pavia) (317), and United States of America (Wisconsin) (13)). In 
another study from Poland (Bialystok), a significantly rising incidence trend was found in the 
rural areas but not in the urban regions (172). In the Province of Rzeszow no differences were 
found between the rural and urban incidences (123), nor in Turin, Italy (45).  
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5 Global incidence trends of T1D 
 
A classical epidemiological method to disentangle the possible effects of 
environmental factors influencing the incidence of T1D at different ages, at different periods 
and in different birth cohorts is the Age-Period-Cohort (APC) method, first proposed by 
Derrick in 1927 (77) in studies of mortality, then extended to other domains of public health 
such as social sciences, psychology, stomatology, ophthalmology, demography, and studies 
of environmental factors related with cancer (110).   
The first part of this chapter briefly describes the model and gives some examples of 
the APC approaches used to answer different questions in the domain of public health.  
The second part of this chapter presents the APC approach we used to explain the 
increase in the incidence of T1D worldwide, as documented in chapters 1, 2 and 3. In the 
APC model presented in this chapter included 2,327,604,529 person-years at risk and 
192,741 cases retrieved from 265 worldwide studies published between 1975 and 2014, 
reporting T1D incidence among individuals aged 0-14 years and collected through a 
systematic review. 
After performing the APC analyses among individuals aged 0-14 years, a clear and 
strong birth cohort effect was observed. In addition, a calendar period effect that has been 
changing over time was also observed. The highest rate of incidence was observed for those 
aged 10-14 years. Environmental factors are no doubt implicated.  
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5.1 Early literature on the Age-Period-Cohort (APC) analyses 
Derrick (1927) (77) first proposed the analyses of cohorts to study the effect of the 
birth cohort on mortality. The history of the first 30 years of the cohort analyses is presented 
in Case’s (1956) (56) historical article: “cohort analysis of mortality rates as a historical or 
narrative technique”. With time, the APC models were improved with the introduction of the 
age (of death, in the case of mortality studies) and period (in which the death/event of interest 
was produced), as described by Gilg Soit Ilg in her doctoral thesis (1999), supervised by 
Professor Alain-Jacques Valleron: “La méthode âge-période-cohorte, outil prévisionnel 
application au mesothéliome en France” at the UPMC (ED 393) (110). 
The Norman Ryder’s classical article published in 1965 (272): “The cohort as a 
concept in the study of social change”, argues that a cohort membership could determine 
behavior as other social structures such as socioeconomic status, and describes in the abstract, 








Later, in 1973, Mason et al. (206) specified the Age-Period-Cohort (APC) 
“identification problem” due to the linear relationship of the variables age, period and birth 
cohort in the model, in their classical article:  “Some methodological issues in cohort analysis 
of archival data”; see abstract below:  
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During the last years, several articles and replies about the methods on APC analyses 
were published and detailed by Kenneth C. Land in the seminar:  “Disentangling Age-Period-
Cohort Effects: New Models, Methods, and Empirical Applications” (178). Land argues that 
recent methodological contributions such as developments of statistics (such as mixed (fixed 
and random) effect models, Markov Chain Monte Carlo (MCMC) estimation of Bayesian 
models) ‘can lead to better methods for APC analyses that can be applied by ordinary [social] 
scientists’.  
Recommendations for the estimation of APC models include: a) graphic 
descriptive analysis of the model, b) model fitting procedures, and when the analyses 
suggest that all three dimensions (age, period and cohort) are operating in the model: c) 
the introduction of an external factor, (e.g., apply the procedure of the Intrinsic Estimator 
(IE)) (178). 
However, in APC analyses based on repeated cross-section sample surveys or data 
registers, such as the data we collected on T1D in this thesis, individual-level data are not 
available, then other research designs have been recently proposed. These new approaches of 
the APC model can use a different temporal grouping for the age (A), period (P), and cohort 
(C) dimensions that breaks the linear dependency: 
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-  Single year of age 
- Time periods correspond to years in which the surveys are conducted 
- Cohorts can be defined either by five- or ten-year intervals  
On this last APC based on population data from surveys or registers, to assess the 
possibility that individuals within the same periods and cohorts could share unobserved 
random variances, and to determine if a period and/or cohort heterogeneity can be explained 
by the given period and/or cohort characteristics, the Hierarchical Age-Period-Cohort 
(HAPC) Models were proposed as an alternative solution. The HAPC models use as 
analytical methods: a) mixed (fixed and random) effect models or hierarchical linear models 
(HLM) and b) cross-classified random effect models (CCREM) (178).  
In chapter 6, thanks to Professor Pierre-Yves Boëlle from the UPMC, HAPC-
CCREM were proposed to explain the effect of the age, the period and the cohort in the 
study of T1D using Poisson regression models, and with a country-level random level 
intercept according the Holford method (133, 134). 
5.1.1 Some examples of APC analyses used in public health  
In spite of limitations of the APC models this method was used extensively in 
mortality analyses (mainly in cancer research), as well as in other domains of public health 
such as phycology, social sciences, psychology, stomatology, ophthalmology, and 
demography (110).  
APC analysis has been proposed to answer fundamental questions the public health 
through different methodological approaches. As examples see the following studies: 
- The study: “Estimation of the past and future burden of mortality from 
mesothelioma in France” (Gilg Soit Ilg et al. 1998) (140), states and predicts the 
mortality due to mesothelioma in France using a classical approach of the APC 
models. 
- The study: “Intrinsic Estimator for Age-Period-Cohort analysis: what it is and 
how to use it”, (Yang et al. 2008) (368), addresses the problem of the APC 
analysis of age-by-time period tables of rates or proportions.  
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- The study: “Aplicación del estimador intrínseco a tasas de mortalidad por cancer 
de mama”, (Arnesi and Hachuel, 2011) (19), contrasts the use Generalized Linear 
Models and IE in an APC analysis.  
- The study: “A mixed models approach to the age-period-cohort analysis of 
repeated cross-section surveys, with an application to data on trends in verbal test 
scores”, (Yang and Land, 2006) (370), uses HAPC-CCREM models applied to 
sociology. 
- The study: “Trends in smoking in Sweden from 1968 to 2002: Age, period, and 
cohort patterns” (Ahacic, et al. 2008) (8), uses HAPC-CCREM models applied to 
the study of tobacco consumption.  
- The study: “Is old age depressing? Growth trajectories and cohort variations in 
late life depression”, (Yang, 2007) (369), uses APC approaches in psychology, 
applied to longitudinal data of an initial sample of individuals from a broad array 
of ages.  
5.1.1.1 Examples of APC analyses used to study T1D trends 
Few studies have used APC models to study incidence trends of T1D. Classical 
approaches of APC models from Denmark, the United Kingdom and Sweden, have described 
a calendar period effect in the incidence of T1D (119, 141, 217, 233, 310), observed when 
trends affect all age groups at the same time. In contrast, in other studies from Norway, 
Sweden and the United States a birth cohort effect (3, 74, 156) was described. Only two 
studies report the analyses of the three interrelated variables: age-period-cohort: the study: 
“Age-Period-Cohort Analyses of 1990-2003 Incidence time trends of childhood diabetes in 
Italy, the RIDI Study” From Italy, (Bruno et al. 2010) (43), in which neither period nor cohort 
effect was observed, and the study: “Spatiotemporal trends and Age-Period-Cohort modeling 
of the incidence of Type 1 diabetes among children aged <15 years in Norway 1973-1982 
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5.2 APC analysis of the Global Incidence trends of Type 1 diabetes 
P. A. Diaz-Valencia, P. Y. Boëlle, P. Bougnères, A. J. Valleron. 
 
5.2.1 Abstract 
Background: Type 1 Diabetes (T1D) has generally been increasing worldwide. In 
contrast, in Scandinavian countries, the decline in cumulative incidence in recent years 
reflects a possible break in the trend. 
Objective: to disentangle the effect of age, calendar period, and birth cohort on the 
temporal trends of T1D incidence in children aged 0-14 years.  
 Methods: the incidence of T1D worldwide was retrieved through a systematic review 
of the literature. To model the effects of age, calendar time and birth cohorts on the variation 
of T1D incidence, a Hierarchical Age-Period-Cohort cross-classified Random Effects Model 
(HAPC-CCREM) was then proposed using Poisson regression.  
Findings: Information on the incidence of T1D was retrieved in 89 countries 
worldwide and increase in the incidence of T1D with age was examined among those aged 
less than 14 years. Global trends of T1D increase with age show increasing incidence in 
successive birth cohorts over the period of analysis. After allowing a cohort effect, little 
change due to period was present.  
Conclusions: The incidence of T1D increases over the 14 first years of life. During the 
last century, dynamic changes of the incidence trends of T1D were observed. Both calendar 
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The incidence of T1D has been studied in several countries worldwide showing an 
enormous variation in trends (90, 122, 241, 243, 300, 318), that is not explained by either 
genetic or social factors or by health care systems (81). In the 1980s, the increase of the T1D 
incidence was recognized (105) and calculated to be on average 3% per year (318).   
T1D is a complex disease with multifactorial causes (338, 342, 343). In the etiology 
of the disease, genetic (89) factors are implicated as well as environmental factors (104, 306); 
in which autoimmune (338, 367) mechanisms are involved. Previous studies have described a 
calendar period effect in the incidence of T1D (119, 141, 217, 233, 310), observed when 
trends affect all age groups at the same time. In contrast, in other studies a birth cohort effect 
(3, 74, 156) was described, in which the increase of the incidence trends was observed in all 
age groups from the same birth cohort. The importance of clarifying whether increases in 
temporal trends of T1D are due to period or cohort effects is fundamental to better understand 
the etiology of this disease. A calendar period effect has been related with short or long-term 
changes and more stable increases in incidence, in which an abrupt exposition to an 
environmental trigger could reflect a non-linear patron, whereas a birth cohort effect has been 
related with long-term changes, in which rapid and unstable changes in the incidence are 
comparable to an epidemic pattern.   
Evidence of the influence of age, period, or birth cohort effects affecting the incidence 
trends of T1D has been studied in some countries; nevertheless, very few studies report the 
analyses of these three interrelated variables: age-period-cohort (3, 43), in part because 
during short periods of time, only a limited number of observations are available in most 
countries and are also due to methodological issues, such as the linear dependence between 
the variables age, calendar period and birth cohort (232). Among the studies reporting an 
APC analysis, neither period nor cohort effects were observed in the Bruno study (43), 
whereas a birth cohort effect was found in the Aamodt study (3). Here, using a systematic 
review of the literature, we have generated a large database containing global information on 
the incidence of T1D; then using a methodological approach based on Mixed Poisson 
Regression Models (MPRM) and introducing a random effect by country, we were able to 
estimate the APC rates of the global incidence of T1D, considering all three variables: age, 
calendar period, and birth cohort. 
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5.2.3.1 Global incidence of T1D data 
A systematic literature search was conducted to obtain data to model trends in T1D 
worldwide. The recommendations of the PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) Group were followed (213) (SI Table 19 - Checklist). The 
registration number in PROSPERO, the International Prospective Register of Systematic 
Reviews is: CRD42012002369 (available on 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012002369). We 
searched MEDLINE, Web of Science and Google Scholar for all relevant original papers 
published in English between 1975 and 2014 including the reviews Diamond (318) and 
Eurodiab studies (90, 242, 243), and the International Diabetes Federation (IDF) atlas (241, 
300).  
The search, conducted on 28/11/2011 and updated in November 2014 included the 
following terms: "diabetes mellitus, type 1/epidemiology" AND "incidence" AND "age" (OR 
"age distribution" OR "age factors" OR "age groups"). All abstracts were read for reports of 
T1D incidence. If present, the full-text was obtained and the article included in the analysis if 
it reported incidence data in the general population at a regional or country level. Figure 27 
shows the flow diagram of the bibliographic search. The complete search strategy is in: 
Supporting information 5.2.5.1. For the entire list of selected references see SI Table 20. 
5.2.3.2 Data abstraction 
T1D incidence rates or counts up to the age of 14 years were extracted from the texts, 
tables or graphs in the articles. We also extracted the country where the study had been 
performed, the period (calendar year) and the age or age class. When available, we also 
extracted the population at risk (in person years). 
5.2.3.3 Preparation of data 
We searched for duplications in the data extracted. When two papers presented the 
same data, we included the more detailed version (in age and period). When local studies 
were included in studies performed on a larger scale, only the largest, up to the country level 
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were included. Finally, the data was grouped in age classes of 5 years each (0-4, 5-9, 10-14) 
and in 5 years period classes (starting in 1935). In all cases, the data was converted back to 
number of cases and populations at risk. If the population was not available, we used 
estimates from the United Nation population (335), and otherwise we checked that the 
population sizes from these references agreed with those reported in the published articles. 
The final database is presented in Appendix A: Database IV.  
The classification of incidence-country-level was arbitrarily proposed as: very low, 
low, intermediate, and high incidence level, corresponding to countries with incidence levels 
of:  ≥2 to <6, ≥6 to <10, ≥10 to <42 and ≥ 42 cases per 100.000 persons per year.  
 
Figure 27: Flow diagram bibliographic search strategy 
 
Articles screened based on title and abstract 
 n = 607 
 
286 Records excluded 
104 Articles excluded:  
o  38, concerned general topics of T1D. 
o  27, contained duplicated data. 
o  18, because the main objective of the studies was 
not incidence of T1D. 
o  7, because they were not performed among the 
general population.   
o  3, because the study did not follow the WHO 
(1985,1999), ADA (1997, 2011), or clinical  
criteria of diagnosis of T1D. 
o  5, because the data were not from original studies 
o  6, because the data on TID  incidence was 
reported for individuals aged more than 14  years.  
Studies included in analyses among 
individuals aged 0-14 years 
 n = 265 
Bibliographic search using PubMed 
 























Full-text articles assessed for elegibility 
 n = 321 
 
Classical studies included in analyses searching 
Google Scholar, reference list of cited articles 
and comparing retrieved information with main 
publications in global epidemiology of T1D 
(Diamond,  Eurodiab, IDF) 
n = 48 
Original papers  included in the database 
n = 217 
Final setudies included in the APC model 
among individuals aged 0-14 years 
 n = 223 
42  Records excluded bacuse information was 
duplicated.    
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We used an APC model, specifically a HAPC-CCREM using Poisson regression, to 
analyze the incidence rates over periods and ages. In the APC models, incidence is described 
as depending on age, calendar period, and birth cohort. Here age was the age at diagnosis of 
T1D - the year of the first insulin injection- reported by the studies, calendar period was the 
year of diagnosis, and birth cohort was the year of birth of the patient (obtained as period – 
age). To avoid over-parametrization, we used a 3-nodes linear spline to model the period and 
cohort components. We analyzed all data jointly, using a country-level random level 
intercept. More precisely, the model for analysis was: 
log! ! !,!,!,!!(!,!,!,!) = !!!! ! + !!!!! ! !+!!!!! ! + !!!  
where D(a,p,c,y) was the number of incident cases at age a, period p and birth cohort 
c in country y, fA(a), fP(p) and fC(c) were the age, period and cohort components, N(a,p,c) 
the number of persons at risk and by a normally distributed country level effect with mean 0 
and variance !!!.    
The R software (version 3.0.1) was used for statistical and graphic analyses (255). 
Packages Epi, Splines, Lme4 and Grid were required.  
 
5.2.3.5 Retrieved global information on T1D 
Thanks to our systematic review, worldwide incidence trends of T1D were retrieved 
from 265 references (223 included in the APC model) between 1975 and 2014 that contained 
information of incident cases of T1D reported during the period 1938-2008 in individuals 
aged less than 14 years. There are enormous variations in incidence trends of T1D after 
stratification of the analysis according to incidence-country-level. Incidences varied widely 
between continents, countries, and regions. Among children aged 0-14 years, the lowest 
nationwide incidences (≤ 1 case per 100.000 individuals/year) were in Eastern Asia (China), 
South-Eastern Asia (Thailand), Melanesia Oceania (Papua New Guinea), and South America 
and the Caribbean (Saint Kitts and Nevis, Dominican Republic, and Paraguay). The highest 
nationwide incidences (≥ 30 cases per 100.000 individuals/year) were in Northern Europe 
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Age$(years)$/$Last$year$of$the$five3year$period$ 1938 1943 1948 1953 1958 1963 1968 1973 1978 1983 1988 1993 1998 2003 2008 2013 Total
AFRICA 6 18 30 12 9 6 81
0(_(4( 2 6 10 4 3 2 27
5(_(9 2 6 10 4 3 2 27
10(_14 2 6 10 4 3 2 27
ASIA 6 21 39 124 202 74 27 6 499
0(_(4( 2 7 13 43 68 25 9 2 169
5(_(9 2 7 13 42 67 24 9 2 166
10(_14 2 7 13 39 67 25 9 2 164
EUROPE 6 15 15 18 18 21 36 73 136 215 309 459 389 201 81 15 2007
0(_(4( 2 5 5 6 6 7 12 24 45 71 102 152 129 66 27 5 664
5(_(9 2 5 5 6 6 7 12 25 46 73 104 155 132 69 27 5 679
10(_14 2 5 5 6 6 7 12 24 45 71 103 152 128 66 27 5 664
LATIN$AMERICA$AND$THE$CARIBBEAN 3 36 108 93 30 36 12 3 321
0(_(4( 1 12 36 31 10 12 4 1 107
5(_(9 1 12 36 31 10 12 4 1 107
10(_14 1 12 36 31 10 12 4 1 107
NORTH$AMERICA 9 40 62 84 69 63 54 45 27 50 21 3 527
0(_(4( 9 25 22 20 23 21 18 15 9 16 7 1 186
5(_(9 15 25 32 23 21 18 15 9 17 7 1 183
10(_14 15 32 23 21 18 15 9 17 7 1 158
OCEANIA 3 6 3 6 30 15 18 15 3 99
0(_(4( 1 2 1 2 10 5 6 5 1 33
5(_(9 1 2 1 2 10 5 6 5 1 33
10(_14 1 2 1 2 10 5 6 5 1 33
Total 6 15 15 18 27 61 101 169 232 365 643 844 550 338 129 21 3534
(Finland, Sweden, Norway). SI Table 20 presents the variability of the incidences within a 
country, the duration of each study, the number of cases and the population at risk taken from 
the information used during these analyses. 
5.2.3.6 APC analyses of the global incidence of T1D 
The mean incidence of T1D was 13.7 cases (95% CI 13.1-14.2) per 100.000 persons 
per year. North America, Europe and Oceania are the regions with the highest incidences, in 
contrast Asia, Africa and Latin America and the Caribbean, showed the lowest incidences. 
Europe is the region in the world with most incidences registered: 147,220 cases and more 
person-years of following at risk: 1,048,075,945. See Table 18.  
Table 18: Incidence rates of T1D among children aged 0-14 years retrieved from 89 countries during 
the years 1975-2014 by main geographical areas  
 Incident 
cases (n) 
Person-years at risk (n) Mean Incidence per 
100.000 person-years 
(95%CI) 
Africa 1,372 30,084,343 5.9 (4.0-7.8) 
Asia 12,169 934,989,765 4.0 (3.1-4.8) 
Europe 147,220 1 048,075,945 15.6 (14.9-16.4) 
    Finland 6,048 15,302,876 43.9 (35.8-51.9) 
Latin America and the Caribbean 5,961 152,894,342 7.2 (6.1-8.3) 
Northern America 13,106 82,974,910 16.6 (15.4-17.8) 
Oceania 12,914 78,585,224 14.7 (13.0-16.4) 
All 192,741 2,327,604,529 13.7 (13.1-14.2) 
Retrieved datasets were predominantly from European countries (n = 2007), followed 
by North America (n = 527) and Asia (n = 499). 1989-1993 was the period reporting the 
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Green-to-red gradient represents the number of datasets from the lower to the higher. Age is the mean for each 
age-class (0-4, 5-9, 10-14), each period correspond to 5 calendar years.  
Figure 28: Distribution of information (datasets) used in the APC model by main geographical areas 
 
 The APC model presented in Figure 29 corresponds to 2,327,604,529 person-years at 
risk and 192,741 cases retrieved from worldwide studies published between 1975 and 2014, 
reporting T1D incidence among individuals aged 0-14 years. A separate analysis of the APC 
model without Finland, the country with the highest reported worldwide incidence, is also 





















On the y-axis: Rate: incidence rates of T1D per 100.000 individuals per year, P. RR: relative risk of the periods, 
C. RR: relative risk of the cohorts. x-axis: in years. w/o: without. 
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5.2.4 Discussion  
The incidence of T1D is highly variable among the 89 countries and regions reporting 
information. Regarding incidence trends, the incidence of T1D increases with age; it presents 
the highest rate for those aged 10-14 years. In addition a birth cohort effect and a calendar 
period effect were observed. The curve representing the birth cohort effect shows a steady 
increase after 1975, been the RR = 1 in the 1980s and RR = 2.5 in the 2000s. Surprisingly, a 
decrease in the curve representing a calendar period effect appears after the peak in 1987; this 
tendency is strongly influenced by the effect of Finland, a very special country in which the 
epidemiology of T1D differs in genetic and maybe in environmental parameters and which 
provides a large amount of information, compared with other countries in this study.  
In general, we observed that the incidence of T1D shows dynamic trends around the 
world. Large and sudden variations in the epidemiology over relatively short periods of time 
have also been described. Studying the ancient literature of T1D, Gale suggests that T1D 
showed a stable low incidence over the first half of the century (105). But in the 90s, 
collaborative studies such as Diamond (318) and Eurodiab (90, 242, 243) reported an increase 
in incidence trends of T1D worldwide. Our results are congruent with this finding and also 
with a nation-wide Swedish study, in which a reversed trend of cumulative incidence of T1D 
after 2000 (p < 0.01) was observed (33).  
It is known that T1D is a multi-causal disease, and several hypotheses have been 
proposed as explanations. Nevertheless most authors agree with the theory that there is a 
strong influence of the environment among the causes of this disease. For example, Dahlquist 
(74) and Jaroz-Chobot (148) strongly support the idea that the most important promoters of 
the increase of T1D are the availability of fast food and the ‘westernisation’ of lifestyles 
(overweight, high growth rate, and having sedentary lifestyles), conditions that are associated 
with other environmental factors (e.g. enterovirus (314, 373)) and could be triggers in the 
initiation of the disease (probably by accelerating the beta-cell destructive process) due to a 
direct influence or to lack of protective agents (74, 148). 
Our findings support the hypothesis that external factors including environmental risk 
determinants, and other non-genetic causes could be promoters or modifying factors 
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significant predictors of T1D incidence were: UV radiation, mobile cellular subscriptions, 
health expenditure per capita, immunization against Hepatitis B and mean BMI (body mass 
index) (81). Nevertheless, more analyses of gene-environment as well as social determinants 
of health for T1D are still necessary.  
Our study has several limitations. We found publications only in 46% (90 of 196) of 
the recognized countries. The variation of the duration of studies - between 1 and 40 years -, 
reflects enormous differences in surveillance and epidemiological reports of T1D worldwide. 
Few studies were carried out in Central and Latin America, Central Asia, and Sub-Saharan 
Africa, geographic regions where the epidemiological surveillance systems are concentrated 
in other priority concerns of health care systems or have under-developed data reports and 
registration systems. Nonetheless, part of the regional differences could also be due to 
different genetic (89) backgrounds of the populations not shown here. This could explain the 
extreme differences observed between and within countries, such as for example, the high 
incidence of Sardinia in Italy or in Newfoundland in Canada, and also the differences between 
ethnic groups, as for example Ashkenazi Jews, or non-Ashkenazi Jews in Israel, or among 
Hispanic or non-Hispanic populations in the United States.  
To minimize the risk of bias, we only considered for the quantitative analyses 
performed here, references with population data-registers and in which an assessment of all 
included references at the study-level and outcome-level was rigorous; nevertheless, data 
plots and summarized results from heterogeneous populations could imply a bias. Also, to 
avoid duplications of the subject, we carefully selected the information to be entered in the 
analyses, excluding repetitions of data from a same region during a specific time period; 
however it is impossible to verify in all cases if any doubling exists. Similarly, we selected 
information reported for a given country or area during a specific period of time only once.  
 In addition, there are methodological issues of the APC models, here were treated the 
over-parametrization by introducing an external random factor, in our case the “country”. 
Using this method it was possible to present a separate analysis excluding Finland, the 
country with the highest incidence in the world. Also, data analyses were started in 1970, a 
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The birth cohort effect we show here should be explored. Researches focusing on 
pregnancy, and neonatal period are necessary to clarify causal factors of the birth cohort 
effect, for example, the implications of congenital infections as well as the absence of 
exposure to protective factors related to the way of delivery and the first moths of life of the 
newborns. Based on the period effect we report here, quick changes such as weight gain 
during early childhood (91) or adolescence could be risk factors of T1D and a manifestation 
of a calendar period effect.  
Our results show that for children 0-14 years old, the global incidence of T1D 
increases with age, with a tendency of steady increase after the 1975 birth cohort. However, 
observing the period effect, after reaching a peak in 1987, the tendency shifted downwards, 
mainly influenced by the effect of information from Finland. Our remaining questions are if 
we are face a true slowdown in the tendency of T1D incidence; in this case, is it still 
necessary to understand the reasons why. Nevertheless, this apparent reversal trend could be 
due to miss or insufficient reporting of the disease in most countries during the last decades. 
Keeping the collection of standardized information, the collaborative studies performed 
worldwide and the promotion of public repositories with available data on the incidence of 
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5.2.5 Supporting Information  
5.2.5.1 Search equation used for the bibliographic analysis  
We used the following equation to search the electronic database Medline on November 6th 
2014:   
 
 
("diabetes mellitus, type 1/epidemiology"[MAJR]) AND (("incidence"[MeSH Major Topic] 
OR incidence[Title/Abstract]) AND (age[Title/Abstract] OR "age distribution"[MeSH Terms] 
OR "age factors"[MeSH Terms] OR "age groups"[MeSH Terms]  ) AND "humans"[MeSH 
Terms]) AND (Journal Article[ptyp] AND English[lang] NOT ("Diabetic 
Neuropathies"[MeSH Terms] OR "Diabetic Nephropathies"[MeSH Terms] OR 
"Autoantibodies"[MeSH Terms] OR "Cholesterol"[MeSH Terms] OR "Antigens"[MeSH 
Terms] OR "histocompatibility antigens class ii"[MeSH Terms] OR "insulin"[MeSH Terms] 
OR "Vitamin D"[MeSH Terms]  OR "Diabetic ketoacidosis"[MeSH Terms] OR "Vascular 
Diseases" [MeSH Terms] OR "Arteriosclerosis" [MeSH Terms] OR "Lipoproteins" [MeSH 
Terms] OR "Vascular Endothelial Growth Factors" [MeSH Terms] OR "Comorbidity" 
[MeSH Terms])5.  
 
 
Note 1. The last terms of the equation (after “Diabetic Neuropathies” were added to focus the 
bibliographic search on incidence papers by removing all those dealing, for example, with the 
incidence of complications of T1D. 
 
                                                
5 Glossary for PubMed search:" [MAJR]: MeSH Major Topic, a MeSH term that is one of the main topics 
discussed in the article; [MeSH]: MeSH Terms, the National Library of Medicine's controlled vocabulary of 
biomedical terms that is used to describe the subject of each indexed journal article in MEDLINE; [SH]: MeSH 
Subheadings; it describes more completely a particular aspect of a subject; [TIAB]: Title/Abstract, the search 
include words and numbers included in the title, abstract, and other abstract of a citation; [PT]: Publication Type, 
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5.2.5.2 CONSORT PRISMA checklist 
SI Table 19: CONSORT PRISMA checklist 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, 
and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
157 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  158 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
158 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
3, 5 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
159 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) 
in the search and date last searched.  
159 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  167 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis).  
161, Figure 27 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators.  
159, Figure 27 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
159 
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
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Section/topic  # Checklist item  Reported on page #  
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  160 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
160 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
160 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
Figure 27 




Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Table 20 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot.  
Table 20 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.   
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
164 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
164 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  164 
FUNDING   




From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  
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5.2.5.3 Selected papers reporting incidence of T1D in 0-14 year-olds 
SI Table 20: List of selected countries and areas reporting incidence of T1D in 0-14 year-olds 
included in the APC model 
Continent/Country Area First Author, publication 
year 








AFRICA     
 
            
Algeria Oran Diamond, 2006 (318) 1990-1999 8.60 NA 2441279 210 NA 
Egypt 
Alexandria, 
Damanhour Arab M, 1992 (18) 1992-1992 8.00 NA 602535 48 NA 
Ethiopia Gondar Alemu S, 2009 (12) 1995-2008 0.33 NA 1727076 6 NA 
Ethiopia Jimma Alemu S, 2009 (12) 2002-2008 0.33 NA 5623928 19 NA 
Libya Benghazi Kadiki O A, 2002 (154) 1991-2000 8.53 6.19 5860200 442 100 
Libya Benghazi Kadiki O A, 1998 (155) 1991-1995 9.27 8.26 1564100 126 100 
Mauritius NW Toumilehto J, 1993 (332) 1986-1990 2.07 0.96 1530250 32 95 
Nigeria Anambra Afoke AO, 1992 (7) 1990-1990 1.96 NA 612245 12 NA 
Sudan Khartoum Elamin A, 1992 (88) 1987-1990 7.93 1.72 4100000 325 95 
Tunisia 
Beja, Monastir, 
Gafsa Ben Khalifa F, 1997 (32) 1990-1994 6.69 4.25 1713430 116 96 
Tanzania (United 
Rep.) Dar es Salaam Swai A B, 1993 (311) 1982-1991 0.92 1.13 4309300 37 NA 
ASIA     
 
            
China 
23 local 
centers Li X H, 2000 (189) 1988-1996 0.60 0.47 142560000 848 NA 
China 22 centers Yang Z, 2005 (371) 1988-1994 0.47 0.05 123929940 580 93 
China Harbin Zhang H, 2008 (375) 1990-2000 0.74 0.49 14147694 103 98 
China North middle Yang Z, 1998 (372) 1985-1994 0.58 0.19 65338202 418 94 
China Shanghai Fu H, 1994 (103) 1980-1991 0.71 0.50 10221570 62 85 
China Shanghai Shen S X , 1996 (291) 1989-1993 0.84 0.25 7008320 58 85 
China South middle Yang Z, 1998 (372) 1985-1994 0.42 0.23 60126801 219 94 
Georgia NW 
Amirkhanashvili K, 
2000 (17) 1998-1999 3.30 1.68 5285667 171 NA 
Hong Kong SAR Hong Kong  Huen K F, 2000 (139) 1984-1996 1.37 0.42 16185143 224 100 
Hong Kong SAR Hong Kong Wong G W K , 1993 (365) 1986-1990 1.93 1.03 1120030 22 94 
India Madras Ramachandran A, 1996 (258) 1991-1994 11.00 1.70 1671170 184 90 
Iran (Islamic 
Republic of) Fars Pishdad G R, 2005 (248) 1991-1996 3.68 1.45 9564000 298 100 
Israel NW Koton S, 2007 (171) 1997-2003 10.38 5.09 12580033 1278 NA 
Israel NW Laron Z V, 1985 (181) 1975-1980 4.20 2.74 7421790 295 95 
Israel NW Shamis I , 1997 (289) 1965-1993 5.03 3.47 1992501 924 95 
Japan Hokkaido Kawasaki E, 2006 (163) 1973-1996 1.89 1.22 3461452 69 NA 




Group, 1993 (145) 1980-1989 1.77 0.30 533623 10 95 
Japan NW Kawasaki E, 2006 (163) 1998-2001 2.35 0.70 73539756 1745 NA 
Japan NW Kida K, 2000 (165) 1986-1990 1.46 0.75 103448508 1578 95 




Group, 1993 (145) 1985-1989 1.62 0.43 11613492 192 95 
Jordan NW Ajlouni K, 1999 (9) 1992-1996 3.33 2.10 8467045 275 95 
Korea (Dem. 
People's Rep.) Seoul Diamond, 2006 (318) 1990-1991 1.10 NA 2369578 26 NA 
Kuwait Farwania Abdul-Rasoul M, 2007 (4) 1995-1999 21.08 12.98 336745 68 98 
Kuwait NW Shaltout A A, 2002 (288) 1992-1997 20.72 8.43 1811204 364 93 
Oman NW Soliman A T, 1996 (297) 1993-1995 2.59 1.35 610175 15 96 
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Continent/Country Area First Author, publication 
year 








Qatar NW Al-Zyoud M, 1997 (10) 1992-1994 11.40 NA 397497 45 NA 
Saudi Arabia 
Al-Madinah 
(North West) Habeb A M, 2011 (125) 2004-2009 31.50 14.71 1519197 419 NA 
Singapore NW Lee WW, 1998 (183) 1992-1994 2.42 1.50 2050302 47 92 
Taiwan (Republic 
of China) NW Tseng CH, 2008 (327) 1992-1996 3.75 NA 4533333 170 NA 
Thailand Bangkok Tuchinda C, 2002 (329) 1991-1995 1.65 0.93 244492 4 100 
Thailand Central Tuchinda C, 2002 (329) 1991-1995 0.19 0.16 11454218 23 100 
Thailand Northestern Panamonta O, 2000 (237) 1991-1995 0.30 0.04 25675073 76 NA 
Thailand Northestern Panamonta O, 2011 (238) 1996-2005 0.64 0.42 53221307 339 NA 
Thailand Northeastern Tuchinda C, 2002 (329) 1991-1995 0.30 0.04 40270354 120 100 
Thailand NW Tuchinda C, 1992 (328) 1984-1985 0.17 0.04 36208676 60 NA 
Thailand Southern Tuchinda C, 2002 (329) 1991-1995 0.42 0.10 9456906 40 100 
Uzbekistan NW Rakhimova GGN, 2002 (257) 1989-1989 1.20 NA 8436250 101 NA 
EUROPE     
 
            
Austria NW Schober E, 2008 (277) 1979-2005 10.02 3.83 35872193 3593 92 
Austria NW Shober E, 2009 (278) 1997-2007 17.55 1.20 2788963 489 93 
Belarus Gomel Martinucci M E, 2002 (205) 1976-1999 5.73 3.33 8591976 493 100 




Srpska Radosevic B, 2013 (256) 1998-2010 8.13 2.67 3904151 320 100 
Bosnia and 
Herzegovina Tuzla Canton Bratina N U, 2001 (42) 1990-1998 3.55 2.39 1142703 41 100 
Bosnia and 
Herzegovina Tuzla Canton Tahirovic H, 2007 (312) 1995-2004 6.93 1.65 1120125 80 100 
Bulgaria Eastern  Tzaneva V, 1998 (334) 1974-1995 6.27 2.73 3186768 200 98 
Croatia NW Stipancic G, 2012 (305) 1995-2003 8.90 2.76 7646381 692 97 
Croatia Zagreb Roglic G, 1995 (268) 1988-1992 7.40 4.81 1003921 72 96 
Cyprus NW Skordis N , 2012 (294) 1990-2009 12.34 3.46 3023124 371 100 
Cyprus NW Toumba M, 2007 (325) 1990-2004 11.95 3.53 2327097 277 NA 
Czech Republic NW Cinek O, 2000 (64) 1990-1997 9.94 3.41 15222265 1539 100 
Czech Republic NW Cinek O, 2003 (65) 1990-2001 14.90 1.64 6905411 1026 99 
Denmark NW Svensson J, 2002 (309) 1970-2000 14.32 6.11 12704194 1856 99 
Denmark NW Svensson J, 2009 (310) 1996-2005 22.23 8.96 10149370 2276 NA 
Estonia NW Teeaar T, 2010 (316) 1983-2006 13.09 5.15 6761392 843 98 
Estonia NW Toumilehto J, 1991 (333) 1980-1988 10.90 2.51 990593 108 100 
Estonia NW Podar T , 2001 (250) 1983-1998 6.93 2.78 8665396 601 NA 
Finland NW Moltchanova E A, 2005 (216) 1965-1996 26.25 3.62 15976566 4160 100 
Finland NW Harjutsalo V, 2008 (127) 1980-2005 42.93 11.52 24615936 10671 NA 








Nor H) Levy-Marchal C, 1990 (188) 1988-1988 7.17 3.04 1736066 124 90 
France Aquitaine Barat P, 2008 (28) 1988-2004 11.70 4.42 3779331 443 95 
France Franche-Comté Mauny F, 2005 (208) 1980-1998 7.01 1.36 4347369 308 81 
Germany 
Baden-
Württemberg Ehehalt S, 2008 (85) 1987-2003 14.06 2.80 28363640 4017 97 
Germany 
Baden-
Württemberg Neu A, 1997 (222) 1987-1993 10.63 3.74 11859042 1251 96 
Germany NW Rosenbauer J, 1999 (270) 1993-1995 8.10 NA 12555556 1017 83 
Germany Saxony Galler A, 2010 (107) 1999-2008 17.43 4.05 4831705 850 94 
Greece Crete Mamoulakis D, 2003 (204) 1990-2001 5.98 1.93 1459728 89 98 
Greece NW 
Dacou-Voutetakis C, 
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Continent/Country Area First Author, publication 
year 









18 of 19 
countries (less 
Budapest) Gyurus EK, 2012 (124) 1989-2009 12.58 4.60 28487914 3610 96 
Hungary 
18 of 19 
countries (less 
Budapest) Soltesz G L, 1990 (299) 1978-1987 6.14 2.71 18763350 1166 96 
Iceland NW Helgason T, 1992 (131) 1970-1989 9.40 1.98 1287610 121 100 







Teramo) Altobelli E, 2002 (14) 1990-1995 9.31 1.73 1099400 102 98 
Italy Central Italy Carle F, 2004 (53) 1990-1999 9.43 1.59 12239675 1161 98 
Italy Liguria Cotellessa M, 2003 (67) 1989-1998 12.35 3.06 1754417 219 99 
Italy Liguria Mazzella M, 1994 (209) 1987-1991 11.89 3.13 973499 118 99 
Italy Lombardia Calori G, 1990 (50) 1983-1984 6.24 3.31 3555925 236 100 
Italy Marche Region Cherubini V, 1994 (61) 1990-1992 7.97 3.41 647951 52 100 
Italy NW_39.7% Bruno G, 2010 (43) 1990-2003 12.55 3.90 42209659 5180 NA 
Italy Pavia Tenconi M T , 1995 (317) 1988-1992 10.03 5.38 291100 31 100 
Italy Piedmont Bruno G, 2009 (46) 1984-2004 11.86 3.13 9536077 1135 NA 
Italy 
Rome and 
Lazio Region Sebastiani L, 1996 (283) 1989-1993 7.87 1.78 5118966 403 85 
Italy 
Sardinia 
(Oristano) Frongia O, 1997 (102) 1993-1996 54.43 14.76 101028 54 100 
Italy Sardinia Casu A, 2004 (57) 1989-1999 38.63 8.32 3083065 1214 91 
Italy Sardinia Karvonen M, 1998 (159) 1989-1992 33.83 8.18 1237440 425 91 
Italy Sardinia Songini M , 1998 (302) 1989-1994 33.24 6.59 1376178 459 91 
Italy 
Sicily 
(Catania) Arpi M, 2002 (20) 1989-1998 12.35 3.31 2205644 273 99 
Italy South Italy Carle F, 2004 (53) 1990-1999 8.87 3.30 17171537 1354 98 
Italy Turin Bruno G, 2001 (44) 1984-1996 9.75 2.47 4127879 401 98 
Italy Turin   Bruno G, 2009  (46) 1984-2004 11.33 3.71 2714027 305 NA 
Italy Veneto Region Pinelli L, 1998 (247) 1993-1994 10.53 2.97 1210502 128 89 
Lithuania NW 
Pundziute-Lycka A, 
2004 (253) 1983-2000 7.50 3.05 13788189 1054 96 
Luxembourg NW De Beaufort C E , 1988 (75) 1977-1986 10.67 3.11 637761 68 94 
Macedonia (TFYR) Skopje Kocova M, 1993 (168) 1985-1991 2.49 0.97 4200000 105 100 
Malta NW Formosa N, 2012 (100) 2006-2010 23.87 14.26 341480 81 100 
Malta NW Schranz A G , 1989 (280) 1980-1987 13.75 6.13 697504 93 NA 
Montenegro NW Samardzic M, 2010 (274) 1997-2006 13.53 5.04 1356619 184 100 
Netherlands NW Ruwaard D, 1994 (271) 1988-1990 11.50 4.48 5435320 624 81 
Norway NW Aamodt G, 2007 (3) 1973-2003 22.66 8.32 22151884 5031 NA 
Norway NW Joner G, 2004 (151) 1989-1998 22.52 7.07 8549357 1905 98 
Poland Bialystok  Kretowski A, 2001 (172) 1994-1998 7.30 4.67 283912 25 99 
Poland 
Cracow 
Province Dziatkowiak H, 2002 (83) 1987-1999 8.08 2.91 3377534 273 100 
Poland Midwestern Rewers M, 1987 (264) 1970-1984 5.44 2.98 9071949 397 100 
Poland NW_35% Jarosz-Chobot P, 2011 (148) 1989-2004 11.23 7.60 5540524 565 NA 
Poland 
Province of 
Rzeszow Grzywa M A, 1995 (123) 1980-1992 5.39 1.53 2445781 130 99 
Poland Silesia Jarosz-Chobot P, 2000 (147) 1989-1997 6.43 3.39 7928628 528 NA 
Poland Silesia Jarosz-Chobot P, 2010 (146) 1989-2005 11.98 5.08 5824740 728 NA 
Poland Warsaw  Dziatkowiak H, 2002 (83) 1987-1999 7.58 2.98 3598612 273 100 
Poland Warsaw Wysocki M J , 1992 (366) 1983-1988 4.87 1.66 1591171 77 90 
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Continent/Country Area First Author, publication 
year 
















Portalegre Diamond, 2006 (318) 1990-1994 14.60 NA 387332 57 87 
Portugal Coimbra Diamond, 2006 (318) 1990-1999 9.60 NA 246302 24 100 
Portugal Madeira Island Diamond, 2006 (318) 1990-1999 6.90 NA 459957 32 100 
Portugal Portalegre Diamond, 2006 (318) 1990-1994 21.30 NA 21261 5 93 
Romania Bucharest 
Ionescu-Tirgoviste C, 
1994 (143) 1981-1991 3.47 1.88 5020730 176 NA 
Romania NW 
Ionescu-Tirgoviste C, 
2004 (142) 1988-1997 3.02 1.48 47040120 1487 100 
Romania NW Serban V , 2001 (285) 1992-1995 3.71 2.29 19791336 706 94 
Russian Federation Moscow Pronina E A, 2008 (251) 1996-2005 12.07 4.65 15784076 2031 94 
Russian Federation Novosibirsk Podar T, 1993 (249) 1983-1989 4.73 3.20 2401787 112 NA 
Serbia Belgrade Vlajinac H D, 1995 (347) 1982-1992 8.00 3.73 3196875 259 90 
Slovakia NW Michalkova D, 2002 (211) 1985-2000 9.15 3.64 19477039 1776 99 
Slovenia NW Battelino T, 1998 (30) 1988-1995 7.77 2.94 3148944 252 100 
Slovenia NW Bratina N U, 2001 (42) 1990-1998 8.72 2.35 3343896 299 96 
Slovenia NW Radosevic B, 2013 (256) 1998-2010 13.83 2.91 3872968 541 100 
Spain Badajoz 
Morales-Perez F M, 
2000 (218) 1992-1996 17.23 7.42 651020 115 95 
Spain Catalonia Goday A, 1992 (112) 1987-1990 10.60 6.58 5029022 581 90 
Spain Caceres Lora-Gomez R E, 2005 (198) 1988-1999 16.67 3.46 817104 137 99 
Spain Madrid Serrano Rios M, 1990 (287) 1985-1988 10.60 0.24 4420972 469 90 
Spain Navarre Bahíllo M, 2007 (27) 2003-2004 22.17 9.24 587206 130 100 
Spain Navarre Chueca M, 1997 (63) 1975-1991 9.04 4.20 1894055 177 98 
Sweden Kronoberg  Thunander M, 2008 (320) 1998-2001 41.10 24.83 96474 40 100 
Sweden Northern Hagglof B, 1982 (126) 1938-1977 24.12 11.39 7931274 1915 100 
Sweden NW Berhan Y, 2011 (33) 1978-2007 30.65 10.73 47617789 14694 96 
Sweden NW Dahlquist G G, 2000 (73) 1978-1997 26.32 7.77 31139774 8210 98 
Sweden NW Dahlquist G G, 2011 (74) 1983-2007 39.24 11.32 15997395 6358 96 
Sweden South-eastern  Holmqvist B M, 2008 (135) 1977-2001 26.75 7.18 7002150 1873 NA 
Sweden Stockholm Gopinath S, 2008 (116) 1990-2003 27.04 4.41 2664436 720 NA 
Switzerland NW Schoenle E J, 2001 (279) 1991-1999 6.31 2.54 11860379 751 97 
Ukraine NW Timchenko OI, 1996 (321) 1985-1992 8.10 NA 89099520 7217 NA 
United Kingdom Bradford Feltbower R G, 2002 (93) 1978-1998 13.10 4.39 2211804 289 NA 
United Kingdom 
England - 
Oxford region Gardner S G, 1997 (109) 1985-1996 18.82 7.27 5637500 1053 96 
United Kingdom 
England - 
Cornwall Zhao H X, 1999 (376) 1975-1996 14.73 4.93 3269332 488 94 
United Kingdom Leicestershire Burden A C , 1989 (48) 1951-1980 6.72 4.55 4963510 349 NA 
United Kingdom Leicestershire Raymond N T , 2001 (261) 1989-1998 18.93 8.75 1718340 309 90 
United Kingdom 
Northern 
Ireland Cardwell C, 2007 (52) 1989-2003 24.79 7.63 5741618 1433 99 
United Kingdom NW Bloom A, 1975 (38) 1973-1974 7.67 0.75 29642000 2274 NA 
United Kingdom NW Imkampe AK, 2011 (141) 1991-2008 19.32 5.17 7637391 1566 NA 
United Kingdom NW Metcalfe M A , 1991 (210) 1988-1988 13.67 3.96 11803542 1600 NA 






Clyde) Barclay R P C, 1988 (29) 1976-1986 17.66 2.08 4983604 874 NA 
United Kingdom Scotland Patterson C C , 1983 (245) 1968-1976 12.83 6.57 9752375 1283 NA 
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United Kingdom Scotland Rangasami J J, 1997 (260) 1984-1993 23.87 8.31 9728160 2326 99 
United Kingdom Yorkshire Feltbower R G, 2003 (94) 1978-2000 8.32 3.17 31358793 2597 98 
United Kingdom Yorkshire Harron KL, 2011 (129) 1978-2007 18.00 6.02 21533206 3911 98 
LATIN AMERICA AND THE 
CARIBBEAN   
 
            
Argentina Avellaneda Sereday M S, 1994 (286) 1985-1989 6.67 0.77 481417 32 NA 
Antigua and 
Barbuda NW Tull E S , 1997 (330) 1989-1993 3.45 NA 125935 4 100 
Bahamas NW Peter SA, 2005 (246) 2001-2002 10.10 NA 89109 9 100 
Barbados NW Jordan O W, 1994 (152) 1982-1991 5.56 2.56 642329 36 94 
Brazil 
Rio Grande do 
Sul (Passo 
Fundo) Lisboa H R K , 1998 (197) 1996-1996 12.00 NA 50098 6 100 
Brazil 
São Paulo 
(Bauru) Negrato C, 2010 (221) 1986-2006 10.40 3.96 1673132 176 NA 





(Tortola) Tull E S , 1997 (330) 1989-1993 3.81 NA 21256 1 100 
Chile IX region Larenas G, 1996 (180) 1980-1993 1.37 0.70 2571228 35 97 
Chile 
Santiago of 






region) Torres-Avilés F, 2010 (323) 2000-2005 6.30 1.11 9754547 613 100 
Colombia Bogota Diamond, 2006 (318) 1990-1990 3.80 NA 1958529 74 97 
Colombia Cali Diamond, 2006 (318) 1995-1999 0.50 NA 3294727 16 NA 
Cuba NW Diamond, 2006 (318) 1990-1999 2.30 NA 24714580 568 63 
Mexico NW Gomez-Diaz RA, 2012 (114) 2000-2010 6.13 2.70 33666691 2095 NA 
Peru Lima Diamond, 2006 (318) 1990-1994 0.50 NA 10674410 53 68 
Puerto Rico NW 
Frazer de Llado T E, 









Croix) Tull E S , 1997 (330) 1989-1993 8.22 2.65 181411 15 100 
Uruguay Montevideo Diamond, 2006 (318) 1992-1992 8.30 NA 320157 27 97 
NORTH 
AMERICA     
 
            
Canada 
Alberta 
(Edmonton) Toth E L, 1997 (324) 1990-1995 26.37 10.25 821729 217 84 
Canada Manitoba Blanchard J F, 1997 (36) 1985-1993 20.33 7.94 2132163 434 95 
Canada Newfoundland Newhook L, 2004 (223) 1987-2002 35.82 18.26 811466 293 95 
Canada 
Newfoundland 
and Labrador Newhook LA, 2012 (225) 1987-2010 39.01 11.18 2471297 931 NA 
Canada Québec Legault L, 2006 (184) 1989-2000 15.34 5.38 1312792 197 NA 
Canada 
Québec 
(Montreal) Siemiatycki J, 1986 (292) 1971-1983 8.46 3.32 9445097 802 94 
Canada 
Québec 
(Montreal) West R, 1979 (356) 1971-1977 8.76 1.63 2430829 213 98 




Wagenknecht L E , 
1991 (350) 1979-1988 13.85 5.46 1479075 207 NA 
United States  
California (San 
Diego) Lorenzi M, 1985 (199) 1978-1981 7.30 2.08 835728 61 86 
United States  Chicago Lipton R, 1995 (196) 1985-1990 10.75 6.17 3109060 333 86 
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 United States  Hawaii (Oahu) Patrick S L, 1997 (240) 1980-1990 7.04 NA 1605483 113 97 
United States  Michigan  North F A , 1977 (228) 1958-1972 12.63 7.73 17884326 2262 NA 
United States  
Pennsylvania 
(Allegheny) Libman I M, 1998 (191) 1990-1994 17.37 8.01 1215083 207 98 
United States  
Pennsylvania 
(Allegheny) Rewers M , 1989 (265) 1970-1985 13.69 7.71 6775996 850 90 
United States  Philadelphia Lipman T H, 2002 (194) 1990-1994 13.30 5.76 1600755 209 96 
United States  Philadelphia Lipman T H, 2006 (195) 1995-1999 14.93 6.82 1600755 234 96 
United States  Philadelphia Lipman T H, 1993 (193) 1985-1989 13.14 5.57 1680113 212 93 
United States  Rhode Island  Fishbein H A, 1982 (96) 1979-1980 12.67 6.51 197887 26 NA 
United States  Seven areas Bell R, 2009 (31) 2002-2005 14.01 9.82 14838874 3297 NA 
United States  Wisconsin Allen C, 1986 (13) 1970-1979 18.20 6.81 1789270 332 90 
OCEANIA     
 
            
Australia 
New South 
Wales Taplin G E, 2005 (313) 1990-2002 19.35 6.75 16179667 3122 100 
Australia 
New South 
Wales Verge C F, 1994 (345) 1990-1991 14.45 6.05 2419498 349 99 





Heath Region) Sutton L, 1989 (308) 1984-1987 12.91 7.29 685476 90 NA 
Australia Victoria Chong J W, 2007 (62) 1999-2002 19.33 6.69 3930965 767 99 
Australia 
Western 
Australia Haynes A, 2004 (130) 1985-2002 16.47 4.75 6874359 1136 100 
Australia 
Western 
Australia Kelly H A, 1992 (164) 1985-1989 13.16 4.16 2006600 265 99 
New Zealand Canterbury Willis J A, 2002 (364) 1970-1999 14.19 5.81 2808234 398 100 
New Zealand NW Crossley J R, 1980 (68) 1968-1972 8.85 NA 4826495 428 NA 
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USA: United States of America; ITA: Italy; POL: Poland; SWE: Sweden; GBR: United Kingdom; AUT: 
Austria; CAN: Canada; JPN: Japan; BGR: Bulgaria. For each country there are several studies, dots represent 
these studies. Information from a particular study are in the same color in each country, color through different 
countries are independent. 
SI Figure 30: Observed vs predicted incidence of T1D in countries with large incidence rates using 
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FRA: France; FIN: Finland; HUN: Hungary; SVK: Slovakia; THA: Thailand; NOR: Norway; AUS: Australia, 
ISR: Israel; CZE: Czech Republic. For each country there are several studies, dots represent these studies. 




SI Figure 31: Observed vs predicted incidence of T1D by countries with medium incidence rates 
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BRA: Brazil; CHL: Chile; ESP: Spain; DEU: Germany; KWT: Kuwait; MLT: Malta; CHN: China; CYP: 
Cyprus; VIR: United States Virgin Islands. 
 
SI Figure 32: Observed vs predicted incidence of T1D by countries with small incidence rates using 
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Cumulative incidence of T1D in persons aged 0−14 years by birth cohorts (1959−2008)
 
5.3 Additional analyses of the global incidence trends of T1D 
 
5.3.1.1 Cumulative incidence of T1D by birth cohorts 
Cumulative incidence of T1D was calculated for the birth cohorts 1959-2008 of the 
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5.3.1.2 Incidence trends of T1D and temporal changes on the economic growth of 
countries 
 In an exploratory analysis, temporal trends of T1D incidence by each one of the 89 
countries were analyzed. Comparing the resulting drift of each country allows to distinguish 
differences in the evolution of the T1D by birth cohort in each country.  
 The following figures show the results retrieved for the countries with a higher 
incidence growth with respect to countries with an average growth: Canada (CAN), Chile 
(CHL), Hungary (HUN), Poland (POL), Singapore (SGP), Slovakia (SVK), Switzerland 
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CAN: Canada, CHL: Chile, HUN: Hungary, POL: Poland, SGP: Singapore, SVK: Slovakia, CHE: Switzerland, 
and THA: Thailand. 
 
SI Figure 34: Countries with a higher incidence growth respect to countries with an average growth 
 
 
The following figures show the results retrieved for the countries with a lower 
incidence growth respect to countries with an average growth: China (CHN), Denmark 
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CHN: China, DNK: Denmark, ISR: Israel, KWT: Kuwait, LBY: Libya, NOR: Norway, and ROU: Romania. 
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5.3.1.3 Correlations between incidence of T1D predicted in the APC model and 
environmental indicators 
Five significant predictors of the country-to-country variation of T1D incidence, 
retrieved in a previous study (81), were correlated with the retrieved intercept of the predicted 




























Sp. cor. = -0.56 
p-value = 4.44 x 10-07 
 
The shaded region 
indicates 95% CI 
 
 
Sp. cor. = -0.16 
p-value = 0.155 
 
The shaded region 
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SI Figure 40: Predicted incidence of T1D and Mobile cellular subscriptions (per 100 people)
Sp. cor. = 0.72 
p-value = < 2.27 x 10-13 
 




Sp. cor. = 0.57 
p-value = 4.47 x 10-08 
 
The shaded region 
indicates 95% CI 
 
 
Sp. cor. = 0.32  
p-value = 0.002 
 
The shaded region 
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5.3.1.4 Comparison of environmental correlations using the intercept of the T1D incidence retrieved in the APC model and the 
incidence of T1D retrieved in the systematic review   
Table 21 compare the retrieved intercept of the incidence of T1D retrieved using the APC model presented above, in which the age, the 
period and the birth cohort of the retrieved incidences were adjusted, and the incidence retrieved in our systematic review and described in 
chapter 3 (81).  











(n of 89) 
Spearman 





(n of 80) 
Spearman 

















Agriculture                       
CA_1 Agricultural land (% of land area) 86 0.03 8.19E-01 37 21 80 0.07 5.29E-01 37 21 WB 
CA_2 Arable land (% of land area) 86 0.00 9.82E-01 17 14 80 0.10 3.96E-01 17 14 WB 
CA_3 Cereal production (metric tons) 82 -0.03 7.94E-01 25999771 77463855 79 -0.03 8.02E-01 27600000 80200000 WB 
CA_4 Cereal yield (kg per hectare) 82 0.30 5.92E-03 4291 2077 78 0.33 2.77E-03 4419 2079 WB 
CA_5 Fertilizer consumption (kilograms per hectare of arable land) 80 0.11 3.23E-01 219 472 76 0.02 8.63E-01 233 488 WB 
CA_6 Forest area (% of land area) 86 -0.08 4.41E-01 30 20 80 -0.06 5.85E-01 29 19 WB 
CA_7 Permanent cropland (% of land area) 85 -0.32 3.00E-03 2 4 79 -0.36 1.08E-03 2 3 WB 
Environment                       
CE_8 Annual precipitation by country: values in millimeters. (Mean 1961-1999) 80 -0.19 9.44E-02 885 601 77 -0.16 1.71E-01 846 583 WB 
CE_9 Annual temperatures by country: values in degrees Celsius. (Mean 1961-1999) 80 -0.33 2.48E-03 14 9 77 -0.44 5.45E-05 14 8 WB 
CE_10 CO2 emissions (metric tons per capita) 85 0.62 3.62E-10 7 6 80 0.61 1.38E-09 7 7 WB 
CE_11 Latitude 89 0.49 1.31E-06 29 25 80 0.56 5.31E-08 30 26 
Google 
Maps 
CE_12 Longitude 89 -0.12 2.60E-01 12 61 80 -0.14 2.15E-01 15 59 
Google 
Maps 
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(n of 89) 
Spearman 





(n of 80) 
Spearman 





CE_14 Nitrous oxide emissions (thousand metric tons of CO2 equivalent) 77 0.48 -8.16E-02 29914 77690 75 -0.15 1.94E-01 30500 79200 WB 
CE_15 Nitrous oxide emissions in industrial and energy processes (% of total nitrous oxide emissions) 77 0.29 1.08E-02 18 12 75 0.32 5.69E-03 18 12 WB 
CE_16 Outdoor air pollution (Annual PM10 [ug/m3]) 81 -0.37 6.53E-04 52 39 77 -0.42 1.38E-04 52 40 WHO 
CE_17 PM10, country level (micrograms per cubic meter) 81 -0.29 9.53E-03 32 26 76 -0.32 5.25E-03 33 27 WB 







Demography                       
DD_19 Adolescent fertility rate (births per 1,000 women ages 15-19) 84 -0.35 1.07E-03 28 27 80 -0.47 1.06E-05 27 26 WB 
DD_20 Female mean age of childbearing (years) 85 0.36 8.47E-04 29 2 80 0.44 3.62E-05 29 2 UN 
DD_21 Fertility rate, total (births per woman) 84 -0.13 2.48E-01 2 1 80 -0.25 2.65E-02 2 1 WB 
DD_22 Life expectancy at birth, female (years) 84 0.52 4.43E-07 78 6 80 0.58 1.94E-08 79 6 WB 
DD_23 Life expectancy at birth, male (years) 84 0.57 1.69E-08 73 6 80 0.60 3.53E-09 73 6 WB 
DD_24 Life expectancy at birth, total (years) 84 0.55 6.25E-08 76 6 80 0.60 2.92E-09 76 6 WB 
DD_25 Population ages 0-14 (% of total) 85 -0.30 5.11E-03 21 8 80 -0.42 1.10E-04 21 8 WB 
DD_26 Population 15-64 years of age (% of total) 85 0.00 9.90E-01 67 5 80 0.07 5.29E-01 67 5 WB 
DD_27 Population ages 65 and above (% of total) 85 0.44 3.13E-05 12 6 80 0.51 1.52E-06 12 6 WB 
DD_28 Population growth (annual %) 87 -0.19 8.52E-02 1 1 80 -0.20 8.05E-02 1 2 WB 
DD_29 Population, female (% of total) 85 0.08 4.77E-01 50 4 80 0.14 2.15E-01 50 4 WB 
DD_30 Probability of dying between birth and the age of 40 years (both sexes combined) (deaths under age 40 per 1,000 live births) 85 -0.56 2.16E-08 54 55 80 -0.65 9.91E-11 52 48 UN 
DD_31 Rural population (% of total population) 87 -0.45 1.51E-05 31 21 80 -0.41 1.46E-04 30 20 WB 
DD_32 Total population 0-14 years (both sexes combined) 85 -0.25 2.23E-02 14825 48326 80 -0.32 4.16E-03 15200 49900 UN 










Country Economy                       
EC_33 GDP growth (annual %) 85 -0.48 3.08E-06 3 4 79 -0.47 1.07E-05 3 4 WB 
EC_34 GDP per capita (constant 2005 US$) 85 0.68 1.04E-12 17207 17402 79 0.72 9.05E-14 17800 17900 WB 
EC_35 GDP per capita, PPP (constant 2005 international $) 83 0.65 3.04E-11 19687 14333 78 0.71 5.24E-13 20100 14500 WB 
Development                       
ED_36 Adjusted savings: education expenditure (% of GNI) 80 0.49 4.43E-06 5 2 75 0.45 5.56E-05 5 2 WB 
ED_37 Improved sanitation facilities (% of population with access) 84 0.66 1.29E-11 88 21 78 0.67 2.08E-11 88 21 WB 
ED_38 Improved water source (% of population with access) 83 0.66 7.52E-12 93 13 79 0.67 1.60E-11 94 13 WB 
ED_39 Energy use (kg of oil equivalent per capita) 84 0.68 9.28E-13 3151 2963 79 0.69 1.22E-12 3303 3045 WB 
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ED_41 Mobile cellular subscriptions (per 100 people) 86 0.32 2.41E-03 116 39 80 0.44 4.93E-05 113 36 WB 
ED_42 Population using solid fuels (Total population: urban + Rural) 84 -0.52 3.87E-07 13 24 80 -0.50 2.68E-06 11 23 WHO 
Health Economy                       
EH_43 External resources for health (% of total expenditure on health) 83 -0.59 5.25E-09 2 7 79 -0.62 7.62E-10 2 7 WB 
EH_44 Health expenditure per capita (current US$) 83 0.71 6.12E-14 1838 2150 79 0.73 1.62E-14 1942 2198 WB 










Risk Factors for Non-Communicable Diseases                       
HR_46 Mean BMI (kg/m2) (age-standardized estimate) Female +20 84 0.15 1.66E-01 26 2 80 0.11 3.32E-01 26 2 WHO 
HR_47 Mean BMI (kg/m2) (age-standardized estimate) Male +20 84 0.59 4.47E-09 26 2 80 0.63 2.58E-10 26 2 WHO 
HR_48 Mean systolic blood pressure in mm Hg (age-standardized estimate) Female +25 84 -0.24 2.56E-02 125 4 80 -0.18 1.19E-01 125 4 WHO 
HR_49 Mean systolic blood pressure in mm Hg (age-standardized estimate) Male +25 84 0.09 4.38E-01 131 4 80 0.19 8.41E-02 131 4 WHO 
HR_50 Mean Total Cholesterol in mmol/l (age-standardized estimate) Female+25 84 0.60 1.94E-09 5 0 80 0.62 1.25E-09 5 0 WHO 
HR_51 Mean Total Cholesterol in mmol/l (age-standardized estimate) Male +25 84 0.65 3.43E-11 5 0 80 0.70 5.18E-13 5 0 WHO 
HR_52 Obesity: % of defined population with a BMI ≥ 30 kg/m2 (age-standardized estimate) Both Sexes +20 84 0.31 3.88E-03 21 8 80 0.33 3.06E-03 21 8 WHO 
HR_53 Overweight: % population with a BMI ≥ 25 kg/m2 (age-standardized estimate) Both Sexes +20 84 0.37 6.16E-04 53 14 80 0.37 7.49E-04 53 14 WHO 
HR_54 Preterm birth rate (per 100 live births) 82 -0.24 3.00E-02 9 2 79 -0.27 1.44E-02 8 2 WHO 
HR_55 Prevalence of undernourishment (% of population) 79 -0.58 1.74E-08 8 8 75 -0.59 2.41E-08 8 8 WB 
HR_56 Total alcohol in litres of pure alcohol  per capita consumption, estimation for 2008, Both Sexes +15 83 0.34 1.83E-03 9 5 79 0.44 4.38E-05 9 5 WHO 
Infectious Diseases and Immunization                       
HI_57 Diphtheria tetanus toxoid and pertussis (DTP3) immunization coverage among 1-year-olds (%) 84 0.17 1.24E-01 93 9 80 0.24 3.00E-02 94 7 WHO 
HI_58 Haemophilus influenzae type B vaccine (Hib3) immunization coverage among 1-year-olds (%) 84 0.38 3.40E-04 82 30 80 0.48 5.20E-06 82 30 WHO 
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HI_60 Incidence of tuberculosis (per 100,000 people) 87 -0.60 1.15E-09 48 70 80 -0.61 1.91E-09 49 72 WB 
HI_61 Measles - number of reported cases (standardized using population 0-14 years, per 100,000 people)  82 0.09 4.17E-01 1873 12117 80 0.05 6.91E-01 1754 12200 WHO 
HI_62 Measles (MCV) immunization coverage among 1-year-olds (%) 84 -0.01 9.47E-01 93 9 80 0.02 8.28E-01 93 7 WHO 
HI_63 Measles immunization coverage among children ages 12-23 months (%) 83 -0.06 6.08E-01 93 8 79 -0.03 7.70E-01 93 8 WB 
HI_64 Pertussis - number of reported cases (standardized using population 0-14 years, per 100,000 people)  77 0.12 2.94E-01 2085 15988 76 0.08 4.91E-01 2113 16093 WHO 
HI_65 Polio (Pol3) immunization coverage among 1-year-olds (%) 84 0.16 1.48E-01 93 8 80 0.23 4.46E-02 94 7 WHO 
Deaths from Non-Communicable Diseases                       
HD_66 Cancers, deaths per 100,000 (age-standardized estimate) Female 84 0.12 2.79E-01 96 17 80 0.22 4.60E-02 94 16 WHO 
HD_67 Cancers, deaths per 100,000 (age-standardized estimate) Male 84 0.21 5.41E-02 147 44 80 0.28 1.26E-02 146 44 WHO 
HD_68 Cardiovascular diseases and diabetes, deaths per 100,000 (age-standardized estimate) Female 84 -0.51 8.98E-07 239 126 80 -0.50 2.77E-06 230 125 WHO 
HD_69 Cardiovascular diseases and diabetes, deaths per 100,000 (age-standardized estimate) Male 84 -0.41 9.45E-05 330 166 80 -0.39 3.10E-04 326 170 WHO 
HD_70 Chronic respiratory diseases, deaths per 100,000 (age-standardized estimate) Female 84 -0.25 2.08E-02 23 21 80 -0.34 1.99E-03 23 21 WHO 
HD_71 Chronic respiratory diseases, deaths per 100,000 (age-standardized estimate) Male 84 -0.27 1.15E-02 42 31 80 -0.37 7.89E-04 42 30 WHO 
HD_72 NCD deaths under age 60 (% of all non communicable diseases deaths) Both Sexes 84 -0.54 1.41E-07 21 11 80 -0.58 1.31E-08 21 11 WHO 
HD_73 
Probability of dying between exact ages 30 and 70 from any of 
cardiovascular disease, cancer, diabetes, or chronic respiratory 
disease (%) 84 -0.45 1.76E-05 19 6 80 -0.44 3.98E-05 19 7 WHO 
Infant and Maternal Mortality Rates                       
HM_75 Infant mortality rate (probability of dying between birth and age 1 per 1000 live births) Both sexes 84 -0.62 2.40E-10 12 14 80 -0.66 2.01E-11 11 13 WHO 
HM_76 Maternal mortality ratio (modeled estimate, per 100,000 live births) 82 -0.57 2.57E-08 61 124 80 -0.62 1.12E-09 56 109 WB 
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6 Genetic determinants of T1D 
In chapter 3, we describe the covariation of T1D incidence worldwide in children 
with environmental factors that could be retrieved thanks to public databases. We found that 
51% of the variation of T1D incidence could be accounted for by country-to-country 
variation in environmental factors. 
T1D has an important genetic component. HLA (Human Leukocyte Antigen) which is 
the best known and best studied locus and alone explains the 40-50% inheritable T1D risk 
(212) was the main subject of this chapter.   
Here, we assessed the proportion of the variability of T1D incidence that could be 
explained by the country-to-country variation of the frequency of susceptible and protective 
HLA alleles and haplotypes identified as T1D determinants. We relied on the Allele 
Frequency Net at http://www.allelefrequencies.net/ (115), a public electronic repository that 
provided 1007 gene/allele HLA and 370 haplotype data for 1025 worldwide populations. In 
this website, we searched for the frequency of susceptible and protective HLA alleles and 
haplotypes and validated based on different populations around the world by the Type 1 
Diabetes Genetics Consortium Families report (2008) (89); we then compared the retrieved 
data with the incidence of T1D retrieved throughout the systematic review using methods 
similar to those presented in chapter 3. 
After Stepwise Multiple Linear Regression (MLR), the significant variables were the 
susceptible alleles: DRB1*04:01 (p = 0.0001) and DRB1*08:01 (p = 0.003). Only the 
protective allele DQB1*06:02 had a significant positive correlation with the geographical 
repartition of T1D incidence. The adjusted % of variance explained (R2) in the model was 
61% and 30% after 10-fold cross validation. Correlation coefficient on partial correlations 
between the incidence of T1D and HLA alleles after controlling environmental variables 
dropped in most cases. A combination of genetic predisposition and environmental factors is 
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6.1 Geographical covariation of T1D incidence and genetic markers  
P. A. Diaz-Valencia, Sophie Le Fur, P. Bougnères, A. J. Valleron. 
 
6.1.1 Abstract  
Background: The incidence of Type 1 Diabetes (T1D) in children varies dramatically 
between countries and has increased during the last decades.  
Methods: Information on the incidence on T1D and on country characteristics were 
searched for the 194 WHO member countries. T1D incidence was extracted from a 
systematic literature review of all papers published between 1975 and 2014, including the 
2013 update from the International Diabetes Federation, and was estimated for 80 WHO 
countries. The frequency of the major HLA (Human Leukocyte Antigen) haplotype 
determinants to T1D was searched for those countries where incidence was retrieved was 
searched in the Allele Frequency Net.  
Bivariate and multivariate analyses were used to determine the correlations between 
the incidence of T1D and selected independent predictors of the geographical variation of 
T1D within each domain and overall.  
Findings: The frequency of documented susceptible and protector HLA haplotypes 
was investigated. We found heterogeneity in the effect of some haplotypes, conferring 
protection or susceptibility among different study populations. Seven significant correlations 
were detected in 21 alleles tested (12 conferring susceptibility to T1D and 9 conferring 
protection). After Stepwise Multiple Linear regression the significant variables were the 
susceptible alleles: DRB1*04:01 (p = 0.0001) and DRB1*08:01 (p = 0.003). Only the 
protective allele DQB1*06:02 had a significant positive correlation with the geographical 
repartition of T1D incidence. 
Conclusions: The frequency of susceptible and protective haplotypes toward T1D was 
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alleles; among 21 alleles studied, DRB1 04:01 and DRB1 08:01 alleles are determinant in the 
risk of T1D. 
PROSPERO Registration number: CRD42012002369 
 
6.1.2 Background  
It has long been noticed that the incidence of Type 1 Diabetes (T1D) is highly 
variable from one country to another (81). For example, the 62.42 per 100.000/ per year 
incidence found in Finland (128) was 780-fold larger than the 0.08 per 100.000/ per year 
incidence in Papua New Guinea (230); the variability of T1D incidence is even visible within 
countries; for example, in Italy, T1D incidence varied between 54.4 per 100.000/ per year 
(Sardinia (102)) 4.4 per 100.000/ per year in Lombardia (108). The reason for these 
differences is not precisely known, but is most unlikely due to classification bias, as the 
disease cannot go untreated, and the diagnosis was relative easy to perform in children, at 
least before the recent rise in obesity rates (263). Moreover there are also differences in 
incidence within countries where the health care systems are comparable. Environmental 
factors have been implicated either in addition or as cofactors to genetic determinants. In a 
previous study we reviewed 77 independent variables; significant environmental predictors of 
the country-to-country variation of T1D incidence included UV radiation, number of mobile 
cell-phone subscriptions in the country, health expenditure per capita, hepatitis B 
immunization and mean body mass index (BMI) (81). The country-to-country T1D 
variability may be partly explained by genetic variations.  
The major and most studied loci of susceptibility are located in HLAs (Human 
Leukocyte Antigens) in the major histocompatibility complex (MHC) on chromosome 6p21, 
that encodes immune response proteins. HLAs alone contribute by 40-50% of the family 
clustering observed in T1D (inheritable T1D risk) (212). Among the three classes of HLAs, 
class II HLAs DR and DQ haplotypes have been associated with a genetic risk of T1D or the 
protection profile within different populations (89).  
One could indeed expect that in this age of information, the country-to-country 
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characteristics, insofar as several global organizations collect such data, and provide them 
free to researchers, with easy interface on the Internet. 
6.1.3 Methods 
6.1.3.1 Incidence of T1D data by country 
The T1D incidence value per 100.000 persons/year for individuals in the age group 0-
14 years for both sexes used here for 80 countries worldwide was obtained through a 
systematic review following the PRISMA recommendations (213).  All relevant original 
papers published in English between 1975 and 2014 including reviews (Diamond (318) and 
Eurodiab studies (90, 242, 243), the International Diabetes Federation (IDF) atlas (241, 300)) 
were analyzed and described in detail elsewhere (81).  
6.1.3.2 HLA DQ/DA haplotype frequencies by country 
Thanks to the report of the Type 1 Diabetes Genetics Consortium Families (2008) 
(89), that collects and analyzes samples of families with T1D from various populations 
around the world, the most susceptible and protective haplotype determinants of T1D have 
been identified.  
To retrieve global information of the frequency of these haplotypes, we explored the 
Allele Frequency Net at http://www.allelefrequencies.net/ (115), a public electronic 
repository that stores allele frequency of worldwide populations. For HLAs, on 11/20/2014 
this website contained data from 1025 population studies, 1007 gene/allele data and 370 
haplotype data. Using the tool “haplotype frequency search” we examined the frequency in 
all populations of the most susceptible haplotypes reported by the T1D Genetics Consortium 
Families: DRB1*0301-DQA1*0501-DQB1*0201 (OR 3.64), DRB1*0405-DQA1*0301-
DQB1*0302 (OR 11.37), DRB1*0401-DQA1*0301-DQB*0302 (OR 8.39), DRB1*0402-
DQA1*0301-DQB1*0302 (OR 3.63), DRB1*0404-DQA1*0301-DQB1*0302 (OR 1.59), 
DRB1*0801-DQA1*0401-DQB1*0402 (OR 1.25) and of the most protective haplotypes: 
DRB1*1501-DQA1*0102-DQB1*0602 (OR 0.03), DRB1*1401-DQA1*0101-DQB1*0503 
(OR 0.02) and DRB1*0701-DQA1*0201-DQB1*0303 (OR 0.02) (89), (Appendix A: 
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taking the total number of copies of the haplotype in the population sample (haplotypes/2n) 
and reported in percentages (%).  
In addition, using the tool “allele frequency search” we examined the four-digit 
resolution (high resolution four subtyping i.e. DRx/DQx*xx00) of each of the alleles 
contained in the haplotypes mentioned above. After retrieve a database containing 6867 lines, 
we then analyzed information from the 80 geographical regions for which we retrieved 
information on T1D incidence as follows. 1) For each of the 80 countries, only one 
population reporting the HLA allele frequency was selected among all those reported in the 
Allele Frequency Net; the same population was used across all the alleles explored. The 
population selected was the one for which we retrieved information for most of the alleles 
studied (12 susceptible and 9 protective HLA alleles related to T1D; 21 alleles in total). 2) 
When for a given country, more than one population was retrieved informing in a similar 
among of alleles, the selected population was the one with the highest sample size and less 
among of “0” values. 3) If no information was available for a given country, this country was 
excluded from the analyses. See Appendix A: Database VI for the final HLA alleles 
frequency database. 
6.1.4 Statistics 
Spearman correlation was used to compute the correlation between the 21 alleles and 
the T1D incidence.   
Stepwise Multiple Linear Regression model (MLR) methods were used to select the 
best HLA alleles independent predictors of T1D incidence. We started with all variables for 
which the p value tested the correlation whose incidence was smaller than 0.05, and we 
successively removed the variables until the maximum value of the adjusted R2 was obtained. 
When a couple of variables was correlated with r >0.80, only one variable was used in the 
regression analysis to avoid the computational issues associated with colinearity. Model 
assumptions for linear models were checked. 10-Fold Cross-validation after bootstrapping 
(273) was used to evaluate the predictive value of the final model. Graphic representation 
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Partial correlations were used to evaluate the effect of genetic factors controlled by 
environmental factors. The first-order partial correlations rXY.Z for the three intercorrelated 
variables were calculated using the application First-Order Partial Correlations at the 
VassarStats website available at: http://vassarstats.net/par.html (2). The R software was used 
for statistical and graphic analyses (255). 
6.1.5 Results  
6.1.5.1 HLA frequency haplotype determinants of T1D  
T1D genetic variation of HLAs haplotypes found are in Appendix A: Database V. 
With the little information available, it was only possible to perform the correlation between 
the incidence of T1D and the susceptible haplotype: DRB1*0301-DQA1*0501-DQB1*0201 
(OR 3.64, Spearman correlation (Sp. Cor.) = 0.18, p = 0.71, n = 7), and the protective 
haplotypes DRB1*15:01-DQA1*01:02-DQB1*06:02 (OR 0.03, Sp. Cor = 0.48, p = 0.36, n = 
6), DRB1*1401 - DQA1*0101 - DQB1*0503 (OR 0.02, Sp. Cor = 0.66, p = 0.18, n = 6), and 
DRB1*0701-DQA1*0201-DQB1*0303 (OR 0.02, Sp. Cor = 0.40, p = 0.75, n = 4); SI Table 
23, SI Figure 42-43. 
6.1.5.2 HLA frequency Alleles related with T1D  
For 56 countries it was possible correlate the 21 alleles contained in the DR-DQ 
haplotypes associated with T1D and the incidence of T1D retrieved in this review (Appendix 
A: Database VI). For susceptible haplotypes, significant positive correlations were found for 
the alleles, DRB1*03:01, DRB1*04:01, DRB1*08:01 and DQB1*02:01, and significant 
negative correlations for the alleles, DRB1*04:05 and DQB1*04:01. For protective alleles, 
only the allele DQB1*06:02 shows a significant (positive) correlation with incidence of T1D. 
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DRB1*03:01 ! 0.46 0.0010
DRB1*04:01 ! 0.55 0.0001
DRB1*04:02 !  .0.33 0.0635
DRB1*04:04  ! 0.26 0.1024
DRB1*04:05 ! .0.41 0.0093
DRB1*08:01 ! 0.42 0.0127
DQA1*03:01 ! .0.20 0.3514
DQA1*05:01 ! 0.16 0.3788
DQB1*02:01 ! 0.33 0.0292
DQB1*03:02 ! 0.04 0.8026
DQB1*04:01 ! .0.46 0.0356
DQB1*04:02 ! 0.03 0.8659
DRB1*07:01 ! 0.12 0.4580
DRB1*14:01 ! .0.10 0.5380
DRB1*15:01 ! 0.15 0.3301
DQA1*01.01 ! 0.08 0.6628
DQA1*01:02 ! .0.13 0.5018
DQA1*02:01 ! 0.15 0.4131
DQB1*03:03 ! 0.19 0.1824
DQB1*05:03 ! .0.01 0.9726


























The correlations were computed in the 56 WHO countries where the incidence of T1D and the frequency of HLA haplotypes 
could be estimated. Significant correlations at p-value <0.05 are highlighted. See supporting information: Database VI for 
the database of the frequency of the HLA alleles. 
Figure 41: Correlations between T1D incidence in 56 countries and susceptible/protective HLA alleles with 
respect to T1D 
Seven of the 21 HLA alleles (6 susceptible and 2 protective) qualified to be entered in 
the model, after the Stepwise MLR selection the five selected variables were: DRB1*03:01, 
DRB1*04:01, DRB1*04:05, DRB1*08:01 and DQB1*04:01. Then, checking for colinearity, 
DQB1*04:01 was excluded because it was highly correlated with DRB1*08:01 (r = 0.99 p-
value = <0.01). In the final model, the significant independent predictors were: DRB1*04:01 
and DRB1*08:01. The adjusted % of variance explained (R2) in the model was 61% (see 
model in Table 22, the details in SI Table 24 -26, the backward selection process in AP 
Table 34, and the graphic validation of the model in AP Figure 71-72). 10-fold cross-
validation indicated that the fraction of the variability of the global incidence of T1D was 
estimated to be 30% (SI Figure 48). See Appendix F for the validation of the model. 
Table 22: Final Stepwise MLR model 
 
Coefficients of 
HLA alleles Estimate Std. Error p -Value 
(Intercept) 6.81 2.48 0.0110 
DRB1*03:01 -8.90 24.97 0.7245 
DRB1*04:01 115.62 25.79 0.0001 
DRB1*04:05 -36.55 37.15 0.3346 
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6.1.5.3 Partial correlations between incidence of T1D and HLA alleles controlling 
environmental factors 
Partial correlations between incidences of T1D and selected HLA alleles after 
adjustment, controlling on independent environmental predictors were established; Appendix 
A: Database VII, SI Table 27-30.  
The incidence of T1D retrieved from 56 countries reporting information on HLA 
alleles and five independent predictors found in a previous study (81) were: UV radiation, 
number of mobile cell-phone subscriptions in the country, health expenditure per capita, 
hepatitis B immunization and mean body mass index (BMI). The selected HLA alleles were 
those of the four alleles that qualified to be included in the final model after checking for 
colinearity: DRB1*03:01, DRB1*04:01, DRB1*04:05, DRB1*08:01.  
Partial correlations between incidence of T1D and HLA alleles, and level of statistical 
significance, at the p-value <0.05, dropped after controlling for environmental variables for 
the allele DRB1*03:01 controlling for: UV radiation, number of mobile cell-phone 
subscriptions in the country, health expenditure per capita and BMI; only controlling for 
hepatitis B immunization the correlation coefficient increase in 1% (p = 0.0003).  
For the alleles DRB1*04:01 and DRB1*04:05 the correlation coefficient at the p-
value <0.05 dropped, after controlling for all five environmental predictors for: mobile cell-
phone subscriptions, hepatitis B immunization and BMI.  
For the allele DRB1*08:01 the correlation coefficient at the p-value <0.05 dropped 
after controlling for: mobile cell-phone subscriptions and hepatitis B immunization; and 
increased after controlling for BMI in 3% (p = 0.001).  
 
6.1.6 Discussion  
Thanks to the information available in public databases, we identified genetic markers 
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T1D is a polygenetic disorder where the susceptibility for T1D follows a recessive 
pattern and incomplete penetrance in which the MHC plays a crucial role in pathogenesis 
(182). A previous study, in which only (HLA)-DQ loci were explored, suggest that the 
variation of the T1D risk for European populations is explained by variations in the 
distribution of DQ genotypes, that confer a high susceptibility of T1D in the general 
population (269). 
We aimed to describe the relationship between certain HLA haplotypes and T1D 
incidence by geographical regions; however, the limited available global information did not 
allow us to reach this goal. Only a description of the currently available information for the 
respective susceptible and protective HLA haplotypes mentioned above is possible. 
For the susceptible haplotype DRB1*03:01-DQA1*05:01-DQB1*02:01 (OR 3.64), 
we retrieved n = 49 populations reporting the frequency of this haplotype. The highest 
frequency (in %) of this haplotype was found in the population of Italy Sardinia Sorgono 
(25.3%), one of the highest incidences reported in the world whereas the lowest value is in 
the population of Russia Siberia Irkutsk Tofalar (1.2%). Surprisingly, countries whose low 
incidence rates of T1D are known, such as China or Slovenia, also present high frequencies 
of this susceptible haplotype: 13.1% in the population of China Urumqi Kazak and 22% in 
the population called Slovenia population 2. Similar heterogeneity across populations was 
observed for the five other susceptible haplotypes studied: DRB1*04:05-DQA1*03:01-
DQB1*03:02 (OR 11.37), n = 14 retrieved populations, DRB1*04:01-DQA1*03:01-
DQB1*03:02 (OR 8.39), n = 7 retrieved populations, DRB1*04:02-DQA1*03:01-
DQB1*03:02 (OR 3.63), n = 14 retrieved populations, DRB1*04:04-DQA1*03:01-
DQB1*03:02 (OR 1.59), n = 11 retrieved populations, and for DRB1*08:01-DQA1*04:01-
DQB1*04:02 (OR 1.25), n = 21 retrieved populations. 
Similar heterogeneity across populations was also observed for the three protective 
haplotypes studied. For example, for the haplotype DRB1*15:01-DQA1*01:02-DQB1*06:02 
(OR 0.03), across n = 38 retrieved populations, the highest frequency was retrieved in the 
population of Russia Tuva Todja (20.5%) and as expected, the lowest value was reported in 
the populations of Italy Sardinia Carbonia and Italy Sardinia Sassari (1.1%); nevertheless 
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lowest frequencies for this protective haplotype (1.5%). For haplotype DRB1*14:01-
DQA1*01:01-DQB1*05:03 (OR 0.02), we retrieved n = 22 populations and for haplotype 
DRB1*07:01-DQA1*02:01-DQB1*03:03 (OR 0.02), n = 24 populations. The complete list 
of the frequency of susceptible and protective HLA haplotypes against T1D and the 
populations where the T1D incidence is available is presented in SI Table 23. The entire list 
of all retrieved populations reporting susceptible and protective HLA haplotypes is available 
in the Appendix A: Database V. 
Nonetheless, the limited data retrieved, revealed that some susceptible and protective 
haplotypes in one population could confer susceptibility or may constitute a certain 
protection in other populations, a phenomenon also described in a study that assessed the 
effect of Asian-specific HLA haplotypes (162). The second finding was that among all the 
alleles studied, DRB1*04:01 and DRB1*08:01 were significant predictors of the incidence of 
T1D in the ensemble of the 56 countries for which we could establish a correlation with the 
information of the frequency of the HLA allele. This finding suggests that these alleles are 
determinants of T1D risk, as was suggested by the Type 1 Diabetes Genetics Consortium 
Families who showed that the risk of T1D is conferred predominantly by DRB1 alleles (89).  
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6.1.7 Supporting Information  
SI Table 23: Susceptible and protective HLA haplotypes against T1D vs incidence of T1D 
 





of T1D (b) 
Susc_1 DRB1*03:01-DQA1*05:01/05:03/05:05-DQB1*02:01/02:02 Russia Siberia Ulchi Russian Federation 1.4 9.5 
Susc_1 DRB1*03:01-DQA1*05:01-DQB1*02:01 Canada British Columbia Athabaskan Canada 3.2 21.7 
Susc_1 DRB1*03:01-DQA1*05:01-DQB1*02:01 India Northeast Vaish India 3.3 11 
Susc_1 DRB1*03:01-DQA1*05:01-DQB1*02:01 South Korea pop 1 Dem. People's Republic of Korea 2.2 1.1 
Susc_1 DRB1*03:01-DQA1*05:01-DQB1*02:01 Tunisia Tunisia 10 7.4 
Susc_1 DRB1*03:01-DQA1*05:01-DQB1*02:01 USA San Francisco Caucasian United States of America 14.4 14 
Susc_1 DRB1*03:01-DQA1*05:01-DQB1*02:01/06:01 Iran Azeri Iran (Islamic Republic of) 6 3.7 
Susc_2 DRB1*04:05-DQA1*03:01/03:02-DQB1*03:02 Ethiopia Amhara Ethiopia 2 0.3 
Susc_2 DRB1*04:05-DQA1*03:01-DQB1*03:02 Japan pop 2 Japan 2.1 2.4 
Susc_3 DRB1*04:01-DQA1*03:01-DQB1*03:02 USA San Francisco Caucasian United States of America 3.9 14 
Susc_4 DRB1*04:02-DQA1*03:01-DQB1*03:02 USA San Francisco Caucasian United States of America 1.4 14 
Susc_5 DRB1*04:04-DQA1*03:01/03:02-DQB1*03:02 Ethiopia Amhara Ethiopia 1 0.3 
Susc_5 DRB1*04:04-DQA1*03:01-DQB1*03:02 
USA San Francisco 
Caucasian United States of America 14.0 2.7 
Susc_6 DRB1*08:01-DQA1*04:01-DQB1*04:02 USA San Francisco Caucasian United States of America 2.3 14 
Prot_1 DRB1*15:01-DQA1*01:02-DQB1*06:02 Ethiopia Amhara Ethiopia 1.5 0.3 
Prot_1 DRB1*15:01-DQA1*01:02-DQB1*06:02 Japan pop 2 Japan 5.6 2.4 
Prot_1 DRB1*15:01-DQA1*01:02-DQB1*06:02 South Korea pop 1 Dem. People's Republic of Korea 6.8 1.1 
Prot_1 DRB1*15:01-DQA1*01:02-DQB1*06:02 Tunisia Tunisia 2 7.4 
Prot_1 DRB1*15:01-DQA1*01:02-DQB1*06:02 USA San Francisco Caucasian United States of America 15.8 14 
Prot_1 DRB1*15:01-DQA1*01:02-DQB1*06:02/06:11 Russia Siberia Ulchi Russian Federation 4.8 9.5 
Prot_2 DRB1*14:01-DQA1*01:01/01:02-DQB1*05:03 Iran Azeri Iran (Islamic Republic of) 3.5 3.7 
Prot_2 DRB1*14:01-DQA1*01:01/01:04/01:05-DQB1*05:03 Russia Siberia Ulchi Russian Federation 4.8 9.5 
Prot_2 DRB1*14:01-DQA1*01:01/01:04-DQB1*05:03 Ethiopia Amhara Ethiopia 1 0.3 
Prot_2 DRB1*14:01-DQA1*01:01-DQB1*05:03 Japan pop 2 Japan 2.6 2.4 
Prot_2 DRB1*14:01-DQA1*01:01-DQB1*05:03 USA San Francisco Caucasian United States of America 2.5 14 
Prot_2 DRB1*14:01-DQA1*01:01-DQB1*05:03:01 Canada British Columbia Athabaskan Canada 16.9 21.7 
Prot_3 DRB1*07:01-DQA1*02:01-DQB1*03:03  Ethiopia Amhara Ethiopia 0.3 1 
Prot_3 DRB1*07:01-DQA1*02:01-DQB1*03:03  India Northeast Vaish India 11 6.3 
Prot_3 DRB1*07:01-DQA1*02:01-DQB1*03:03  Tunisia Tunisia 7.4 2 
Prot_3 DRB1*07:01-DQA1*02:01-DQB1*03:03  USA San Francisco Caucasian United States of America 14 1.8 
 
 (b) Haplotype Frequencies: Total number of copies of the haplotype in the population sample 
(Haplotypes / 2n) shown in percentages (%). (a) Incidence of T1D per 100.000 persons per year among 0-14 
years of age. Haplotypes source: Allele frequency net: a database and online repository for immune gene 
frequencies in worldwide populations. Gonzalez-Galarza FF, Christmas S, Middleton D and Jones AR Nucleic 
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6.1.7.1 Susceptible/protective HLA haplotypes related with T1D 
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6.1.7.2 Susceptible/protective HLA alleles related with T1D 
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6.1.7.3 Details of the final Stepwise MLR model 
 
SI Table 24: Final Stepwise MLR model 
 
Model Coefficients  Estimate CI 2.5% CI 97.5% Std. Error t-valeu Pr(>|t|) 
Res. standard error: 
5.272 on 25 DF; 
Adjusted R2: 0.6108;  
F-statistic: 12.38 on 4 
and 25 DF,  p-value: 
1.097e-05 
(Intercept) 6.810 1.700 11.921 2.481 2.745 0.0110 
DRB1*03:01 -8.900 -60.334 42.529 24.972 -0.356 0.7245 
DRB1*04:01 115.620 62.493 168.739 25.794 4.482 0.0001 
DRB1*04:05 -36.550 -113.053 39.962 37.148 -0.984 0.3346 
DRB1*08:01 92.620 34.104 151.137 28.412 3.260 0.0032 
 
 
SI Table 25: Analysis of variance (Anova) 
 
Coefficients Df Sum Sq Mean Sq F-value Pr(>F) 
DRB1*03:01 1 235.110 235.110 8.460 0.0075 
DRB1*04:01 1 790.830 790.830 28.456 1.57 x 10-4 
DRB1*04:05 1 54.650 54.650 1.967 0.1731 
DRB1*08:01 1 295.330 295.330 10.627 0.0032 
Residuals 25 694.770 27.790     
 
 
SI Table 26: Residuals 
 
Min 1Q Median 3Q Max 
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 Small symbols show cross-validated predicted values of T1D incidence vs. HLA alleles. Raw R2  = 
0.664, 10-Fold cross-validated R2 =0.299.  
 
SI Figure 48: 10-Fold Cross-Validation 10 fold-Cross validation of the final model  
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6.1.7.5 Partial correlations between incidence of T1D and HLA alleles controlling for 
environmental factors 
SI Table 27: Partial correlation for DRB1*03.01 
 
!! !! Partial'correlations'for'DRB1.03.01' Sp.'cor' r2' t' p!
! ! ' ' ' ' '
!! XY! Incidence'*'DRB1.03.01' 0.459' 0.211' '' 0.001'
! ! ! ! ! ! !
Z1! XZ1! Incidence!*!UV!radiation! /0.709! 0.503! !! !!
!! YZ1! DRB1.03.01!*!UV!radiation! /0.301! 0.091! !! !!
!! XY.Z1! Incidence'*'DRB1.03.01'*'UV'radiation' 0.365' 0.133' 2.86' 0.006'
! ! ! ! ! ! !
Z2! XZ2! Incidence!*!Mobile!cellular!subscriptions!! 0.409! 0.167! !! !!
!! YZ2! DRB1.03.01!*!Mobile!cellular!subscriptions!! 0.245! 0.060! !! !!
!! XY.Z2! Incidence'*'DRB1.03.01'*'Mobile'cellular'subscriptions'' 0.406' 0.164' 3.23' 0.002'
! ! ! ! ! ! !
Z3! XZ3! Incidence!*!Health!expenditure!per!capita!! 0.765! 0.585! !! !!
!! YZ3! DRB1.03.01!*!Health!expenditure!per!capita!! 0.391! 0.153! !! !!
!! XY.Z3! Incidence'*'DRB1.03.01'*'Health'expenditure'per'capita'' 0.270' 0.073' 2.04' 0.046'
! ! ! ! ! ! !
Z4! XZ4! Incidence!*!Hepatitis!B!immunization!! /0.184! 0.034! !! !!
!! YZ4! DRB1.03.01!*!Hepatitis!B!immunization! 0.024! 0.001! !! !!
!! XY.Z4! Incidence'*'DRB1.03.01'*'Hepatitis'B'immunization' 0.472' 0.222' 3.89' 0.0003'
! ! ! ! ! ! !
Z5! XZ5! Incidence!*!Mean!BMI!Male! 0.587! 0.345! !! !!
!! YZ5! DRB1.03.01!*!Mean!BMI!Male! 0.297! 0.880! !! !!
!! XY.Z5! Incidence'*'DRB1.03.01'*'Mean'BMI'Male' 0.368' 0.136' 2.88' 0.006'
 
SI Table 28: Partial correlation for DRB1*04.01 
 
!! !! Partial'correlations'for'DRB1.04.01' Sp.'cor' r2' t' p!
! ! ' ' ' ' '
!! XY! Incidence'*'DRB1.04.01' 0.549' 0.301' '' 0.0001'
! ! ! ! ! ! !
Z1! XZ1! Incidence!*!UV!radiation! /0.709! 0.503! !! !!
!! YZ1! DRB1.04.01!*!UV!radiation! /0.668! 0.446! !! !!
!! XY.Z1! Incidence'*'DRB1.04.01'*'UV'radiation' 0.144' 0.224' 1.06' 0.294'
! ! ! ! ! ! !
Z2! XZ2! Incidence!*!Mobile!cellular!subscriptions!! 0.409! 0.167! !! !!
!! YZ2! DRB1.04.01!*!Mobile!cellular!subscriptions!! 0.355! 0.126! !! !!
!! XY.Z2! Incidence'*'DRB1.04.01'*'Mobile'cellular'subscriptions'' 0.473' 0.224' 3.91' 0.0003'
! ! ! ! ! ! !
Z3! XZ3! Incidence!*!Health!expenditure!per!capita!! 0.765! 0.585! !! !!
!! YZ3! DRB1.04.01!*!Health!expenditure!per!capita!! 0.578! 0.334! !! !!
!! XY.Z3! Incidence'*'DRB1.04.01'*'Health'expenditure'per'capita'' 0.203' 0.042' 1.51' 0.137'
! ! ! ! ! ! !
Z4! XZ4! Incidence!*!Hepatitis!B!immunization!! /0.184! 0.034! !! !!
!! YZ4! DRB1.04.01!*!Hepatitis!B!immunization! /0.351! 0.123! !! !!
!! XY.Z4! Incidence'*'DRB1.04.01'*'Hepatitis'B'immunization' 0.526' 0.277' 4.51' <0.0001'
! ! ! ! ! ! !
Z5! XZ5! Incidence!*!Mean!BMI!Male! 0.587! 0.345! !! !!
!! YZ5! DRB1.04.01!*!Mean!BMI!Male! 0.392! 0.154! !! !!
!! XY.Z5! Incidence'*'DRB1.04.01'*'Mean'BMI'Male' 0.428' 0.183' 3.45' 0.001'
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SI Table 29: Partial correlation for DRB1*04.05 
 
!! !! Partial'correlations'for'DRB1.04.05' Sp.'cor' r2' t' p!
! ! ' ' ' ' '
!! XY! Incidence'*'DRB1.04.05' L0.406' 0.165' '' 0.0093'
! ! ! ! ! ! !
Z1! XZ1! Incidence!*!UV!radiation! /0.709! 0.503! !! !!
!! YZ1! DRB1.04.05!*!UV!radiation! 0.386! 0.149! !! !!
!! XY.Z1! Incidence'*'DRB1.04.05'*'UV'radiation' L0.203' 0.041' L1.51' 0.137'
! ! ! ! ! ! !
Z2! XZ2! Incidence!*!Mobile!cellular!subscriptions!! 0.409! 0.167! !! !!
!! YZ2! DRB1.04.05!*!Mobile!cellular!subscriptions!! /0.140! !0.020! !! !!
!! XY.Z2! Incidence'*'DRB1.04.05'*'Mobile'cellular'subscriptions'' L0.386' 0.149' L3.05' 0.004'
! ! ! ! ! ! !
Z3! XZ3! Incidence!*!Health!expenditure!per!capita!! 0.765! 0.585! !! !!
!! YZ3! DRB1.04.05!*!Health!expenditure!per!capita!! /0.399! 0.159! !! !!
!! XY.Z3! Incidence'*'DRB1.04.05'*'Health'expenditure'per'capita'' L0.171' 0.029' L1.26' 0.213'
! ! ! ! ! ! !
Z4! XZ4! Incidence!*!Hepatitis!B!immunization!! /0.184! 0.034! !! !!
!! YZ4! DRB1.04.05!*!Hepatitis!B!immunization! 0.320! 0.102! !! !!
!! XY.Z4! Incidence'*'DRB1.04.05'*'Hepatitis'B'immunization' L0.373' 0.139' L2.92' 0.005'
! ! ! ! ! ! !
Z5! XZ5! Incidence!*!Mean!BMI!Male! 0.587! 0.345! !! !!
!! YZ5! DRB1.04.05!*!Mean!BMI!Male! /0.330! 0.109! !! !!
!! XY.Z5! Incidence'*'DRB1.04.05'*'Mean'BMI'Male' L0.278' 0.077' L2.11' 0.040'
 
 
SI Table 30: Partial correlation for DRB1*08.01 
 
!! !! Partial'correlations'for'DRB1.08.01' Sp.'cor' r2' t' p!
! ! ' ' ' ' '
!! XY! Incidence'*'DRB1.08.01' 0.417' 0.174' '' 0.0127'
! ! ! ! ! ! !
Z1! XZ1! Incidence!*!UV!radiation! /0.709! 0.503! !! !!
!! YZ1! DRB1.08.01!*!UV!radiation! /0.501! 0.251! !! !!
!! XY.Z1! Incidence'*'DRB1.08.01'*'UV'radiation' 0.101' 0.010' 0.74' 0.463'
! ! ! ! ! ! !
Z2! XZ2! Incidence!*!Mobile!cellular!subscriptions!! 0.409! 0.167! !! !!
!! YZ2! DRB1.08.01!*!Mobile!cellular!subscriptions!! 0.264! 0.070! !! !!
!! XY.Z2! Incidence'*'DRB1.08.01'*'Mobile'cellular'subscriptions'' 0.351' 0.123' 2.73' 0.009'
! ! ! ! ! ! !
Z3! XZ3! Incidence!*!Health!expenditure!per!capita!! 0.765! 0.585! !! !!
!! YZ3! DRB1.08.01!*!Health!expenditure!per!capita!! 0.367! 0.135! !! !!
!! XY.Z3! Incidence'*'DRB1.08.01'*'Health'expenditure'per'capita'' 0.227' 0.052' 1.70' 0.095'
! ! ! ! ! ! !
Z4! XZ4! Incidence!*!Hepatitis!B!immunization!! /0.184! 0.034! !! !!
!! YZ4! DRB1.08.01!*!Hepatitis!B!immunization! /0.300! 0.090! !! !!
!! XY.Z4! Incidence'*'DRB1.08.01'*'Hepatitis'B'immunization' 0.386' 0.149' 3.04' 0.004'
! ! ! ! ! ! !
Z5! XZ5! Incidence!*!Mean!BMI!Male! 0.587! 0.345! !! !!
!! YZ5! DRB1.08.01!*!Mean!BMI!Male! 0.088! 0.008! !! !!













 UPMC - ED 393 - 2015  Epidemiology of Type I Diabetes: 





Conclusions and Perspectives 
      
      “In laboratory science, technological advances typically have meant new 
   instruments or techniques. However, in diabetes epidemiology, the population is our laboratory.  
 Can there be a revolution in diabetes epidemiology based on new techniques to facilitate measurement? 
     Can this directly lead to a revolution in how we view and quantitate health? We believe so”.
     
   LaPorte, et al. Diabetes Care, 1993 (179)  
T1D is a chronic pathological condition that affects millions of children and young 
people around the world, with devastating consequences on patients, parents, and society. The 
well-known genetic component of T1D cannot explain the increase in the incidence and the 
decreased age at onset that has been observed worldwide. The geographic variability and the 
changes in temporal trends of incidence of T1D are influenced by still unknown 
environmental factors affecting the natural course of childhood diabetes. Understanding these 
environmental effects as they interact with the genetic component in T1D would be critical to 
identify potential modifiable factors of this disease.  
In chapter 2 of this thesis, we show that countries with information on T1D incidence 
present lower temperatures and UV radiation and are more “urbanized”, characterized by 
reduced rural population, higher obesity rates and overweight, higher CO2 emissions per 
inhabitant, as well as stronger economies (higher Gross National Income (GNI), improved 
sanitary facilities, and more expenses in health resources). 
Then, observing in depth the countries with high T1D incidence for which we could 
collect information, three main related categories of environmental determinants were 
identified. First, higher incidences were present in wealthy countries with a large national 
income and a “western” life style, defined here as countries with high concentrations of urban 
population and more CO2 emissions, in addition to higher rates of obesity and overweight; 
such factors may be implicated (or may cooperate) in accelerated beta-cell destruction, as 
proposed in the accelerator hypothesis (361) and the overload hypothesis (71)-. Second, high 
incidences were observed in countries in northern latitudes, in countries with traditionally low 
temperatures and with low UV exposition, factors that could be associated, for example, with 
a vitamin D deficiency, currently described in autoimmunity and alterations in the regulation 
of gene expression (367). Third, higher incidences were also found in countries with better 
health care, large education expenditure, and a more aged population, factors that could 
mirror better health care registers.  
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Paradoxically, countries with low incidence or without available information could be 
the result of an under-diagnosis and lack of notifications rather than real absence of incident 
cases. Nevertheless, it is also possible that both situations are present in the epidemiology of 
T1D: lower incidence countries presenting higher rates of under-diagnosis or miss-
notifications of T1D incidence levels.  
This enormous geographic variability in the incidence of T1D, and the changes in the 
incidence trends shown here in chapters 1 and 5, remains a challenge for the scientific 
community. The variety of climatic, environmental, economic, and health factors that seem 
correlated with T1D incidence presented in chapter 3 of this thesis deserve deeper 
exploration. The strong geographical correlation of the incidence in adults and children as 
observed in chapter 4 may be explained by the fact that adults with T1D could share the 
same genetic alleles known to be associated to juvenile T1D, for example the alleles 
DRB1*04:01 and DRB1*08:01 that we found here to be significant predictors of the 
incidence of T1D in children described in chapter 6, but also because they share some 
predisposing environmental causes (81). 
The string birth cohort effect presented in chapter 5 allow us to suggest that research 
focused on pregnancy, and the neonatal period is required to recognize the factors implicated 
in T1D reflecting the birth cohort effect. In addition, epidemics due to infection diseases, 
environmental expositions or quick changes, such as weight gain during early childhood (91) 
or adolescence, could be risk factors of T1D and a manifestation of a calendar period effect 
also observed. If the downward tendency observed when we observe the model with out the 
effect of Finland is real, it means that variations of environmental factors could induce 
changes in the incidence of T1D in relatively short periods. Revealing all the factors 
associated with T1D incidence is not a feasible task for the moment, since most of them are 
unknown and/or information is unavailable. However, this thesis showed that some 
environmental and genetic factors available publicly, could be associated at the level of the 
global epidemiology of T1D. We are confident that in the near future high quality information 
on the incidence of T1D will be accessible, as well as genetic and environmental indicators 
that will allow deepening the approach used here, and will unravel new clues on the gene-
environment causality of T1D and potential target factors for preventive measures. 
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8.1 Appendix A: List of Databases 
The databases mentioned here will be placed for public examination and access, in the 
author’s Github website at: https://github.com/PaulaDiaz, once the press embargo of the 
manuscripts expires. 
- Database I: 6824 lines x 59 columns tidy database. It contains raw data extracted 
from articles and introduced manually into a standard data collection grid.  
- Database II: 529 lines x 67 columns tidy database. It contains the detailed list and 
breakdown by place and time of the mean incidence, retrieved in 265 references 
reporting incidence of T1D among children aged 0-14 years retrieved during the 
entire SR (234 primary research papers from PubMed and Google Scholar. 28 
additional papers, abstracts and updated information were from the IDF Atlas 
(300)). 
- Database III: 85 lines x 80 columns tidy database. It contains the T1D incidence 
retrieved in 80 countries and the list of 77 environmental indicators used in the 
correlations of environmental factors and T1D incidence among children.  
- Database IV: 1974 lines x 26 columns tidy database. It contains the selected 
information of incidence of T1D among children by age class, period, and country 
used in the APC analyses. 
- Database V: 204 lines x 7 columns tidy database. It contains the HLA haplotypes 
used in the analyses of chapter 6. 
- Database VI: 82 lines x 25 columns tidy database. It contains the HLA alleles 
frequency database used in the analyses of chapter 6. 
- Database VII: 58 lines x 13 columns tidy database. It contains information of 
HLA alleles frequency and environmental variables used in the partial correlation 
analyses presented in chapter 6. 
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8.2 Appendix B: First search query of the literature (Query # 0) 
Two independent searches performed during December 2011, which allow the 
identification of the initial 92 references. The first in the database MedLine access through 
PubMed and the second in Thompson Reuters through Web of Science. AP Figure 49. 
Definition of used terms at the end of this appendix.  
8.2.1 PubMed  
Advanced search was used, for published articles in the literature between 1 January 
1990 and November 2011.  
The equations for the query in the search history section were:  
- Search #1 ("diabetes mellitus, type 1/epidemiology" [Mesh Terms]) AND 
("incidence" [MeSH Terms] OR "models, statistical"[MeSH Terms] OR cohort 
studies [MH]) 
- Search #2 ((trend [TI] AND incidence [TI]) OR (trends [TI] AND incidence [TI]) 
OR (onset [TI] AND Incidence [TI]) OR "birth cohort"[TIAB] OR "age period 
cohort"[TIAB] OR age-period-cohort [TIAB]) OR "incidence" [TIAB])  
- Search #3 Journal Article [PT] NOT (Letter [PT] OR comment [PT] OR editorial 
[PT] OR news [PT]) AND ("1990/1/1" [PDAT]: "2011/11/28" [PDAT]). Limits: 
Humans.  
- At the end the equation was search ((#1) AND #2) AND #3). We will call this 
query #0. 
8.2.2 Web of Science  
Search articles published during the period 1 January 1990 and November 2011 using 
the following search equation:  
- Topic = (cohort studies OR (trend* OR incidence* OR tendency*) OR 
epidemiology*) AND  
- Title = ("type 1 diabetes" OR "IDDM" OR "childhood diabetes" OR "juvenile 
diabetes" OR "diabetes") AND  
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- Title = ((trend AND incidence) OR (trends AND incidence) OR (onset AND 
Incidence) OR "birth cohort" OR "age period cohort" OR age-period-cohort).  
- The search was refined excluding: document type = (proceedings paper OR 









































Articles retrieved from literature searh in combinade database 
 n = 985 
 
677 articles excluded based and title or abstract     
review. 10 references that pottencially satisfying  
inclusion criterya by title were excluded because 
the abstract was not available, and 26 because 
there were meeting abstract. 
 
308 articles remaining  
112 articles were excluded: 94 because we   
       could not retrieved the full text, and 18 because  
       we could not translate the article. 
 
196 articles remaining 
104 articles excluded: 24 because the main objective was  
not the study of incidence of T1D, 54 because the 
length of the study was ≤5 years, 3 because the study 
did not follow the WHO-1985, WHO-1999, ADA-1997 
or ADA-2011 as criteria of diagnosis of T1D, 6 because 
the study was performed in special populations, 10 
because the study is a review or a general topic, and 7 
because the data were not from original studies. 
 
n = 825 
Duplicated excluded (n =38) 
 
92 papers finally included 
 
n = 198 
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8.2.3 Glossary for searching:  
8.2.3.1 PubMed:  
- MeSH Major Topic [MAJR]: a MeSH term that is one of the main topics 
discussed in the article denoted by an asterisk on the MeSH term or 
MeSH/Subheading combination, e.g., Cytokines/physiology*. See MeSH Terms 
[MH] below. 
- MeSH Subheadings [SH]: MeSH Subheadings are used with MeSH terms to help 
describe more completely a particular aspect of a subject. For example, the drug 
therapy of asthma is displayed as asthma/drug therapy, see MeSH/Subheading 
Combinations in MeSH Terms [MH] below. 
- MeSH Terms [MH]: the NLM Medical Subject Headings controlled vocabulary of 
biomedical terms that is used to describe the subject of each journal article in 
MEDLINE. MeSH terms are arranged hierarchically by subject categories with 
more specific terms arranged beneath broader terms. MeSH terms in PubMed 
automatically include the more specific MeSH terms in a search.  
- Publication Type [PT]: describes the type of material the article represents (e.g., 
Review, Clinical Trial, Retracted Publication, Letter); see the PubMed Publication 
Types, e.g., review[pt].  
- Title/Abstract [TIAB]: words and numbers included in the title, abstract, and 
other abstract of a citation. English language abstracts are taken directly from the 
published article. If an article does not have a published abstract, NLM does not 
create one. 
- Publication Date [DP]: the date that the article was published. 
- Source and details in: http://www.ncbi.nlm.nih.gov.gate2.inist.fr/books/NBK3827/ 
 
8.2.3.2 Web of Science:  
- SCI-EXPANDED: Science Citation Index Expanded (--1975-present) 
- SSCI: Social Sciences Citation Index (--1975-present) 
- A&HCI: Arts & Humanities Citation Index (--1975-present) 
- CPCI-S: Conference Proceedings Citation Index- Science (--1990-present) 
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- CPCI-SSH: Conference Proceedings Citation Index- Social Science & 
Humanities (--1990-present) 
- Searching the Topic Field:  enter Topic terms to search the following fields 
within a record: title, abstract, author keywords, Keywords Plus®. The product 
returns every record containing all your search terms.  
- Searching the Title Field: enter Title terms to limit your search to article titles. 
- Lemmatization: it finds (On) or not (Off) alternative forms of the search term, 
for example, tooth and teeth.  
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8.3 Appendix C: Seven steps used to obtain the final query equation 
8.3.1 Step 1.  MeSH term reported in the articles retrieved from query# 0 
All MeSH term included in the 92 database references were listed and ordered using 
Excel. Nine hundred and ninety-one (991) MeSH terms were found using relevant MeSH 
terms (for example Diabetes Mellitus, Type 1) reported in each article. One hundred and 
fourteen (114) irrelevant terms as Kuwait/epidemiology or Hospitalizations/statistics or 
numerical data were discarded. AP Figure 50 presents the distribution of the main MeSH 




AP Figure 50: Frequency of MeSH terms included in selected articles 
8.3.2 Step 2.  Query # 1 using the main MeSH terms retrieved from selected articles  
Query #1 No. Ref. retrieved Observations 
("diabetes mellitus, type 1/epidemiology"[MAJR] OR "type 1 
diabetes"[TIAB]) AND (("incidence"[MeSH Major Topic] OR 
incidence[Title/Abstract]) AND age[Title/Abstract] OR "age 
distribution"[MeSH Terms] OR "age factors"[MeSH Terms] OR "age 
9817 Query #1 included 
the main MeSH 
terms retrieved in 









































Age of Onset 
Diabetes Mellitus, Type 1/ epidemiology 
Cohort Studies 
Diabetes Mellitus, Type 1 
Diabetes Mellitus, Type 2/*epidemiology 
Longitudinal Studies 
Prevalence 
Frequency of MeSH reported i the first 92 articles 
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groups"[MeSH Terms]6 AND "humans"[MeSH Terms]) AND (Journal 
Article[ptyp] AND English[lang] AND ("1990/1/1"[PDAT] : 
"2011/11/28"[PDAT])) 
8.3.3 Step 3. Frequent MeSH term retrieved from irrelevant papers 
The query # 1 showed 9817 references arranged in 491 pages into PubMed Website. I 
examined all MeSH terms reported in the first irrelevant reference each 50 pages, starting on 
the first page (for example: reference 1 in page 1, reference 981 in page 50, reference 1981 in 
page 100, … reference 8889 in page 450). Using Excel software, 167 MeSH terms were listed 
and arranged. Following criteria of relevance and frequency, 8 MeSH terms were selected as 
irrelevant. See AP Figure 51. 
 
AP Figure 51: Frequency of irrelevant MeSH terms included in query #1 
 
8.3.4 Step 4. New query including selected MeSH terms retrieved from irrelevant 
papers 
 
Query #2 No. Ref. retrieved Observations 
("diabetes mellitus, type 1/epidemiology"[MAJR] OR "type 1 
diabetes"[TIAB]) AND (("incidence"[MeSH Major Topic] OR 
incidence[Title/Abstract]) AND age[Title/Abstract] OR "age 
distribution"[MeSH Terms] OR "age factors"[MeSH Terms] OR "age 
groups"[MeSH Terms] AND "humans"[MeSH Terms]) AND (Journal 
Article[ptyp] AND English[lang] AND ("1990/1/1"[PDAT] : 
"2011/11/28"[PDAT])) NOT ("Diabetic Neuropathies"[MeSH Terms] 
OR "Diabetic Nephropathies"[MeSH Terms] OR 
"Autoantibodies"[MeSH Terms] OR "Blood Glucose"[MeSH Terms] 
OR "Cholesterol"[MeSH Terms] OR "Antigens"[MeSH Terms] OR 
"histocompatibility antigens class ii"[MeSH Terms] OR 
4230 Query #2 is equal to 
query #1, except for the 
inclusion of the terms: 
("Diabetic 
Neuropathies"[MeSH 




Terms] OR "Blood 
Glucose"[MeSH Terms] 
                                                
6 "age groups"[MeSH Terms] included: Adolescent, Adult, Aged +, Middle Aged, Young Adult, Child, Child, Preschool, 
Infant, Infant, Newborn +.  
1 
2 







Blood Glucose Cholesterol Antigens HLA Insulin 
Frequent MeSH term in irrelevant pepers query # 1 
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8.3.5 Step 5. Analysis of references linked in different queries:  
i) Query #2 vs. query #3 
Query #3 No. Ref. retrieved Observations 
("diabetes mellitus, type 1/epidemiology"[MAJR] OR "type 1 
diabetes"[TIAB]) AND (("incidence"[MeSH Major Topic] OR 
incidence[Title/Abstract]) AND age[Title/Abstract] OR "age 
distribution"[MeSH Terms] OR "age factors"[MeSH Terms] AND 
"humans"[MeSH Terms]) AND (Journal Article[ptyp] AND 
English[lang] AND ("1990/1/1"[PDAT] : "2011/11/28"[PDAT])) NOT 
("Diabetic Neuropathies"[MeSH Terms] OR "Diabetic 
Nephropathies"[MeSH Terms] OR "Autoantibodies"[MeSH Terms] OR 
"Blood Glucose"[MeSH Terms] OR "Cholesterol"[MeSH Terms] OR 
"Antigens"[MeSH Terms] OR "histocompatibility antigens class 
ii"[MeSH Terms] OR "insulin"[MeSH Terms]) 
956 Query #3 is equal to 
query #2, except for 





Query # 2 = 4230 references 
 
Query # 3 = 956 references 
 
Query # 2 NOT Query # 3 = 3274 references  
 
Query # 3 NOT Query #2 = 0 references  
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Note: according to step 4, the query selected to continue the process is the # 3.  
Repeating step 3 for frequent MeSH term in irrelevant papers of query # 3.  
The query # 3 showed 956 references arranged in 48 pages into PubMed Website. I 
examined all MeSH terms reported in the first irrelevant reference each 5 pages, starting on 
the first page. Using Excel software, 150 MeSH terms were listed and arranged. Following 
criteria of relevance and frequency, 3 MeSH terms were selected as irrelevant7. See AP 
Figure 52. 
 
AP Figure 52:  Frequency of irrelevant MeSH terms included in query #3 
 
ii) Query #3 vs. query #4 
 
Query #4 No. Ref. retrieved Observations 
("diabetes mellitus, type 1/epidemiology"[MAJR] OR "type 1 
diabetes"[TIAB]) AND (("incidence"[MeSH Major Topic] OR 
incidence[Title/Abstract]) AND age[Title/Abstract] OR "age 
distribution"[MeSH Terms] OR "age factors"[MeSH Terms] AND 
"humans"[MeSH Terms]) AND (Journal Article[ptyp] AND 
English[lang] AND ("1990/1/1"[PDAT] : "2011/11/28"[PDAT])) NOT 
("Diabetic Neuropathies"[MeSH Terms] OR "Diabetic 
Nephropathies"[MeSH Terms] OR "Autoantibodies"[MeSH Terms] 
OR "Blood Glucose"[MeSH Terms] OR "Cholesterol"[MeSH Terms] 
OR "Antigens"[MeSH Terms] OR "histocompatibility antigens class 
ii"[MeSH Terms] OR "insulin"[MeSH Terms] OR "Vitamin D"[MeSH 
Terms]  OR "Diabetic ketoacidosis"[MeSH Terms] OR "immunology" 
[Subheading]) 
866 Query #4 is equal to 
query #3, except for the 
inclusion of the terms: 
"Vitamin D"[MeSH 






Query # 3 = 956 references 
 
                                                




Vitamin D Diabetic 
Ketoacidosis 
Inmunology 
Frequent MeSH term in irrelevant 






11 relevant / 60 examined 
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Query # 4 = 866 references 
 
 
Query # 3 NOT Query # 4 = 90 references 
 
 
Query # 4 NOT Query #3 = 0 references  
 
 
Note: In the Query # 3 NOT Query # 4 = 90, were found 2 relevant references in the 
first 60 examined. The common MeSH term of these references was immunology. In 
consequence, a new query to keep the Subheading immunology was necessary.  
 
Query #5 No. Ref. retrieved Observations 
("diabetes mellitus, type 1/epidemiology"[MAJR] OR "type 1 
diabetes"[TIAB]) AND (("incidence"[MeSH Major Topic] OR 
incidence[Title/Abstract]) AND age[Title/Abstract] OR "age 
distribution"[MeSH Terms] OR "age factors"[MeSH Terms] AND 
"humans"[MeSH Terms]) AND (Journal Article[ptyp] AND 
English[lang] AND ("1990/1/1"[PDAT] : "2011/11/28"[PDAT])) NOT 
("Diabetic Neuropathies"[MeSH Terms] OR "Diabetic 
Nephropathies"[MeSH Terms] OR "Autoantibodies"[MeSH Terms] OR 
"Blood Glucose"[MeSH Terms] OR "Cholesterol"[MeSH Terms] OR 
"Antigens"[MeSH Terms] OR "histocompatibility antigens class 
ii"[MeSH Terms] OR "insulin"[MeSH Terms] OR "Vitamin D"[MeSH 
Terms]  OR "Diabetic ketoacidosis"[MeSH Terms]) 
915 
 
Query #5 is equal to 
query #4, except for 
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The query # 5 showed 915 references arranged in 46 pages into PubMed Website. I 
examined all MeSH terms reported in the first irrelevant reference each 5 pages, starting on 
the first page. Using Excel software, 188 MeSH terms were listed and arranged. Following 




AP Figure 53: Frequency of irrelevant MeSH terms included in query #5 
 
iii) Query #5 vs. query #6 
 
Query #6 No. Ref. retrieved Observations 
("diabetes mellitus, type 1/epidemiology"[MAJR] OR "type 1 
diabetes"[TIAB]) AND (("incidence"[MeSH Major Topic] OR 
incidence[Title/Abstract]) AND age[Title/Abstract] OR "age 
distribution"[MeSH Terms] OR "age factors"[MeSH Terms] AND 
"humans"[MeSH Terms]) AND (Journal Article[ptyp] AND 
English[lang] AND ("1990/1/1"[PDAT] : "2011/11/28"[PDAT])) NOT 
("Diabetic Neuropathies"[MeSH Terms] OR "Diabetic 
Nephropathies"[MeSH Terms] OR "Autoantibodies"[MeSH Terms] OR 
"Blood Glucose"[MeSH Terms] OR "Cholesterol"[MeSH Terms] OR 
"Antigens"[MeSH Terms] OR "histocompatibility antigens class 
ii"[MeSH Terms] OR "insulin"[MeSH Terms] OR "Vitamin D"[MeSH 
Terms]  OR "Diabetic ketoacidosis"[MeSH Terms] OR "Vascular 
Diseases" [MeSH Terms] OR "Arteriosclerosis" [MeSH Terms] OR 
"Lipoproteins" [MeSH Terms] OR "Vascular Endothelial Growth 
Factors" [MeSH Terms] OR "Comorbidity" [MeSH Terms] OR "Risk 
Factors" [MeSH Terms]) 
605 Query #6 is equal to 
query #5, except for 





[MeSH Terms] OR 
"Lipoproteins" 



















Arteriosclerosis Lipoproteins Vascular 
Endothelial 
Growth Factors 
Comorbidity Risk factors 
Frequent MeSH term in irrelevant pepers query # 5 
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Query # 5 = 915 references  
 
 
Query # 6 = 605 references 
 
 
Query # 5 NOT Query # 6 = 310 references 
 
 
Query # 6 NOT Query # 5 = 0 references  
 
 
Note: In the Query # 5 NOT Query # 6 = 310, were found 4 relevant references in the 
first 60 examined. The common MeSH term of these references was risk factors. In 
consequence, a new query to keep the MeSH term Risk Factors was necessary.  
 
Query #7 No. Ref. retrieved Observations 
("diabetes mellitus, type 1/epidemiology"[MAJR] OR "type 1 
diabetes"[TIAB]) AND (("incidence"[MeSH Major Topic] OR 
incidence[Title/Abstract]) AND age[Title/Abstract] OR "age 
distribution"[MeSH Terms] OR "age factors"[MeSH Terms] AND 
"humans"[MeSH Terms]) AND (Journal Article[ptyp] AND 
English[lang] AND ("1990/1/1"[PDAT] : "2011/11/28"[PDAT])) NOT 
("Diabetic Neuropathies"[MeSH Terms] OR "Diabetic 
Nephropathies"[MeSH Terms] OR "Autoantibodies"[MeSH Terms] OR 
"Blood Glucose"[MeSH Terms] OR "Cholesterol"[MeSH Terms] OR 
"Antigens"[MeSH Terms] OR "histocompatibility antigens class 
ii"[MeSH Terms] OR "insulin"[MeSH Terms] OR "Vitamin D"[MeSH 
Terms]  OR "Diabetic ketoacidosis"[MeSH Terms] OR "Vascular 
776 Query #7 is equal to 
query #6, except for 
the exclusion of the 
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Diseases" [MeSH Terms] OR "Arteriosclerosis" [MeSH Terms] OR 
"Lipoproteins" [MeSH Terms] OR "Vascular Endothelial Growth 
Factors" [MeSH Terms] OR "Comorbidity" [MeSH Terms]) 
 
 
Repeating step 3 for frequent MeSH term in irrelevant papers of query # 7.  
The query # 7 showed 776 references arranged in 39 pages into PubMed Website. We 
examined all MeSH terms reported in the first irrelevant reference each 5 pages, starting on 
the first page. Using Excel software, 115 MeSH terms were listed and arranged. Following 
criteria of relevance and frequency, 0 MeSH terms were selected as irrelevant. As 
consequence, we decided to exclude only the term "type 1 diabetes"[TIAB] of the equation in 
order to analyze if was possible obtain a query more specific but keeping sensitivity. 
iv) Query #7 vs. query #8 
 
Query #8 No. Ref. retrieved Observations 
("diabetes mellitus, type 1/epidemiology"[MAJR]) AND 
(("incidence"[MeSH Major Topic] OR incidence[Title/Abstract]) AND 
age[Title/Abstract] OR "age distribution"[MeSH Terms] OR "age 
factors"[MeSH Terms] AND "humans"[MeSH Terms]) AND (Journal 
Article[ptyp] AND English[lang] AND ("1990/1/1"[PDAT] : 
"2011/11/28"[PDAT])) NOT ("Diabetic Neuropathies"[MeSH Terms] 
OR "Diabetic Nephropathies"[MeSH Terms] OR 
"Autoantibodies"[MeSH Terms] OR "Blood Glucose"[MeSH Terms] 
OR "Cholesterol"[MeSH Terms] OR "Antigens"[MeSH Terms] OR 
"histocompatibility antigens class ii"[MeSH Terms] OR "insulin"[MeSH 
Terms] OR "Vitamin D"[MeSH Terms]  OR "Diabetic 
ketoacidosis"[MeSH Terms] OR "Vascular Diseases" [MeSH Terms] 
OR "Arteriosclerosis" [MeSH Terms] OR "Lipoproteins" [MeSH Terms] 
OR "Vascular Endothelial Growth Factors" [MeSH Terms] OR 
"Comorbidity" [MeSH Terms]) 
459 Query #8 is equal to 
query #7, except for 
the exclusion of the 
term: OR "type 1 
diabetes"[TIAB] 
Query # 7 = 776 references 
 
 





! N 776  





N 459  
29 relevant / 60 examined !
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Query # 7 NOT Query # 8 = 317 references 
 
 
Query # 8 NOT Query # 7 = 0 references  
 
 
Note: according to step 5, the query selected to continue the process is the # 8.  
8.3.6 Step 6. The results of selected query are compared with the 92 references found 
in query #0    
We compared each one of the references retrieved from the query # 0 (92 references) 
with each reference retrieved from the query #8 (423 references).  The following 8 references 
were missed: 
1. Bruno G, Merletti F, De Salvia A, Lezo A, Arcari R, Pagano G. Comparison of incidence of 
insulin-dependent diabetes mellitus in children and young adults in the Province of Turin, 
Italy, 1984-91. Piedmont Study Group for Diabetes Epidemiology. Diabet Med. 1997 
Nov;14(11):964-9. 
2. Cardwell C, Carson D, Patterson C. Secular trends, disease maps and ecological analyses of 
the incidence of childhood onset Type 1 diabetes in Northern Ireland, 1989-2003. Diabetic 
Med. 2007;24:289-95. 
3. Carrasco E, Angel B, Codner E, Garcia D, Ugarte F, Bruzzone ME, et al. [Type 1 diabetes 
mellitus incidence in Santiago, Chile. Analysis by counties in the period 2000-2004]. Rev 
Med Chil. 2006 Oct;134(10):1258-64. ESPANOL 
4. Pishdad GR. Low incidence of type 1 diabetes in Iran. Diabetes Care. 2005 Apr;28(4):927-8. 
5. Rytkönen M, Ranta J, Tuomilehto J, Karvonen M. Bayesian analysis of geographical variation 
in the incidence of Type I diabetes in Finland. SPAT Study Group The Finnish Childhood 
Diabetes Registry Group. Diabetologia. 2001;44(Suppl 3):B37-44. 
6. Skordis N, Theodorou S, Apsiotou T, Stavrou S, Herakleous E, Savva SC. The incidence of 
type 1 diabetes mellitus in Greek-Cypriot children and adolescents in 1990-2000. Pediatr 
Diabetes. 2002 Dec;3(4):200-4. NO MESH 
7. Vehik K, Hamman RF, Lezotte D, Norris JM, Klingensmith G, Bloch C, et al. Increasing 
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8. Vlajinac HD, Bojovic BM, Sipetic SB, Adanja BJ, Jarebinski MS, Radmanovic SZ, et al. 
Insulin dependent diabetes mellitus: incidence in childhood in Belgrade 1982-92. J Epidemiol 
Community Health. 1995 Feb;49(1):107-8. 
All MeSH terms reported in these 8 references were listed and arranged using Excel 
software, 100 in total. The MeSH term "Blood Glucose" introduced in the query #2 was found 
in the article No.1 (Bruno, 1997). Also, the report of groups of age (adolescent, child, etc.) 
was a predominant condition of the MeSH terms in the lost references. 
Two articles of this list have particular conditions: the article No.3 (Carrasco E, 2006) 
was published in Spanish, and the article No. 6 (Skordis, 2002) did not report any MeSH 
term. 
As consequence of this analyses, the decision was to modify the query #8, excluding 
the term: "Blood Glucose"[MeSH Terms] of the equation and including the term: "age 
groups"[MeSH Terms]. 
 
8.3.7 Step 7.  Repetition of steps 2 to 7 until the majority of 92 articles are included. 
Repeating step 2: Query # 9 using the main MeSH terms retrieved from articles retrieved 
in step 6. 
Query #9 No. Ref. retrieved Observations 
("diabetes mellitus, type 1/epidemiology"[MAJR]) AND 
(("incidence"[MeSH Major Topic] OR incidence[Title/Abstract]) AND 
(age[Title/Abstract] OR "age distribution"[MeSH Terms] OR "age 
factors"[MeSH Terms] OR "age groups"[MeSH Terms]  ) AND 
"humans"[MeSH Terms]) AND (Journal Article[ptyp] AND 
English[lang] AND ("1990/1/1"[PDAT] : "2011/11/28"[PDAT])) NOT 
("Diabetic Neuropathies"[MeSH Terms] OR "Diabetic 
Nephropathies"[MeSH Terms] OR "Autoantibodies"[MeSH Terms] OR 
"Cholesterol"[MeSH Terms] OR "Antigens"[MeSH Terms] OR 
"histocompatibility antigens class ii"[MeSH Terms] OR "insulin"[MeSH 
Terms] OR "Vitamin D"[MeSH Terms]  OR "Diabetic 
ketoacidosis"[MeSH Terms] OR "Vascular Diseases" [MeSH Terms] 
OR "Arteriosclerosis" [MeSH Terms] OR "Lipoproteins" [MeSH Terms] 
OR "Vascular Endothelial Growth Factors" [MeSH Terms] OR 
"Comorbidity" [MeSH Terms]) 
423 Query #9 is equal to 
query #8, except for 




Terms], and the 
inclusion of the 
term: OR 
"age groups"[MeSH 
Terms]   
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With the query # 9 we lost 2 of 92 database references: the article No.3 (Carrasco E, 
2006) because it was published in Spanish, and the article No. 6 (Skordis, 2002) because it 
did not report any MeSH term.  
We retrieved 57 additional papers expanding the search for all published articles 
before 1990/01/01. After 2011/11/28, there were not new indexed references by February 
2012. Updated searches were performed on November 2014 and January 2015.    
With the methodology proposed in this document, the best query equation for conduct 
a literature review of the study of incidence of T1D considering the age at onset worldwide is 
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8.4 Appendix D: Correlation matrix between incidence of T1D and 
independent variables by domains presented in chapter 3 
8.4.1 Correlation matrix incidence of T1D and climate and environment domain 
Selected variables: CA_1 + CE_10 + CE_15 + CE_16 + CE_8 + CE_11 + CE_18. 














AP Figure 54: Correlation matrix: environment domain (Agriculture)  
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AP Figure 56: Correlation matrix: climate and environment domain (Environment 2 of 2) 
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8.4.2 Correlation matrix incidence of T1D and demography domain 
 
Selected variables: DD_19 + DD_21 + DD_20 + DD_24 + DD_27 + DD_33. See SM 















AP Figure 57: Correlation matrix: demography domain (Demography 1 of 2) 
 
 UPMC - ED 393 - 2015  Epidemiology of Type I Diabetes: 






























































































 UPMC - ED 393 - 2015  Epidemiology of Type I Diabetes: 















































0 20000 40000 60000 80000
EC_35
8.4.3 Correlation matrix incidence of T1D and economic factors domain  
 
Selected variables: ED_39 + ED_41 + ED_42 + ED_36 + ED_37 + EH_43 + EH_45 





















AP Figure 59: Correlation matrix: economic factors domain (Country economy) 
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AP Figure 61: Correlation matrix: economic factors domain (Health economy) 
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8.4.4 Correlation matrix incidence of T1D and health conditions domain 
Selected variables: HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + 
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AP Figure 64: Correlation matrix: health conditions domain (Infant and maternal mortality rates) 
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AP Figure 65: Correlation matrix: health conditions domain (Infectious diseases and immunization) 
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8.5 Appendix E: Selection of variables by domain and graphic validation 
of the models presented in chapter 3 
8.5.1.1 Stepwise selection climate and environment domain 
AP Table 31: Manual backward selection of the variables of climate and environment domain 
Backwards elimination - adjusted R2 
 
   Domain: climate and environment 
 
   Step Variables included Removed Adjusted R2 
 Full Inc T1D ~ CA_1 + CE_10 + CE_15 + CE_16 + CE_8 + CE_11 + CE_18 0.2886 
 Step 1 Inc T1D ~ CE_10 + CE_15 + CE_16 + CE_8 + CE_11 + CE_18 [- CA_1] 0.3000 
   Inc T1D ~ CA_1  + CE_15 + CE_16 + CE_8 + CE_11 + CE_18 [- CE_10] 0.2476 
   Inc T1D ~ CA_1 + CE_10 + CE_16 + CE_8 + CE_11 + CE_18 [- CE_15] 0.3166 * 
  Inc T1D ~ CA_1 + CE_10 + CE_15 + CE_8 + CE_11 + CE_18 [- CE_16] 0.2977 
   Inc T1D ~ CA_1 + CE_10 + CE_15 + CE_16 + CE_11 + CE_18 [- CE_8] 0.2983 
   Inc T1D ~ CA_1 + CE_10 + CE_15 + CE_16 + CE_8 + CE_18 [- CE_11] 0.2993 
   Inc T1D ~ CA_1 + CE_10 + CE_15 + CE_16 + CE_8 + CE_11  [- CE_18] 0.2258 
 Step 2 Inc T1D ~ CE_10 + CE_16 + CE_8 + CE_11 + CE_18 [- CA_1] 0.3254 
   Inc T1D ~ CA_1 + CE_16 + CE_8 + CE_11 + CE_18 [- CE_10] 0.2703 
   Inc T1D ~ CA_1 + CE_10  + CE_8 + CE_11 + CE_18 [- CE_16] 0.3240 
   Inc T1D ~ CA_1 + CE_10 + CE_16 + CE_11 + CE_18 [- CE_8] 0.3325 * 
  Inc T1D ~ CA_1 + CE_10 + CE_16 + CE_8 + CE_18 [- CE_11] 0.3266 
   Inc T1D ~ CA_1 + CE_10 + CE_16 + CE_8 + CE_11  [- CE_18] 0.2459 
 Step 3 Inc T1D ~ CE_10 + CE_16 + CE_11 + CE_18 [- CA_1] 0.3433 * 
  Inc T1D ~ CA_1 + CE_16 + CE_11 + CE_18 [- CE_10] 0.2551 
   Inc T1D ~ CA_1 + CE_10 + CE_11 + CE_18 [- CE_16] 0.3314 
   Inc T1D ~ CA_1 + CE_10 + CE_16 + CE_18 [- CE_11] 0.3419 
   Inc T1D ~ CA_1 + CE_10 + CE_16 +  CE_11  [- CE_18] 0.2445 
 Step 4 Inc T1D ~ CE_16 + CE_11 + CE_18 [- CE_10] 0.2559 
   Inc T1D ~ CE_10 + CE_11 + CE_18 [- CE_16] 0.3417 
   Inc T1D ~ CE_10 + CE_16 + CE_18 [- CE_11] 0.3519 ** 
  Inc T1D ~ CE_10 + CE_16 + CE_11 [- CE_18] 0.2541 
 Step 5 Inc T1D ~ CE_16 + CE_18 [- CE_10] 0.2612 
   Inc T1D ~ CE_10 + CE_18 [- CE_16] 0.3499 
   Inc T1D ~ CE_10 + CE_16  [- CE_18] 0.1891 
 (*) Model with higher adjusted R2, (**) Best model 





















AP Figure 66: Graphic validation of the best model for the climate and environment domain 
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8.5.1.2 Stepwise selection demography domain 
 
AP Table 32: Manual backward selection of the variables of demography domain 
 
Backwards elimination - adjusted R2 
 
   Domain: demography 
 
   Step Variables included Removed Adjusted R2 
 Full Inc T1D ~ DD_19 + DD_21 + DD_20 + DD_24 + DD_27 + DD_33   0.3236 
 Step 1 Inc T1D ~ DD_21 + DD_20 + DD_24 + DD_27 + DD_33 [- DD_19] 0.3235 
   Inc T1D ~ DD_19 + DD_20 + DD_24 + DD_27 + DD_33 [- DD_21] 0.3210 
   Inc T1D ~ DD_19 + DD_21 + DD_24 + DD_27 + DD_33 [- DD_20] 0.3266 ** 
  Inc T1D ~ DD_19 + DD_21 + DD_20 + DD_27 + DD_33 [- DD_24] 0.3304 
   Inc T1D ~ DD_19 + DD_21 + DD_20 + DD_24 + DD_33 [- DD_27] 0.2632 
   Inc T1D ~ DD_19 + DD_21 + DD_20 + DD_24 + DD_27 [- DD_33] 0.3121 
 Step 2 Inc T1D ~ DD_21 + DD_24 + DD_27 + DD_33 [- DD_19] 0.2829 
   Inc T1D ~ DD_19 + DD_24 + DD_27 + DD_33 [- DD_21] 0.2780 
   Inc T1D ~ DD_19 + DD_21 + DD_27 + DD_33 [- DD_24] 0.3274 
   Inc T1D ~ DD_19 + DD_21 + DD_24 + DD_33 [- DD_27] 0.2674 
   Inc T1D ~ DD_19 + DD_21 + DD_24 + DD_27 [- DD_33] 0.3148 
 (**) Best model 




AP Figure 67: Graphic validation of the best model for the demography domain 
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8.5.1.3 Stepwise selection economic factors domain 
AP Table 33: Manual backward selection of the variables of economic factors domain 
Backwards elimination - adjusted R2 
 
   Domain: economic factors 
 
   Step Variables included Removed Adjusted R2 
 
Full 
Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_36 + ED_37 + EH_43 + EH_45 + EC_33 
 + EC_34 0.4240 
 Step 1 Inc T1D ~  ED_41 + ED_42 + ED_36 + ED_37 + EH_43 + EH_45 + EC_33 + EC_34 [- ED_39] 0.4187 
   Inc T1D ~ ED_39 + ED_42 + ED_36 + ED_37 + EH_43 + EH_45 + EC_33 + EC_34 [- ED_41] 0.3479 
   Inc T1D ~ ED_39 + ED_41 + ED_36 + ED_37 + EH_43 + EH_45 + EC_33 + EC_34 [- ED_42] 0.4327 
   Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_37 + EH_43 + EH_45 + EC_33 + EC_34 [- ED_36] 0.3959 
   Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_36 + EH_43 + EH_45 + EC_33 + EC_34 [- ED_37] 0.4274 
   Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_36 + ED_37 + EH_45 + EC_33 + EC_34 [- EH_43] 0.4329 
   Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_36 + ED_37 + EH_43 + EC_33 + EC_34 [- EH_45] 0.4150 
   Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_36 + ED_37 + EH_43 + EH_45 + EC_34 [- EC_33] 0.4094 
   Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_36 + ED_37 + EH_43 + EH_45 + EC_33 [- EC_34] 0.4330 * 
Step 2 Inc T1D ~  ED_41 + ED_42 + ED_36 + ED_37 + EH_43 + EH_45 + EC_33  [- ED_39] 0.4153 
   Inc T1D ~ ED_39 + ED_42 + ED_36 + ED_37 + EH_43 + EH_45 + EC_33  [- ED_41] 0.3577 
   Inc T1D ~ ED_39 + ED_41 + ED_36 + ED_37 + EH_43 + EH_45 + EC_33  [- ED_42] 0.4414 
   Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_37 + EH_43 + EH_45 + EC_33 [- ED_36] 0.4045 
   Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_36 + EH_43 + EH_45 + EC_33  [- ED_37] 0.4358 
   Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_36 + ED_37 + EH_45 + EC_33  [- EH_43] 0.4416 * 
  Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_36 + ED_37 + EH_43 + EC_33  [- EH_45] 0.3680 
   Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_36 + ED_37 + EH_43 + EH_45  [- EC_33] 0.4184 
 Step 3 Inc T1D ~  ED_41 + ED_42 + ED_36 + ED_37 + EH_45 + EC_33  [- ED_39] 0.4241 
   Inc T1D ~ ED_39 + ED_42 + ED_36 + ED_37 + EH_45 + EC_33  [- ED_41] 0.3671 
   Inc T1D ~ ED_39 + ED_41 + ED_36 + ED_37 + EH_45 + EC_33  [- ED_42] 0.4499 ** 
  Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_37 + EH_45 + EC_33 [- ED_36] 0.4118 
   Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_36 + EH_45 + EC_33  [- ED_37] 0.4399 
   Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_36 + ED_37 + EC_33  [- EH_45] 0.3753 
   Inc T1D ~ ED_39 + ED_41 + ED_42 + ED_36 + ED_37 + EH_45  [- EC_33] 0.4270 
 Step 4 Inc T1D ~  ED_41 + ED_36 + ED_37 + EH_45 + EC_33  [- ED_39] 0.4326 
   Inc T1D ~ ED_39 + ED_36 + ED_37 + EH_45 + EC_33  [- ED_41] 0.3766 
   Inc T1D ~ ED_39 + ED_41 + ED_37 + EH_45 + EC_33 [- ED_36] 0.4199 
   Inc T1D ~ ED_39 + ED_41 + ED_36 + EH_45 + EC_33  [- ED_37] 0.4400 
   Inc T1D ~ ED_39 + ED_41 + ED_36 + ED_37 + EC_33  [- EH_45] 0.3842 
   Inc T1D ~ ED_39 + ED_41 + ED_36 + ED_37 + EH_45  [- EC_33] 0.4343 
 (*) Model with higher adjusted R2, (**) Best model 


















AP Figure 68: Graphic validation of the best model for the economic factors domain 
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8.5.1.4 Stepwise selection health conditions domain  
AP Table 34: Manual backward selection of the variables of health conditions domain 
 
 
Backwards elimination - adjusted R2 
 
   Domain: health conditions 
 
   Step Variables included Removed Adjusted R2 
 
Full 
Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 +  
HM_75 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 0.4293 
 Step 1 Inc T1D ~ HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + HM_75 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HD_68] 0.4365 
   Inc T1D ~ HD_68 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + HM_75 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HD_71] 0.4142 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_57 + HI_59 + HI_58 + HM_75 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HD_72] 0.4385 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_57 + HI_59 + HI_58 + HM_75 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_60] 0.4263 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_59 + HI_58 + HM_75 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_57] 0.4369 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_58 + HM_75 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_59] 0.2861 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HM_75 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_58] 0.4321 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HM_75] 0.4387 * 
  Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + HM_75+ HR_47 + HR_51 + HR_54 + HR_55 [- HR_56] 0.4240 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + HM_75 + HR_56 + HR_51 + HR_54 + HR_55 [- HR_47] 0.3600 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + HM_75 + HR_56 + HR_47 + HR_54 + HR_55 [- HR_51] 0.4210 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + HM_75 + HR_56 + HR_47 + HR_51 + HR_55 [- HR_54] 0.4159 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + HM_75 + HR_56 + HR_47 + HR_51 + HR_54  [- HR_55] 0.4353 
 Step 2 Inc T1D ~ HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HD_68] 0.4455 
   Inc T1D ~ HD_68 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HD_71] 0.4236 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_57 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HD_72] 0.4477 * 
  Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_57 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_60] 0.4353 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_57] 0.4457 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_59] 0.2977 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_58] 0.4412 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + HR_47 + HR_51 + HR_54 + HR_55 [- HR_56] 0.4333 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + HR_56 + HR_51 + HR_54 + HR_55 [- HR_47] 0.3673 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + HR_56 + HR_47 + HR_54 + HR_55 [- HR_51] 0.4301 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_55 [- HR_54] 0.4246 
   Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54  [- HR_55] 0.4438 
 Step 3 Inc T1D ~ HD_71 + HI_60 + HI_57 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HD_68] 0.4527 
   Inc T1D ~ HD_68 + HI_60 + HI_57 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HD_71] 0.4318 
   Inc T1D ~ HD_68 + HD_71 + HI_57 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_60] 0.4443 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_57] 0.4544 * 
  Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_57 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_59] 0.3075 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_57 + HI_59 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_58] 0.4500 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_57 + HI_59 + HI_58 + HR_47 + HR_51 + HR_54 + HR_55 [- HR_56] 0.4423 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_57 + HI_59 + HI_58 + HR_56 + HR_51 + HR_54 + HR_55 [- HR_47] 0.3755 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_57 + HI_59 + HI_58 + HR_56 + HR_47 + HR_54 + HR_55 [- HR_51] 0.4387 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_57 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_55 [- HR_54] 0.4333 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_57 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54  [- HR_55] 0.4480 
 Step 4 Inc T1D ~ HD_71 + HI_60 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HD_68] 0.4584 * 
  Inc T1D ~ HD_68 + HI_60 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HD_71] 0.4403 
   Inc T1D ~ HD_68 + HD_71 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_60] 0.4508 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_59] 0.3169 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_59 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_58] 0.4573 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_59 + HI_58 + HR_47 + HR_51 + HR_54 + HR_55 [- HR_56] 0.4478 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_59 + HI_58 + HR_56 + HR_51 + HR_54 + HR_55 [- HR_47] 0.3807 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_59 + HI_58 + HR_56 + HR_47 + HR_54 + HR_55 [- HR_51] 0.4448 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_55 [- HR_54] 0.4362 
   Inc T1D ~ HD_68 + HD_71 + HI_60 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54  [- HR_55] 0.4383 
 Step 5 Inc T1D ~ HI_60 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HD_71] 0.4428 
   Inc T1D ~ HD_71 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_60] 0.4580 
   Inc T1D ~ HD_71 + HI_60 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_59] 0.3174 
   Inc T1D ~ HD_71 + HI_60 + HI_59 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_58] 0.4595 * 
  Inc T1D ~ HD_71 + HI_60 + HI_59 + HI_58 + HR_47 + HR_51 + HR_54 + HR_55 [- HR_56] 0.4520 
   Inc T1D ~ HD_71 + HI_60 + HI_59 + HI_58 + HR_56 + HR_51 + HR_54 + HR_55 [- HR_47] 0.3898 
   Inc T1D ~ HD_71 + HI_60 + HI_59 + HI_58 + HR_56 + HR_47 + HR_54 + HR_55 [- HR_51] 0.4251 
   Inc T1D ~ HD_71 + HI_60 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_55 [- HR_54] 0.4429 
   Inc T1D ~ HD_71 + HI_60 + HI_59 + HI_58 + HR_56 + HR_47 + HR_51 + HR_54  [- HR_55] 0.4433 
 Step 6 Inc T1D ~ HI_60 + HI_59 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HD_71] 0.4433 
   Inc T1D ~ HD_71 + HI_59 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_60] 0.4604 ** 
  Inc T1D ~ HD_71 + HI_60 +HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_59] 0.3158 
   Inc T1D ~ HD_71 + HI_60 + HI_59 + HR_47 + HR_51 + HR_54 + HR_55 [- HR_56] 0.4538 
   Inc T1D ~ HD_71 + HI_60 + HI_59 + HR_56 + HR_51 + HR_54 + HR_55 [- HR_47] 0.3627 
   Inc T1D ~ HD_71 + HI_60 + HI_59 + HR_56 + HR_47 + HR_54 + HR_55 [- HR_51] 0.4288 
   Inc T1D ~ HD_71 + HI_60 + HI_59 + HR_56 + HR_47 + HR_51 + HR_55 [- HR_54] 0.4450 
   Inc T1D ~ HD_71 + HI_60 + HI_59 + HR_56 + HR_47 + HR_51 + HR_54  [- HR_55] 0.4399 
 Step 7 Inc T1D ~ HI_60 + HI_59 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HD_71] 0.4399 
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Backwards elimination - adjusted R2 
 
   Domain: health conditions 
 
   Step Variables included Removed Adjusted R2 
 
Full 
Inc T1D ~ HD_68 + HD_71 + HD_72 + HI_60 + HI_57 + HI_59 + HI_58 +  
HM_75 + HR_56 + HR_47 + HR_51 + HR_54 + HR_55 0.4293 
   Inc T1D ~ HD_71 + HI_60 +HR_56 + HR_47 + HR_51 + HR_54 + HR_55 [- HI_59] 0.3238 
   Inc T1D ~ HD_71 + HI_60 + HI_59 + HR_47 + HR_51 + HR_54 + HR_55 [- HR_56] 0.4580 
   Inc T1D ~ HD_71 + HI_60 + HI_59 + HR_56 + HR_51 + HR_54 + HR_55 [- HR_47] 0.3699 
   Inc T1D ~ HD_71 + HI_60 + HI_59 + HR_56 + HR_47 + HR_54 + HR_55 [- HR_51] 0.4362 
   Inc T1D ~ HD_71 + HI_60 + HI_59 + HR_56 + HR_47 + HR_51 + HR_55 [- HR_54] 0.4510 
   Inc T1D ~ HD_71 + HI_60 + HI_59 + HR_56 + HR_47 + HR_51 + HR_54  [- HR_55] 0.4477 
 (*) Model with higher adjusted R2, (**) Best model 




AP Figure 69: Graphic validation of the best model for the health conditions domain 
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8.5.1.5 Stepwise selection all significant variables 
AP Table 35: Manual backward selection of all significant variables  
Backwards elimination - adjusted R2 
 
   All significant variables at p-value ≤0.05 after applied MLM by each domain 
   Step Variables included Removed Adjusted R2 
 
Full 
Inc T1D ~ CE_10 + CE_18 + DD_19 + DD_21 + DD_27 + DD_33 + ED_41  
+ ED_36 + EH_45 + HI_59 + HR_47 0.4915 
 Step 1 Inc T1D ~ CE_18 + DD_19 + DD_21 + DD_27 + DD_33 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- CE_10] 0.4872 
   Inc T1D ~ CE_10 + DD_19 + DD_21 + DD_27 + DD_33 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- CE_18] 0.4873 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + DD_27 + DD_33 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- DD_19] 0.4984 * 
  Inc T1D ~ CE_10 + CE_18 + DD_19 + DD_27 + DD_33 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- DD_21] 0.4747 
   Inc T1D ~ CE_10 + CE_18 + DD_19 + DD_21 + DD_33 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- DD_27] 0.4977 
   Inc T1D ~ CE_10 + CE_18 + DD_19 + DD_21 + DD_27 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- DD_33] 0.4978 
   Inc T1D ~ CE_10 + CE_18 + DD_19 + DD_21 + DD_27 + DD_33 + ED_36 + EH_45 + HI_59 + HR_47 [- ED_41] 0.4688 
   Inc T1D ~ CE_10 + CE_18 + DD_19 + DD_21 + DD_27 + DD_33 + ED_41 + EH_45 + HI_59 + HR_47 [- ED_36] 0.4970 
   Inc T1D ~ CE_10 + CE_18 + DD_19 + DD_21 + DD_27 + DD_33 + ED_41 + ED_36 + HI_59 + HR_47 [- EH_45] 0.4827 
   Inc T1D ~ CE_10 + CE_18 + DD_19 + DD_21 + DD_27 + DD_33 + ED_41 + ED_36 + EH_45 + HR_47 [- HI_59] 0.4351 
   Inc T1D ~ CE_10 + CE_18 + DD_19 + DD_21 + DD_27 + DD_33 + ED_41 + ED_36 + EH_45 + HI_59 [- HR_47] 0.4891 
 Step 2 Inc T1D ~ CE_18 + DD_21 + DD_27 + DD_33 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- CE_10] 0.4891 
   Inc T1D ~ CE_10 + DD_21 + DD_27 + DD_33 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- CE_18] 0.4883 
   Inc T1D ~ CE_10 + CE_18 + DD_27 + DD_33 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- DD_21] 0.4828 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + DD_33 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- DD_27] 0.5046 * 
  Inc T1D ~ CE_10 + CE_18 + DD_21 + DD_27 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- DD_33] 0.5040 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + DD_27 + DD_33 + ED_36 + EH_45 + HI_59 + HR_47 [- ED_41] 0.4725 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + DD_27 + DD_33 + ED_41 + EH_45 + HI_59 + HR_47 [- ED_36] 0.5009 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + DD_27 + DD_33 + ED_41 + ED_36 + HI_59 + HR_47 [- EH_45] 0.4879 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + DD_27 + DD_33 + ED_41 + ED_36 + EH_45 + HR_47 [- HI_59] 0.4437 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + DD_27 + DD_33 + ED_41 + ED_36 + EH_45 + HI_59 [- HR_47] 0.4969 
 Step 3 Inc T1D ~ CE_18 + DD_21 + DD_33 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- CE_10] 0.4968 
   Inc T1D ~ CE_10 + DD_21 + DD_33 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- CE_18] 0.4809 
   Inc T1D ~ CE_10 + CE_18 + DD_33 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- DD_21] 0.4891 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- DD_33] 0.5101 * 
  Inc T1D ~ CE_10 + CE_18 + DD_21 + DD_33 + ED_36 + EH_45 + HI_59 + HR_47 [- ED_41] 0.4777 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + DD_33 + ED_41 + EH_45 + HI_59 + HR_47 [- ED_36] 0.5073 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + DD_33 + ED_41 + ED_36 + HI_59 + HR_47 [- EH_45] 0.4855 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + DD_33 + ED_41 + ED_36 + EH_45 + HR_47 [- HI_59] 0.4469 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + DD_33 + ED_41 + ED_36 + EH_45 + HI_59 [- HR_47] 0.5033 
 Step 4 Inc T1D ~ CE_18 + DD_21 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- CE_10] 0.5034 
   Inc T1D ~ CE_10 + DD_21 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- CE_18] 0.4814 
   Inc T1D ~ CE_10 + CE_18 + ED_41 + ED_36 + EH_45 + HI_59 + HR_47 [- DD_21] 0.4929 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + ED_36 + EH_45 + HI_59 + HR_47 [- ED_41] 0.4855 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + ED_41 + EH_45 + HI_59 + HR_47 [- ED_36] 0.5138 ** 
  Inc T1D ~ CE_10 + CE_18 + DD_21 + ED_41 + ED_36 + HI_59 + HR_47 [- EH_45] 0.4930 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + ED_41 + ED_36 + EH_45 + HR_47 [- HI_59] 0.4552 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + ED_41 + ED_36 + EH_45 + HI_59 [- HR_47] 0.5106 
 Step 5 Inc T1D ~ CE_18 + DD_21 + ED_41 + EH_45 + HI_59 + HR_47 [- CE_10] 0.5114 * 
  Inc T1D ~ CE_10 + DD_21 + ED_41 + EH_45 + HI_59 + HR_47 [- CE_18] 0.4849 
   Inc T1D ~ CE_10 + CE_18 + ED_41 + EH_45 + HI_59 + HR_47 [- DD_21] 0.5017 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + EH_45 + HI_59 + HR_47 [- ED_41] 0.4919 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + ED_41 + HI_59 + HR_47 [- EH_45] 0.5026 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + ED_41 + EH_45 + HR_47 [- HI_59] 0.4470 
   Inc T1D ~ CE_10 + CE_18 + DD_21 + ED_41 + EH_45 + HI_59 [- HR_47] 0.5024 
 (*) Model with higher adjusted R2, (**) Best model 












AP Figure 70: Graphic validation of the final summary model with all significant variables 
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8.6 Appendix F: Validation of the model presented in chapter 6 
8.6.1 Selection of HLA alleles related with T1D incidence and graphic validation of the 
model 
For details see Table 23 and SI Table 24-26.  
AP Table 36: Manual backward selection of the HLA alleles against T1D 
 
Backwards elimination - adjusted R2 
 
   Significant HLA alleles correlated with incidence of T1D at p-value ≤0.05  
 
   Step Variables included Removed Adjusted R2 
 
Full 
Inc T1D ~ DRB1.03.01+ DRB1.04.01+DRB1.04.05+ DRB1.08.01+  
DQB1.02.01+DQB1.04.01+ DQB1.06.02 0.9432 
 Step 1 Inc T1D ~ DRB1.04.01+ DRB1.04.05+ DRB1.08.01+ DQB1.02.01+ DQB1.04.01+ DQB1.06.02  [-DRB1.03.01] 0.6531 
   Inc T1D ~ DRB1.04.05+ DRB1.03.01+ DRB1.08.01+ DQB1.02.01+ DQB1.04.01+ DQB1.06.02  [-DRB1.04.05] 0.5219 
   Inc T1D ~ DRB1.03.01+ DRB1.04.01+ DRB1.08.01+ DQB1.02.01+ DQB1.04.01+ DQB1.06.02  [-DRB1.04.05] -0.1261 
   Inc T1D ~ DRB1.03.01+ DRB1.04.01+ DRB1.04.05+ DQB1.02.01+ DQB1.04.01+ DQB1.06.02  [-DRB1.08.01] 0.8368 
   Inc T1D ~ DRB1.03.01+ DRB1.04.01+ DRB1.04.05+ DRB1.08.01+ DQB1.04.01+ DQB1.06.02 [-DQB1.02.01]  0.9606 *  
  Inc T1D ~ DRB1.03.01+ DRB1.04.01+ DRB1.04.05+ DRB1.08.01+ DQB1.02.01+ DQB1.06.02 [-DQB1.04.01]  0.5877 
   Inc T1D ~ DRB1.03.01+ DRB1.04.01+ DRB1.04.05+ DRB1.08.01+ DQB1.02.01+ DQB1.04.01 [-DQB1.06.02] 0.9544 
 Step 2 Inc T1D ~ DRB1.04.01+ DRB1.04.05+ DRB1.08.01+ DQB1.04.01+ DQB1.06.02 [-DRB1.03.01] 0.6685 
   Inc T1D ~ DRB1.03.01+ DRB1.04.05+ DRB1.08.01+ DQB1.04.01+ DQB1.06.02 [-DRB1.04.01] 0.5795 
   Inc T1D ~ DRB1.03.01+ DRB1.04.01+ DRB1.08.01+ DQB1.04.01+ DQB1.06.02 [-DRB1.04.05] 0.0971 
   Inc T1D ~ DRB1.03.01+ DRB1.04.01+ DRB1.04.05+ DQB1.04.01+ DQB1.06.02 [-DRB1.08.01] 0.8218 
   Inc T1D ~ DRB1.03.01+ DRB1.04.01+ DRB1.04.05+ DRB1.08.01+ DQB1.06.02 [-DQB1.04.01]  0.6288 
   Inc T1D ~ DRB1.03.01+ DRB1.04.01+ DRB1.04.05+ DRB1.08.01+ DQB1.04.01 [-DQB1.06.02]  0.9640 * * 
Step 3 Inc T1D ~ DRB1.04.01+ DRB1.04.05+ DRB1.08.01+ DQB1.04.01 [-DRB1.03.01] 0.7008 
   Inc T1D ~ DRB1.03.01+ DRB1.04.05+ DRB1.08.01+ DQB1.04.01 [-DRB1.04.01]  0.2945 
   Inc T1D ~ DRB1.03.01+ DRB1.04.01+ DRB1.08.01+ DQB1.04.01 [-DRB1.04.05] 0.0968 
   Inc T1D ~ DRB1.03.01+ DRB1.04.01+ DRB1.04.05+ DQB1.04.01  [-DRB1.08.01]  0.6874 
   Inc T1D ~ DRB1.03.01+ DRB1.04.01+ DRB1.04.05+ DRB1.08.01 [-DQB1.04.01]  0.6108 ***  
(*) Model with higher adjusted R2, (**) Best model by higher adjusted R2 but colinearity problem. (***) Best model. Included variables in the full model were 





AP Figure 71: Graphic validation of the final model 
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8.6.2 Correlation matrix of HLA alleles against T1D included in the final model  
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Épidémiologie de diabète du type 1: incidence mondiale et ses déterminants 
 
Résumé : 
Introduction : Le diabète de type 1 (DT1) est une des maladies métaboliques les plus répandues chez les enfants 
(298). L'augmentation de l'incidence mondiale du DT1 a été calculée à 3,0% par année en moyenne et il a été 
prédit qu'elle serait de 40% en 2010 (231) chez les enfants âgés de 0 à 14 ans. Les causes de cette augmentation 
ne sont pas encore déterminées; cette thèse met à jour les connaissances actuelles sur l'incidence mondiale du 
DT1, en profitant de la disponibilité croissante des bases de données publiques et en examinant la corrélation 
entre l’incidence et les caractéristiques des pays. 
Méthodes : Une recherche exhaustive et systématique des articles publiés sur l'incidence du DT1 dans le monde 
a été effectuée pour étudier les variations globales de cette incidence dans les divers pays. Nous avons suivi les 
recommandations de PRISMA8 (213). L'objectif initial de cette thèse était d'étudier la corrélation entre les 
variables environnementales disponibles dans les bases de données publiques, et l'incidence du DT1 selon les 
pays. Nous avons également réalisé une analyse similaire à celle décrite ci-dessus concernant les variables 
environnementales, pour les composantes génétiques du DT1. La fréquence des haplotypes de HLA (Human 
Leukocyte Antigens) qui confèrent la susceptibilité à, ou la protection contre le DT1, a été exploré (89). Les 
principales méthodes statistiques utilisées étaient des corrélations et des modèles de régression linéaire. Enfin, 
afin de mieux comprendre les tendances dynamiques du DT1 avec toutes les informations récupérées sur 
l'incidence du DT1, nous avons utilisé l'Âge-Période-Cohorte (APC). Pour les analyses statistiques et graphiques 
le logiciel R (version 3.0.1) a été utilisé (255), et pour la visualisation des données le logiciel Tableau (262). 
Principaux résultats : Grâce à la revue de la littérature publiée entre 1975 et 2014, 265 références ont été 
sélectionnées, qui contenaient les données épidémiologiques sur les cas incidents de DT1 chez les individus âgés 
de 0-14 ans portant sur 90 pays. Chez les personnes de plus de 15 ans, 70 références ont été sélectionnées portant 
sur 35 pays. L’incidence du DT1 est très variable selon les pays et régions du monde pour les enfants et les 
adultes. Contrairement à ce qui est connu chez les enfants, chez les adultes l'incidence était généralement plus 
élevée chez les hommes que chez les femmes. Indépendamment de l'incidence initiale, on a trouvé une 
tendance à l’augmentation de l'incidence dans tous les continents entre 1960 et 2010. Finalement, nous avons 
extrait des données à analyser (223 articles sélectionnés) en utilisant des modèles Age-Période-Cohorte, des 
informations équivalentes à 2,327,604,529 années-personnes à risque de 192,741 cas de DT1. Avec le modèle 
APC un fort effet de cohorte a été observé; le modèle indique également un effet période probable qui diminue 
après 1987. Comme prévu, l'incidence du DT1 augmente avec l'âge. Ces variations s'expliquent en partie par 
l'interaction entre les facteurs environnementaux et les composants génétiques des populations. Pour la 
composante environnementale, en utilisant des modèles de régressions linéaires multiples (MLR) Stepwise, les 
facteurs prédictifs environnementaux les plus importants de la variation de l'incidence du DT1 d'un pays à l'autre 
étaient: les rayons UV, le nombre d'abonnements aux téléphones mobiles dans le pays, les dépenses de santé par 
habitant, la vaccination contre l'hépatite B et l'IMC (indice  de masse corporelle) moyen. Pour les composants 
génétiques, en utilisant des modèles de MLR Stepwise, les variables significatives étaient les allèles sensibles: 
DRB1*04:01 (p = 0,0001) et DRB1*08:01 (p = 0,003). Aussi, une grande hétérogénéité des haplotypes 
susceptibles ou protecteurs face au DT1 au sein des populations a été trouvée. 
Conclusions et implications : Au cours de cette thèse, nous avons quantifié la variation pays par pays de 
l'incidence du DT1 dans le monde chez les enfants et les adultes, montrons qu'une grande partie de cette 
incidence pourrait s’expliquer par la variabilité de facteurs environnementaux d’un pays à l’autre. Cette thèse a 
également profité de la disponibilité croissante de données publiques sur la variation des facteurs 
environnementaux et génétiques de pays à pays, qui peuvent être impliqués dans le fort effet de cohorte de 
naissance qui a été observé ; il est conseillé d'approfondir la recherche sur la grossesse et la période néonatale et 
son implication dans DT1. Nous avons pu quantifier que l'augmentation de l'incidence du DT1 était encore plus 
grande que ce qui avait été prédit dans une étude antérieure (231). 
Mots clés : Le diabète de type 1,  l'incidence, corrélations, modèles de régression linéaire, modèles de Âge-
Période-Cohorte, Revue systématique. 
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Background: Type 1 Diabetes (T1D) is one of the most common metabolic diseases in childhood (298). The 
increase of worldwide incidence of T1D was calculated to be on average 3.0% per year and it was predicted that 
it would be 40% higher in 2010 (231) in children aged 0-14 years. The causes of this increase are still under 
study; this thesis updates our current knowledge on the global incidence of T1D, and taking advantage of the 
increasing availability of public databases examines the correlation between incidence and country 
characteristics.  
 
Methods: A comprehensive systematic literature search of published articles on the incidence of T1D worldwide 
was conducted to study global variations of the incidence within countries. We followed the PRISMA9group 
recommendations (213). The initial goal of this thesis was to study the correlation between environmental 
variables available in public databases with the country incidence of T1D.  We also achieved a similar analysis 
of the genetic component of T1D. The frequency of major HLA susceptible and protective haplotypes reported 
elsewhere (89) was explored. The principal statistical methods used were correlations and multiple linear 
regressions (MLR).  Finally, we used the Age-Period-Cohort (APC) approaches. For statistical and graphical 
analyses the R software (255), and for data visualization the Tableau software (262) were used.  
 
Key findings: Through the literature review, 265 selected references that contained epidemiological data about 
incidence cases of T1D among individuals aged 0-14 years, and 70 references of T1D incidence in those aged 
over 15 years, published between 1975 and 2014, were collected. Information was available on 90 countries and 
in 35 countries for those over 15 years of age. The incidence of T1D is highly variable among countries and 
regions worldwide in both children and adults. T1D incidence in adults paralleled those reported in children. 
Also, as opposed to what is known in children, we found that the incidence was in most studies larger in males 
than in females. 
Independently of the initial level of incidence, an increase in incidence was observed in all continents from 1960 
to 2010. Finally, using the Age-Period-Cohort model we analyzed information from 2,327,604,529 person-years 
at risk from 192,741 cases. A strong effect cohort was observed; in addition the model shows an apparent effect 
period that decreases after 1987. Also as expected, the incidence of T1D increases with age. These variations are 
in part explained by the interaction between the environmental factors and the genetic components of the 
populations.  
For the environmental component, using Stepwise MLR models the most significant environmental predictors of 
the country-to-country variation of T1D incidence were UV radiation, number of mobile cellular subscriptions in 
the country, health expenditure per capita, hepatitis B immunization and mean BMI. For the genetic component, 
using Stepwise MLR models, significant variables were the susceptible alleles: DRB1*04:01 and DRB1*08:01. 
High heterogeneity of susceptible and protector haplotypes for T1D within populations was found.  
 
Conclusions and implications: During this thesis, we quantified the country-to-country variation in T1D 
incidence worldwide in children and adults, and show that a large part of this incidence could be accounted for 
by the variability of environmental factors within the countries taking advantage of the increasing availability of 
public databases. Environmental factors may be involved in the strong cohort effect we found; it is advisable to 
deepen the research on pregnancy and neonatal period and its implications on T1D. Here we could quantify that 
the increase of T1D was even larger than had been predicted in an earlier study (231). 
 
Keywords : Type 1 Diabetes, incidence, correlation, multiple linear regressions, Age-Period-Cohort model, 
systematic literature review.  
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